



(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 47/4813 (2006.01)
C07D 471/14 (2006.01) A61K 47/48346 (2006.01)

(21) International Application Number:

PCT/US2016/039048

(22) International Filing Date:

23 June 2016 (23.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/189,502 7 July 2015 (07.07.2015) US
PCT/US2015/000274
23 December 2015 (23.12.2015) US

(71) Applicant: **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, Massachusetts 02215 (US).

(72) Inventors: **BRADNER, James**; 6 Buckskin Dr., Weston, Massachusetts 02493 (US). **BUCKLEY, Dennis**; 47 Seaverns Ave., Apt.6, Jamaica Plain, Massachusetts 02130 (US). **WINTER, Georg**; 99 Pond Ave., Apt.512, Brookline, Massachusetts 02445 (US).

(74) Agents: **KNOWLES, Sherry, M.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace NE, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES

(57) Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.



METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES

RELATED APPLICATIONS

5 This application claims the benefit of and priority to U.S. Provisional Application No. 62/189,502, filed July 7, 2015 and International Application No. PCT/US2015/000274, filed on December 23, 2015, which claims the benefit of and priority to U.S. Provisional Application Nos. 62/096,318, filed December 23, 2014; 62/128,457, filed March 4, 2015; 62/149,170, filed April 17, 2015; 62/159,048, filed May 8, 2015; and 62/189,502, filed July 10 7, 2015; the contents of each of which are incorporated by reference in their entireties.

BACKGROUND

Ubiquitin-Proteasome Pathway (UPP) is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. These ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity.

Cereblon (CRBN) interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 where it functions as a substrate receptor in which the proteins recognized by CRBN might be ubiquitinated and degraded by proteasomes. Proteasome-mediated degradation of unneeded or damaged proteins plays a very important role in maintaining regular function of a cell, such as cell survival, proliferation and growth. A new role for CRBN has been identified, *i.e.*, the binding of immunomodulatory drugs (IMiDs), *e.g.* thalidomide, to CRBN has now been associated with teratogenicity and also the cytotoxicity of IMiDs, including lenalidomide, which are widely used to treat multiple myeloma patients. CRBN is likely a key player in the binding, ubiquitination and degradation of factors involved in maintaining function of myeloma cells. These new findings regarding the role of CRBN in IMiD action stimulated intense investigation of CRBN's downstream factors involved in maintaining regular function of a cell (Chang X. Int J Biochem Mol Biol. 2011; 2(3): 287–294).

The UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome-dependent degradation. Proteolysis Targeting Chimeras (PROTACs), heterobifunctional compounds composed of a target protein-binding ligand and an E3 ubiquitin ligase ligand, induced proteasome-mediated degradation of selected proteins via their recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression. Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins (Crews C., Chemistry & Biology, 2010, 17(6):551-555; Schnnekloth JS Jr., Chembiochem, 2005, 6(1):40-46).

Successful treatment of various oncologic and immunologic disorders, such as cancer, is still a highly unmet need. Therefore, continued development of alternative approaches to cure or treat such disorders, including developing therapies involving protein degradation technology, remains of strong interest. Novel methods of more general nature than existing methods with respect to possible targets and different cell lines or different in vivo systems could potentially lead to the development of future therapeutic treatments.

SUMMARY

The present application relates novel bifunctional compounds, which function to recruit targeted proteins to E3 Ubiquitin Ligase for degradation, and methods of preparation and uses thereof.

The present application further relates to targeted degradation of proteins through the use of bifunctional molecules, including bifunctional molecules that link a cereblon-binding moiety to a ligand that binds the targeted protein.







The present application also relates to a bifunctional compound having the following structure:





Degron–Linker–Targeting Ligand,


wherein the Linker is covalently bound to at least one Degron and at least one Targeting Ligand, the Degron is a compound capable of binding to a ubiquitin ligase such as an E3 Ubiquitin Ligase (*e.g.*, cereblon), and the Targeting Ligand is capable of binding to the targeted protein(s).

The present application also relates to a novel degradation inducing moiety, or Degron, which is small in size and highly effective in recruiting targeted proteins for degradation.


The present application further relates to a compound having Formula D0, D, D0', D',
 5 D1, D3, D'1, D'3, D0'I, or D0'II:





5 or an enantiomer, diastereomer, or stereoisomer thereof, wherein  ^a_b, X, X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, t, m and n are each as defined herein.

The present application further relates to a Linker having Formula L0:










or an enantiomer, diastereomer, or stereoisomer thereof, wherein p₁, p₂, p₃, W, Q, and Z are




10 each as defined herein, the Linker is covalently bonded to the Degron with the  next to

Q, and covalently bonded to the Targeting Ligand with the  next to Z.


The present application further relates to the Targeting Ligands described herein, including a compound of Formula TL-I to TL-VII.

The present application further relates to a bifunctional compound of Formula X0, X0', X, XI, I, II, III, IV, X0'I, or X0'II:





or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof,
 5 wherein the Linker is a group that covalently binds to the Targeting Ligand and Y, and the
 Targeting Ligand is capable of binding to or binds to a targeted protein, and wherein



^a, X, X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, t, m and n are each as defined herein.

The present application further relates to a pharmaceutical formulation comprising a
 therapeutically effective amount of a bifunctional compound of Formula X0, X0', X, XI, I, II,
 10 III, IV, X0'I, or X0'II, and a pharmaceutically acceptable carrier.

The present application also relates to a method for treating a disease or condition
 which is modulated by a targeted protein by administering a therapeutically effective amount
 of a bifunctional compound of Formula X0, X0', X, XI, I, II, III, IV, X0'I, or X0'II to a
 subject in need thereof. In certain embodiments, the disease or condition is resistant to
 15 treatment with the Targeting Ligand.

The present application also relates to use of a bifunctional compound of Formula X0,
 X0', X, XI, I, II, III, IV, X0'I, or X0'II or a pharmaceutical formulation of the application for
 treating a disease or condition which is modulated by a targeted protein. In certain
 embodiments, the disease or condition is resistant to treatment with the Targeting Ligand.

20 The present application also relates to use of a bifunctional compound of Formula X0,
 X0', X, XI, I, II, III, IV, X0'I, or X0'II, or a pharmaceutical formulation of the application in
 the manufacture of a medicament for treating a disease or condition which is modulated by a

targeted protein. In certain embodiments, the disease or condition is resistant to treatment with the Targeting Ligand.

The present application also relates to methods for treating cancer by administering a therapeutically effective amount of a bifunctional compound of Formula X0, X0', X, XI, I, II, 5 III, IV, X0'I, or X0'II to a subject in need thereof. In certain embodiments, the cancer is resistant to treatment with the Targeting Ligand.

The present application also relates to use of a bifunctional compound of Formula X0, X0', X, XI, I, II, III, IV, X0'I, or X0'II or a pharmaceutical formulation of the application for treating cancer. In certain embodiments, the cancer is resistant to treatment with the 10 Targeting Ligand.

The present application also relates to use of a bifunctional compound of Formula X0, X0', X, XI, I, II, III, IV, X0'I, or X0'II or a pharmaceutical formulation of the application in the manufacture of a medicament for treating cancer. In certain embodiments, the cancer is resistant to treatment with the Targeting Ligand.

15 The compounds and methods of the present application address unmet needs in the treatment of diseases or disorders in which pathogenic or oncogenic endogenous proteins play a role, such as, for example, cancer.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application 20 belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. The references cited 25 herein are not admitted to be prior art to the claimed application. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the present application will be apparent from the following detailed description and claims.

30

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of the application, will be better understood when read in conjunction with the appended drawings.

Figs. 1A-1H: Design and characterization of dBET1. Fig. 1A shows the chemical structure of JQ1(S), JQ1(R) and the phthalimides; Fig. 1B shows the chemical structure of dBET1; Fig. 1C shows DMSO normalized BRD4 binding signal measured by AlphaScreen for the indicated compounds (values represent mean $\pm$ stdev of triplicate analysis); Fig. 1D shows the crystal structure of dBET1 bound to bromodomain 1 of BRD4; Fig. 1E shows docking of the structure in Fig. 1D into the published DDB1-CRBN structure; Fig. 1F shows immunoblot analysis for BRD4 and Vinculin after 18 h treatment of MV4-11 cells with the indicated concentrations of dBET1; Fig. 1G shows the crystal structure of dBET1 bound to BRD4 overlaid with the structure of JQ1 bound to BRD4; Fig. 1H is a Western blot illustrating the degree of degradation of BRD4 and reduction in c-MYC by treatment of cells with increased concentrations of a bifunctional compound of the application, dBET1.

Figs. 2A-2Q: Fig. 2A shows the immunoblot analysis for BRD4 after treatment of MV4-11 cells with the indicated concentrations of dBET1(R) for 18 h; Fig. 2B shows cell count normalized BRD4 levels as determined by high-content assay in SUM149 cells treated with the indicated concentrations of dBET1 and dBET1(R) for 18 h (values represent mean $\pm$ stdev of triplicate analysis, normalized to DMSO treated cells and baseline corrected based on immunoblots in Fig. 2C); Fig. 2C shows immunoblot analysis for BRD4 and Vinculin after treatment of SUM149 cells with the indicated concentrations of dBET1 and dBET1(R) for 18 h; Fig. 2D shows immunoblot analysis for BRD4 and Vinculin after treatment of MV4-11 cells with 100 nM dBET1 at the indicated time points; Fig. 2E shows cellular viability dose-response of dBET1 and JQ1 treatment for 24 h in MV4-11 as determined ATP levels (values represent mean $\pm$ stdev of quadruplicate analysis); Fig. 2F is a bar graph depiction of fold increase of apoptosis assessed via caspase glo assay relative to DMSO treated controls after 24 h treatment in MV4-11 or DHL4 cells (values represent mean $\pm$ stdev of quadruplicate analysis); Fig. 2G shows immunoblot analysis for BRD4 and Vinculin after treatment of primary patient cells with the indicated concentrations of dBET1 for 24 hours; Fig. 2H is a bar graph depiction of fraction of Annexin V positive primary patient cells after 24 h treatment with either dBET1 or JQ1 at the indicated concentrations (values represent the average of duplicates and the range as error bars) (representative counter plots shown in Figs. 2L and 2M); Figs. 2I and 2J are immunoblot analysis showing BRD4 and Vinculin 18h after dBET1 treatment with the indicated concentrations in SUM159 and MOLM13, respectively; Fig. 2K shows immunoblot analysis for BRD2, BRD3, and BRD4 and c-Myc at different time points after treatment of cells with the 100 nM of dBET1; Fig. 2L are a series of flow cytometry plots illustrating Annexin V/PI data of primary patient cells

treated with the indicated concentrations of JQ1 and dBET1 for 24h; Fig. 2M is a bar graph depiction of Annexin V positive MV4-11 cells after treatment with dBET1 or JQ1 at the indicated concentrations (data represents mean $\pm$ stdev of triplicate analysis); Fig. 2N is an immunoblot analysis of cleaved caspase 3, PARP cleavage and vinculin after treatment with dBET1 and JQ1 at the indicated concentrations for 24 h; Fig. 2O are bar graphs illustrating the kinetic advantage of BET degradation on apoptosis (Caspase-GLO) relative to treated controls: MV4-1 cells were treated for 4 or 8 h with JQ1 or dBET1 at the indicated concentrations, followed by drug wash-out before being plated in drug-free media for 24 h; Fig. 2P is a bar graph depiction of fold increase of apoptosis of MV4-11 cells treated for 4 or 8 h with JQ1 or dBET1 at the indicated concentrations, relative to DMSO treated controls assessed via caspase glo assay (drug were washed out with PBS (3x) before being plated in drug-free media for a final treatment duration of 24 h); Fig. 2Q is an immunoblot analysis of cleaved caspase 3, PARP cleavage and vinculin after identical treatment conditions in Fig. 2P.

Figs. 3A-3F: Figs. 3A-3D show chemical and genetic rescue of dBET1-mediated degradation of BRD4. Fig. 3A shows immunoblot analysis for BRD4 and Vinculin after treatment of MV4-11 cells with the indicated concentrations of dBET1, JQ1, and thalidomide for 24 h; Fig. 3B shows immunoblot analysis for BRD4 and Vinculin after 4 h pre-treatment with either DMSO, Carfilzomib (0.4 μ M), JQ1 (10 μ M) or thalidomide (10 μ M) followed by 2 h dBET1 treatment at a concentration of 100 nM; Fig. 3C shows immunoblot analysis for BRD4 and Vinculin after a 4 h pre-treatment with 1 μ M MLN4924 followed by 2 h dBET1 treatment at the indicated concentrations; Fig. 3D shows immunoblot analysis for BRD4, CRBN and tubulin after treatment of MM1S^{WT} or MM1S^{CRBN-/-} with dBET1 for 18 h at the indicated concentrations; Fig. 3E is an immunoblot analysis comparing the concentration of BRD4 in cells treated with various concentrations of thalidomide, JQ1, and dBET1; Fig. 3F is an immunoblot analysis showing the concentration of BRD4 in cells treated with carfilzomib (400nM), JQ1 (20uM), or thalidomide (20 uM) for 4 hours and with dBET1 (100nM) as indicated for 2 hours.

Figs. 4A-4F: Figs. 4A-4E show selective BET bromodomain degradation by expression proteomics: MV4-11 cells were treated for 2 hours with DMSO, 250 nM dBET1 or 250 nM JQ1. Fig. 4A depicts fold change of abundance of 7429 proteins comparing JQ1 to DMSO treatment as well as their respective p-value (T-test) (data from triplicate analysis); Fig. 4B depicts fold change of abundance of 7429 proteins comparing 250 nM dBET1 to DMSO treatment (data from triplicate analysis); Fig. 4C is a bar graph depiction of changes

in protein levels of the selected proteins as shown normalized to DMSO (values represent mean $\pm$ stdev of triplicates); Fig. 4D shows immunoblot analysis of BRD2, BRD3, BRD4, MYC, PIM1 and VINC after 2 h treatment of MV4-11 cells with either DMSO, 250 nM dBET1 or 250 nM JQ1; Fig. 4E is a bar graph depiction of qRT-PCR analysis of transcript levels of BRD2, BRD3, BRD4, MYC and PIM1 after 2 h treatment of MV4-11 cells with either DMSO, 250 nM dBET1 or 250 nM JQ1 (values represent mean $\pm$ stdev of triplicates); Fig. 4F is an immunoblot analysis for IKZF3 and Vinculin after 24 h treatment with thalidomide or the indicated concentrations of dBET1 in MM1S cell line.

Figs. 5A-5B: Fig. 5A is a Western blot showing the concentration of BRD4 in cells treated with various concentrations of JQ1-Rev, in comparison with 100 nM of a bifunctional compound of the application, dBET1. Fig. 5B is a drawing of the chemical structure of JQ1-Rev (JQ1-11-079).

Figs. 6A-6B: Fig. 6A and 6B are a series of graphs that illustrate the transcription levels of BRD4 assayed via qRT-PCR after 2 hrs (Fig. 6A) or 4 hrs (Fig. 6B) from cells treated with various concentrations of JQ1 or dBET.

Fig. 7 is a Western blot illustrating the degree of degradation of BRD4 by treatment of a human cell line MM1S and a human cell line MM1S that is deficient in cereblon with increased concentrations of a bifunctional compound of the application, dBET1.

Fig. 8 is a Western blot illustrating the degree of degradation of BRD4 by treatment of cells with increased concentrations of a bifunctional compound of the application, dBET2.

Figs. 9A-9B: Fig. 9A is a Western blot illustrating reduction in PLK1 by treatment of cells with increased concentrations of a bifunctional compound of the application, dBET2; Fig. 9B is a bar graph depicting PLK intensity in dBET2 treated cells as percentage of that in DMSO treated cells.

Figs. 10A-10D: dFKBP-1 and dFKBP-2 mediated degradation of FKBP12. Fig. 10A depicts chemical structures of dFKBP-1 and dFKBP-2; Fig. 10B illustrates immunoblot analysis for FKBP12 and Vinculin after 18 h treatment with the indicated compounds; Fig. 10C shows immunoblot analysis for FKBP12 and Vinculin after a 4 h pre-treatment with either DMSO, Carfilzomib (400 nM), MLN4924 (1 μ M), SLF (20 μ M) or thalidomide (10 μ M) followed by a 4 h dFKBP-1 treatment at a concentration of 1 μ M in MV4-11 cells; Fig. 10D shows immunoblot analysis for FKBP12, CRBN and tubulin after treatment of 293FT^{WT} or 293FT^{CRBN-/-} with dFKBP-1 at the indicated concentrations for 18 h.

Figs. 11A-11C: Fig. 11A is a diagram showing selectivity of dBET1 for binding to BETs over other human bromodomains, as determined by single point screening

(BromoScan); Fig. 11B shows results from a dimerization assay measuring dBET1 induced proximity (at 111 nM) between recombinant BRD4 bromodomain and recombinant CRBN-DDB1 (values represent mean $\pm$ stdev of quadruplicate analysis and are normalized to DMSO); Fig. 11C is a bar graph showing the competition of dBET1 induced proximity in the presence of DMSO (vehicle), JQ1(S), thal(-), JQ1(R) and thal(+), all at a final concentration of 1 μ M (values represent mean $\pm$ stdev of quadruplicate analysis and are normalized to DMSO).

Figs. 12A-12E: Fig. 12A is a bar graph showing the tumor volume of vehicle treated mice (n=5) or mice treated with dBET1 at a concentration of 50 mg/kg (n=6) over a treatment period of 14 days; Fig. 12B is a bar graph comparing the tumor weight after termination of the experiment shown in Fig. 12A on day 14; Fig. 12C is an immunoblot analysis for BRD4, MYC and Vinculin using tumor lysates from mice treated either once for 4 h or twice for 22 h and 4h compared to a vehicle treated control; Fig. 12D shows immunohistochemistry staining for BRD4, MYC and Ki67 of a representative tumor of a dBET1 treated and a control treated mouse; Fig. 12E is a bar graph depicting quantification of the staining in Fig. 12D based on 3 independent areas within that section (data represents mean $\pm$ stdev of triplicate analysis and is normalized to DMSO).

Figs. 13A-13D: Pharmacokinetic studies of dBET1 in CD1 mice. Fig. 13A is a graph showing concentration of dBET1 in CD1 mice following intraperitoneal injection of dBET1 formulated in 0.5% MC in water; Fig. 13B is a table depicting pharmacokinetic parameters in mice from Fig. 13A; Fig. 13C is a graph showing the change in weight of mice treated with 50mg/kg q.d. of dBET1 or vehicle; Fig. 13D are bar graphs showing changes in HTC, WBC, or PLT in mice from Fig. 13C.

Figs. 14A-14L: High content assay measuring BRD4 levels in cells (293FT^{WT} or 293FT^{CRBN-/-}) after 4 hour treatment with indicated concentrations of the bifunctional compounds of the present application. Figs. 14A-14B: BRD4 levels in 293FT^{WT} (Fig. 14A) or 293FT^{CRBN-/-} (Fig. 14B) after 4 hour treatment with indicated concentrations of JQ1; Figs. 14C-14D: BRD4 levels in 293FT^{WT} (Fig. 14C) or 293FT^{CRBN-/-} (Fig. 14D) after 4 hour treatment with indicated concentrations of dBET1; Fig. 14E-14F: BRD4 levels in 293FT^{WT} (Fig. 14E) or 293FT^{CRBN-/-} (Fig. 14F) after 4 hour treatment with indicated concentrations of dBET2; Figs. 14G-14H: BRD4 levels in 293FT^{WT} (Fig. 14G) or 293FT^{CRBN-/-} (Fig. 14H) after 4 hour treatment with indicated concentrations of dBET3; Figs. 14I-14J: BRD4 levels in 293FT^{WT} (Fig. 14I) or 293FT^{CRBN-/-} (Fig. 14J) after 4 hour treatment with indicated concentrations of dBET4; Figs. 14K-14L: BRD4 levels in 293FT^{WT} (Fig. 14K) or

293FT^{CRBN-/-} (Fig. 14L) after 4 hour treatment with indicated concentrations of dBET5; Figs. 14M-14N: BRD4 levels in 293FT^{WT} (Fig. 14M) or 293FT^{CRBN-/-} (Fig. 14N) after 4 hour treatment with indicated concentrations of dBET6; Figs. 14O-14P: BRD4 levels in 293FT^{WT} (Fig. 14O) or 293FT^{CRBN-/-} (Fig. 14P) after 4 hour treatment with indicated concentrations of dBET7; Figs. 14Q-14R: BRD4 levels in 293FT^{WT} (Fig. 14Q) or 293FT^{CRBN-/-} (Fig. 14R) after 4 hour treatment with indicated concentrations of dBET8; Figs. 14S-14T: BRD4 levels in 293FT^{WT} (Fig. 14S) or 293FT^{CRBN-/-} (Fig. 14T) after 4 hour treatment with indicated concentrations of dBET9; Figs. 14U-14V: BRD4 levels in 293FT^{WT} (Fig. 14U) or 293FT^{CRBN-/-} (Fig. 14V) after 4 hour treatment with indicated concentrations of dBET10; Figs. 14W-14X: BRD4 levels in 293FT^{WT} (Fig. 14W) or 293FT^{CRBN-/-} (Fig. 14X) after 4 hour treatment with indicated concentrations of dBET15; Figs. 14Y-14Z: BRD4 levels in 293FT^{WT} (Fig. 14Y) or 293FT^{CRBN-/-} (Fig. 14Z) after 4 hour treatment with indicated concentrations of dBET17; Figs. 14AA-14BB: BRD4 levels in 293FT^{WT} (Fig. 14AA) or 293FT^{CRBN-/-} (Fig. 14BB) after 4 hour treatment with indicated concentrations of dBET18.

Figs. 15A-15F: Immunoblots of BRD levels in cells treated with varying concentrations of the bifunctional compounds of the present application. Fig. 15A is an immunoblot showing BRD4 levels in BAF3_K-RAS cells treated with the indicated concentrations of dBET1 or dBET6 for 16.5 hours; Fig. 15B is an immunoblot showing BRD4 levels in BAF3_K-RAS or SEMK2 cells treated with the indicated concentrations of dBET1 for 16.5 hours; Fig. 15C is an immunoblot showing BRD4 levels in SEMK2 cells treated with the indicated concentrations of dBET1 or dBET6 for 16.5 hours; Fig. 15D is an immunoblot showing BRD4 levels in Monomac1 cells treated with the indicated concentrations of dBET1 or dBET6 for 16 hours; Fig. 15E is an immunoblot showing levels of BRD4, BRD2, and BRD3 at various time points in MV4-11 cells treated with 50 nM of dBET6; Fig. 15F is an immunoblot showing BRD4 levels in MM1S^{WT} or MM1S^{CRBN-/-} cells treated with the indicated concentrations of dBET6 for 16 hours.

Figs. 16A-16B: Immunoblots of protein levels in cells treated with the bifunctional compounds of the present application. Fig. 16A is an immunoblot showing levels of BRD4 and PLK1 in cells (WT or CRBN^{-/-}) treated with 1 μ M of dBET2, dBET7, dBET8, or dBET10; Fig. 16B is an immunoblot showing BRD4 levels at the indicated time points after the cells were treated with 100 nM dBET18.

Figs. 17A-17E: Cell viability after treatment with the bifunctional compounds of the present application. Figs. 17A-17B indicate cell viability EC₅₀ values of the bifunctional

compounds of the present application in various cells lines; Figs. 17C-17E show cell viability after treatment with increasing concentrations of JQ1, dBET1, dBET6, dBET7, or dBET8.

Figs. 18A-18C show viability of MOLT4 (Fig. 18A), DND41 (Fig. 18B), and CUTLL1 (Fig. 18C) cells after being treated with increasing concentrations of dBET compounds.

Fig. 19 is an immunoblot showing GR levels in cells treated with indicated concentrations of dGR3.

Fig. 20 is a series of graphs showing viability of various types of cells after treatment with increasing concentrations of JQ1 or dBET6.

Fig. 21 is a series of graphs showing viability of various types of cells after treatment with increasing concentrations of JQ1 or dBET6.

Fig. 22 is a series of graphs showing viability of various types of cells after treatment with increasing concentrations of JQ1 or dBET6.

Fig. 23 is a series of graphs showing viability of various types of cells after treatment with increasing concentrations of JQ1 or dBET6.

Fig. 24 is a series of graphs showing viability of various types of cells after treatment with increasing concentrations of JQ1 or dBET6.

Figs. 25A and 25B are Western blots displaying levels of BRD4 and MYCN in NGP cells after 4-hour incubation with increasing concentrations of either JQ1 (Fig. 25A) or dBET6 (Fig. 25B). Fig. 25C is a Western blot showing levels of BRD2, BRD3, BRD4, and MYCN in NGP cells at the indicated time points after incubation with 250 nM dBET6. Fig. 25D is a bar graph showing relative mRNA expression of MYCN in NGP cells at the indicated time points after incubation with 250 nM dBET6, as assessed by RT-PCR.

DETAILED DESCRIPTION

Small-molecule antagonists disable discrete biochemical properties of the protein targets. For multi-domain protein targets, the pharmacologic consequence of drug action is limited by selective disruption of one domain-specific activity. Also, target inhibition is kinetically limited by the durability and degree of the target engagement. These features of traditional drug molecules are challenging to the development of inhibitors targeting transcription factors and chromatin-associated epigenetic proteins, which function as multi-domain biomolecular scaffolds and generally feature rapid association and dissociation kinetics. A chemical strategy was devised to prompt ligand-dependent target protein degradation via chemical conjugation with derivatized phthalimides that hijack the function

of the Cereblon E3 ubiquitin ligase complex. Using this approach, an acetyl-lysine competitive antagonist that displaces BET bromodomains from chromatin (JQ1) was converted to a phthalimide-conjugated ligand that prompts immediate Cereblon-dependent BET protein degradation (dBET1). Expression proteomics confirmed high specificity for BET family members BRD2, BRD3 and BRD4 among 7429 proteins detected. Degradation of BET bromodomains is associated with a more rapid and robust apoptotic response compared to bromodomain inhibition in primary human leukemic blasts and in human leukemia xenograft *in vivo*. Following this approach, additional series of phthalimide-conjugated ligands targeting other proteins for degradation, such as FKBP12, were also developed. A facile new strategy to control the stability of target proteins, including previously intractable protein targets, is described herein.

As discussed above, there remains a need for the development of novel therapies for the treatment of various disorders, including oncologic and immunologic disorders. The present application provides novel compounds of general Formula I, which induce formation of a complex between two proteins to result in a desired biological effect. These compounds can be prepared by using traditional synthetic methods and used by means of addition to a subject as drugs.

The present application provides a novel class of compounds useful for the treatment of cancer and other proliferative conditions.

The present application relates to small molecule E3 ligase ligands (Degrons) which are covalently linked to a targeted protein ligand through a Linker of varying length and functionality, which can be used as therapeutics for treating various diseases including cancer. The present application also relates to a technology platform of bringing targeted proteins to E3 ligases, for example CRBN, for ubiquitination and subsequent proteasomal degradation using the bifunctional small molecules comprising a thalidomide-like Degron and a Targeting Ligand connected to each other via a Linker.

This technology platform provides therapies based upon depression of target protein levels by degradation. The novel technology allows for targeted degradation to occur in a more general nature than existing methods with respect to possible targets and different cell lines or different *in vivo* systems.

Compounds of the present application may offer important clinical benefits to patients, in particular for the treatment of the disease states and conditions modulated by the proteins of interest.

Compounds of the Application


The present application relates to bifunctional compounds which find utility as modulators of ubiquitination and proteosomal degradation of targeted proteins, especially compounds comprising an inhibitor of a polypeptide or a protein that is degraded and/or otherwise inhibited by the bifunctional compounds of the present application. In particular, the present application is directed to compounds which contain a ligand, *e.g.*, a small molecule ligand (*i.e.*, having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), such as a thalidomide-like ligand, which is capable of binding to a ubiquitin ligase, such as cereblon, and a moiety that is capable of binding to a target protein, in such a way that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and/or inhibition) of that protein.

In general, the present application provides compounds having the general structure:

Degron–Linker–Targeting Ligand,

wherein the Linker is covalently bound to at least one Degron and at least one Targeting Ligand, the Degron is a compound capable of binding to a ubiquitin ligase such as an E3 Ubiquitin Ligase (*e.g.*, cereblon), and the Targeting Ligand is capable of binding to the targeted protein(s).

In certain embodiments, the present application provides a compound of Formula X0:




or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof,

wherein:

the Linker is a group that covalently binds to the Targeting Ligand and Y; and


the Targeting Ligand is capable of binding to or binds to a targeted protein;



and wherein a , b , Y, R_1 , R_3 , R_3' , R_4 , R_5 , t , m and n are each as defined herein.

In certain embodiments, the present application provides a compound of Formula


X0':



or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof,
wherein:



the Linker is a group that covalently binds to the Targeting Ligand and Y; and

5 the Targeting Ligand is capable of binding to or binds to a targeted protein;



and wherein A , Y, R_1 , R_3 , R_3' , R_4 , R_5 , m and n are each as defined herein.


In certain embodiments, the present application provides a compound of Formula X or XI:



or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof,
wherein:


the Linker is a group that covalently binds to the Targeting Ligand and Y; and

the Targeting Ligand is capable of binding to or binds to a targeted protein;




15 and wherein A , Y, R_1 , R_3 , R_3' , R_4 , R_5 , m and n are each as defined herein.


In certain embodiments, the present application provides a compound of Formula I, III, or X0'I:



(I),



(III), or



(X0'I),

or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof,

5 wherein:


the Linker is a group that covalently binds to the Targeting Ligand and Y; and

the Targeting Ligand is capable of binding to or binds to a targeted protein;


and wherein X, Y, R₁, R₃, R₃', R₄, R₅, m and n are each as defined herein.

In certain embodiments, the present application provides a compound of Formula II,


10 IV, or X0'II:



(II),



(IV), or



(X0'II),

or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:

the Linker is a group that covalently binds to the Targeting Ligand and Y; and


the Targeting Ligand is capable of binding to or binds to a targeted protein;

5 and wherein X_1 , X_2 , Y, R_1 , R_3 , R_3' , R_4 , R_5 , m and n are each as defined herein.


Degron

The Degron is a compound that serves to link a targeted protein, through the Linker and Targeting Ligand, to a ubiquitin ligase for proteosomal degradation. In certain
embodiments, the Degron is a compound that is capable of binding to or binds to a ubiquitin
10 ligase. In further embodiments, the Degron is a compound that is capable of binding to or
binds to a E3 Ubiquitin Ligase. In further embodiments, the Degron is a compound that is
capable of binding to or binds to cereblon. In further embodiments, the Degron is a
thalidomide or a derivative or analog thereof.

In certain embodiments, the Degron is a compound having Formula D0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein:



20 Y is a bond, Y_1 , O, NH, NR_2 , $C(O)O$, $OC(O)$, $C(O)NR_2'$, $NR_2'C(O)$, Y_1-O , Y_1-NH , Y_1-NR_2 , $Y_1-C(O)$, $Y_1-C(O)O$, $Y_1-OC(O)$, $Y_1-C(O)NR_2'$, or $Y_1-NR_2'C(O)$, wherein Y_1 is C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or C_2 - C_6 alkynylene;

X is $C(O)$ or $C(R_3)_2$;

X_1-X_2 is $C(R_3)=N$ or $C(R_3)_2-C(R_3)_2$;

each R_1 is independently halogen, nitro, NH_2 , OH, $C(O)OH$, C_1 - C_6 alkyl, or C_1 - C_6 alkoxy;

25 R_2 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_3 - C_8 cycloalkyl, 3- to 8-membered heterocycloalkyl, $C(O)$ - C_1 - C_6 alkyl, $C(O)$ - C_2 - C_6 alkenyl, $C(O)$ - C_3 - C_8 cycloalkyl, or $C(O)$ -3- to 8-membered heterocycloalkyl, and R_2 is optionally substituted with one or more of halogen, $N(R_a)_2$, $NHC(O)R_a$, $NHC(O)OR_a$, OR_b , C_3 - C_8 cycloalkyl, 3- to 8-membered

heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

5 R₂' is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, or 3- to 8-membered heterocycloalkyl, and R₂', when not being H, is optionally substituted with one or more of halogen, N(R_a)₂, NHC(O)R_a, NHC(O)OR_a, OR_b, C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl
10 is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

each R₃ is independently H or C₁-C₃ alkyl optionally substituted with C₆-C₁₀ aryl or 5- to 10-membered heteroaryl;

each R₃' is independently C₁-C₃ alkyl;

15 each R₄ is independently H or C₁-C₃ alkyl; or two R₄, together with the carbon atom to which they are attached, form C(O), a C₃-C₆ carbocycle, or a 4-, 5-, or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from N and O;

R₅ is H, C₁-C₃ alkyl, F, or Cl;

each R_a independently is H or C₁-C₆ alkyl;

20 R_b is H or tosyl;

t is 0 or 1;


m is 0, 1, 2 or 3; and

n is 0, 1 or 2;


wherein the compound is covalently bonded to another moiety (*e.g.*, a compound, or a

25 Linker) via $\text{---}\overset{\text{S}}{\underset{\text{S}}{\text{---}}}\text{---}$.

In certain embodiments, the Degron is a compound having Formula D0':




or an enantiomer, diastereomer, or stereoisomer thereof, wherein




R_4 , R_5 , m and n are each as defined above in Formula D0.

The compound of formula D0 or D0', or an enantiomer, diastereomer, or stereoisomer thereof can have one or more of the following features when applicable.


5 In certain embodiments, the Degron is a compound having Formula D:




In certain embodiments, the Degron is a compound having Formula D':



In certain embodiments,



10 In certain embodiments,



In certain embodiments, X is C(O).

In certain embodiments, X is C(R₃)₂; and each R₃ is H. In certain embodiments, X is C(R₃)₂; and one of R₃ is H, and the other is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In certain embodiments, X is C(R₃)₂; and each R₃ is independently selected from

15 methyl, ethyl, and propyl. In certain embodiments, X₁-X₂ is C(R₃)=N. In certain embodiments, X₁-X₂ is CH=N. In certain embodiments, X₁-X₂ is C(R₃)=N; and R₃ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In certain embodiments, X₁-X₂ is C(CH₃)=N.

In certain embodiments, X₁-X₂ is C(R₃)₂-C(R₃)₂; and each R₃ is H. In certain

20 embodiments, X₁-X₂ is C(R₃)₂-C(R₃)₂; and one of R₃ is H, and the other three R₃ are independently C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In certain embodiments,

X_1-X_2 is $C(R_3)_2-C(R_3)_2$; and two of the R_3 are H, and the other two R_3 are independently C_1-C_3 alkyl selected from methyl, ethyl, and propyl. In certain embodiments, X_1-X_2 is $C(R_3)_2-C(R_3)_2$; and three of the R_3 are H, and the remaining R_3 is C_1-C_3 alkyl selected from methyl, ethyl, and propyl.

5 In certain embodiments, Y is a bond.

In certain embodiments, Y is a linear or branched C_1-C_6 alkylene. For example, Y is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. In certain embodiments, Y is $(CH_2)_1$, $(CH_2)_2$, or $(CH_2)_3$. In certain embodiments, Y is $(CH_2)_1$ or $(CH_2)_2$.

10 In certain embodiments, Y is O.

In certain embodiments, Y is Y_1-O with either Y_1 or O being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is CH_2-O , $(CH_2)_2-O$, $(CH_2)_3-O$, $(CH_2)_4-O$, $(CH_2)_5-O$, or $(CH_2)_6-O$. In certain embodiments, Y is CH_2-O , $(CH_2)_2-O$, or $(CH_2)_3-O$. In certain
15 embodiments, Y is CH_2-O .

In certain embodiments, Y is $C(O)$.

In certain embodiments, Y is $C(O)O$ with either O or $C(O)$ being proximal to the phenyl ring to which Y is connected.

20 In certain embodiments, Y is $Y_1-C(O)$ with either Y_1 or $C(O)$ being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is $(CH_2)_{1-6}-C(O)$.

In certain embodiments, Y is $Y_1-(CO)O$ with either Y_1 or O being proximal to the
25 phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is $(CH_2)_{1-6}-C(O)O$.

In certain embodiments, Y is $Y_1-OC(O)$ with either Y_1 or $C(O)$ being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene.
30 For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is $(CH_2)_{1-6}-OC(O)$.

In certain embodiments, Y is $C(O)NR_2'$.

In certain embodiments, Y is $Y_1-C(O)NR_2'$ with either Y_1 or NR_2' being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6

alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is $CH_2-C(O)NR_2'$, $(CH_2)_2-C(O)NR_2'$, $(CH_2)_3-C(O)NR_2'$, $(CH_2)_4-C(O)NR_2'$, $(CH_2)_5-C(O)NR_2'$, or $(CH_2)_6-C(O)NR_2'$. In certain embodiments, Y is $CH_2-C(O)NR_2'$, $(CH_2)_2-C(O)NR_2'$, or $(CH_2)_3-C(O)NR_2'$. In certain embodiments, Y is $CH_2-C(O)NR_2'$.

In certain embodiments, Y is $NR_2'C(O)$.

In certain embodiments, Y is $Y_1-NR_2'C(O)$ with either Y_1 or $C(O)$ being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is $CH_2-NR_2'C(O)$, $(CH_2)_2-NR_2'C(O)$, $(CH_2)_3-NR_2'C(O)$, $(CH_2)_4-NR_2'C(O)$, $(CH_2)_5-NR_2'C(O)$, or $(CH_2)_6-NR_2'C(O)$. In certain embodiments, Y is $CH_2-NR_2'C(O)$, $(CH_2)_2-NR_2'C(O)$, or $(CH_2)_3-NR_2'C(O)$. In certain embodiments, Y is $CH_2-NR_2'C(O)$.

In certain embodiments, R_2' is H. In certain embodiments, R_2' is selected from methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In certain embodiments, R_2' is C_1-C_3 alkyl selected from methyl, ethyl, and propyl.

In certain embodiments, R_2' is C_1-C_6 alkyl substituted with one or more of halogen, $N(R_a)_2$, $NHC(O)R_a$, $NHC(O)OR_a$, OR_b , 3- to 8-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, wherein each of the 3- to 8-membered heterocycloalkyl, C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally further substituted with one or more of halogen, NH_2 , CN, nitro, OH, $C(O)OH$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, or C_1-C_6 haloalkoxy.

In certain embodiments, R_2' is C_2-C_6 alkenyl.

In certain embodiments, Y is NH.

In certain embodiments, Y is Y_1-NH with either Y_1 or NH being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$, $(CH_2)_4$, $(CH_2)_5$, or $(CH_2)_6$. For example, Y is CH_2-NH , $(CH_2)_2-NH$, $(CH_2)_3-NH$, $(CH_2)_4-NH$, $(CH_2)_5-NH$, or $(CH_2)_6-NH$. In certain embodiments, Y is CH_2-NH , $(CH_2)_2-NH$, or $(CH_2)_3-NH$. In certain embodiments, Y is CH_2-NH .

In certain embodiments, Y is NR_2 .

In certain embodiments, Y is Y_1-NR_2 with either Y_1 or NR_2 being proximal to the phenyl ring to which Y is connected. For example, Y_1 is a linear or branched C_1-C_6 alkylene. For example, Y_1 is $(CH_2)_1$, $CH(CH_3)$, $C(CH_3)_2$, $(CH_2)_2$, $(CH_2)_3$, $CH_2CH(CH_3)$, $CH_2C(CH_3)_2$,

(CH₂)₄, (CH₂)₅, or (CH₂)₆. For example, Y is CH₂-NR₂, (CH₂)₂-NR₂, (CH₂)₃-NR₂, (CH₂)₄-NR₂, (CH₂)₅-NR₂, or (CH₂)₆-NR₂. In certain embodiments, Y is CH₂-NR₂, (CH₂)₂-NR₂, or (CH₂)₃-NR₂. In certain embodiments, Y is CH₂-NR₂.

In certain embodiments, R₂ is selected from methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In certain embodiments, R₂ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In certain embodiments, R₂ is C₁-C₆ alkyl substituted with one or more of halogen, OH or OR_b. For example, R₂ is CH₂CHF₂, CH₂CH₂CHF₂, CF₃, CH₂CF₃, CH₂CH₂CF₃, CH₂CH₂OH, CH₂CH₂O-tosyl, or CH(OH)CH₂OH.

In certain embodiments, R₂ is C₁-C₆ alkyl substituted with one or more of N(R_a)₂, NHC(O)R_a, or NHC(O)OR_a. For example, R₂ is CH₂CH₂NH₂ or CH₂CH₂NHC(O)O-t-butyl.

In certain embodiments, R₂ is C₁-C₆ alkyl substituted with 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. For example, R₂ is C₁-C₆ alkyl substituted with 3- to 8-membered heterocycloalkyl (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine) which is optionally further substituted with one or more C₁-C₆ alkyl. For example, R₂ is CH₂-oxirane, CH₂CH₂-piperazine or CH₂CH₂-4-methylpiperazine. For example, R₂ is C₁-C₆ alkyl substituted with phenyl or 5- to 10-membered heteroaryl (e.g., pyridyl, indolyl, furyl, or imidazolyl), each of which is optionally further substituted with one or more substituent selected from halogen, NH₂, CN, nitro, OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkoxy.

In certain embodiments, R₂ is C₂-C₆ alkenyl, such as ethenyl, propenyl, and butenyl.

In certain embodiments, R₂ is C₃-C₈ cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. In certain embodiments, cyclopentyl, cyclohexyl or cycloheptyl.

In certain embodiments, R₂ is 3- to 8-membered heterocycloalkyl (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine). In certain embodiments, R₂ is oxetane.

In certain embodiments, R₂ is selected from C(O)-methyl, C(O)-ethyl, C(O)-propyl, C(O)-butyl, C(O)-i-butyl, C(O)-t-butyl, C(O)-pentyl, C(O)-i-pentyl, and C(O)-hexyl. In certain embodiments, R₂ is C(O)-C₁-C₃ alkyl selected from C(O)-methyl, C(O)-ethyl, and

C(O)-propyl. In certain embodiments, R₂ is C(O)-C₁-C₃ alkyl substituted with one or more of halogen (e.g., C(O)-CH₂Cl).

In certain embodiments, R₂ is C(O)-C₂-C₆ alkenyl, such as C(O)-ethenyl.

In certain embodiments, R₂ is selected from C(O)-cyclopropyl, C(O)-cyclobutyl, 5 C(O)-cyclopentyl, C(O)-cyclohexyl and C(O)-cycloheptyl. In certain embodiments, R₂ is C(O)-cyclopropyl. In certain embodiments, R₂ is C(O)-cyclopentyl, C(O)-cyclohexyl or C(O)-cycloheptyl.

In certain embodiments, R₂ is C(O)-3- to 8-membered heterocycloalkyl (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine). In 10 certain embodiments, R₂ is C(O)- oxirane.

In certain embodiments, R₃ is H.

In certain embodiments, R₃ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In certain embodiments, R₃ is methyl.

In certain embodiments, R₃ is C₁-C₃ alkyl substituted with phenyl or 5- to 6- 15 membered heteroaryl. In certain embodiments, R₃ is benzyl.

In certain embodiments, n is 0.

In certain embodiments, n is 1.

In certain embodiments, n is 2.

In certain embodiments, each R₃' is independently C₁-C₃ alkyl selected from methyl, 20 ethyl, and propyl.

In certain embodiments, m is 0.

In certain embodiments, m is 1.

In certain embodiments, m is 2.

In certain embodiments, m is 3.

25 In certain embodiments, each R₁ is independently selected from halogen (e.g., F, Cl, Br, and I), OH, C₁-C₆ alkyl (e.g., methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl), and C₁-C₆ alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, i-butoxy, t-butoxy, and pentoxy). In further embodiments, each R₁ is independently selected from F, Cl, OH, methyl, ethyl, propyl, butyl, i-butyl, t-butyl, methoxy, and ethoxy.

30 In certain embodiments, each R₄ is H.

In certain embodiments, one of R₄ is H, and the other R₄ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In certain embodiments, each R₄ is independently C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In certain embodiments, two R₄, together with the carbon atom to which they are attached, form C(O).

In certain embodiments, two R₄, together with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

5 In certain embodiments, two R₄, together with the carbon atom to which they are attached, form a 4-, 5-, or 6-membered heterocycle selected from oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, and morpholine. In certain embodiments, two R₄, together with the carbon atom to which they are attached, form oxetane.

10 In certain embodiments, R₅ is H, deuterium, or C₁-C₃ alkyl. In further embodiments, R₅ is in the (*S*) or (*R*) configuration. In further embodiments, R₅ is in the (*S*) configuration. In certain embodiments, the compound comprises a racemic mixture of (*S*)-R₅ and (*R*)-R₅.


In certain embodiments, R₅ is H.

In certain embodiments, R₅ is deuterium.


15 In certain embodiments, R₅ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In certain embodiments, R₅ is methyl.

In certain embodiments, R₅ is F or Cl. In further embodiments, R₅ is in the (*S*) or (*R*) configuration. In further embodiments, R₅ is in the (*R*) configuration. In certain embodiments, the compound comprises a racemic mixture of (*S*)-R₅ and (*R*)-R₅. In certain

20 embodiments, R₅ is F.




Each of the moieties defined for one of X, X₁, X₂, Y, Y₁, R₁, R₂, R₂', R₃, R₃', R₄, R₅, t, m, and n, can be combined with any of the moieties defined for the others of



X, X₁, X₂, Y, Y₁, R₁, R₂, R₂', R₃, R₃', R₄, R₅, t, m, and n.


In certain embodiments, the Degron is a compound having Formula D1 or D'1:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein X, Y, R₁, R₃, R_{3'}, R₄, R₅, m, and n are each as defined above in Formula D0.


- 5 Each of X, Y, R₁, R₃, R_{3'}, R₄, R₅, m, and n can be selected from the moieties described above in Formula D0. Each of the moieties defined for one of X, Y, R₁, R₃, R_{3'}, R₄, R₅, m, and n, can be combined with any of the moieties defined for the others of X, Y, R₁, R₃, R_{3'}, R₄, R₅, m, and n, as described above in Formula D0.

In certain embodiments, the Degron is a compound of Formula D0'III:




10 or an enantiomer, diastereomer, or stereoisomer thereof, wherein each of R₁, R_{3'}, Y, m and n is as defined above and can be selected from any moieties or combinations thereof described above.

In certain embodiments, the Degron is a compound of Formula D2:




15 or an enantiomer, diastereomer, or stereoisomer thereof, wherein each of R₁, R_{3'}, m and n is as defined above and can be selected from any moieties or combinations thereof described above.

In certain embodiments, the Degron is a compound of the following structure:



or an enantiomer, diastereomer, or stereoisomer thereof.

In certain embodiments, the Degron is a compound of Formula D3 or D'3:





5 or an enantiomer, diastereomer, or stereoisomer thereof, wherein X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, m, and n are each as defined above in Formula D0.


Each of X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, m, and n can be selected from the moieties described above in Formula D0. Each of the moieties defined for one of X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, m, and n, can be combined with any of the moieties defined for the others of X₁, X₂, Y, R₁, R₃, R₃', R₄, R₅, m, and n, as described above in Formula D0.



In certain embodiments, the Degron is selected from the following in Table D, wherein X is H, deuterium, C₁-C₃ alkyl, or halogen; and R is a Linker.


Table D












In certain embodiments, the Degron is selected from the following in Table D1:


5

Table D1



In certain embodiments, the Degron is selected from the following in Table D2:

Table D2















In certain embodiments, the Degron is selected from the following in Table D3.






5







Table D3






Compound No.	Structure
D-1	
D-2	
D-3	
D-4	
D-5	






Compound No.	Structure
D-6	
D-7	
D-8	
D-9	
D-10	
D-11	







Compound No.	Structure
D-12	
D-13	
D-14	
D-15	
D-16	
D-17	






Compound No.	Structure
D-18	
D-19	
D-20	
D-21	
D-22	






Compound No.	Structure
D-23	
D-24	
D-25	
D-26	
D-27	
D-28	







Compound No.	Structure
D-29	
D-30	
D-31	
D-32	
D-33	








Compound No.	Structure
D-34	
D-35	
D-36	
D-37	
D-38	

Compound No.	Structure
D-39	
D-40	
D-41	
D-42	
D-43	
D-44	

Compound No.	Structure
D-45	
D-46	
D-47	
D-48	
D-49	

Compound No.	Structure
D-50	
D-51	
D-52	
D-53	
D-54	



Compound No.	Structure
D-55	
D-56	
D-57	
D-58	
D-59	
D-60	

Compound No.	Structure
D-61	
D-62	
D-63	
D-64	
D-65	
D-66	
D-67	


Compound No.	Structure
D-68	


In certain embodiments, the Degron is selected from the following in Table D4.

Table D4



, wherein





In certain embodiments, the Degron of the present application is capable of targeting proteins for degradation (*e.g.*, through a ubiquitination pathway), inducing protein degradation, or degrading proteins, without being bound to a Targeting Ligand through a Linker. In certain embodiments, the Degron of the present application is capable of degrading one or more cellular proteins (*e.g.*, IKZF1) after being administered to the cell. In certain embodiments, the Degron of the present application capable of degrading one or more cellular proteins (*e.g.*, IKZF1) is selected from Tables D, D1, D2, D3, and D4. In certain embodiments, the Degron of the present application capable of degrading one or more cellular proteins (*e.g.*, IKZF1) is selected from Table D3. In certain embodiments, the Degron of the present application capable of degrading one or more cellular proteins (*e.g.*, IKZF1) is selected from D-1 to D-5, D-8 to D-11, D-13 to D-19, and D-21 to D-27. In certain embodiments, the Degron of the present application capable of degrading one or more cellular proteins (*e.g.*, IKZF1) is selected from D-3, D-4, D-8, D-9, D-16 to D-19, and D-21 to D-23.

Linker

The Linker is a bond or a carbon chain that serves to link a Targeting Ligand with a Degron. In certain embodiments, the carbon chain optionally comprises one, two, three, or more heteroatoms selected from N, O, and S. In certain embodiments, the carbon chain comprises only saturated chain carbon atoms. In certain embodiments, the carbon chain optionally comprises two or more unsaturated chain carbon atoms (*e.g.*, C=C or C≡C). In certain embodiments, one or more chain carbon atoms in the carbon chain are optionally substituted with one or more substituents (*e.g.*, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆


alkynyl, C₁-C₃ alkoxy, OH, halogen, NH₂, NH(C₁-C₃ alkyl), N(C₁-C₃ alkyl)₂, CN, C₃-C₈ cycloalkyl, heterocyclyl, phenyl, and heteroaryl).

In certain embodiments, the Linker comprises at least 5 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises less than 20 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises 5, 7, 9, 11, 13, 15, 17, or 19 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises 5, 7, 9, or 11 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises 6, 8, 10, 12, 14, 16, or 18 chain atoms (*e.g.*, C, O, N, and S). In certain embodiments, the Linker comprises 6, 8, 10, or 12 chain atoms (*e.g.*, C, O, N, and S).

In certain embodiments, the Linker comprises one or more (*e.g.*, one, two, or three) carbocycles and heterocycles along the chain (*e.g.*, one or more chain atoms being replaced with, *e.g.*, C₃-C₈ cycloalkylene, 3- to 8-membered heterocycloalkylene, C₆-C₁₀ arylene, or 5- to 10- membered heteroarylene, wherein each of the C₃-C₈ cycloalkylene, 3- to 8-membered heterocycloalkylene, C₆-C₁₀ arylene or 5- to 10-membered heteroarylene is optionally substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy).

In certain embodiments, the Linker is a carbon chain optionally substituted with non-bulky substituents (*e.g.*, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₃ alkoxy, OH, halogen, NH₂, NH(C₁-C₃ alkyl), N(C₁-C₃ alkyl)₂, and CN). In certain embodiments, the non-bulky substitution is located on the chain carbon atom proximal to the Degron (*i.e.*, the carbon atom is separated from the carbon atom to which the Degron is bonded by at least 3, 4, or 5 chain atoms in the Linker).

In certain embodiments, the Linker is of Formula L0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein

p1 is an integer selected from 0 to 12;

p2 is an integer selected from 0 to 12;

p3 is an integer selected from 0 to 6;

each W is independently absent, CH₂, O, S, NH or NR₅;

Z is absent, CH₂, O, NH or NR₅;

each R_5 is independently C_1 - C_3 alkyl; and








Q is absent, $-C(O)NH-$, $-C(O)O-$, $-CH_2C(O)NH-$, or $-CH_2C(O)O-$ when p_3 is an integer selected from 1 to 6; or Q is Q_1 , $-C_1$ - C_4 alkylene- Q_2 , or Q_1 - C_1 - C_4 alkylene- Q_2 when p_3 is an integer selected from 0 to 6, wherein each of Q_1 and Q_2 independently is C_3 - C_8 cycloalkylene, 3- to 8-membered heterocycloalkylene, C_6 - C_{10} arylene, or 5- to 10-membered heteroarylene, each of which is optionally substituted with one or more of halogen, NH_2 , CN, nitro, OH, $C(O)OH$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, or C_1 - C_6 haloalkoxy;


wherein the Linker is covalently bonded to the Degron with the $\text{---}\xi\text{---}$ next to Q, and

covalently bonded to the Targeting Ligand with the $\text{---}\xi\text{---}$ next to Z.

10 In certain embodiments, the total number of chain atoms (including all ring atoms when Q is Q_1 or Q_1 - C_1 - C_4 alkylene- Q_2) in the Linker is about 30 or less (e.g., about 20 or less or less than 20).

In certain embodiments, the Linker-Targeting Ligand (TL) has the structure of any of Formulae L1 through L9:





or an enantiomer, diastereomer, or stereoisomer thereof, wherein:

p1 is an integer selected from 0 to 12;

5 p2 is an integer selected from 0 to 12;

p3 is an integer selected from 1 to 6;

each W is independently absent, CH₂, O, S, NH or NR₅;

Z is absent, CH₂, O, NH or NR₅;

each R₅ is independently C₁-C₃ alkyl;

10 each of Q₁ and Q₂ independently is C₃-C₈ cycloalkylene, 3- to 8-membered

heterocycloalkylene, C₆-C₁₀ arylene or 5- to 10-membered heteroarylene, each of which is optionally substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy; and

TL is a Targeting Ligand,

15 wherein the Linker is covalently bonded to the Degron with $\text{---}\text{---}\text{---}$.

In certain embodiments, p1 is an integer selected from 0 to 10.

In certain embodiments, p1 is an integer selected from 2 to 10.

In certain embodiments, p1 is selected from 1, 2, 3, 4, 5, and 6.

In certain embodiments, p1 is selected from 1, 3, and 5.

20 In certain embodiments, p1 is selected from 1, 2, and 3.

In certain embodiments, p1 is 3.

In certain embodiments, p2 is an integer selected from 0 to 10.

In certain embodiments, p2 is selected from 0, 1, 2, 3, 4, 5, and 6.

In certain embodiments, p2 is an integer selected from 0 and 1.

25 In certain embodiments, p3 is an integer selected from 1 to 5.

In certain embodiments, p3 is selected from 2, 3, 4, and 5.

In certain embodiments, p3 is selected from 1, 2, and 3.

In certain embodiments, p3 is selected from 2 and 3.

In certain embodiments, at least one W is CH₂.

30 In certain embodiments, at least one W is O.

In certain embodiments, at least one W is S.

In certain embodiments, at least one W is NH.

In certain embodiments, at least one W is NR₅; and R₅ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

5 In certain embodiments, W is O.

In certain embodiments, Z is absent.

In certain embodiments, Z is CH₂.

In certain embodiments, Z is O.

In certain embodiments, Z is NH.

10 In certain embodiments, Z is NR₅; and R₅ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In certain embodiments, Z is part of the Targeting Ligand that is bonded to the Linker, namely, Z is formed from reacting a functional group of the Targeting Ligand with the Linker.

15 In certain embodiments, W is CH₂, and Z is CH₂.

In certain embodiments, W is O, and Z is CH₂.

In certain embodiments, W is CH₂, and Z is O.

In certain embodiments, W is O, and Z is O.

In certain embodiments, Q₁ is C₃-C₈ cycloalkylene, 3- to 8-membered
 20 heterocycloalkylene (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine), C₆-C₁₀ arylene (e.g., phenyl) or 5- to 10-membered heteroarylene (e.g., pyridyl, indolyl, furyl, or imidazolyl), each of which is optionally substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. For example, Q₁ is 3- to 8-membered
 25 heterocycloalkylene (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine) which is optionally substituted with one or more C₁-C₆ alkyl. For example, Q₁ is piperazine or 4-methylpiperazine. For example, Q₁ is phenyl or 5- to 10-membered heteroaryl (e.g., pyridyl, indolyl, furyl, or imidazolyl), each of which is optionally substituted with one or more substituent selected from halogen, NH₂, CN, nitro,
 30 OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkoxy.


In certain embodiments, Q₂ is C₃-C₈ cycloalkylene, 3- to 8-membered heterocycloalkylene (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine), C₆-C₁₀ arylene (e.g., phenyl) or 5- to 10-membered heteroarylene (e.g., pyridyl, indolyl, furyl, or imidazolyl), each of which is optionally

substituted with one or more of halogen, NH_2 , CN, nitro, OH, $\text{C}(\text{O})\text{OH}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ alkoxy, or $\text{C}_1\text{-C}_6$ haloalkoxy. For example, Q_2 is 3- to 8-membered heterocycloalkylene (e.g., oxirane, oxetane, azetidine, tetrahydrofuran, pyrrolidine, piperidine, piperazine, or morpholine) which is optionally substituted with one or more $\text{C}_1\text{-C}_6$ alkyl. For example, Q_2 is piperazine or 4-methylpiperazine. For example, Q_2 is phenyl or 5- to 10-membered heteroaryl (e.g., pyridyl, indolyl, furyl, or imidazolyl), each of which is optionally substituted with one or more substituent selected from halogen, NH_2 , CN, nitro, OH, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, and $\text{C}_1\text{-C}_6$ alkoxy.

In certain embodiments, Q_1 is optionally substituted phenyl and Q_2 is optionally substituted 5- to 6-membered heterocycloalkylene or 5- to 10-membered heteroaryl. In certain embodiments, Q_2 is optionally substituted phenyl and Q_1 is optionally substituted 5- to 6-membered heterocycloalkylene or 5- to 10-membered heteroaryl.

In certain embodiments, the Linker-Targeting Ligand has the structure selected from Table L:







Table L



wherein Z, TL, p1, p2, and p3 are each as described above, and R₆ is O, CHR_c, CH, N, or NR_c, R_c being H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

Any one of the Degrons described herein can be covalently bound to any one of the Linkers described herein.


- 5 In certain embodiments, the present application relates to the Degron-Linker (DL) having the following structure:




wherein each of the variables is as described above in Formula D0 and Formula L0, and a

Targeting Ligand is covalently bonded to the DL with the  next to Z.


In certain embodiments, the present application relates to the Degron-Linker (DL) having the following structure:



(DLa1),



(DLa2), or




(DLa3),

wherein each of the variables is as described above in Formula D0 and Formula L0, and a

Targeting Ligand is covalently bonded to the DL with the  next to Z.

In certain embodiments, the present application relates to the Degron-Linker (DL) intermediates having the following structure:




(DLa1A)

or an enantiomer, diastereomer, or stereoisomer thereof,

wherein p is 1-19 and X and R1 are as described above.

In certain embodiments, the DLs have the following structure:




(DLa2A)


or an enantiomer, diastereomer, or stereoisomer thereof,

wherein p is 1-19.


In certain embodiments, the DL intermediate has the following structure:




(DL1),




(DL2),




(DL3),




(DL4),



(DL5),




(DL6); or




(DL7).

Some embodiments of the present application relate to a bifunctional compound having the following structure:




- 5 or an enantiomer, diastereomer, or stereoisomer thereof, wherein each of the variables is as described above in Formula D0 and Formula L0, and the Targeting Ligand is described herein below.

Further embodiments of the present application relate to a bifunctional compound having the following structure:




10




or an enantiomer, diastereomer, or stereoisomer thereof, wherein each of the variables is as described above in Formula D0 and Formula L0, and the Targeting Ligand is described herein below.


- 5 Certain embodiments of the present application relate to bifunctional compounds having one of the following structures:




(DL1-TL),




(DL2-TL),




(DL3-TL),



(DL4-TL),




(DL5-TL),



(DL6-TL), or

10



In certain embodiments, the Linker may be a polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units,
 5 between about 2 and 4 ethylene glycol units.

In certain embodiments, the Linker is designed and optimized based on SAR (structure-activity relationship) and X-ray crystallography of the Targeting Ligand with regard to the location of attachment for the Linker.

In certain embodiments, the optimal Linker length and composition vary by target and
 10 can be estimated based upon X-ray structures of the original Targeting Ligand bound to its target. Linker length and composition can be also modified to modulate metabolic stability and pharmacokinetic (PK) and pharmacodynamics (PD) parameters.

In certain embodiments, where the Target Ligand binds multiple targets, selectivity may be achieved by varying Linker length where the ligand binds some of its targets in
 15 different binding pockets, *e.g.*, deeper or shallower binding pockets than others.

Targeting Ligand

Targeting Ligand (TL) (or target protein moiety or target protein ligand or ligand) is a small molecule which is capable of binding to or binds to a target protein of interest.

20 Some embodiments of the present application relate to TLs which include but are not limited to Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, compounds targeting cytosolic signaling protein FKBP12, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon
 25 receptor (AHR).

In certain embodiments, the Targeting Ligand is a compound that is capable of binding to or binds to a kinase, a BET bromodomain-containing protein, a cytosolic signaling protein (*e.g.*, FKBP12), a nuclear protein, a histone deacetylase, a lysine methyltransferase, a protein regulating angiogenesis, a protein regulating immune response, an aryl hydrocarbon
 30 receptor (AHR), an estrogen receptor, an androgen receptor, a glucocorticoid receptor, or a transcription factor (*e.g.*, SMARCA4, SMARCA2, TRIM24).

In certain embodiments, a kinase to which the Targeting Ligand is capable of binding or binds includes, but is not limited to, a tyrosine kinase (*e.g.*, AATK, ABL, ABL2, ALK, AXL, BLK, BMX, BTK, CSF1R, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, 5 EPHB6, ERBB2, ERBB3, ERBB4, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN, GSG2, HCK, IGF1R, ILK, INSR, INSR, IRAK4, ITK, JAK1, JAK2, JAK3, KDR, KIT, KSR1, LCK, LMTK2, LMTK3, LTK, LYN, MATK, MERTK, MET, MLTK, MST1R, MUSK, NPR1, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PLK4, PTK2, PTK2B, PTK6, PTK7, RET, ROR1, ROR2, ROS1, RYK, SGK493, 10 SRC, SRMS, STYK1, SYK, TEC, TEK, TEX14, TIE1, TNK1, TNK2, TNNI3K, TXK, TYK2, TYRO3, YES1, or ZAP70), a serine/threonine kinase (*e.g.*, casein kinase 2, protein kinase A, protein kinase B, protein kinase C, Raf kinases, CaM kinases, AKT1, AKT2, AKT3, ALK1, ALK2, ALK3, ALK4, Aurora A, Aurora B, Aurora C, CHK1, CHK2, CLK1, CLK2, CLK3, DAPK1, DAPK2, DAPK3, DMPK, ERK1, ERK2, ERK5, GCK, GSK3, 15 HIPK, KHS1, LKB1, LOK, MAPKAPK2, MAPKAPK, MNK1, MSSK1, MST1, MST2, MST4, NDR, NEK2, NEK3, NEK6, NEK7, NEK9, NEK11, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PIM1, PIM2, PLK1, RIP2, RIP5, RSK1, RSK2, SGK2, SGK3, SIK1, STK33, TAO1, TAO2, TGF-beta, TLK2, TSSK1, TSSK2, ULK1, or ULK2), a cyclin dependent kinase (*e.g.*, Cdk1 – Cdk11), and a leucine-rich repeat kinase (*e.g.*, LRRK2).


20 In certain embodiments, a BET bromodomain-containing protein to which the Targeting Ligand is capable of binding or binds includes, but is not limited to, BRD1, BRD2, BRD3, BRD4, BRD5, BRD6, BRD7, BRD8, BRD9, BRD10, and BRDT. In certain embodiments, a BET bromodomain-containing protein is BRD4.

25 In certain embodiments, a nuclear protein to which the Targeting Ligand is capable of binding or binds includes, but is not limited to, BRD2, BRD3, BRD4, Antennapedia Homeodomain Protein, BRCA1, BRCA2, CCAAT-Enhanced-Binding Proteins, histones, Polycomb-group proteins, High Mobility Group Proteins, Telomere Binding Proteins, FANCA, FANCD2, FANCE, FANCF, hepatocyte nuclear factors, Mad2, NF-kappa B, Nuclear Receptor Coactivators, CREB-binding protein, p55, p107, p130, Rb proteins, p53, c- 30 fos, c-jun, c-mdm2, c-myc, and c-rel.

In certain embodiments, the Targeting Ligand is selected from a kinase inhibitor, a BET bromodomain-containing protein inhibitor, cytosolic signaling protein FKBP12 ligand, an HDAC inhibitor, a lysine methyltransferase inhibitor, an angiogenesis inhibitor, an immunosuppressive compound, and an aryl hydrocarbon receptor (AHR) inhibitor.


Non-limiting examples of TLs are shown in below and represent Targeting Ligands of certain types of proteins of interest.



BRD Targeting Ligand



R: Degron-Linker; R': methyl or ethyl





CREBBP Targeting Ligand









R: Degron-Linker; X: N or CH; n: 0-8



SMARCA4/PB1/SMARCA2 Targeting Ligand



R: Degron-Linker; X: N or CH; n: 0-8








TRIM24/BRPF1 Targeting Ligand







R: Degron-Linker; n: 0-8










Glucocorticoid receptor Targeting Ligand








R: Degron-Linker

Estrogen/Androgen Receptor Targeting Ligand






R: Degron-Linker

DOT1L Targeting Ligand




R: Degron-Linker; X: N or CH; n: 0-8






BRAF Targeting Ligand



R: Degron-Linker







Ras Targeting Ligand







R: Degron-Linker





RasG12C Targeting Ligand





R: Degron-Linker

Her3 Targeting Ligand



R: Degron-Linker; R': or








Bcl-2/Bcl-XL Targeting Ligand

R: Degron-Linker	
HDAC Targeting Ligand	
R: Degron-Linker	
PPAR-gamma Targeting Ligand	
R: Degron-Linker	


In certain embodiments, the present application relates to the compounds containing the TL moieties shown in Table 1.

Table 1. Targeting Ligands 1-6


Compound	Structure	Compound	Structure

TL1	 Ang. Chem. Int'l. Ed. 50, 9378 (2011)	TL3	
TL2		TL4	
TL5	 JACS 115, 9925 (1993)	TL6	
TL7			

In certain embodiments, a Targeting Ligand is a compound of Formula TL-I:



or a pharmaceutically acceptable salt thereof, wherein:



A₁ is S or C=C;

A₂ is NR₅ or O;

nn1 is 0, 1, or 2;

each Ra_1 is independently C_1 - C_3 alkyl, $(CH_2)_{0-3}$ -CN, $(CH_2)_{0-3}$ -halogen, $(CH_2)_{0-3}$ -OH, $(CH_2)_{0-3}$ - C_1 - C_3 alkoxy, $C(O)NRa_5L$, OL , NRa_5L , or L ;

Ra_2 is H, C_1 - C_6 alkyl, $(CH_2)_{0-3}$ -heterocyclyl, $(CH_2)_{0-3}$ -phenyl, or L , wherein the heterocyclyl comprises one saturated 5- or 6-membered ring and 1-2 heteroatoms selected from N, O, and S and is optionally substituted with C_1 - C_3 alkyl, L , or $C(O)L$, and wherein the phenyl is optionally substituted with C_1 - C_3 alkyl, CN, halogen, OH, C_1 - C_3 alkoxy, or L ;

nn_2 is 0, 1, 2, or 3;



each Ra_3 is independently C_1 - C_3 alkyl, $(CH_2)_{0-3}$ -CN, $(CH_2)_{0-3}$ -halogen, L , or $C(O)NRa_5L$;

Ra_4 is C_1 - C_3 alkyl;

Ra_5 is H or C_1 - C_3 alkyl; and

L is a Linker,

provided that the compound of Formula TL-I is substituted with only one L .



In certain embodiments, A_1 is S.

In certain embodiments, A_1 is $C=C$.

In certain embodiments, A_2 is NRa_5 . In further embodiments, Ra_5 is H. In other embodiments, Ra_5 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, Ra_5 is methyl.

In certain embodiments, A_2 is O.

In certain embodiments, nn_1 is 0.

In certain embodiments, nn_1 is 1.

In certain embodiments, nn_1 is 2.

In certain embodiments, at least one Ra_1 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, at least one Ra_1 is methyl. In further embodiments, two Ra_1 are methyl.

In certain embodiments, at least one Ra_1 is CN, (CH_2) -CN, $(CH_2)_2$ -CN, or $(CH_2)_3$ -CN. In further embodiments, at least one Ra_1 is (CH_2) -CN.

In certain embodiments, at least one R_{a1} is halogen (*e.g.*, F, Cl, or Br), (CH_2) -halogen, $(CH_2)_2$ -halogen, or $(CH_2)_3$ -halogen. In further embodiments, at least one R_{a1} is Cl, (CH_2) -Cl, $(CH_2)_2$ -Cl, or $(CH_2)_3$ -Cl.

5 In certain embodiments, at least one R_{a1} is OH, (CH_2) -OH, $(CH_2)_2$ -OH, or $(CH_2)_3$ -OH.

In certain embodiments, at least one R_{a1} is C_1 - C_3 alkoxy (*e.g.*, methoxy, ethoxy, or propoxy), (CH_2) - C_1 - C_3 alkoxy, $(CH_2)_2$ - C_1 - C_3 alkoxy, or $(CH_2)_3$ - C_1 - C_3 alkoxy. In certain embodiments, at least one R_{a1} is methoxy.

10 In certain embodiments, one R_{a1} is $C(O)NR_{a5}L$. In further embodiments, R_{a5} is H. In other embodiments, R_{a5} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In certain embodiments, one R_{a1} is OL.

In certain embodiments, one R_{a1} is $NR_{a5}L$. In further embodiments, R_{a5} is H. In other embodiments, R_{a5} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In other embodiments, R_{a5} is methyl.

15 In certain embodiments, one R_{a1} is L.

In certain embodiments, R_{a2} is H.

In certain embodiments, R_{a2} is straight-chain C_1 - C_6 or branched C_3 - C_6 alkyl (*e.g.*, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, or hexyl). In further embodiments, R_{a2} is methyl, ethyl, or t-butyl.

20 In certain embodiments, R_{a2} is heterocyclyl, (CH_2) -heterocyclyl, $(CH_2)_2$ -heterocyclyl, or $(CH_2)_3$ -heterocyclyl. In further embodiments, R_{a2} is $(CH_2)_3$ -heterocyclyl. In further embodiments, the heterocyclyl is selected from pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, hexahydropyrimidinyl, morpholinyl, and thiomorpholinyl. In further embodiments, the
25 heterocyclyl is piperazinyl.

In certain embodiments, the heterocyclyl is substituted with C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In certain embodiments, the heterocyclyl is substituted with $C(O)L$.

In certain embodiments, the heterocyclyl is substituted with L.

30 In certain embodiments, R_{a2} is phenyl, (CH_2) -phenyl, $(CH_2)_2$ -phenyl, or $(CH_2)_3$ -phenyl. In further embodiments, R_{a2} is phenyl.

In certain embodiments, the phenyl is substituted with C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In certain embodiments, the phenyl is substituted with CN. In certain embodiments, the phenyl is substituted with halogen (*e.g.*, F, Cl, or Br). In certain

embodiments, the phenyl is substituted with OH. In certain embodiments, the phenyl is substituted with C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy).

In certain embodiments, the phenyl is substituted with L.

In certain embodiments, Ra₂ is L.

5 In certain embodiments, nn2 is 0.

In certain embodiments, nn2 is 1.

In certain embodiments, nn2 is 2.

In certain embodiments, nn2 is 3.

In certain embodiments, at least one Ra₃ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In further embodiments, at least one Ra₃ is methyl.

In certain embodiments, at least one Ra₃ is CN, (CH₂)-CN, (CH₂)₂-CN, or (CH₂)₃-CN. In further embodiments, at least one Ra₃ is CN.

In certain embodiments, at least one Ra₃ is halogen (*e.g.*, F, Cl, or Br), (CH₂)-halogen, (CH₂)₂-halogen, or (CH₂)₃-halogen. In further embodiments, at least one Ra₃ is Cl, (CH₂)-Cl, (CH₂)₂-Cl, or (CH₂)₃-Cl. In further embodiments, at least one Ra₃ is Cl.

In certain embodiments, one Ra₃ is L.

In certain embodiments, one Ra₃ is C(O)NRa₅L. In further embodiments, Ra₅ is H. In other embodiments, Ra₅ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In certain embodiments, Ra₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).



20 In further embodiments, Ra₄ is methyl.



In certain embodiments, Ra₅ is H.



In certain embodiments, Ra₅ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In further embodiments, Ra₅ is methyl.

Each of the moieties defined for one of T₁, T₂, T₃, T₄, T₅, A₁, A₂, Ra₁, Ra₂, Ra₃, Ra₄, Ra₅, nn1, and nn2, can be combined with any of the moieties defined for the others of T₁, T₂, T₃, T₄, T₅, A₁, A₂, Ra₁, Ra₂, Ra₃, Ra₄, Ra₅, nn1, and nn2.

In certain embodiments,  is , and A₁ is S.

In certain embodiments,  is , and A₁ is C=C.

In certain embodiments,  is , and A₁ is C=C.

In certain embodiments, A_2 is NH, and Ra_2 is $(CH_2)_{0-3}$ -heterocyclyl. In further embodiments, Ra_2 is $(CH_2)_3$ -heterocyclyl. In further embodiments, the heterocyclyl is piperazinyl. In further embodiments, the heterocyclyl is substituted with C_1 - C_3 alkyl, L, or $C(O)L$.


5 In certain embodiments, A_2 is NH, and Ra_2 is $(CH_2)_{0-3}$ -phenyl. In further embodiments, Ra_2 is phenyl. In further embodiments, the phenyl is substituted with OH or L.

In certain embodiments, A_2 is NH, and Ra_2 is L.

In certain embodiments, A_2 is NH, and Ra_2 is H or C_1 - C_6 alkyl. In further embodiments, Ra_2 is C_1 - C_4 alkyl.

10 In certain embodiments, A_2 is O, and Ra_2 is H or C_1 - C_6 alkyl. In further embodiments, Ra_2 is C_1 - C_4 alkyl.


In certain embodiments, a Targeting Ligand is a compound of Formula TL-II:




or a pharmaceutically acceptable salt thereof, wherein A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ are each as defined above in Formula TL-I.


Each of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ may be selected from the moieties described above in Formula TL-I. Each of the moieties defined for one of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, can be combined with any of the moieties defined for the others of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, as described above in Formula TL-I.

20 In certain embodiments, a Targeting Ligand is a compound of Formula TL-IIa – TL-IId:





(TL-I1c), or



(TL-I1d),

or a pharmaceutically acceptable salt thereof, wherein:

each Ra_6 is independently C_1 - C_3 alkyl, $(CH_2)_{0-3}$ -CN, $(CH_2)_{0-3}$ -halogen, $(CH_2)_{0-3}$ -OH, or $(CH_2)_{0-3}$ - C_1 - C_3 alkoxy;

- 5 Ra_7 is $(CH_2)_{0-3}$ -heterocyclyl, $(CH_2)_{0-3}$ -phenyl, or L, wherein the heterocyclyl comprises one saturated 5- or 6-membered ring and 1-2 heteroatoms selected from N, O, and S and is substituted with L or $C(O)L$, and wherein the phenyl is substituted with L;

- Ra_8 is H, C_1 - C_6 alkyl, $(CH_2)_{0-3}$ -heterocyclyl, or $(CH_2)_{0-3}$ -phenyl, wherein the heterocyclyl comprises one saturated 5- or 6-membered ring and 1-2 heteroatoms selected from N, O, and S and is optionally substituted with C_1 - C_3 alkyl, and wherein the phenyl is optionally substituted with C_1 - C_3 alkyl, CN, halogen, OH, or C_1 - C_3 alkoxy;

Ra_{10} is C_1 - C_3 alkyl, $(CH_2)_{0-3}$ -CN, or $(CH_2)_{0-3}$ -halogen; and

A_2 , Ra_4 , Ra_5 , $nn1$, and L are each as defined above in Formula TL-I.

In certain embodiments, $nn1$ is 0.

- 15 In certain embodiments, $nn1$ is 1.

In certain embodiments, $nn1$ is 2.

In certain embodiments, at least one Ra_6 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, at least one Ra_6 is methyl. In further embodiments, two Ra_6 are methyl.

- 20 In certain embodiments, at least one Ra_6 is CN, (CH_2) -CN, $(CH_2)_2$ -CN, or $(CH_2)_3$ -CN. In further embodiments, at least one Ra_6 is (CH_2) -CN.

In certain embodiments, at least one Ra_6 is halogen (*e.g.*, F, Cl, or Br), (CH_2) -halogen, $(CH_2)_2$ -halogen, or $(CH_2)_3$ -halogen. In further embodiments, at least one Ra_6 is Cl, (CH_2) -Cl, $(CH_2)_2$ -Cl, or $(CH_2)_3$ -Cl.

- 25 In certain embodiments, at least one Ra_6 is OH, (CH_2) -OH, $(CH_2)_2$ -OH, or $(CH_2)_3$ -OH.

In certain embodiments, at least one Ra_6 is C_1 - C_3 alkoxy (*e.g.*, methoxy, ethoxy, or propoxy), (CH_2) - C_1 - C_3 alkoxy, $(CH_2)_2$ - C_1 - C_3 alkoxy, or $(CH_2)_3$ - C_1 - C_3 alkoxy. In certain embodiments, at least one Ra_6 is methoxy.

In certain embodiments, R_{a7} is heterocyclyl, (CH_2) -heterocyclyl, $(CH_2)_2$ -heterocyclyl, or $(CH_2)_3$ -heterocyclyl. In further embodiments, R_{a7} is $(CH_2)_3$ -heterocyclyl. In further embodiments, the heterocyclyl is selected from pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, 5 hexahydropyrimidinyl, morpholinyl, and thiomorpholinyl. In further embodiments, the heterocyclyl is piperazinyl.

In certain embodiments, the heterocyclyl is substituted with $C(O)L$.

In certain embodiments, the heterocyclyl is substituted with L .

In certain embodiments, R_{a7} is phenyl, (CH_2) -phenyl, $(CH_2)_2$ -phenyl, or $(CH_2)_3$ - 10 phenyl. In further embodiments, R_{a7} is phenyl.

In certain embodiments, R_{a7} is L .

In certain embodiments, R_{a8} is H .

In certain embodiments, R_{a8} is straight-chain C_1 - C_6 or branched C_3 - C_6 alkyl (*e.g.*, methyl, ethyl, propyl, *i*-propyl, butyl, *i*-butyl, *t*-butyl, pentyl, or hexyl). In further 15 embodiments, R_{a8} is methyl, ethyl, or *t*-butyl.

In certain embodiments, R_{a8} is heterocyclyl, (CH_2) -heterocyclyl, $(CH_2)_2$ -heterocyclyl, or $(CH_2)_3$ -heterocyclyl. In further embodiments, R_{a8} is $(CH_2)_3$ -heterocyclyl. In further embodiments, the heterocyclyl is selected from pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, 20 hexahydropyrimidinyl, morpholinyl, and thiomorpholinyl. In further embodiments, the heterocyclyl is piperazinyl.

In certain embodiments, the heterocyclyl is substituted with C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, R_{a8} is phenyl, (CH_2) -phenyl, $(CH_2)_2$ -phenyl, or $(CH_2)_3$ - 25 phenyl. In further embodiments, R_{a8} is phenyl.

In certain embodiments, the phenyl is substituted with C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In certain embodiments, the phenyl is substituted with CN . In certain embodiments, the phenyl is substituted with halogen (*e.g.*, F , Cl , or Br). In certain embodiments, the phenyl is substituted with OH . In certain embodiments, the phenyl is 30 substituted with C_1 - C_3 alkoxy (*e.g.*, methoxy, ethoxy, or propoxy).


In certain embodiments, R_{a10} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, R_{a10} is CN , (CH_2) - CN , $(CH_2)_2$ - CN , or $(CH_2)_3$ - CN .

In certain embodiments, Ra_{10} is halogen (*e.g.*, F, Cl, or Br), (CH_2) -halogen, $(CH_2)_2$ -halogen, or $(CH_2)_3$ -halogen. In further embodiments, Ra_{10} is Cl, (CH_2) -Cl, $(CH_2)_2$ -Cl, or $(CH_2)_3$ -Cl. In further embodiments, Ra_{10} is Cl.

Each of A_2 , Ra_4 , Ra_5 , and $nn1$ may be selected from the moieties described above in
 5 Formula TL-I. Each of the moieties defined for one of A_2 , Ra_4 , Ra_5 , Ra_6 , Ra_7 , Ra_8 , Ra_{10} , and $nn1$, can be combined with any of the moieties defined for the others of A_2 , Ra_4 , Ra_5 , Ra_6 , Ra_7 , Ra_8 , Ra_{10} , and $nn1$, as described above and in Formula TL-I.




In certain embodiments, a Targeting Ligand is a compound of Formula TL-I2:



10 or a pharmaceutically acceptable salt thereof, wherein A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ are each as defined above in Formula TL-I.

Each of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ may be selected from the moieties described above in Formula TL-I. Each of the moieties defined for one of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, can be combined with any of the moieties defined for the others of
 15 A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, as described above in Formula TL-I.


In certain embodiments, a Targeting Ligand is a compound of Formula TL-I2a – TL-I2c:



or a pharmaceutically acceptable salt thereof, wherein A_2 , Ra_4 , Ra_5 , $nn1$, and L are each as defined above in Formula TL-I, and Ra_6 , Ra_7 , Ra_8 , and Ra_{10} are each as defined above in Formula TL-IIa – TL-IId.

Each of A_2 , Ra_4 , Ra_5 , and $nn1$ may be selected from the moieties described above in Formula TL-I, and each of Ra_6 , Ra_7 , Ra_8 , and Ra_{10} may be selected from the moieties described above in Formula TL-IIa – TL-IId. Each of the moieties defined for one of A_2 , Ra_4 , Ra_5 , Ra_6 , Ra_7 , Ra_8 , Ra_{10} , and $nn1$, can be combined with any of the moieties defined for the others of A_2 , Ra_4 , Ra_5 , Ra_6 , Ra_7 , Ra_8 , Ra_{10} , and $nn1$, as described above in Formula TL-I and TL-IIa – TL-IId.



In certain embodiments, a Targeting Ligand is a compound of Formula TL-I3:




or a pharmaceutically acceptable salt thereof.

A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ are each as defined above in Formula TL-I. Each of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$ may be selected from the moieties described above in Formula TL-I. Each of the moieties defined for one of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, can be combined with any of the moieties defined for the others of A_2 , Ra_1 , Ra_2 , Ra_3 , Ra_4 , Ra_5 , $nn1$, and $nn2$, as described above in Formula TL-I.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-I3a – TL-I3c:





or a pharmaceutically acceptable salt thereof, wherein:

Ra₉ is C(O)NRa₅L, OL, NRa₅L, or L;

A₂, Ra₄, Ra₅, nn1, and L are each as defined above in Formula TL-I; and

5 Ra₆, Ra₇, Ra₈, and Ra₁₀ are each as defined above in Formula TL-I1a – TL-I1d.

In certain embodiments, Ra₉ is C(O)NRa₅L. In further embodiments, Ra₅ is H. In other embodiments, Ra₅ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).


In certain embodiments, Ra₉ is OL.

10 In certain embodiments, Ra₉ is NRa₅L. In further embodiments, Ra₅ is H. In other embodiments, Ra₅ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other embodiments, Ra₅ is methyl.

In certain embodiments, Ra₉ is L.

Each of A₂, Ra₄, Ra₅, and nn1 may be selected from the moieties described above in Formula TL-I, and each of Ra₆, Ra₇, Ra₈, and Ra₁₀ may be selected from the moieties
15 described above in Formula TL-I1a – TL-I1d. Each of the moieties defined for one of A₂, Ra₄, Ra₅, Ra₆, Ra₇, Ra₈, Ra₉, Ra₁₀, and nn1, can be combined with any of the moieties defined for the others of A₂, Ra₄, Ra₅, Ra₆, Ra₇, Ra₈, Ra₉, Ra₁₀, and nn1, as described above and in Formula TL-I and TL-I1a – TL-I1d.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-II:



or a pharmaceutically acceptable salt thereof, wherein:

T₆ is CRb₄ or N;

Rb₁, Rb₂, and Rb₅ are each independently H or C₁-C₃ alkyl;

Rb₃ is C₃-C₆ cycloalkyl;

25 each Rb₄ is independently H, C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

nn3 is 0, 1, 2, or 3;

each Rb₆ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

Rb₇ is C(O)NRb₈L, OL, NRb₈L, or L;

Rb₈ is H or C₁-C₃ alkyl; and

L is a Linker.

5 In certain embodiments, T₆ is CRb₄.

In certain embodiments, T₆ is N.

In certain embodiments, Rb₁ is H. In certain embodiments, Rb₁ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, Rb₁ is methyl.

10 In certain embodiments, Rb₂ is H. In certain embodiments, Rb₂ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, Rb₂ is methyl or ethyl.

In certain embodiments, Rb₅ is H. In certain embodiments, Rb₅ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rb₃ is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, Rb₃ is cyclopentyl.

15 In certain embodiments, Rb₄ is H.

In certain embodiments, Rb₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rb₄ is C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy).

In certain embodiments, Rb₄ is CN.

In certain embodiments, Rb₄ is halogen (*e.g.*, F, Cl, or Br).

20 In certain embodiments, nn3 is 0.

In certain embodiments, nn3 is 1.

In certain embodiments, nn3 is 2.

In certain embodiments, nn3 is 3.

25 In certain embodiments, at least one Rb₆ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, at least one Rb₆ is methyl.

In certain embodiments, at least one Rb₆ is C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, at least one Rb₆ is methoxy.

In certain embodiments, at least one Rb₆ is CN.

In certain embodiments, at least one Rb₆ is halogen (*e.g.*, F, Cl, or Br).

30 In certain embodiments, Rb₇ is C(O)NRb₈L. In further embodiments, Rb₈ is H. In other embodiments, Rb₈ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rb₇ is OL.


In certain embodiments, Rb₇ is NRb₈L. In further embodiments, Rb₈ is H. In other embodiments, Rb₈ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other embodiments, Rb₈ is methyl.

In certain embodiments, Rb₇ is L.

- 5 Each of the moieties defined for one of T₆, Rb₁, Rb₂, Rb₃, Rb₄, Rb₅, Rb₆, Rb₇, Rb₈, and nn3, can be combined with any of the moieties defined for the others of T₆, Rb₁, Rb₂, Rb₃, Rb₄, Rb₅, Rb₆, Rb₇, Rb₈, and nn3.

In certain embodiments, Rb₃ is cyclopentyl, and Rb₇ is C(O)NRb₈L.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-III:




10

or a pharmaceutically acceptable salt thereof, wherein T₆, Rb₂, Rb₄, Rb₆, Rb₇, and Rb₈ are each as defined above in Formula TL-II.

Each of T₆, Rb₂, Rb₄, Rb₆, Rb₇, and Rb₈ may be selected from the moieties described above in Formula TL-II. Each of the moieties defined for one of T₆, Rb₂, Rb₄, Rb₆, Rb₇, and Rb₈, can be combined with any of the moieties defined for the others of T₆, Rb₂, Rb₄, Rb₆, Rb₇, and Rb₈, as described above in Formula TL-II.

15

In certain embodiments, a Targeting Ligand is a compound of Formula TL-IIIa:




20

or a pharmaceutically acceptable salt thereof, wherein T₆, Rb₂, and Rb₄ are each as defined above in Formula TL-II.

Each of T₆, Rb₂, and Rb₄ may be selected from the moieties described above in Formula TL-II. Each of the moieties defined for one of T₆, Rb₂, and Rb₄, can be combined with any of the moieties defined for the others of T₆, Rb₂, and Rb₄, as described above in Formula TL-II.

25

In certain embodiments, a Targeting Ligand is a compound of Formula TL-III:



or a pharmaceutically acceptable salt thereof, wherein:

nn4 is 0 or 1;

Rc₁ is C(O)NRc₆L, OL, NRc₆L, or L;

5 Rc₂ is H, C₁-C₃ alkyl, C(O)NRc₆L, OL, NRc₆L, or L;

Rc₃ is H, C₁-C₃ alkyl, C(O)L, or L;

nn5 is 0, 1, or 2;

each Rc₄ is independently C₁-C₃ alkyl or C₁-C₃ alkoxy;

each Rc₅ is independently H or C₁-C₃ alkyl;

10 Rc₆ is independently H or C₁-C₃ alkyl; and

L is a Linker,

provided that the compound of Formula TL-III is substituted with only one L.

In certain embodiments, nn4 is 0.

In certain embodiments, nn4 is 1.

15 In certain embodiments, Rc₁ is C(O)NRc₆L. In further embodiments, Rc₆ is H. In other embodiments, Rc₆ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rc₁ is OL.

In certain embodiments, Rc₁ is NRc₆L. In further embodiments, Rc₆ is H. In other embodiments, Rc₆ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other

20 embodiments, Rc₆ is methyl.

In certain embodiments, Rc₁ is L.

In certain embodiments, Rc₂ is H.

In certain embodiments, Rc₂ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In further embodiments, Rc₂ is methyl.

25 In certain embodiments, Rc₂ is C(O)NRc₆L. In further embodiments, Rc₆ is H. In other embodiments, Rc₆ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rc₂ is OL.

In certain embodiments, R_{c2} is $NR_{c6}L$. In further embodiments, R_{c6} is H. In other embodiments, R_{c6} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other embodiments, R_{c6} is methyl.

In certain embodiments, R_{c2} is L.

5 In certain embodiments, R_{c3} is H.

In certain embodiments, R_{c3} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, R_{c3} is $C(O)L$.

In certain embodiments, R_{c3} is L.

In certain embodiments, $nn5$ is 0.

10 In certain embodiments, $nn5$ is 1.

In certain embodiments, $nn5$ is 2.

In certain embodiments, at least one R_{c4} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, at least one R_{c4} is methyl.


15 In certain embodiments, at least one R_{c4} is C_1 - C_3 alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, at least one R_{c4} is methoxy.

In certain embodiments, at least one R_{c5} is H.


In certain embodiments, at least one R_{c5} is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In further embodiments, at least one R_{c5} is methyl. In further embodiments, two R_{c5} are methyl.

20 Each of the moieties defined for one of R_{c1} , R_{c2} , R_{c3} , R_{c4} , R_{c5} , R_{c6} , $nn4$, and $nn5$, can be combined with any of the moieties defined for the others of R_{c1} , R_{c2} , R_{c3} , R_{c4} , R_{c5} , R_{c6} , $nn4$, and $nn5$.


In certain embodiments, a Targeting Ligand is a compound of Formula TL-III1 – TL-III3:



(TL-III1),



(TL-III2), or




(TL-III3),

or a pharmaceutically acceptable salt thereof, wherein Rc_1 , Rc_2 , Rc_3 , Rc_4 , and $nn5$ are each as defined above in Formula TL-III.

Each of Rc_1 , Rc_2 , Rc_3 , Rc_4 , and $nn5$ may be selected from the moieties described above in Formula TL-III. Each of the moieties defined for one of Rc_1 , Rc_2 , Rc_3 , Rc_4 , and $nn5$, can be combined with any of the moieties defined for the others of Rc_1 , Rc_2 , Rc_3 , Rc_4 , and $nn5$, as described above in Formula TL-III.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-IV:



(TL-IV),

or a pharmaceutically acceptable salt thereof, wherein:

each Rd_1 is independently H or C_1 - C_3 alkyl;

$nn6$ is 0, 1, 2, or 3;

$nn7$ is 0, 1, 2, or 3;

each Rd_2 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

Rd_3 is $C(O)NRd_4L$, OL, NRd_4L , or L;

Rd_4 is H or C_1 - C_3 alkyl; and

L is a Linker.

In certain embodiments, Rd_1 is H.

In certain embodiments, Rd_1 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In further embodiments, Rd_1 is methyl.

In certain embodiments, $nn6$ is 0.

In certain embodiments, $nn6$ is 1.

In certain embodiments, $nn6$ is 2.

In certain embodiments, $nn6$ is 3.

In certain embodiments, $nn7$ is 0.

In certain embodiments, nn7 is 1.

In certain embodiments, nn7 is 2.

In certain embodiments, nn7 is 3.

In certain embodiments, at least one Rd₂ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In further embodiments, at least one Rd₂ is methyl.

In certain embodiments, at least one Rd₂ is C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, at least one Rd₂ is methoxy.

In certain embodiments, at least one Rd₂ is CN.

In certain embodiments, at least one Rd₂ is halogen (*e.g.*, F, Cl, or Br).

In certain embodiments, Rd₃ is C(O)NR₄L. In further embodiments, Rd₄ is H. In other embodiments, Rd₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).


In certain embodiments, Rd₃ is OL.

In certain embodiments, Rd₃ is NR₄L. In further embodiments, Rd₄ is H. In other embodiments, Rd₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In other embodiments, Rd₄ is methyl.

In certain embodiments, Rd₃ is L.

Each of the moieties defined for one of Rd₁, Rd₂, Rd₃, Rd₄, nn6, and nn7, can be combined with any of the moieties defined for the others of Rd₁, Rd₂, Rd₃, Rd₄, nn6, and nn7.


In certain embodiments, a Targeting Ligand is a compound of Formula TL-IV1:



or a pharmaceutically acceptable salt thereof, wherein Rd₃ is as defined above in Formula TL-IV.

Rd₃ may be selected from the moieties described above in Formula TL-IV.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-V:



or a pharmaceutically acceptable salt thereof, wherein:

each Re₁ is independently H or C₁-C₃ alkyl;

nn8 is 0, 1, 2, or 3;

nn9 is 0, 1, 2, or 3;

each Re₂ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

Re₃ is NH-(CH₂)₁₋₃-C(O)NRe₄L, C(O)NRe₄L, OL, NRe₄L, or L;

Re₄ is H or C₁-C₃ alkyl; and

5 L is a Linker.

In certain embodiments, Re₁ is H.

In certain embodiments, Re₁ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In further embodiments, Re₁ is methyl.

In certain embodiments, nn8 is 0.

10 In certain embodiments, nn8 is 1.

In certain embodiments, nn8 is 2.

In certain embodiments, nn8 is 3.

In certain embodiments, nn9 is 0.

In certain embodiments, nn9 is 1.

15 In certain embodiments, nn9 is 2.

In certain embodiments, nn9 is 3.

In certain embodiments, at least one Re₂ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In further embodiments, at least one Re₂ is methyl.

In certain embodiments, at least one Re₂ is C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, at least one Re₂ is methoxy.

20 In certain embodiments, at least one Re₂ is CN.

In certain embodiments, at least one Re₂ is halogen (*e.g.*, F, Cl, or Br).

In certain embodiments, Re₃ is NH-CH₂-C(O)NRe₄L, NH-(CH₂)₂-C(O)NRe₄L, or

NH-(CH₂)₃-C(O)NRe₄L. In further embodiments, Re₃ is NH-CH₂-C(O)NRe₄L. In further

25 embodiments, Re₄ is H. In other embodiments, Re₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

In certain embodiments, Re₃ is C(O)NRe₄L. In further embodiments, Re₄ is H. In other embodiments, Re₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).


In certain embodiments, Re₃ is OL.

30 In certain embodiments, Re₃ is NRe₄L. In further embodiments, Re₄ is H. In other embodiments, Re₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In other embodiments, Re₄ is methyl.

In certain embodiments, Re₃ is L.

Each of the moieties defined for one of Re_1 , Re_2 , Re_3 , Re_4 , $nn8$, and $nn9$, can be combined with any of the moieties defined for the others of Re_1 , Re_2 , Re_3 , Re_4 , $nn8$, and $nn9$.


In certain embodiments, a Targeting Ligand is a compound of Formula TL-V1:



- 5 or a pharmaceutically acceptable salt thereof, wherein Re_3 is as defined above in Formula TL-V.

Re_3 may be selected from the moieties described above in Formula TL-V.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-VI:



- 10 or a pharmaceutically acceptable salt thereof, wherein:

Rf_1 is $C(O)NRf_2L$, OL , NRf_2L , or L ;

Rf_2 is independently H or C_1 - C_3 alkyl; and

L is a Linker.

In certain embodiments, Rf_1 is $C(O)NRf_2L$. In further embodiments, Rf_2 is H . In


- 15 other embodiments, Rf_2 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rf_1 is OL .

In certain embodiments, Rf_1 is NRe_4L . In further embodiments, Rf_2 is H . In other embodiments, Rf_2 is C_1 - C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other embodiments, Rf_2 is methyl.

- 20 In certain embodiments, Rf_1 is L .

In certain embodiments, a Targeting Ligand is a compound of Formula TL-VII:



or a pharmaceutically acceptable salt thereof, wherein:

T_7 is CH_2 or CH_2CH_2 ;

Rg₁ is C(O)Rg₅ or C₁-C₃ alkyl substituted with Rg₆;

nn10 is 0, 1, 2, or 3;

nn11 is 0, 1, 2, or 3;

each Rg₂ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

5 Rg₃ is C(O)NRg₄L, OL, NRg₄L, L, O-(CH₂)₁₋₃-C(O)NRg₄L, or NHC(O)-(CH₂)₁₋₃-C(O)NRg₄L;

Rg₄ is H or C₁-C₃ alkyl;

Rg₅ is C₁-C₆ alkyl;

Rg₆ is phenyl optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

10 and

L is a Linker.

In certain embodiments, T₇ is CH₂.

In certain embodiments, T₇ is CH₂CH₂.

In certain embodiments, Rg₁ is C(O)Rg₅.

15 In certain embodiments, Rg₁ is (CH₂)-Rg₆, (CH₂)₂-Rg₆, (CH₂Rg₆)-CH₃, (CH₂)₃-Rg₆, (CH₂Rg₆)-CH₂CH₃, or CH₂-(CH₂Rg₆)-CH₃. In certain embodiments, Rg₁ is (CH₂)-Rg₆. In certain embodiments, Rg₁ is (CH₂Rg₆)-CH₂CH₃.

In certain embodiments, Rg₅ is straight-chain C₁-C₆ or branched C₃-C₆ alkyl (*e.g.*, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, or hexyl).

20 In certain embodiments, Rg₆ is unsubstituted phenyl.

In certain embodiments, Rg₆ is phenyl substituted with one, two, three, or more substituents independently selected from C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl), C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy), CN, and halogen (*e.g.*, F, Cl, or Br).

In certain embodiments, nn10 is 0.

25 In certain embodiments, nn10 is 1.

In certain embodiments, nn10 is 2.

In certain embodiments, nn10 is 3.

In certain embodiments, nn11 is 0.

In certain embodiments, nn11 is 1.

30 In certain embodiments, nn11 is 2.

In certain embodiments, nn11 is 3.

In certain embodiments, at least one Rg₂ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In further embodiments, at least one Rg₂ is methyl.

In certain embodiments, at least one Rg₂ is C₁-C₃ alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, at least one Rg₂ is methoxy.

In certain embodiments, at least one Rg₂ is CN.

In certain embodiments, at least one Rg₂ is halogen (*e.g.*, F, Cl, or Br).

5 In certain embodiments, Rg₃ is C(O)NRg₄L. In further embodiments, Rg₄ is H. In other embodiments, Rg₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rg₃ is OL.

In certain embodiments, Rg₃ is NRg₄L. In further embodiments, Rg₄ is H. In other embodiments, Rg₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In other
10 embodiments, Rg₄ is methyl.


In certain embodiments, Rg₃ is L.

In certain embodiments, Rg₃ is O-(CH₂)-C(O)NRg₄L, O-(CH₂)₂-C(O)NRg₄L, or O-(CH₂)₃-C(O)NRg₄L. In further embodiments, Rg₃ is O-(CH₂)-C(O)NRg₄L. In further
15 embodiments, Rg₄ is H. In other embodiments, Rg₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, Rg₃ is NHC(O)-(CH₂)-C(O)NRg₄L, NHC(O)-(CH₂)₂-C(O)NRg₄L, or NHC(O)-(CH₂)₃-C(O)NRg₄L. In further embodiments, Rg₃ is NHC(O)-
(CH₂)-C(O)NRg₄L, NHC(O)-(CH₂)₂-C(O)NRg₄L. In further embodiments, Rg₃ is NHC(O)-
(CH₂)₂-C(O)NRg₄L. In further embodiments, Rg₄ is H. In other embodiments, Rg₄ is C₁-C₃
20 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

Each of the moieties defined for one of T₇, nn10, nn11, Rg₁, Rg₂, Rg₃, Rg₄, Rg₅, and Rg₆ can be combined with any of the moieties defined for the others of T₇, nn10, nn11, Rg₁, Rg₂, Rg₃, Rg₄, Rg₅, and Rg₆.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-VIII:



25 or a pharmaceutically acceptable salt thereof, wherein T₇, Rg₁, Rg₂, Rg₃, Rg₄, Rg₅, and Rg₆ are each as defined above in Formula TL-VII.

Each of T₇, Rg₁, Rg₂, Rg₃, Rg₄, Rg₅, and Rg₆ may be selected from the moieties described above in Formula TL-VII. Each of the moieties defined for one of T₇, Rg₁, Rg₂,

Rg₃, Rg₄, Rg₅, and Rg₆ can be combined with any of the moieties defined for the others of T₇, Rg₁, Rg₂, Rg₃, Rg₄, Rg₅, and Rg₆, as described above in Formula TL-VII.

In certain embodiments, T₇ is CH₂.

In certain embodiments, T₇ is CH₂CH₂.

5 In certain embodiments, R_{g1} is $C(O)R_{g5}$.

In certain embodiments, Rg₁ is (CH₂)-Rg₆, (CH₂)₂-Rg₆, (CH(Rg₆))-CH₃, (CH₂)₃-Rg₆, (CH(Rg₆))-CH₂CH₃, or CH₂-(CH(Rg₆))-CH₃. In certain embodiments, Rg₁ is (CH₂)-Rg₆. In certain embodiments, Rg₁ is (CH(Rg₆))-CH₂CH₃.

In certain embodiments, at least one Rg_2 is C_1 - C_3 alkoxy (*e.g.*, methoxy, ethoxy, or propoxy). In further embodiments, both Rg_2 are methoxy.

In certain embodiments, R_{g3} is O-(CH₂)-C(O)NR_{g4}L, O-(CH₂)₂-C(O)NR_{g4}L, or O-(CH₂)₃-C(O)NR_{g4}L. In further embodiments, R_{g3} is O-(CH₂)-C(O)NR_{g4}L. In further embodiments, R_{g4} is H. In other embodiments, R_{g4} is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

15 In certain embodiments, R_{g3} is NHC(O)-(CH₂)-C(O)NR_{g4}L, NHC(O)-(CH₂)₂-C(O)NR_{g4}L, or NHC(O)-(CH₂)₃-C(O)NR_{g4}L. In further embodiments, R_{g3} is NHC(O)-(CH₂)-C(O)NR_{g4}L, NHC(O)-(CH₂)₂-C(O)NR_{g4}L. In further embodiments, R_{g3} is NHC(O)-(CH₂)₂-C(O)NR_{g4}L. In further embodiments, R_{g4} is H. In other embodiments, R_{g4} is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).

20 In further embodiments, both R_{g2} are methoxy; T_7 is CH_2 ; and R_{g1} is $C(O)R_{g5}$.

In further embodiments, both R_{g2} are methoxy; T₇ is CH₂; R_{g1} is C(O)R_{g5}; and R_{g3} is O-(CH₂)-C(O)NR_{g4}L.

In further embodiments, both R_{g2} are methoxy; T₇ is CH₂; R_{g1} is C(O)R_{g5}; and R_{g3} is NHC(O)-(CH₂)₇-C(O)NR_{g4}L.

25 In further embodiments, both R_{g2} are methoxy; T₇ is CH₂; and R_{g1} is (CHR_{g6})-
CH₂CH₃

In further embodiments, both Rg₂ are methoxy; T₇ is CH₂; Rg₁ is (CHRg₆)-CH₂CH₃; and Rg₃ is O-(CH₂)-C(O)NRg₄L.

In further embodiments, both R_{g2} are methoxy; T₇ is CH₂; R_{g1} is (CHR_{g6})-CH₂CH₃; and R_{g3} is NHC(O)-(CH₂)₂-C(O)NR_{g4}L.

In further embodiments, both R_{g2} are methoxy; T₇ is CH₂CH₂; and R_{g1} is C(O)R_{g5}.

In further embodiments, both R_{g2} are methoxy; T₇ is CH₂CH₂; R_{g1} is C(O)R_{g5}; and R_{g3} is O-(CH₂)-C(O)NR_{g4}L.


In further embodiments, both R_{g2} are methoxy; T_7 is CH_2CH_2 ; R_{g1} is $C(O)R_{g5}$; and R_{g3} is $NHC(O)-(CH_2)_2-C(O)NR_{g4}L$.

In further embodiments, both R_{g2} are methoxy; T_7 is CH_2CH_2 ; and R_{g1} is $(CHR_{g6})-CH_2CH_3$.

5 In further embodiments, both R_{g2} are methoxy; T_7 is CH_2CH_2 ; R_{g1} is $(CHR_{g6})-CH_2CH_3$; and R_{g3} is $O-(CH_2)-C(O)NR_{g4}L$.

In further embodiments, both R_{g2} are methoxy; T_7 is CH_2CH_2 ; R_{g1} is $(CHR_{g6})-CH_2CH_3$; and R_{g3} is $NHC(O)-(CH_2)_2-C(O)NR_{g4}L$.

In certain embodiments, a Targeting Ligand is a compound of Formula TL-VIII:



(TL-VIII),

10 or a pharmaceutically acceptable salt thereof, wherein:

each R_{h1} is independently H or C_1-C_3 alkyl;

$nn12$ is 0, 1, 2, or 3;

each R_{h2} is independently C_1-C_3 alkyl, C_1-C_3 alkoxy, CN, or halogen;

15 R_{h3} is $C(O)L$ or $C(O)-(CH_2)_{1-3}-C(O)NR_{h6}L$;

R_{h6} is H or C_1-C_3 alkyl;

R_{h4} is H or C_1-C_3 alkyl;

R_{h5} is C_1-C_6 alkyl; and

L is a Linker.

20 In certain embodiments, R_{h1} is H. In other embodiments, R_{h1} is C_1-C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl).

In certain embodiments, $nn12$ is 0.

In certain embodiments, $nn12$ is 1.

In certain embodiments, $nn12$ is 2.

25 In certain embodiments, $nn12$ is 3.

In certain embodiments, at least one R_{h2} is C_1-C_3 alkyl (*e.g.*, methyl, ethyl, propyl, or *i*-propyl). In certain embodiments, at least one R_{h2} is C_1-C_3 alkoxy (*e.g.*, methoxy, ethoxy, or

propoxy). In certain embodiments, at least one Rh₂ is CN. In certain embodiments, at least one Rh₂ is halogen (*e.g.*, F, Cl, or Br).

In certain embodiments, Rh₃ is C(O)L.

In certain embodiments, Rh₃ is C(O)-(CH₂)-C(O)NRh₆L, C(O)-(CH₂)₂-C(O)NRh₆L,
 5 C(O)-(CH₂)₃-C(O)NRh₆L. In certain embodiments, Rh₃ is C(O)-(CH₂)₂-C(O)NRh₆L.


In certain embodiments, Rh₆ is H. In other embodiments, Rh₆ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl).


In certain embodiments, Rh₄ is H. In other embodiments, Rh₄ is C₁-C₃ alkyl (*e.g.*, methyl, ethyl, propyl, or i-propyl). In certain embodiments, Rh₄ is methyl.


10 In certain embodiments, Rh₅ is straight-chain C₁-C₆ or branched C₃-C₆ alkyl (*e.g.*, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, or hexyl). In certain embodiments, Rh₅ is t-butyl.


In certain embodiments, the Targeting Ligand is selected from the following in Table T, wherein R is a Linker:


15 **Table T**











5 In certain embodiments, the TLs or targets are chosen based on existence (known target protein binding moieties) and ability to develop potent and selective ligands with functional positions that can accommodate a Linker. Some embodiments relate to targets with less selectivity, which may benefit from degradation coupled with proteomics as a measure of compound selectivity or target ID. Such cases include, but are not limited to a) targets that



have multiple functionalities that are unable to be targeted by inhibition; b) targets that are resistant to inhibitors without altering their binding; c) targets that have ligands that do not alter the function of the target; and d) targets that would benefit from irreversible inhibition but lack reactive residues that can be targeted with covalent ligands.

- 5 In certain embodiments, the present application relates to small molecule inducers of protein degradation, which have numerous advantages over inhibitors of protein function and can a) overcome resistance in certain cases; b) prolong the kinetics of drug effect by destroying the protein requiring resynthesis even after the small molecule has been metabolized; c) target all functions of a protein at once rather than a specific catalytic activity
10 or binding event; d) expand the number of drug targets by including all proteins that a ligand can be developed for, rather than proteins whose activity can be affected by a small molecule inhibitor, antagonist or agonist; and e) have increased potency compared to inhibitors due to the possibility of the small molecule acting catalytically.







Some embodiments of the present application relate to degradation or loss of 30% to
15 100% of the target protein. Certain embodiments relate to the loss of 50-100% of the target protein. Other embodiments relate to the loss of 75-95% of the targeted protein.








Some embodiments of present application relate to the bifunctional compounds having the following structures, as shown in Table I-1 and Table I-2, their synthesis and methods of use:







20 **Table I-1**







Cmpd. No.	Structure
dBET3	
dBET1	







dBET4	
dBET5	
dBET6	
dBET17	
dBET19	
dBET58	







dBET59	
dBET61	
dBET24	
dBET52	
dBET53	
dBET54	







dBET55	
dBET63	
dBET56	
dBET38	
dBET9	
dBET18	
dBET41	






dBET28	
dBET29	
dBET21	
dBET39	
dBET27	
dBET40	





dBET42	
dBET43	
dBET44	
dBET36	
dBET37	
dBET60	








dBET57	
dBET64	
dBET35	
dBET62	
dBET15	
dBET50	








dBET51	 Chemical structure of dBET51: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 1,3-dioxane ring and a 2,6-pyridinedione moiety.
dBET22	 Chemical structure of dBET22: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 2,6-pyridinedione moiety.
dBET23	 Chemical structure of dBET23: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 2,6-pyridinedione moiety.
dBET30	 Chemical structure of dBET30: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 2,6-pyridinedione moiety and a 1,3-dioxane ring.
dBET31	 Chemical structure of dBET31: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 2,6-pyridinedione moiety and a 1,3-dioxane ring.
dBET25	 Chemical structure of dBET25: A complex molecule featuring a 6-chlorophenyl group attached to a thiazine ring system. This system is linked via a carbonyl group to a long chain containing a 2,6-pyridinedione moiety.






dBET26	
dBET11	
dBET12	
dBET13	
dBET14	
dBET20	







dBET32	 Chemical structure of dBET32: A complex molecule featuring a 4-((4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl)amino)phenyl)piperazine-1-carboxamide group linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group. This is further linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group, which is then linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group, and finally linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group.
dBET33	 Chemical structure of dBET33: Similar to dBET32, but the linker between the two pyrimidine rings is a 3-oxopropyl chain instead of a 3-oxopropyl chain.
dBET34	 Chemical structure of dBET34: Similar to dBET32, but the linker between the two pyrimidine rings is a 3-oxopropyl chain instead of a 3-oxopropyl chain.
dBET2	 Chemical structure of dBET2: A complex molecule featuring a 4-((4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl)amino)phenyl)piperazine-1-carboxamide group linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group. This is further linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group, which is then linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group, and finally linked via a 3-oxopropyl chain to a 4-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-methylpyrimidin-5-yl group.
dBET7	 Chemical structure of dBET7: Similar to dBET2, but the linker between the two pyrimidine rings is a 3-oxopropyl chain instead of a 3-oxopropyl chain.





dBET8	 Chemical structure of dBET8, a complex molecule featuring a central benzimidazole core. The benzimidazole is substituted with a methyl group, an ethyl group, and a cyclopentyl group. It is linked via an amine to a 4-methoxyphenyl group, which is further connected to a long, flexible poly(ether) chain. This chain terminates in a succinimide ring, which is fused to a benzene ring, and is also linked to a pyridine ring.
dBET10	 Chemical structure of dBET10, similar to dBET8, but with a different poly(ether) chain connecting the 4-methoxyphenyl group to the succinimide ring.
dBET16	 Chemical structure of dBET16, featuring a central benzimidazole core substituted with a methyl group, an ethyl group, and a cyclopentyl group. It is linked via an amine to a 4-methoxyphenyl group, which is further connected to a long, flexible poly(ether) chain. This chain terminates in a succinimide ring, which is fused to a benzene ring, and is also linked to a pyridine ring.
dBET45	 Chemical structure of dBET45, featuring a central benzimidazole core substituted with a methyl group, an ethyl group, and a cyclopentyl group. It is linked via an amine to a 4-methoxyphenyl group, which is further connected to a long, flexible poly(ether) chain. This chain terminates in a succinimide ring, which is fused to a benzene ring, and is also linked to a pyridine ring.





dBET46	
	
	
	
	
	
	






	
	
dFKBP-1	
dFKBP-2	
dFKBP-3	
dFKBP-4	
dFKBP-5	







dFKBP-6	 Chemical structure of dFKBP-6. It features a 3,4,5-trimethoxyphenyl group connected via a chiral center to a piperidine ring. The piperidine is linked to a 4-methoxyphenyl group, which is further connected to a 4-((6-oxo-1,2,3,4-tetrahydropyridin-2-yl)methoxy)phenyl group. The structure includes a long aliphatic chain with amide and ester linkages, and a terminal 6-oxo-1,2,3,4-tetrahydropyridin-2-yl group.
dFKBP-8	 Chemical structure of dFKBP-8. It is similar to dFKBP-6 but features a longer aliphatic chain between the 4-methoxyphenyl and 4-((6-oxo-1,2,3,4-tetrahydropyridin-2-yl)methoxy)phenyl groups.
dFKBP-9	 Chemical structure of dFKBP-9. It is similar to dFKBP-8 but features a different aliphatic chain length between the 4-methoxyphenyl and 4-((6-oxo-1,2,3,4-tetrahydropyridin-2-yl)methoxy)phenyl groups.
dFKBP-17	 Chemical structure of dFKBP-17. It features a 3,4,5-trimethoxyphenyl group connected via a chiral center to a piperidine ring. The piperidine is linked to a 4-methoxyphenyl group, which is further connected to a 4-((6-oxo-1,2,3,4-tetrahydropyridin-2-yl)methoxy)phenyl group. The structure includes a long aliphatic chain with amide and ester linkages, and a terminal 6-oxo-1,2,3,4-tetrahydropyridin-2-yl group.
dFKBP-7	 Chemical structure of dFKBP-7. It features a 3,4,5-trimethoxyphenyl group connected via a chiral center to a piperidine ring. The piperidine is linked to a 4-methoxyphenyl group, which is further connected to a 4-((6-oxo-1,2,3,4-tetrahydropyridin-2-yl)methoxy)phenyl group. The structure includes a long aliphatic chain with amide and ester linkages, and a terminal 6-oxo-1,2,3,4-tetrahydropyridin-2-yl group.



dFKBP-26	
dFKBP-24	
dFKBP-27	
dFKBP-28	
dFKBP-25	
dFKBP-29	










dFKBP-21	 Chemical structure of dFKBP-21. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 4-methoxyphenyl group, and a 2-ethyl-2-oxo-1,3-dioxane-5-carboxylate group. The piperidine ring is also linked to a 4-methoxyphenyl group via an ester linkage. This 4-methoxyphenyl group is further linked to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is connected to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is finally linked to a 4-((4-methoxyphenyl)methoxy)benzoate group.
dFKBP-16	 Chemical structure of dFKBP-16. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 4-methoxyphenyl group, and a 2-ethyl-2-oxo-1,3-dioxane-5-carboxylate group. The piperidine ring is also linked to a 4-methoxyphenyl group via an ester linkage. This 4-methoxyphenyl group is further linked to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is connected to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is finally linked to a 4-((4-methoxyphenyl)methoxy)benzoate group.
dFKBP-20	 Chemical structure of dFKBP-20. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 4-methoxyphenyl group, and a 2-ethyl-2-oxo-1,3-dioxane-5-carboxylate group. The piperidine ring is also linked to a 4-methoxyphenyl group via an ester linkage. This 4-methoxyphenyl group is further linked to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is connected to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is finally linked to a 4-((4-methoxyphenyl)methoxy)benzoate group.
dFKBP-18	 Chemical structure of dFKBP-18. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 4-methoxyphenyl group, and a 2-ethyl-2-oxo-1,3-dioxane-5-carboxylate group. The piperidine ring is also linked to a 4-methoxyphenyl group via an ester linkage. This 4-methoxyphenyl group is further linked to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is connected to a 4-((4-methoxyphenyl)methoxy)benzoate group, which is finally linked to a 4-((4-methoxyphenyl)methoxy)benzoate group.










dFKBP-13	 Chemical structure of dFKBP-13. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 3,4-dimethoxyphenyl group, and a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The piperidine ring is also substituted with a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The structure is connected via an ether linkage to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group, which is further connected to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group.
dFKBP-14	 Chemical structure of dFKBP-14. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 3,4-dimethoxyphenyl group, and a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The piperidine ring is also substituted with a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The structure is connected via an ether linkage to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group, which is further connected to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group.
dFKBP-19	 Chemical structure of dFKBP-19. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 3,4-dimethoxyphenyl group, and a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The piperidine ring is also substituted with a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The structure is connected via an ether linkage to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group, which is further connected to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group.
dFKBP-15	 Chemical structure of dFKBP-15. It features a central piperidine ring substituted with a 3,4,5-trimethoxyphenyl group, a 3,4-dimethoxyphenyl group, and a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The piperidine ring is also substituted with a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group. The structure is connected via an ether linkage to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group, which is further connected to a 2-((3,4-dimethoxyphenyl)methoxy)acetyl group.










	 Chemical structure of dFKBP-33, featuring a 3,4,5-trimethoxyphenyl group linked via an ester to a piperidine ring, which is further linked via an ester to a 4-(3,4-dimethoxyphenyl)phenyl group, connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, which is connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group.
dFKBP-34	 Chemical structure of dFKBP-34, featuring a 3,4,5-trimethoxyphenyl group linked via an ester to a piperidine ring, which is further linked via an ester to a 4-(3,4-dimethoxyphenyl)phenyl group, connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, which is connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group.
dFKBP-36	 Chemical structure of dFKBP-36, featuring a 3,4,5-trimethoxyphenyl group linked via an ester to a piperidine ring, which is further linked via an ester to a 4-(3,4-dimethoxyphenyl)phenyl group, connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, which is connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group.
dFKBP-35	 Chemical structure of dFKBP-35, featuring a 3,4,5-trimethoxyphenyl group linked via an ester to a piperidine ring, which is further linked via an ester to a 4-(3,4-dimethoxyphenyl)phenyl group, connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, which is connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group.
dFKBP-37	 Chemical structure of dFKBP-37, featuring a 3,4,5-trimethoxyphenyl group linked via an ester to a piperidine ring, which is further linked via an ester to a 4-(3,4-dimethoxyphenyl)phenyl group, connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, which is connected to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group, and finally linked via an ester to a 4-((3,4-dimethoxyphenyl)methyl)phenyl group.










dFKBP-30	 The chemical structure of dFKBP-30 features a 3,4,5-trimethoxyphenyl group connected via an ester linkage to a piperidine ring. This piperidine is further linked to a 3,4-dimethoxyphenyl group, which is connected via an ester to a 3,4,5-trimethoxyphenyl group. A long alkyl chain (10 carbons) connects the 3,4-dimethoxyphenyl group to a 3,4-dimethoxyphenyl group, which is then linked via an ester to a 3,4,5-trimethoxyphenyl group. The structure also includes a 3,4,5-trimethoxyphenyl group and a 3,4,5-trimethoxyphenyl group.
dFKBP-32	 The chemical structure of dFKBP-32 is similar to dFKBP-30, but the long alkyl chain connecting the 3,4-dimethoxyphenyl group to the 3,4,5-trimethoxyphenyl group is 12 carbons long.
dFKBP-31	 The chemical structure of dFKBP-31 is similar to dFKBP-30, but the long alkyl chain connecting the 3,4-dimethoxyphenyl group to the 3,4,5-trimethoxyphenyl group is 10 carbons long.
dFKBP-33	 The chemical structure of dFKBP-33 is similar to dFKBP-30, but the long alkyl chain connecting the 3,4-dimethoxyphenyl group to the 3,4,5-trimethoxyphenyl group is 12 carbons long.
dFKBP-38	 The chemical structure of dFKBP-38 features a 3,4,5-trimethoxyphenyl group connected via an ester linkage to a piperidine ring. This piperidine is further linked to a 3,4-dimethoxyphenyl group, which is connected via an ester to a 3,4,5-trimethoxyphenyl group. A long alkyl chain (10 carbons) connects the 3,4-dimethoxyphenyl group to a 3,4-dimethoxyphenyl group, which is then linked via an ester to a 3,4,5-trimethoxyphenyl group. The structure also includes a 3,4,5-trimethoxyphenyl group and a 3,4,5-trimethoxyphenyl group.
dGR1	 The chemical structure of dGR1 features a steroid-like core with a hydroxyl group and a fluorine atom. It is connected via an ester linkage to a piperidine ring, which is further linked to a 3,4-dimethoxyphenyl group, which is connected via an ester to a 3,4,5-trimethoxyphenyl group. A long alkyl chain (10 carbons) connects the 3,4-dimethoxyphenyl group to a 3,4-dimethoxyphenyl group, which is then linked via an ester to a 3,4,5-trimethoxyphenyl group. The structure also includes a 3,4,5-trimethoxyphenyl group and a 3,4,5-trimethoxyphenyl group.










dGR2	
dGR3	










		
N/A	N/A	N/A
		
		
dFKBP-1-I-o	dFKBP-1-I-o''	dFKBP-1-I-p

		
N/A	N/A	N/A
		
		
dFKBP-1-I-p''	dFKBP-2-I-m	dFKBP-2-I-m''










		
N/A	N/A	N/A
		
		
dFKBP-2-I-o	dFKBP-2-I-o''	dFKBP-2-I-p










		
N/A	N/A	N/A
		
		
dFKBP-2-I-p''	dFKBP-2'-I-m	dFKBP-2'-I-m''












		
N/A	N/A	N/A
		
		
dFKBP- 2'-I-o	dFKBP- 2'-I-o''	dFKBP- 2'-I-p













		
N/A	N/A	N/A
		
		
dFKBP-2'-I-p''	dFKBP-3-I-m	dFKBP-3-I-m''













N/A	N/A	N/A
dFKBP-3-I-o	dFKBP-3-I-o''	dFKBP-3-I-p













		
N/A	N/A	N/A
		
		
dFKBP-3-I-p''	dFKBP-4-I-m	dFKBP-4-I-m''













		
N/A	N/A	N/A
		
		
dFKBP-4-I-o	dFKBP-4-I-o''	dFKBP-4-I-p













		
N/A		
		
		
dFKBP-4-I-p''	dFKBP-5-I-m	dFKBP-5-I-m''













		
		
		
		
dFKBP-5-I-o	dFKBP-5-I-o''	dFKBP-5-I-p













		
		
		
		
dFKBP-5-I-p''	dFKBP-6-I-m	dFKBP-6-I-m''













		
		
		
		
dFKBP-6-I-o	dFKBP-6-I-o''	dFKBP-6-I-p













		
		
		
		
dFKBP-6-I-p''	dFKBP-7-I-m	dFKBP-7-I-m''













		
		
		
		
dFKBP-7-I-o	dFKBP-7-I-o''	dFKBP-7-I-p













		
		
		
		
dFKBP-7-I-p''	dFKBP-8-I-m	dFKBP-8-I-m''













		
		
		
		
dFKBP-8-I-o	dFKBP-8-I-o''	dFKBP-8-I-p













		
		
		
		
dFKBP-8-I-p''	dFKBP-9-I-m	dFKBP-9-I-m''













		
		
		
		
dFKBP-9-I-o	dFKBP-9-I-o''	dFKBP-9-I-p













		
		
		
		
dFKBP-9-I-p''	dFKBP-17-I-m	dFKBP-17-I-m''













		
		
		
		
dFKBP-17-I-o	dFKBP-17-I-o	dFKBP-17-I-p













		
		
		
		
dFKBP-17-I-p"	dFKBP-26-I-m	dFKBP-26-I-m"













		
		
		
		
dFKBP- 26-I-o	dFKBP- 26-I-o"	dFKBP- 26-I-p













		
		
		
		
dFKBP-26-I-p"	dFKBP-24-I-m	dFKBP-24-I-m"













		
		
		
		
dFKBP- 24-I-o	dFKBP- 24-I-o	dFKBP- 24-I-p













 Chemical structure of dFKBP-24-I-p, featuring a 6-oxo-1,6-dihydro-2H-pyridine-2-ylidene group linked via an ester to a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, similar to dFKBP-24-I-p but with a different polyether chain length.	 Chemical structure of dFKBP-27-I-m, similar to dFKBP-24-I-p but with a different polyether chain length.
 Chemical structure of dFKBP-24-I-p, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.
 Chemical structure of dFKBP-24-I-p, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.
 Chemical structure of dFKBP-24-I-p, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.	 Chemical structure of dFKBP-27-I-m, showing a repeating unit of a polyether chain with a terminal amide group.
dFKBP-24-I-p"	dFKBP-27-I-m	dFKBP-27-I-m"













 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.
 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.
 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.
 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-o, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.	 Chemical structure of dFKBP-27-I-p, featuring a 27-membered macrocyclic lactone with a 4-methoxyphenyl group and a 4-methoxyphenyl ether linkage.
dFKBP- 27-I-o	dFKBP- 27-I-o"	dFKBP- 27-I-p













 Chemical structure of dFKBP-27-I-p, featuring a 27-membered macrocyclic lactam with a p-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.
 Chemical structure of dFKBP-27-I-p, featuring a 27-membered macrocyclic lactam with a p-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.
 Chemical structure of dFKBP-27-I-p, featuring a 27-membered macrocyclic lactam with a p-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.
 Chemical structure of dFKBP-27-I-p, featuring a 27-membered macrocyclic lactam with a p-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.	 Chemical structure of dFKBP-28-I-m, featuring a 28-membered macrocyclic lactam with a m-phenylene substituent and a polyether chain.
dFKBP-27-I-p"	dFKBP-28-I-m	dFKBP-28-I-m"













		
		
		
		
dFKBP-28-I-o	dFKBP-28-I-o''	dFKBP-28-I-p












		
		
		
		
dFKBP-28-I-p''	dFKBP-25-I-m	dFKBP-25-I-m''













 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.
 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.
 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.
 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-o, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.	 Chemical structure of dFKBP-25-I-p, featuring a polyether backbone with a 25-membered macrocyclic lactone and a 2,5-dimethoxyphenyl group.
dFKBP-25-I-o	dFKBP-25-I-o	dFKBP-25-I-p

 Chemical structure of dFKBP-25-I-p, featuring a polyether chain with a repeating unit of 8, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, featuring a polyether chain with a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, featuring a polyether chain with a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).
 Chemical structure of dFKBP-25-I-p, showing a repeating unit of 8, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).
 Chemical structure of dFKBP-25-I-p, showing a repeating unit of 8, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).
 Chemical structure of dFKBP-25-I-p, showing a repeating unit of 8, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).	 Chemical structure of dFKBP-29-I-m, showing a repeating unit of 10, terminated by a hydroxyl group (H) and a carboxylic acid group (COOH).
dFKBP-25-I-p"	dFKBP-29-I-m	dFKBP-29-I-m"

		
		
		
		
dFKBP- 29-I-o	dFKBP- 29-I-o"	dFKBP- 29-I-p













		
		
		
		
dFKBP- 21-I-o	dFKBP- 21-I-o"	dFKBP- 21-I-p













 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-p, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.
 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-p, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.
 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-p, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.
 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-o, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.	 Chemical structure of dFKBP-16-I-p, featuring a 6-aminocaprolactam core with a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 6-position and a 2-oxo-2,3-dihydro-1H-indolizin-5-yl group at the 1-position.
dFKBP-16-I-o	dFKBP-16-I-o	dFKBP-16-I-p













dFKBP- 16-I-p''			
dFKBP- 20-I-m			
dFKBP- 20-I-m''			













dFKBP-20-I-o	
dFKBP-20-I-o''	
dFKBP-20-I-p	

		
		
		
		
dFKBP-20-I-p''	dFKBP-18-I-m	dFKBP-18-I-m''













dFKBP- 18-I-o				
dFKBP- 18-I-o''				
dFKBP- 18-I-p				

		
		
		
		
dFKBP-18-I-p''	dFKBP-13-I-m	dFKBP-13-I-m''

 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-p: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).
 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-p: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).
 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-p: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).
 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-o: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).	 Chemical structure of dFKBP-13-I-p: A molecule featuring a 5-membered lactam ring (pyrrolidine-2-one) connected via a carbonyl group to a benzene ring. The benzene ring is linked through an ether oxygen to a 6-carbon alkyl chain, which is terminated by a carbamate group (NH-CO-O-).
dFKBP-13-I-o	dFKBP-13-I-o"	dFKBP-13-I-p













		
		
		
		
dFKBP-13-I-p''	dFKBP-14-I-m	dFKBP-14-I-m''













dFKBP-14-I-o	
dFKBP-14-I-o''	
dFKBP-14-I-p	













		
		
		
		
dFKBP-14-I-p''	dFKBP-19-I-m	dFKBP-19-I-m''













dFKBP-19-I-o						
dFKBP-19-I-o''						
dFKBP-19-I-p						













dFKBP-19-I-p''	
dFKBP-15-I-m	
dFKBP-15-I-m''	













		
		
		
		
dFKBP-15-I-o	dFKBP-15-I-o''	dFKBP-15-I-p

		
		
		
		
dFKBP-15-I-p''	dFKBP-A-m	dFKBP-A-m''













		
		
		
		
dFKBP-A-p''	dFKBP-34-I-m	dFKBP-34-I-m''

		
		
		
		
dFKBP-34-I-p''	dFKBP-36-I-m	dFKBP-36-I-m''













 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.
 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.
 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.
 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-o: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.	 Chemical structure of dFKBP-36-I-p: A molecule featuring a 6-aminocapric acid derivative linked via an amide bond to a 2-((2-oxo-2,3,4,5-tetrahydro-1H-benzotriazin-4-ylidene)amino)benzoic acid derivative.
dFKBP-36-I-o	dFKBP-36-I-o"	dFKBP-36-I-p

		
		
		
		
dFKBP-36-I-p''	dFKBP-35-I-m	dFKBP-35-I-m''

dFKBP- 35-I-o			
dFKBP- 35-I-o''			
dFKBP- 35-I-p			

		
		
		
		
dFKBP-35-I-p''	dFKBP-37-I-m	dFKBP-37-I-m''













dFKBP- 37-I-o			
dFKBP- 37-I-o''			

		
		
		
		
dFKBP-37-I-p''	dFKBP-30-I-m	dFKBP-30-I-m''













dFKBP- 30-I-o			
dFKBP- 30-I-o''			
dFKBP- 30-I-p			













dFKBP-30-I-p''	
dFKBP-32-I-m	
dFKBP-32-I-m''	













dFKBP-32-I-o		
dFKBP-32-I-o''		
dFKBP-32-I-p		

		
		
		
		
dFKBP-32-I-p''	dFKBP-31-I-m	dFKBP-31-I-m''

dFKBP-31-I-o	
dFKBP-31-I-o''	
dFKBP-31-I-p	


		
		
		
		
dFKBP-31-I-p''	dFKBP-33-I-m	dFKBP-33-I-m''

		
		
		
		
dFKBP-33-I-o	dFKBP-33-I-o"	dFKBP-33-I-p



		
		
		
		
dFKBP-33-I-p''	dFKBP-38-I-m	dFKBP-38-I-m''

dFKBP-38-I-o	
dFKBP-38-I-o''	
dFKBP-38-I-p	


Some embodiments of the present application also relate to the bifunctional compounds selected from the following:




dFKBP-1-o

dFKBP-1-*p*



dFKBP-2-o





dFKBP-2-p




dFKBP*6-o

dFKBP*6-*p*


dFKBP*7-o

dFKBP*7-*p*


dFKBP*8-o




dFKBP*8-o







dFKBP*9-o




dFKBP*9-p




X2-o







dFKBP14-p




dFKBP15-o




dFKBP15-p




dFKBP16-o




dFKBP16-p




dFKBP17-o







dFKBP19-o








dFKBP19-p




dFKBP20-o









dFKBP26-p




dFKBP27-o




dFKBP27-p




dFKBP28-o




dFKBP28-p




dFKBP29-o




dFKBP29-p




dFKBP30-o







dFKBP30-p




dFKBP31-o




dFKBP31-p







dFKBP34-o







dFKBP34-p




FKBP38-p




FKBP38-o





, and




In certain embodiments, a bifunctional compound of the present application (*e.g.*, a
5 bifunctional compound of any of the formulae described herein, or selected from any
bifunctional compounds described herein) is more efficacious in treating a disease or
condition (*e.g.*, cancer) than the Targeting Ligand, which is covalently bound to the Linker
and Degron in the bifunctional compound. In certain embodiments, a bifunctional compound
of the present application (*e.g.*, a bifunctional compound of any of the formulae described
10 herein, or selected from any bifunctional compounds described herein) is capable of treating a
disease or condition (*e.g.*, cancer) that is resistant to the Targeting Ligand, which is
covalently bound to the Linker and Degron in the bifunctional compound.

In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), comprises the Targeting Ligand, a Linker as described herein, and a Degron of Formula D0, D, D0', D', D1, D2, D3, D'1, D'3, D0'I, D0'II or D0'III. In further embodiments, the bifunctional compound comprises a Targeting Ligand and a Linker, as described herein, and a Degron of Formula D1. In further

embodiments, the Degron selected from Table D. In further embodiments, the Degron is selected from Table D1. In further embodiments, the Degron is selected from Table D2. In further embodiments, the Degron is selected from those in Table D3 and derivatives thereof. In further embodiments, the Degron is selected from those in Table D4 and derivatives

5 thereof. In further embodiments, the Degron is a Linker.



, wherein R is a

In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and
10 Degron in the bifunctional compound), comprises the Targeting Ligand, a Degron as described herein, and a Linker of any of Formulae L0 through L9. In further embodiments, the Linker is selected from Table L.

In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or
15 condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), comprises the Targeting Ligand, and a Degron-Linker selected from DL, DL_a, and DL_b. In further embodiments, the Degron-Linker is selected from DL_a1, DL_a2, and DL_a3. In further embodiments, the Degron-Linker is DL_a1A or DL_a2A. In further embodiments, the Degron-Linker is selected from DL1 to DL7.

20 In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), comprises a Linker and a Degron, as described herein, and a Targeting Ligand selected from Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors,
25 compounds targeting Human BET Bromodomain-containing proteins, compounds targeting cytosolic signaling protein FKBP12, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR). In further embodiments, the Targeting Ligand is a compound that is capable of binding to or binds to a kinase, a BET bromodomain-containing
30 protein, a cytosolic signaling protein (*e.g.*, FKBP12), a nuclear protein, a histone deacetylase, a lysine methyltransferase, a protein regulating angiogenesis, a protein regulating immune

response, an aryl hydrocarbon receptor (AHR), an estrogen receptor, an androgen receptor, a glucocorticoid receptor, or a transcription factor (*e.g.*, SMARCA4, SMARCA2, TRIM24). In further embodiments, the Targeting Ligand is a compound that is capable of binding to or binds to a BET bromodomain-containing protein or a cytosolic signaling protein. In further
 5 embodiments, the Targeting Ligand is of any one of Formulae TL-I to TL-VII. In further embodiments, the Targeting Ligand is of any one of Formulae TL-II, TL-IIa to TL-IId, TL-I2, TL-I2a to TL-I2c, TL-I3, TL-I3a to TL-I3c, TL-III1, TL-III1a, TL-III1 to TL-III3, TL-IV1, and TL-V1. In further embodiments, the Targeting Ligand is of any one of Formulae TL-II, TL-IIa to TL-IId, TL-I2, TL-I2a to TL-I2c, TL-I3, and TL-I3a to TL-I3c. In further
 10 embodiments, the Targeting Ligand is selected from any one of TL1-TL7. In further embodiments, the Targeting Ligand is TL2. In certain embodiments, the Targeting Ligand is selected from Table T.

In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or
 15 condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), is selected from dBET1 to dBET16, dGR1 to dGR3, and dFKBP1 to dFKBP9. In further embodiments, the bifunctional compound is selected from dBET1 to dBET16. In further embodiments, the bifunctional compound is dBET6.

In certain embodiments, the bifunctional compound of the present application that is
 20 more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), is more potent in inhibiting the growth of cells (*e.g.*, cancer cells) or decreasing the viability of cells (*e.g.*, cancer cells), than the Targeting Ligand. In certain embodiments, the bifunctional compound inhibits the growth of cells (*e.g.*, cancer
 25 cells) or decreases the viability of cells (*e.g.*, cancer cells) at an IC_{50} that is lower than the IC_{50} of the Targeting Ligand for inhibiting the growth or decreasing the viability of the cells. In certain embodiments, the IC_{50} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In certain embodiments, the IC_{50} of the
 30 bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In certain embodiments, the IC_{50} of the bifunctional compound is at most 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In certain embodiments, the IC_{50} of the bifunctional compound is at most 10%, 8%,

5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC₅₀ of the Targeting Ligand. In certain embodiments, the IC₅₀ of the bifunctional compound is at most 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC₅₀ of the Targeting Ligand. In certain embodiments, the IC₅₀ of the bifunctional compound is at most 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC₅₀ of the Targeting Ligand. In certain embodiments, the IC₅₀ of the bifunctional compound is at most 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC₅₀ of the Targeting Ligand. In certain embodiments, the bifunctional compound inhibits the growth of cells (*e.g.*, cancer cells) or decreases the viability of cells (*e.g.*, cancer cells) at an E_{max} that is lower than the E_{max} of the Targeting Ligand for inhibiting the growth or decreasing the viability of the cells. In certain embodiments, the E_{max} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the E_{max} of the Targeting Ligand. In certain embodiments, the E_{max} of the bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the E_{max} of the Targeting Ligand. In certain embodiments, the E_{max} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the E_{max} of the Targeting Ligand. In certain embodiments, the E_{max} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, or 30% of the E_{max} of the Targeting Ligand.

In certain embodiments, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand (which is covalently bound to the Linker and Degron in the bifunctional compound), wherein the disease or condition is cancer (*e.g.*, cancer described herein). In further embodiments, the cancer is selected from bladder cancer, brain cancer, breast cancer, colon cancer, gastric cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, astrocytoma, glioblastoma, leukemia, lymphoma, melanoma, and neuroblastoma. In further embodiments, the cancer is selected from breast cancer, gastric cancer, lung cancer, pancreatic cancer, astrocytoma, lymphoma, melanoma, and neuroblastoma.

Some of the foregoing compounds can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, *e.g.*, stereoisomers and/or diastereomers. Thus, inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the application are enantiopure compounds. In certain other embodiments, mixtures of stereoisomers or diastereomers are provided.

Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The application additionally encompasses the compounds as individual isomers substantially free of other isomers and alternatively, as mixtures of various isomers, *e.g.*, racemic mixtures of stereoisomers. In addition to the above-mentioned compounds per se, this application also encompasses pharmaceutically acceptable derivatives of these compounds and compositions comprising one or more compounds of the application and one or more pharmaceutically acceptable excipients or additives.

The present disclosure is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14. For example, when a certain variable (*e.g.*, any of R_2' , R_3 , R_4 , and R_5) in any of the formulae disclosed herein is H or hydrogen, it can be either hydrogen or deuterium.


Compounds of the application may be prepared by crystallization of the compound under different conditions and may exist as one or a combination of polymorphs of the compound forming part of this application. For example, different polymorphs may be identified and/or prepared using different solvents, or different mixtures of solvents for recrystallization; by performing crystallizations at different temperatures; or by using various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffractogram and/or other techniques. Thus, the present application encompasses inventive compounds, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

In certain embodiments, the compounds of the present application are useful as anticancer agents, and thus may be useful in the treatment of cancer, by effecting tumor cell death or inhibiting the growth of tumor cells. In certain exemplary embodiments, the disclosed anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, leukemias (*e.g.*, myeloid,


lymphocytic, myelocytic and lymphoblastic leukemias), malignant melanomas, T-cell lymphoma.

Synthesis of the Compounds of the Application

5 Exemplary synthetic schemes for preparing the bifunctional compounds of the present application are shown in below.



- In one aspect of the application, a method for the synthesis of the core structure of Degron-Linker moiety of certain compounds is provided, the method comprising steps of:
- reacting *tert*-Butyl (2-aminoethyl)carbamate or its analog (*e.g.*, *n* = 1-20) (1) or its analog (*e.g.*, *n* = 1-20) with chloroacetyl chloride under suitable conditions to generate *tert*-butyl (2-(2-chloroacetamido)ethyl)carbamate or its analog (*e.g.*, *n* = 1-20) (2);
 - reacting *tert*-butyl (2-(2-chloroacetamido)ethyl)carbamate or its analog (2) with dimethyl 3-hydroxyphthalate under suitable conditions to provide dimethyl 3-(2-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-oxoethoxy)phthalate or its analog (3);
 - reacting dimethyl 3-(2-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-oxoethoxy)phthalate or its analog (3) with strong base, followed by 3-aminopiperidine-2,6-dione hydrochloride to generate *tert*-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)ethyl)carbamate or its analog (4);
 - deprotecting compound (4) to provide diaminoethyl-acetyl-O-thalidomide trifluoroacetate or its analog (5).



Diaminobutyl-acetyl-O-thalidomide trifluoroacetate can be prepared according to the procedure in Fischer *et al.* Nature, 2014, 512, 49–53.


- 5 In another aspect of the application, a method for the synthesis of the exemplary bifunctional compound is provided, the method comprising reacting a Degron-Linker moiety, for example, compound (5) with an acid derivative of a Target Ligand R - compound (6) under suitable conditions to yield a bifunctional compound (7).

10 Those of skill in the art will realize that based on this teaching and those known in the art, one could prepare any of the compounds of the present application.


In yet another aspect of the application, methods for producing intermediates useful for the preparation of certain compounds of the application are provided.

In some aspects of the application, the Degron-Linker intermediates can be prepared according to the following steps:


15 DL5:



DL6:




DL7:




5

In other aspects of the application, the bifunctional compounds dBET1 – dBET6 can be prepared according to the following schemes using a moiety targeting bromodomain:


dBET1:




dBET2:




ref: ACIEE, 2011, 50, 9378



dBET3:




dBET4:




5

dBET5:




10 dBET6:




In other aspects of the application, the bifunctional compounds dGR1 and dGR2 can be prepared according to the following schemes using TL4 target moiety (dexamethasone):

15

dGR1:




dGR2:



5


In other embodiments of the disclosure, the bifunctional compounds dFKBP-1 and dFKBP-2 can be prepared using TL5 target moiety (AP1479) according to the general methods illustrated above, as shown in the following schemes:

dFKBP-1:




10

dFKBP-2:




Scheme for synthesis of amino acid-thalidomide linker

(1)




(2)




5


(3)




(4)




(5)



(6)



(7)



5

In certain embodiments, the methods described above are carried out in solution phase. In certain other embodiments, the methods described above are carried out on a solid phase. In certain embodiments, the synthetic method is amenable to high-throughput techniques or to techniques commonly used in combinatorial chemistry.

Pharmaceutical Compositions

Accordingly, in another aspect of the present application, pharmaceutical compositions are provided, which comprise any one of the compounds described herein (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), and optionally comprise a pharmaceutically acceptable carrier. In certain
5 embodiments, these compositions optionally further comprise one or more additional therapeutic agents. Alternatively, a compound of this application may be administered to a patient in need thereof in combination with the administration of one or more other therapeutic agents. For example, additional therapeutic agents for conjoint administration or inclusion in a pharmaceutical composition with a compound of this application may be, for
10 example, an approved chemotherapeutic agent, or it may be any one of a number of agents undergoing approval in the Food and Drug Administration that ultimately obtain approval for the treatment of any disorder associated with cellular hyperproliferation. In certain other embodiments, the additional therapeutic agent is an anticancer agent, as discussed in more detail herein.

15 It will also be appreciated that certain of the compounds of present application can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present application, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or a pro-drug or other adduct or derivative of a compound of this application
20 which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like,
25 and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds, are well known in the art. For example, S. M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in J Pharmaceutical Sciences, 66:1-19 (1977), incorporated herein by reference. The salts can be prepared in situ during the final isolation and purification of the compounds of the
30 application, or separately by reacting a free base or free acid function with a suitable reagent, as described generally below. For example, a free base function can be reacted with a suitable acid. Furthermore, where the compounds of the application carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, *e.g.* sodium or potassium salts; and alkaline earth metal salts, *e.g.* calcium or magnesium

salts. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using
5 other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate,
10 lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium,
15 calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

Additionally, as used herein, the term "pharmaceutically acceptable ester" refers to
20 esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include
25 formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

Furthermore, the term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a
30 reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the application. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium

Series, and in Edward B. Roche, ed., *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

As described above, the pharmaceutical compositions of the present application additionally comprise a pharmaceutically acceptable carrier, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the application, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this application. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),

glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

5 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and
10 solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

15 The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

 In order to prolong the effect of a drug, it is often desirable to slow the absorption of
20 the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension or crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in
25 an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in
30 liposomes or microemulsions which are compatible with body tissues.

 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this application with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which

are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one
5 inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain
10 silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills,
15 the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric
20 coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.

Examples of embedding compositions that can be used include polymeric substances
25 and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and
30 granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose and starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, *e.g.*, tableting lubricants and other tableting

aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The present application encompasses pharmaceutically acceptable topical formulations of inventive compounds. The term "pharmaceutically acceptable topical formulation", as used herein, means any formulation which is pharmaceutically acceptable for intradermal administration of a compound of the application by application of the formulation to the epidermis. In certain embodiments of the application, the topical formulation comprises a carrier system. Pharmaceutically effective carriers include, but are not limited to, solvents (*e.g.*, alcohols, poly alcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (*e.g.*, hypotonic or buffered saline) or any other carrier known in the art for topically administering pharmaceuticals. A more complete listing of art-known carriers is provided by reference texts that are standard in the art, for example, Remington's Pharmaceutical Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published by Mack Publishing Company, Easton, Pa., the disclosures of which are incorporated herein by reference in their entireties. In certain other embodiments, the topical formulations of the application may comprise excipients. Any pharmaceutically acceptable excipient known in the art may be used to prepare the inventive pharmaceutically acceptable topical formulations. Examples of excipients that can be included in the topical formulations of the application include, but are not limited to, preservatives, antioxidants, moisturizers, emollients, buffering agents, solubilizing agents, other penetration agents, skin protectants, surfactants, and propellants, and/or additional therapeutic agents used in combination to the inventive compound. Suitable preservatives include, but are not limited to, alcohols, quaternary amines, organic acids, parabens, and phenols. Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents like EDTA and citric acid. Suitable moisturizers include, but are not limited to, glycerine, sorbitol, polyethylene glycols, urea, and propylene glycol. Suitable buffering agents for use with the application include, but are not limited to, citric, hydrochloric, and lactic acid buffers. Suitable solubilizing agents include, but are not limited to, quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates. Suitable

skin protectants that can be used in the topical formulations of the application include, but are not limited to, vitamin E oil, allantoin, dimethicone, glycerin, petrolatum, and zinc oxide.

In certain embodiments, the pharmaceutically acceptable topical formulations of the application comprise at least a compound of the application and a penetration enhancing

5 agent. The choice of topical formulation will depend on several factors, including the condition to be treated, the physicochemical characteristics of the inventive compound and other excipients present, their stability in the formulation, available manufacturing equipment, and costs constraints. As used herein the term "penetration enhancing agent" means an agent capable of transporting a pharmacologically active compound through the
10 stratum corneum and into the epidermis or dermis, preferably, with little or no systemic absorption. A wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, *Percutaneous Penetration Enhancers*, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla. (1995), which surveys the use and testing of various skin penetration enhancers, and
15 Buyuktimkin *et al.*, *Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems*, Gosh T. K., Pfister W. R., Yum S. I. (Eds.), Interpharm Press Inc., Buffalo Grove, Ill. (1997). In certain exemplary embodiments, penetration agents for use with the application include, but are not limited to, triglycerides (*e.g.*, soybean oil), aloe compositions (*e.g.*, aloe-vera gel), ethyl alcohol, isopropyl alcohol,
20 octylphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters (*e.g.*, isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate), and N-methylpyrrolidone.

In certain embodiments, the compositions may be in the form of ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. In certain exemplary
25 embodiments, formulations of the compositions according to the application are creams, which may further contain saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl or oleyl alcohols, and stearic acid being particularly preferred. Creams of the application may also contain a non-ionic surfactant, for example, polyoxy-40-stearate. In certain embodiments, the active component is admixed under sterile
30 conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this application. Additionally, the present application contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are made by dissolving or

dispensing the compound in the proper medium. As discussed above, penetration enhancing agents can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

5 It will also be appreciated that the compounds and pharmaceutical compositions of the present application can be formulated and employed in combination therapies, that is, the compounds and pharmaceutical compositions can be formulated with or administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to
10 employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another immunomodulatory agent or anticancer agent, or they may achieve different effects (*e.g.*,
15 control of any adverse effects).

For example, other therapies or anticancer agents that may be used in combination with the compounds of the present application include surgery, radiotherapy, endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF) to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects
20 (*e.g.*, antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabine, Gemcitabine), spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan),
25 antibiotics (Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), to name a few. For a more comprehensive discussion of updated cancer therapies see, The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference. See also the National Cancer
30 Institute (CNI) website (www.nci.nih.gov) and the Food and Drug Administration (FDA) website for a list of the FDA approved oncology drugs (www.fda.gov/cder/cancer/druglistframe).

In certain embodiments, the pharmaceutical compositions of the present application further comprise one or more additional therapeutically active ingredients (*e.g.*,

chemotherapeutic and/or palliative). For purposes of the application, the term "palliative" refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not curative. For example, palliative treatment encompasses painkillers, antinausea medications and anti-sickness drugs. In addition, chemotherapy, radiotherapy and surgery can all be used palliatively (that is, to reduce symptoms without going for cure; *e.g.*, for shrinking tumors and reducing pressure, bleeding, pain and other symptoms of cancer).

Additionally, the present application provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents.

It will also be appreciated that certain of the compounds of present application can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present application, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or a prodrug or other adduct or derivative of a compound of this application which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.

Methods of Treatment

In general, methods of using the compounds of the present application comprise administering to a subject in need thereof a therapeutically effective amount of a compound of the present application. The compounds of the application are generally inducers of target protein degradation.

In certain embodiments, compounds of the application are useful in the treatment of proliferative diseases (*e.g.*, cancer, benign neoplasms, inflammatory disease, and autoimmune diseases). In certain embodiments, according to the methods of treatment of the present application, levels of cell proteins of interest, *e.g.*, pathogenic and oncogenic proteins are modulated, or their growth is inhibited by contacting said cells with an inventive compound or composition, as described herein. In other embodiments, the compounds are useful in treating cancer. In certain embodiments, the proliferative diseases (*e.g.*, cancer, benign neoplasms, inflammatory disease, and autoimmune diseases) are resistant to treatment with a Targeting Ligand, as described herein.

“Resistant to a Targeting Ligand”, “resistance to a Targeting Ligand”, or “Targeting Ligand resistance”, as used herein, means that a disease or condition cannot be treated by the Targeting Ligand. For example, the Targeting Ligand is incapable of preventing the disease or condition from worsening, or alleviating or reducing one or more symptoms of the disease or condition, or improving the quality of life of a patient suffering from the disease or condition. For example, the Targeting Ligand is incapable of reducing or inhibiting growth or proliferation of a targeted cell (*e.g.*, cancer cell), or inducing death of a targeted cell (*e.g.*, cancer cell). For example, the Targeting Ligand is incapable of inducing degradation of a targeted protein in a targeted (*e.g.*, cancer cell). In another example, the Targeting Ligand can, only at a high concentration (*e.g.*, a concentration higher than the concentration needed of the Targeting Ligand in a non-resistant disease or condition (*e.g.*, at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, 150-fold, 200-fold, or 500-fold higher)), prevent the disease or condition from worsening, or alleviate or reduce one or more symptoms of the disease or condition, or improve the quality of life of a patient suffering from the disease or condition, or reduce or inhibit growth or proliferation of a targeted cell (*e.g.*, cancer cell), or induce death of a targeted cell (*e.g.*, cancer cell), or induce degradation of a targeted protein in a targeted (*e.g.*, cancer cell). In another example, the Targeting Ligand can, only at a high concentration (*e.g.*, a concentration higher than that of a bifunctional compound of the present application (*e.g.*, at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, 150-fold, 200-fold, or 500-fold higher)), prevent the disease or condition from worsening, or alleviate or reduce one or more symptoms of the disease or condition, or improve the quality of life of a patient suffering from the disease or condition, or reduce or inhibit growth or proliferation of a targeted cell (*e.g.*, cancer cell), or induce death of a targeted cell (*e.g.*, cancer cell), or induce degradation of a targeted protein in a targeted (*e.g.*, cancer cell).

Thus, in another aspect of the application, methods for the treatment of cancer are provided comprising administering a therapeutically effective amount of an inventive compound, as described herein, to a subject in need thereof. In certain embodiments, a method for the treatment of cancer is provided comprising administering a therapeutically effective amount of an inventive compound, or a pharmaceutical composition comprising an inventive compound to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result. Preferably, the compounds of present application are administered orally or intravenously. In certain embodiments of the present application a "therapeutically effective amount" of the inventive compound or pharmaceutical composition

is that amount effective for killing or inhibiting the growth of tumor cells. The compounds and compositions, according to the method of the present application, may be administered using any amount and any route of administration effective for killing or inhibiting the growth of tumor cells. Thus, the expression "amount effective to kill or inhibit the growth of tumor cells," as used herein, refers to a sufficient amount of agent to kill or inhibit the growth of tumor cells. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular anticancer agent, its mode of administration, and the like. In certain embodiments of the present application a "therapeutically effective amount" of the inventive compound or pharmaceutical composition is that amount effective for reducing the levels of target proteins. In certain embodiments of the present application a "therapeutically effective amount" of the compound or pharmaceutical composition is that amount effective to kill or inhibit the growth of skin cells.

In certain embodiments, the method involves the administration of a therapeutically effective amount of the compound or a pharmaceutically acceptable derivative thereof to a subject (including, but not limited to a human or animal) in need of it. In certain embodiments, the bifunctional compounds are useful for the treatment of cancer (including, but not limited to, glioblastoma, retinoblastoma, breast cancer, cervical cancer, colon and rectal cancer, leukemia, lymphoma, lung cancer (including, but not limited to small cell lung cancer), melanoma and/or skin cancer, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer and gastric cancer, bladder cancer, uterine cancer, kidney cancer, testicular cancer, stomach cancer, brain cancer, liver cancer, or esophageal cancer.

In certain embodiments, the inventive anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, and gastric cancer. In certain embodiments, the inventive anticancer agents are active against solid tumors.

In certain embodiments, the inventive compounds also find use in the prevention of restenosis of blood vessels subject to traumas such as angioplasty and stenting. For example, it is contemplated that the compounds of the application will be useful as a coating for implanted medical devices, such as tubings, shunts, catheters, artificial implants, pins, electrical implants such as pacemakers, and especially for arterial or venous stents, including balloon-expandable stents. In certain embodiments inventive compounds may be bound to an

implantable medical device, or alternatively, may be passively adsorbed to the surface of the implantable device. In certain other embodiments, the inventive compounds may be formulated to be contained within, or, adapted to release by a surgical or medical device or implant, such as, for example, stents, sutures, indwelling catheters, prosthesis, and the like.

5 For example, drugs having antiproliferative and anti-inflammatory activities have been evaluated as stent coatings, and have shown promise in preventing restenosis (See, for example, Presbitero P. *et al.*, "Drug eluting stents do they make the difference?", *Minerva Cardioangiol*, 2002, 50(5):431-442; Ruygrok P. N. *et al.*, "Rapamycin in cardiovascular medicine", *Intern. Med. J.*, 2003, 33(3):103-109; and Marx S. O. *et al.*, "Bench to bedside: the development of rapamycin and its application to stent restenosis", *Circulation*, 2001, 104(8):852-855, each of these references is incorporated herein by reference in its entirety).

Accordingly, without wishing to be bound to any particular theory, Applicant proposes that inventive compounds having antiproliferative effects can be used as stent coatings and/or in stent drug delivery devices, inter alia for the prevention of restenosis or reduction of

15 restenosis rate. Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer,

polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable

20 topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition. A variety of compositions and methods related to stent coating and/or local stent drug delivery for preventing restenosis are known in the art (see, for example, U.S. Pat. Nos. 6,517,889;

6,273,913; 6,258,121; 6,251,136; 6,248,127; 6,231,600; 6,203,551; 6,153,252; 6,071,305;

25 5,891,507; 5,837,313 and published U.S. patent application No.: US2001/0027340, each of which is incorporated herein by reference in its entirety). For example, stents may be coated with polymer-drug conjugates by dipping the stent in polymer-drug solution or spraying the

stent with such a solution. In certain embodiment, suitable materials for the implantable device include biocompatible and nontoxic materials, and may be chosen from the metals

such as nickel-titanium alloys, steel, or biocompatible polymers, hydrogels, polyurethanes,

30 polyethylenes, ethylenevinyl acetate copolymers, *etc.* In certain embodiments, the inventive compound is coated onto a stent for insertion into an artery or vein following balloon angioplasty.

The compounds of this application or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present application, in another aspect, includes a composition for coating an implantable
5 device comprising a compound of the present application as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present application includes an implantable device coated with a composition comprising a compound of the present application as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable
10 device.

Additionally, the present application provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents.

15 Another aspect of the application relates to a method of treating or lessening the severity of a disease or condition associated with a proliferation disorder in a patient, said method comprising a step of administering to said patient, a compound of Formula I or a composition comprising said compound.

It will be appreciated that the compounds and compositions, according to the method
20 of the present application, may be administered using any amount and any route of administration effective for the treatment of cancer and/or disorders associated with cell hyperproliferation. For example, when using the inventive compounds for the treatment of cancer, the expression "effective amount" as used herein, refers to a sufficient amount of agent to inhibit cell proliferation, or refers to a sufficient amount to reduce the effects of
25 cancer. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the diseases, the particular anticancer agent, its mode of administration, and the like.

The compounds of the application are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used
30 herein refers to a physically discrete unit of therapeutic agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present application will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder

being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or
5 coincidental with the specific compound employed; and like factors well known in the medical arts (see, for example, Goodman and Gilman's, "The Pharmacological Basis of Therapeutics", Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is incorporated herein by reference in its entirety).

Furthermore, after formulation with an appropriate pharmaceutically acceptable
10 carrier in a desired dosage, the pharmaceutical compositions of this application can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, creams or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the application may be administered at
15 dosage levels of about 0.001 mg/kg to about 50 mg/kg, from about 0.01 mg/kg to about 25 mg/kg, or from about 0.1 mg/kg to about 10 mg/kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. It will also be appreciated that dosages smaller than 0.001 mg/kg or greater than 50 mg/kg (for example 50-100 mg/kg) can be administered to a subject. In certain embodiments, compounds are administered orally or
20 parenterally.

The present application provides methods for the treatment of a cell proliferative disorder in a subject in need thereof by administering to a subject in need of such treatment, a therapeutically effective amount of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof. The cell
25 proliferative disorder can be cancer or a precancerous condition. The present application further provides the use of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, for the preparation of a medicament useful for the treatment of a cell proliferative disorder.

The present application also provides methods of protecting against a cell
30 proliferative disorder in a subject in need thereof by administering a therapeutically effective amount of compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, to a subject in need of such treatment. The cell proliferative disorder can be cancer or a precancerous condition. The present application also provides the use of compound of the present application, or a

pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, for the preparation of a medicament useful for the prevention of a cell proliferative disorder.

As used herein, a “subject in need thereof” is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder
5 relative to the population at large. A subject in need thereof can have a precancerous condition. Preferably, a subject in need thereof has cancer. A “subject” includes a mammal. The mammal can be *e.g.*, any mammal, *e.g.*, a human, primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig. Preferably, the mammal is a human.

As used herein, the term “cell proliferative disorder” refers to conditions in which
10 unregulated or abnormal growth, or both, of cells can lead to the development of an unwanted condition or disease, which may or may not be cancerous. Exemplary cell proliferative disorders of the application encompass a variety of conditions wherein cell division is deregulated. Exemplary cell proliferative disorder include, but are not limited to, neoplasms, benign tumors, malignant tumors, pre-cancerous conditions, *in situ* tumors, encapsulated
15 tumors, metastatic tumors, liquid tumors, solid tumors, immunological tumors, hematological tumors, cancers, carcinomas, leukemias, lymphomas, sarcomas, and rapidly dividing cells. The term “rapidly dividing cell” as used herein is defined as any cell that divides at a rate that exceeds or is greater than what is expected or observed among neighboring or juxtaposed cells within the same tissue. A cell proliferative disorder includes a precancer or a
20 precancerous condition. A cell proliferative disorder includes cancer. Preferably, the methods provided herein are used to treat or alleviate a symptom of cancer. The term “cancer” includes solid tumors, as well as, hematologic tumors and/or malignancies. A “precancer cell” or “precancerous cell” is a cell manifesting a cell proliferative disorder that is a precancer or a precancerous condition. A “cancer cell” or “cancerous cell” is a cell
25 manifesting a cell proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells or precancerous cells. Cancer cells or precancerous cells can be identified by histological typing or grading of a tissue sample (*e.g.*, a biopsy sample). Cancer cells or precancerous cells can be identified through the use of appropriate molecular markers.

30 Exemplary non-cancerous conditions or disorders include, but are not limited to, rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary

inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain;
 5 allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple
 10 Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus.

Exemplary cancers include, but are not limited to, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma,
 15 basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and
 20 hypothalamic glioma, breast cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid neoplasm, mycosis
 25 fungoides, Sezary Syndrome, endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor glioma, head and neck cancer, hepatocellular (liver)
 30 cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, ocular cancer, islet cell tumors (endocrine pancreas), Kaposi Sarcoma, kidney cancer, renal cancer, kidney cancer, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-

related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, merkel cell carcinoma, mesothelioma malignant, mesothelioma, metastatic squamous neck cancer, mouth cancer, cancer of the tongue, multiple endocrine neoplasia

5 syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/ myeloproliferative diseases, chronic myelogenous leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low malignant potential tumor, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and

10 nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, ewing family of sarcoma tumors, Kaposi Sarcoma, soft tissue sarcoma, uterine

15 cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor,

20 urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer, and Wilm's Tumor.

A "cell proliferative disorder of the hematologic system" is a cell proliferative disorder involving cells of the hematologic system. A cell proliferative disorder of the hematologic system can include lymphoma, leukemia, myeloid neoplasms, mast cell

25 neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid granulomatosis, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. A cell proliferative disorder of the hematologic system can include hyperplasia, dysplasia, and metaplasia of cells of the hematologic system. Preferably, compositions of the present application may be used to treat

30 a cancer selected from the group consisting of a hematologic cancer of the present application or a hematologic cell proliferative disorder of the present application. A hematologic cancer of the present application can include multiple myeloma, lymphoma (including Hodgkin's lymphoma, non-Hodgkin's lymphoma, childhood lymphomas, and lymphomas of lymphocytic and cutaneous origin), leukemia (including childhood leukemia, hairy-cell

leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia), myeloid neoplasms and mast cell neoplasms.

A “cell proliferative disorder of the lung” is a cell proliferative disorder involving
5 cells of the lung. Cell proliferative disorders of the lung can include all forms of cell proliferative disorders affecting lung cells. Cell proliferative disorders of the lung can include lung cancer, a precancer or precancerous condition of the lung, benign growths or lesions of the lung, and malignant growths or lesions of the lung, and metastatic lesions in
10 tissue and organs in the body other than the lung. Preferably, compositions of the present application may be used to treat lung cancer or cell proliferative disorders of the lung. Lung cancer can include all forms of cancer of the lung. Lung cancer can include malignant lung neoplasms, carcinoma *in situ*, typical carcinoid tumors, and atypical carcinoid tumors. Lung cancer can include small cell lung cancer (“SCLC”), non-small cell lung cancer (“NSCLC”), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, large cell carcinoma,
15 adenosquamous cell carcinoma, and mesothelioma. Lung cancer can include “scar carcinoma”, bronchioalveolar carcinoma, giant cell carcinoma, spindle cell carcinoma, and large cell neuroendocrine carcinoma. Lung cancer can include lung neoplasms having histologic and ultrastructural heterogeneity (e.g., mixed cell types).

Cell proliferative disorders of the lung can include all forms of cell proliferative
20 disorders affecting lung cells. Cell proliferative disorders of the lung can include lung cancer, precancerous conditions of the lung. Cell proliferative disorders of the lung can include hyperplasia, metaplasia, and dysplasia of the lung. Cell proliferative disorders of the lung can include asbestos-induced hyperplasia, squamous metaplasia, and benign reactive mesothelial metaplasia. Cell proliferative disorders of the lung can include replacement of
25 columnar epithelium with stratified squamous epithelium, and mucosal dysplasia. Individuals exposed to inhaled injurious environmental agents such as cigarette smoke and asbestos may be at increased risk for developing cell proliferative disorders of the lung. Prior lung diseases that may predispose individuals to development of cell proliferative disorders of the lung can include chronic interstitial lung disease, necrotizing pulmonary disease, scleroderma,
30 rheumatoid disease, sarcoidosis, interstitial pneumonitis, tuberculosis, repeated pneumonias, idiopathic pulmonary fibrosis, granulomata, asbestosis, fibrosing alveolitis, and Hodgkin's disease.

A “cell proliferative disorder of the colon” is a cell proliferative disorder involving cells of the colon. Preferably, the cell proliferative disorder of the colon is colon cancer.

Preferably, compositions of the present application may be used to treat colon cancer or cell proliferative disorders of the colon. Colon cancer can include all forms of cancer of the colon. Colon cancer can include sporadic and hereditary colon cancers. Colon cancer can include malignant colon neoplasms, carcinoma *in situ*, typical carcinoid tumors, and atypical
5 carcinoid tumors. Colon cancer can include adenocarcinoma, squamous cell carcinoma, and adenosquamous cell carcinoma. Colon cancer can be associated with a hereditary syndrome selected from the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis. Colon cancer can be caused by a hereditary syndrome selected from
10 the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis.

Cell proliferative disorders of the colon can include all forms of cell proliferative disorders affecting colon cells. Cell proliferative disorders of the colon can include colon
15 cancer, precancerous conditions of the colon, adenomatous polyps of the colon and metachronous lesions of the colon. A cell proliferative disorder of the colon can include adenoma. Cell proliferative disorders of the colon can be characterized by hyperplasia, metaplasia, and dysplasia of the colon. Prior colon diseases that may predispose individuals to development of cell proliferative disorders of the colon can include prior colon cancer.
20 Current disease that may predispose individuals to development of cell proliferative disorders of the colon can include Crohn's disease and ulcerative colitis. A cell proliferative disorder of the colon can be associated with a mutation in a gene selected from the group consisting of p53, *ras*, *FAP* and *DCC*. An individual can have an elevated risk of developing a cell proliferative disorder of the colon due to the presence of a mutation in a gene selected from
25 the group consisting of p53, *ras*, *FAP* and *DCC*.

A "cell proliferative disorder of the pancreas" is a cell proliferative disorder involving cells of the pancreas. Cell proliferative disorders of the pancreas can include all forms of cell proliferative disorders affecting pancreatic cells. Cell proliferative disorders of the pancreas can include pancreas cancer, a precancer or precancerous condition of the
30 pancreas, hyperplasia of the pancreas, and dysaplasia of the pancreas, benign growths or lesions of the pancreas, and malignant growths or lesions of the pancreas, and metastatic lesions in tissue and organs in the body other than the pancreas. Pancreatic cancer includes all forms of cancer of the pancreas. Pancreatic cancer can include ductal adenocarcinoma, adenosquamous carcinoma, pleomorphic giant cell carcinoma, mucinous adenocarcinoma,

osteoclast-like giant cell carcinoma, mucinous cystadenocarcinoma, acinar carcinoma, unclassified large cell carcinoma, small cell carcinoma, pancreatoblastoma, papillary neoplasm, mucinous cystadenoma, papillary cystic neoplasm, and serous cystadenoma. Pancreatic cancer can also include pancreatic neoplasms having histologic and ultrastructural
5 heterogeneity (*e.g.*, mixed cell types).

A “cell proliferative disorder of the prostate” is a cell proliferative disorder involving cells of the prostate. Cell proliferative disorders of the prostate can include all forms of cell proliferative disorders affecting prostate cells. Cell proliferative disorders of the prostate can include prostate cancer, a precancer or precancerous condition of the prostate, benign growths
10 or lesions of the prostate, and malignant growths or lesions of the prostate, and metastatic lesions in tissue and organs in the body other than the prostate. Cell proliferative disorders of the prostate can include hyperplasia, metaplasia, and dysplasia of the prostate.

A “cell proliferative disorder of the skin” is a cell proliferative disorder involving cells of the skin. Cell proliferative disorders of the skin can include all forms of cell
15 proliferative disorders affecting skin cells. Cell proliferative disorders of the skin can include a precancer or precancerous condition of the skin, benign growths or lesions of the skin, melanoma, malignant melanoma and other malignant growths or lesions of the skin, and metastatic lesions in tissue and organs in the body other than the skin. Cell proliferative disorders of the skin can include hyperplasia, metaplasia, and dysplasia of the skin.

A “cell proliferative disorder of the ovary” is a cell proliferative disorder involving cells of the ovary. Cell proliferative disorders of the ovary can include all forms of cell
20 proliferative disorders affecting cells of the ovary. Cell proliferative disorders of the ovary can include a precancer or precancerous condition of the ovary, benign growths or lesions of the ovary, ovarian cancer, malignant growths or lesions of the ovary, and metastatic lesions in
25 tissue and organs in the body other than the ovary. Cell proliferative disorders of the skin can include hyperplasia, metaplasia, and dysplasia of cells of the ovary.

A “cell proliferative disorder of the breast” is a cell proliferative disorder involving cells of the breast. Cell proliferative disorders of the breast can include all forms of cell
30 proliferative disorders affecting breast cells. Cell proliferative disorders of the breast can include breast cancer, a precancer or precancerous condition of the breast, benign growths or lesions of the breast, and malignant growths or lesions of the breast, and metastatic lesions in
tissue and organs in the body other than the breast. Cell proliferative disorders of the breast can include hyperplasia, metaplasia, and dysplasia of the breast.

A cancer that is to be treated can be staged according to the American Joint Committee on Cancer (AJCC) TNM classification system, where the tumor (T) has been assigned a stage of TX, T1, T1mic, T1a, T1b, T1c, T2, T3, T4, T4a, T4b, T4c, or T4d; and where the regional lymph nodes (N) have been assigned a stage of NX, N0, N1, N2, N2a, N2b, N3, N3a, N3b, or N3c; and where distant metastasis (M) can be assigned a stage of MX, M0, or M1. A cancer that is to be treated can be staged according to an American Joint Committee on Cancer (AJCC) classification as Stage I, Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC, or Stage IV. A cancer that is to be treated can be assigned a grade according to an AJCC classification as Grade GX (*e.g.*, grade cannot be assessed), Grade 1, Grade 2, Grade 3 or Grade 4. A cancer that is to be treated can be staged according to an AJCC pathologic classification (pN) of pNX, pN0, PN0 (I-), PN0 (I+), PN0 (mol-), PN0 (mol+), PN1, PN1(mi), PN1a, PN1b, PN1c, pN2, pN2a, pN2b, pN3, pN3a, pN3b, or pN3c.

A cancer that is to be treated can include a tumor that has been determined to be less than or equal to about 2 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be from about 2 to about 5 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be greater than or equal to about 3 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be greater than 5 centimeters in diameter. A cancer that is to be treated can be classified by microscopic appearance as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. A cancer that is to be treated can be classified by microscopic appearance with respect to mitosis count (*e.g.*, amount of cell division) or nuclear pleiomorphism (*e.g.*, change in cells). A cancer that is to be treated can be classified by microscopic appearance as being associated with areas of necrosis (*e.g.*, areas of dying or degenerating cells). A cancer that is to be treated can be classified as having an abnormal karyotype, having an abnormal number of chromosomes, or having one or more chromosomes that are abnormal in appearance. A cancer that is to be treated can be classified as being aneuploid, triploid, tetraploid, or as having an altered ploidy. A cancer that is to be treated can be classified as having a chromosomal translocation, or a deletion or duplication of an entire chromosome, or a region of deletion, duplication or amplification of a portion of a chromosome.

A cancer that is to be treated can be evaluated by DNA cytometry, flow cytometry, or image cytometry. A cancer that is to be treated can be typed as having 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of cells in the synthesis stage of cell division (*e.g.*, in S

phase of cell division). A cancer that is to be treated can be typed as having a low S-phase fraction or a high S-phase fraction.

As used herein, a “normal cell” is a cell that cannot be classified as part of a “cell proliferative disorder”. A normal cell lacks unregulated or abnormal growth, or both, that can lead to the development of an unwanted condition or disease. Preferably, a normal cell possesses normally functioning cell cycle checkpoint control mechanisms.

As used herein, “contacting a cell” refers to a condition in which a compound or other composition of matter is in direct contact with a cell, or is close enough to induce a desired biological effect in a cell.

As used herein, “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.

A compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, can also be used to prevent a disease, condition or disorder. As used herein, “preventing” or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.

As used herein, the term “alleviate” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased. Importantly, a sign or symptom can be alleviated without being eliminated. In a preferred embodiment, the administration of pharmaceutical compositions of the application leads to the elimination of a sign or symptom, however, elimination is not required. Effective dosages are expected to decrease the severity of a sign or symptom. For instance, a sign or symptom of a disorder such as cancer, which can occur in multiple locations, is alleviated if the severity of the cancer is decreased within at least one of multiple locations.

The compounds described herein (*e.g.*, the bifunctional compounds), once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have the desired biological activity. For example, the molecules can be characterized by conventional assays, including but not limited to those assays described below (*e.g.*, treating cells of interest, such as MV4-11 cells, human cell line MM1S, or a human cell line MM1S that is deficient in cereblon, with a test compound and then performing immunoblotting against the indicated proteins such as BRD2, BRD3, and BRD4, or treating certain cells of interest with a test compound and then measuring BRD4 transcript

levels via qRT-PCR), to determine whether they have a predicted activity, binding activity and/or binding specificity.

One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (2005); Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (3rd edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000); Coligan *et al.*, *Current Protocols in Immunology*, John Wiley & Sons, N.Y.; Enna *et al.*, *Current Protocols in Pharmacology*, John Wiley & Sons, N.Y.; Fingl *et al.*, *The Pharmacological Basis of Therapeutics* (1975), *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 18th edition (1990). These texts can, of course, also be referred to in making or using an aspect of the application

Definitions

Certain compounds of the present application, and definitions of specific functional groups are also described in more detail below.

It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term "substituted" whether preceded by the term "optionally" or not, and substituents contained in formulas of this application, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. For purposes of this application, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.

The term "Linker", "linker", "Linker group" or "linker group" as used herein, refers to a chemical moiety utilized to attach one part of a compound of interest to another compound of interest. These binding moieties of the present application are linked to the ubiquitin ligase binding moiety preferably through a Linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation. Exemplary Linkers are described herein.

The term "compound" or "chemical compound" as used herein can include organometallic compounds, organic compounds, metals, transitional metal complexes, and small molecules. In certain preferred embodiments, polynucleotides are excluded from the definition of compounds. In other preferred embodiments, polynucleotides and peptides are excluded from the definition of compounds. In a particularly preferred embodiment, the term compounds refers to small molecules (*e.g.*, preferably, non-peptidic and non-oligomeric) and excludes peptides, polynucleotides, transition metal complexes, metals, and organometallic compounds.

As used herein, the term "small molecule" refers to a non-peptidic, non-oligomeric organic compound either synthesized in the laboratory or found in nature. Small molecules, as used herein, can refer to compounds that are "natural product-like", however, the term "small molecule" is not limited to "natural product-like" compounds. Rather, a small molecule is typically characterized in that it contains several carbon-carbon bonds, and has a molecular weight of less than 2000 g/mol, preferably less than 1500 g/mol, although this characterization is not intended to be limiting for the purposes of the present application. In certain other preferred embodiments, synthetic small molecules are utilized.

The term "independently" is used herein to indicate that the variable, such as atom or functional group, which is independently applied, varies independently from application to application. For example, where more than one substituent or atom (carbon or heteroatom, such as oxygen (O), sulfur (S), or nitrogen (N)) occurs, each substituent or atom is independent of another substituent or atom and such substituents or atom can also alternate.

In chemistry, a "derivative" is a compound that is derived from a similar compound by some chemical or physical process. It is also used to mean that a compound can arise from another compound, if one atom is replaced with another atom or group of atoms. A term "structural analogue" can be also used for this meaning.

The term "structural analogue" or term "analogue" has always been used to describe structural and functional similarity. Extended to drugs, this definition implies that the analogue of an existing drug molecule shares structural and pharmacological similarities with the original compound. Formally, this definition allows the establishment of three categories of drug analogues: analogues possessing chemical and pharmacological similarities (direct analogues); analogues possessing structural similarities only (structural analogues); and chemically different compounds displaying similar pharmacological properties (functional analogues). For example, lenalidomide and pomalidomide are among thalidomide analogs, and are believed to act in a similar fashion.

The term "E3 Ubiquitin Ligase" or "Ubiquitin Ligase" (UL) is used herein to describe a target enzyme(s) binding site of ubiquitin ligase moieties in the bifunctional compounds according to the present application. E3 UL is a protein that in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein; the E3 ubiquitin ligase targets specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first, a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to monoubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.

The term "protein target moiety" or "target protein ligand" is used herein to describe a small molecule, which is capable of binding to or binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur. Any protein, which can bind to a protein target moiety and acted on or degraded by an ubiquitin ligase is a target protein according to the present application. In general, target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity,

carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eukaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, 5 microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others. Non-limiting examples of small molecule target protein binding moieties include Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, 10 human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of these small molecule target protein.

As used herein, the term “BRD4” or “Brd4” relates to Bromodomain-containing 15 protein 4 is a protein that in humans is encoded by the BRD4 gene. BRD4 is a member of the BET (bromodomain and extra terminal domain) family, along with BRD2, BRD3, and BRDT. BRD4, similar to its BET family members, contains two bromodomains that recognize acetylated lysine residues. An increase in Brd4 expression led to increased P-TEFb-dependent phosphorylation of RNA polymerase II (RNAPII) CTD and stimulation of 20 transcription from promoters in vivo. Conversely, a reduction in Brd4 expression by siRNA reduced CTD phosphorylation and transcription, revealing that Brd4 is a positive regulatory component of P-TEFb. In chromatin immunoprecipitation (ChIP) assays, the recruitment of P-TEFb to a promoter was dependent on Brd4 and was enhanced by an increase in chromatin acetylation. Together, P-TEFb alternately interacts with Brd4 and the inhibitory subunit to 25 maintain functional equilibrium in the cell.

BRD4 is an exemplary, non-enzymatic protein target. BRD4 is a transcriptional co-activator involved in dynamic transcriptional activation and elongation. BRD4 binds to enhancer and promoter regions adjacent to target genes, via recognition of side-chain acetylated lysine on histone proteins and transcription factors (TFs) by twin acetyl-lysine 30 binding modules or bromodomains. Recently, a first direct-acting inhibitor of BET bromodomains (JQ1) was developed (P. Filippakopoulos *et al.*, *Nature* **468**, 1067-1073 (2010)), that displaces BRD4 from chromatin leading to impaired signal transduction from master regulatory TFs to RNA Polymerase II (B. Chapuy *et al.*, *Cancer Cell* **24**, 777-790 (2013); J. E. Delmore *et al.*, *Cell* **146**, 904-917 (2011); J. Lovén *et al.*, *Cell* **153**, 320-334

(2013).). Molecular recognition of the BRD4 bromodomains by JQ1 is stereo-specific, and only the (+)-JQ1 enantiomer (JQ1S; from here forward JQ1) is active; the (-)-JQ1 enantiomer (JQ1R) is inactive. Silencing of BRD4 expression by RNA interference in murine and human models of MM and acute myeloid leukemia (AML) elicited rapid transcriptional
5 downregulation of the *MYC* oncogene and a potent anti-proliferative response (J. E. Delmore *et al.*, *Cell* **146**, 904-917 (2011); J. Zuber *et al.*, *Nature* **478**, 524-528 (2011)). These and other studies in cancer, inflammation (E. Nicodeme *et al.*, *Nature* **468**, 1119-1123 (2010)) and heart disease (P. Anand *et al.*, *Cell* **154**, 569-582 (2013); J. D. Brown *et al.*, *Mol. Cell* **56**, 219-231 (2014)), establish a desirable mechanistic and translational purpose to target BRD4
10 for selective degradation.

As used herein, the term “FKBP” relates to a family of proteins that have prolyl isomerase activity and are related to the cyclophilins in function, though not in amino acid sequence (Siekierka *et al.* *Nature* **341** (6244): 755–7 (1989)). FKBP s have been identified in many eukaryotes from yeast to humans and function as protein folding chaperones for
15 proteins containing proline residues. Along with cyclophilin, FKBP s belong to the immunophilin family (Balbach *et al.* *Mechanisms of protein folding* (2nd ed.). Oxford: Oxford University Press. pp. 212–237 (2000)). Cytosolic signaling protein FKBP12 is notable in humans for binding the immunosuppressant molecule tacrolimus (originally designated FK506), which is used in treating patients after organ transplant and patients
20 suffering from autoimmune disorders (Wang *et al.* *Science* **265** (5172): 674–6 (1994)). Tacrolimus has been found to reduce episodes of organ rejection over a related treatment, the drug ciclosporin, which binds cyclophilin (Mayer *et al.* *Transplantation* **64** (3): 436–43 (1997)). Both the FKBP-tacrolimus complex and the ciclosporin-cyclophilin complex inhibit a phosphatase called calcineurin, thus blocking signal transduction in the T-
25 lymphocy tetransduction pathway (Liu *et al.* *Cell* **66** (4): 807–15 (1991)). This therapeutic role is not related to prolyl isomerase activity. AP1497 (Table 1, TL5) is a synthetic peptidyl α -ketoamide designed to be recognized by FKBP12 (Holt *et al.*, *J. Am. Chem. Soc.* **115**, 9925 (1993))

As used herein the term “CREBBP” relates to CREB binding protein. This gene is
30 ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to

transcription factor recognition. Chromosomal translocations involving this gene have been associated with acute myeloid leukemia.

As used herein the term “SMARCA4” relates to transcription activator BRG1 also known as ATP-dependent helicase SMARCA4 is a protein that in humans is encoded by the SMARCA4 gene. Mutations in this gene were first recognized in human lung cancer cell lines. It has been demonstrated that BRG1 plays a role in the control of retinoic acid and glucocorticoid-induced cell differentiation in lung cancer and in other tumor types.

As used herein the term “nuclear receptor” relates to a class of proteins found within cells that are responsible for sensing steroid and thyroid hormones and certain other molecules. In response, these receptors work with other proteins to regulate the expression of specific genes, thereby controlling the development, homeostasis, and metabolism of the organism. Since the expression of a large number of genes is regulated by nuclear receptors, ligands that activate these receptors can have profound effects on the organism.

The representative examples which follow are intended to help illustrate the application, and are not intended to, nor should they be construed to, limit the scope of the application. Indeed, various modifications of the application and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. It should further be appreciated that, unless otherwise indicated, the entire contents of each of the references cited herein are incorporated herein by reference to help illustrate the state of the art. The following examples contain important additional information, exemplification and guidance which can be adapted to the practice of this application in its various embodiments and the equivalents thereof.

These and other aspects of the present application will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain particular embodiments of the application but are not intended to limit its scope, as defined by the claims.

EXAMPLES

General Description of Synthetic Methods

The various references cited herein provide helpful background information on preparing compounds similar to the inventive compounds described herein or relevant


intermediates, as well as information on formulation, uses, and administration of such compounds which may be of interest.

Moreover, the practitioner is directed to the specific guidance and examples provided in this document relating to various exemplary compounds and intermediates thereof.

According to the present application, any available techniques can be used to make or prepare the inventive compounds or compositions including them. For example, a variety of a variety combinatorial techniques, parallel synthesis and/or solid phase synthetic methods such as those discussed in detail below may be used. Alternatively or additionally, the inventive compounds may be prepared using any of a variety of solution phase synthetic methods known in the art.

The starting materials, intermediates, and compounds of this application may be isolated and purified using conventional techniques, including filtration, distillation, crystallization, chromatography, and the like. They may be characterized using conventional methods, including physical constants and spectral data.

Synthesis of IMiD derivatives and Degrons



General procedure I: IMiD condensation

2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (D-1)

In a 20 mL glass vial, a mixture of 3-hydroxyphthalic anhydride (500 mg, 3.05 mmol, 1 equiv), potassium acetate (927 mg, 9.44 mmol, 3.1 equiv) and 3-aminopiperidine-2,6-dione hydrochloride (552 mg, 3.35 mmol, 1.1 equiv) in acetic acid (10.2 mL, 0.3 M) was heated to 90 °C overnight. The black reaction mixture was cooled to room temperature and diluted to 20 mL with water, and subsequently cooled on ice for 30 min. The resulting slurry was transferred to a 50 mL Falcon tube, which was centrifuged at 3500 rpm for 5 min. The supernatant was discarded and the black solid was transferred to a 250 mL RBF with methanol and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (CH₂Cl₂:MeOH (9:1)) to afford the title compound as a white solid (619 mg, 74%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.07 (s, 1H), 7.65 (dd, *J* = 8.4, 6.8 Hz, 1H), 7.31 (d, *J* = 6.8 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 1H), 5.06 (dd, *J* = 12.8, 5.4 Hz, 1H),

2.94 – 2.82 (m, 1H), 2.64 – 2.43 (m, 2H), 2.08 – 1.97 (m, 1H); MS (ESI) calcd for $C_{13}H_{11}N_2O_5$ $[M+H]^+$ 275.07, found 275.26.

2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione (D-10)

General procedure I was followed using 3-nitrophthalic anhydride (300 mg, 1.55 mmol, 1 equiv), potassium acetate (473 mg, 4.82 mmol, 3.1 equiv) and 3-aminopiperidine-2,6-dione hydrochloride (281 mg, 1.71 mmol, 1.1 equiv) to afford the title compound as a light yellow solid (280 mg, 59%) following purification by flash column chromatography on silica gel (CH_2Cl_2 :MeOH (9:1)). ^1H NMR (500 MHz, $DMSO-d_6$) δ 11.17 (s, 1H), 8.35 (d, J = 8.1 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H), 8.14 – 8.10 (m, 1H), 5.20 (dd, J = 12.9, 5.5 Hz, 1H), 2.93 – 2.84 (m, 1H), 2.64 – 2.45 (m, 2H), 2.11 – 2.04 (m, 1H); MS (ESI) calcd for $C_{13}H_{10}N_3O_6$ $[M+H]^+$ 304.06, found 304.19.

2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (D-2)

General procedure I was followed using 4-nitrophthalic anhydride (300 mg, 1.55 mmol), potassium acetate (473 mg, 4.82 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (281 mg, 1.71 mmol) to afford the title compound as a white solid (409 mg, 87%) following purification by flash column chromatography on silica gel (CH_2Cl_2 :MeOH (30:1)). ^1H NMR (500 MHz, $DMSO-d_6$) δ 11.18 (s, 1H), 8.68 (dd, J = 8.1, 1.9 Hz, 1H), 8.56 (d, J = 1.9 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H), 5.24 (dd, J = 12.9, 5.4 Hz, 1H), 2.90 (ddd, J = 17.2, 13.9, 5.5 Hz, 1H), 2.69 – 2.48 (m, 2H), 2.14 – 2.05 (m, 1H); MS (ESI) calcd for $C_{13}H_{10}N_3O_6$ $[M+H]^+$ 304.06, found 304.19.

2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-6)

General procedure I was followed using phthalic anhydride (155 mg, 1.05 mmol), potassium acetate (318 mg, 3.24 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (189 mg, 1.15 mmol) to afford the title compound as a white solid (235 mg, 87%) following purification by flash column chromatography on silica gel (CH_2Cl_2 :MeOH (15:1)). ^1H NMR (500 MHz, $DMSO-d_6$) δ 11.13 (s, 1H), 8.00 – 7.76 (m, 4H), 5.16 (dd, J = 12.8, 5.4 Hz, 1H), 2.89 (ddd, J = 16.8, 13.7, 5.4 Hz, 1H), 2.65 – 2.42 (m, 2H), 2.12 – 1.99 (m, 1H); MS (ESI) calcd for $C_{13}H_{11}N_2O_4$ $[M+H]^+$ 259.07, found 259.23.

2-(2,5-dioxopyrrolidin-3-yl)isoindoline-1,3-dione (D-7)

General procedure I was followed using phthalic anhydride (90 mg, 0.608 mmol), potassium acetate (185 mg, 1.88 mmol) and 3-aminopyrrolidine-2,5-dione hydrochloride (101 mg, 0.668 mmol) to afford the title compound as a white solid (95 mg, 64%) following purification by flash column chromatography on silica gel (CH_2Cl_2 :MeOH (14:1)). MS (ESI) calcd for $C_{12}H_9N_2O_4$ $[M+H]^+$ 245.06, found 245.26.

2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxylic acid (D-13)

General procedure I was followed using 1,2,4-benzenetricarboxylic anhydride (200 mg, 1.04 mmol), potassium acetate (317 mg, 3.23 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (188 mg, 1.15 mmol) to afford the title compound as a white solid (178 mg, 57%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (9:1)). MS (ESI) calcd for C₁₄H₁₁N₂O₆ [M+H]⁺ 303.06, found 303.24.

2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (D-14)

General procedure I was followed using 3-fluorophthalic anhydride (200 mg, 1.20 mmol), potassium acetate (366 mg, 3.73 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (218 mg, 1.32 mmol) to afford the title compound as a white solid (288 mg, 86%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (50:1)). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.15 (s, 1H), 7.96 (ddd, *J* = 8.3, 7.3, 4.5 Hz, 1H), 7.82 – 7.71 (m, 2H), 5.17 (dd, *J* = 13.0, 5.4 Hz, 1H), 2.90 (ddd, *J* = 17.1, 13.9, 5.4 Hz, 1H), 2.65 – 2.47 (m, 2H), 2.10 – 2.04 (m, 1H), MS (ESI) calcd for C₁₃H₁₀FN₂O₄ [M+H]⁺ 277.06, found 277.25.

2-(2,6-dioxopiperidin-3-yl)-4-methylisindoline-1,3-dione (D-19)


General procedure I was followed using 3-methylphthalic anhydride (150 mg, 0.925 mmol), potassium acetate (281 mg, 2.87 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (167 mg, 1.02 mmol) to afford the title compound as a white solid (168 mg, 67%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (15:1)). MS (ESI) calcd for C₁₄H₁₃N₂O₄ [M+H]⁺ 273.09, found 273.24.

2-(2,6-dioxopiperidin-3-yl)-5-fluoroisindoline-1,3-dione (D-24)

General procedure I was followed using 4-fluorophthalic anhydride (200 mg, 1.20 mmol), potassium acetate (366 mg, 3.73 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (218 mg, 1.32 mmol) to afford the title compound as a white solid (254 mg, 76%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (15:1)). MS (ESI) calcd for C₁₃H₁₀FN₂O₄ [M+H]⁺ 277.06, found 277.24.

2-(2,6-dioxopiperidin-4-yl)isindoline-1,3-dione (D-43)

General procedure I was followed using phthalic anhydride (60 mg, 0.311 mmol), potassium acetate (95 mg, 0.963 mmol) and 4-aminopiperidine-2,6-dione hydrochloride (56 mg, 0.342 mmol) to afford the title compound as a white solid (40 mg, 43%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (9:1)). MS (ESI) calcd for C₁₃H₁₁N₂O₄ [M+H]⁺ 259.07, found 259.18.



General procedure II: Reduction of aromatic nitro groups

4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-4)

A solution of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione (173 mg, 0.854 mmol), Pd(OAc)₂ (12.8 mg, 0.0854 mmol, 10 mol%) and potassium fluoride (66 mg, 1.71 mmol, 2 equiv) in THF:water (8:1) (5.7 mL, 0.1 M) was stirred at room temperature.

Triethylsilane (365 μ L, 3.41 mmol, 4 equiv) was added slowly, and the resulting black solution was stirred at room temperature for 1 hour. The reaction mixture was filtered through a pad of celite, which was washed excessively with ethyl acetate. The filtrate was

concentrated *in vacuo* and the residue was purified by flash column chromatography on silica gel (CH₂Cl₂:MeOH (7:1)) to afford the title compound as a yellow powder (72 mg, 46%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.08 (s, 1H), 7.47 (dd, *J* = 8.5, 7.0 Hz, 1H), 7.06 – 6.95 (m, 1H), 6.59 – 6.44 (m, 1H), 5.04 (dd, *J* = 12.7, 5.4 Hz, 1H), 2.93 – 2.82 (m, 1H), 2.64 – 2.45 (m, 2H), 2.05 – 1.98 (m, 1H); MS (ESI) calcd for C₁₃H₁₁N₃O₄ [M+H]⁺ 274.08, found 274.23.

2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (D-8)

General procedure II was followed using 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (100 mg, 0.330 mmol), Pd(OAc)₂ (7.4 mg, 0.033 mmol), potassium fluoride (38 mg, 0.660 mmol) and triethylsilane (211 μ L, 1.32 mmol) to afford the title compound as a yellow solid (33 mg, 37%) following purification by flash column chromatography on silica gel (CH₂Cl₂:MeOH (9:1)). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.05 (s, 1H), 7.52 (d, *J* = 8.2 Hz, 1H), 6.94 (d, *J* = 2.0 Hz, 1H), 6.83 (dd, *J* = 8.2, 2.0 Hz, 1H), 6.55 (s, 2H), 5.01 (dd, *J* = 12.8, 5.4 Hz, 1H), 2.86 (ddd, *J* = 16.9, 13.9, 5.5 Hz, 1H), 2.68 – 2.43 (m, 2H), 2.03 – 1.93 (m, 1H); MS (ESI) calcd for C₁₃H₁₂N₃O₄ [M+H]⁺ 274.08, found 274.59.

4-amino-2-(1-benzyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-12)


General procedure II was followed using 2-(1-benzyl-2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione (48 mg, 0.122 mmol), Pd(OAc)₂ (2.7 mg, 0.0122 mmol), potassium fluoride (14 mg, 0.244 mmol) and triethylsilane (78 μ L, 0.488 mmol) to afford the title compound as a yellow solid (7 mg, 16%) following purification by flash column chromatography on silica gel (0 to 100% EtOAc in hexanes). MS (ESI) calcd for C₂₀H₁₈N₃O₄ [M+H]⁺ 364.13, found 364.34.

3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-17)

General procedure II was followed using 3-(2-methyl-5-nitro-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (21 mg, 0.0664 mmol), Pd(OAc)₂ (1.5 mg, 0.0066 mmol), potassium fluoride (7.7 mg, 0.133 mmol) and triethylsilane (42 μ L, 0.266 mmol) to afford the title compound as a white solid (7 mg, 37%) following purification by preparative HPLC. MS (ESI) calcd for C₁₄H₁₅N₄O₃ [M+H]⁺ 287.11, found 287.30.

3-(7-amino-1-oxoisindolin-2-yl)piperidine-2,6-dione (D-41)

General procedure II was followed using 3-(7-nitro-1-oxoisindolin-2-yl)piperidine-2,6-dione (11 mg, 0.038 mmol), Pd(OAc)₂ (0.9 mg, 0.0038 mmol), potassium fluoride (4.4 mg, 0.076 mmol) and triethylsilane (24 μ L, 0.152 mmol) to afford the title compound as a yellow solid (2 mg, 21%) following purification by flash column chromatography on silica gel (0 to 10% MeOH in CH₂Cl₂). MS (ESI) calcd for C₁₃H₁₄N₃O₃ [M+H]⁺ 260.10, found 260.52.

**General procedure III: Acylation of anilines****N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)acetamide (D-5)**

In a 4 mL glass vial, a mixture of 5-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (30 mg, 0.110 mmol, 1 equiv) and acetyl chloride (26 μ L, 0.220 mmol, 2 equiv) in THF (1.8 mL, 0.1 M) was heated to reflux overnight. The reaction mixture was filtered, and the filter cake was washed with Et₂O to give the title compound as a white solid (27 mg, 47%), that was used without further purification. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.11 (s, 1H), 10.63 (s, 1H), 8.24 (d, *J* = 1.5 Hz, 1H), 7.91 – 7.83 (m, 2H), 5.11 (dd, *J* = 12.8, 5.4 Hz, 1H), 2.88 (ddd, *J* = 17.0, 13.8, 5.4 Hz, 1H), 2.63 – 2.46 (m, 2H), 2.13 (s, 3H), 2.09 – 2.00 (m, 1H); MS (ESI) calcd for C₁₅H₁₄N₃O₅ [M+H]⁺ 316.09, found 316.23.

N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)acetamide (D-3)

General procedure III was followed using 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (50 mg, 0.183 mmol) and acetyl chloride (26 μ L, 0.366 mmol) to afford the title compound as a white solid (10 mg, 17%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.14 (s, 1H), 9.73 (s, 1H), 8.44 (d, *J* = 8.4 Hz, 1H), 7.83 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.62 (d, *J* = 7.2 Hz, 1H), 5.14 (dd, *J* = 12.9, 5.4 Hz, 1H), 2.90 (ddd, *J* = 17.1, 13.9, 5.4 Hz, 1H), 2.66 –

2.45 (m, 2H), 2.19 (s, 3H), 2.14 – 2.00 (m, 1H); MS (ESI) calcd for $C_{15}H_{14}N_3O_5$ $[M+H]^+$ 316.09, found 316.27.

2-chloro-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)acetamide (D-32)

General procedure III was followed using 5-amino-2-(2,6-dioxopiperidin-3-yl)isindoline-1,3-dione (10 mg, 0.0366 mmol) and chloroacetyl chloride (6 μ L, 0.0732 mmol) to afford the title compound as a white solid (7.1 mg, 55%). MS (ESI) calcd for $C_{15}H_{13}ClN_3O_5$ $[M+H]^+$ 350.05, found 350.23.

2-chloro-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)acetamide (D-34)

General procedure III was followed using 3-(4-amino-1-oxoisindolin-2-yl)piperidine-2,6-dione (20 mg, 0.0771 mmol) and chloroacetyl chloride (12 μ L, 0.154 mmol) to afford the title compound as a white solid (14.9 mg, 56%). ^1H NMR (500 MHz, DMSO- d_6) δ 11.02 (s, 1H), 10.20 (s, 1H), 7.81 (dd, J = 7.7, 1.3 Hz, 1H), 7.65 – 7.47 (m, 2H), 5.16 (dd, J = 13.3, 5.1 Hz, 1H), 4.45 – 4.34 (m, 2H), 4.33 (s, 2H), 3.00 – 2.85 (m, 1H), 2.68 – 2.56 (m, 1H), 2.41 – 2.28 (m, 1H), 2.09 – 1.97 (m, 1H); MS (ESI) calcd for $C_{15}H_{15}ClN_3O_4$ $[M+H]^+$ 336.07, found 336.31.

N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)acrylamide (D-35)

General procedure III was followed using 3-(4-amino-1-oxoisindolin-2-yl)piperidine-2,6-dione (20 mg, 0.0771 mmol) and acryloyl chloride (13 μ L, 0.154 mmol) to afford the title compound as a white solid (18 mg, 76%). ^1H NMR (500 MHz, DMSO- d_6) δ 15.77 (s, 1H), 14.81 (s, 1H), 12.65 (dd, J = 7.4, 1.6 Hz, 1H), 12.37 – 12.18 (m, 2H), 11.28 (dd, J = 17.0, 10.2 Hz, 1H), 11.06 (dd, J = 17.0, 1.9 Hz, 1H), 10.57 (dd, J = 10.2, 1.9 Hz, 1H), 9.91 (dd, J = 13.3, 5.1 Hz, 1H), 9.24 – 9.05 (m, 2H), 7.67 (ddd, J = 17.2, 13.7, 5.5 Hz, 1H), 7.36 (dt, J = 17.3, 3.8 Hz, 1H), 7.20 – 7.03 (m, 1H), 6.83 – 6.72 (m, 1H); MS (ESI) calcd for $C_{16}H_{16}N_3O_4$ $[M+H]^+$ 314.11, found 314.24.

N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)acrylamide (D-36)


General procedure III was followed using 5-amino-2-(2,6-dioxopiperidin-3-yl)isindoline-1,3-dione (10 mg, 0.0366 mmol) and acryloyl chloride (6 μ L, 0.0732 mmol) to afford the title compound as a white solid (8.8 mg, 73%). ^1H NMR (500 MHz, DMSO- d_6) δ 11.12 (s, 1H), 10.83 (s, 1H), 8.33 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 8.2, 1.9 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 6.48 (dd, J = 17.0, 10.1 Hz, 1H), 6.36 (dd, J = 17.0, 1.9 Hz, 1H), 5.88 (dd, J = 10.0, 1.9 Hz, 1H), 5.13 (dd, J = 12.8, 5.5 Hz, 1H), 2.95 – 2.84 (m, 1H), 2.67 – 2.46 (m, 2H), 2.09 – 2.01 (m, 1H); MS (ESI) calcd for $C_{16}H_{14}N_3O_5$ $[M+H]^+$ 328.09, found 328.23.

N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)acetamide (D-37)

General procedure III was followed using 3-(4-amino-1-oxoisindolin-2-yl)piperidine-2,6-dione (20 mg, 0.0771 mmol) and acetyl chloride (11 μ L, 0.154 mmol) to afford the title compound as a white solid (17 mg, 71%). MS (ESI) calcd for $C_{15}H_{16}N_3O_4$ $[M+H]^+$ 302.11, found 301.99.

5 ***N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)cyclopropanecarboxamide (D-38)**

General procedure III was followed using 3-(4-amino-1-oxoisindolin-2-yl)piperidine-2,6-dione (20 mg, 0.0771 mmol) and cyclopropanecarbonyl chloride (14 μ L, 0.154 mmol) to afford the title compound as a white solid (19 mg, 75%). ^1H NMR (500 MHz, DMSO- d_6) δ 11.01 (s, 1H), 10.06 (s, 1H), 7.84 (dd, J = 7.2, 1.9 Hz, 1H), 7.66 – 7.38 (m, 2H),
 10 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.52 – 4.30 (m, 2H), 2.92 (ddd, J = 17.3, 13.6, 5.4 Hz, 1H), 2.64 – 2.54 (m, 1H), 2.45 – 2.27 (m, 1H), 2.08 – 1.95 (m, 1H), 1.93 – 1.83 (m, 1H), 0.90 – 0.75 (m, 4H); MS (ESI) calcd for $C_{17}H_{18}N_3O_4$ $[M+H]^+$ 328.13, found 328.00.



General procedure IV: Quinazolinone condensation

15 **3-(2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-9)**

In a 20 mL glass vial, anthranilic acid (100 mg, 0.729 mmol, 1 equiv), acetic acid (42 μ L, 0.729 mmol, 1 equiv) and $P(OPh)_3$ (479 μ L, 1.82 mmol, 2.5 equiv) in pyridine (1.0 uL, 0.7 M) was heated to 90 $^{\circ}C$. After 4 hours, the reaction mixture was cooled to room temperature and 3-aminopiperidine-2,6-dione hydrochloride (144 mg, 0.875 mmol, 1.2 equiv)
 20 was added. The reaction mixture was reheated to 90 $^{\circ}C$ for 1.5 h, whereupon it was stirred at room temperature overnight. The reaction mixture was taken up in EtOAc (15 mL) and water (15 mL). The organic layer was washed with brine (2x25 mL), dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (0-5% MeOH in CH_2Cl_2) to afford the title compound as a white solid (79 mg, 40%). ^1H
 25 NMR (500 MHz, DMSO- d_6) δ 11.03 (s, 1H), 8.03 (dd, J = 7.9, 1.5 Hz, 1H), 7.82 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.62 (dd, J = 8.3, 1.1 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.27 (dd, J = 11.5, 5.7 Hz, 1H), 2.92 – 2.78 (m, 1H), 2.73 – 2.56 (m, 5H), 2.26 – 2.06 (m, 1H); MS (ESI) calcd for $C_{14}H_{14}N_3O_3$ $[M+H]^+$ 272.10, found 272.33.

3-(2-methyl-4-oxoquinazolin-3(4H)-yl)pyrrolidine-2,5-dione (D-11)

General procedure IV was followed using anthranilic acid (200 mg, 1.46 mmol), acetic acid (84 μ L, 1.46 mmol), P(OPh)₃ (959 μ L, 3.65 mmol) and 3-aminopyrrolidine-2,5-dione hydrochloride (263 mg, 1.75 mmol) to afford the title compound as a white solid (25 mg, 7%) following purification by flash column chromatography on silica gel


(CH₂Cl₂:MeOH (15:1)). MS (ESI) calcd for C₁₃H₁₂N₃O₃ [M+H]⁺ 258.09, found 258.22.

3-(5-fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-66)

General procedure IV was followed using 6-fluoro anthranilic acid (100 mg, 0.645 mmol), acetic acid (37 μ L, 0.644 mmol), P(OPh)₃ (424 μ L, 1.61 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (127 mg, 0.774 mmol) to afford the title compound as a white solid (70 mg, 38%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH₂Cl₂). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.03 (s, 1H), 7.84 – 7.76 (m, 1H), 7.44 (dd, *J* = 8.2, 1.0 Hz, 1H), 7.25 (ddd, *J* = 11.1, 8.2, 1.0 Hz, 1H), 5.24 (dd, *J* = 11.3, 5.7 Hz, 1H), 2.90 – 2.75 (m, 1H), 2.62 (s, 3H), 2.61 – 2.56 (m, 2H), 2.20 – 2.12 (m, 1H); MS (ESI) calcd for C₁₄H₁₃FN₃O₃ [M+H]⁺ 290.09, found 290.27.

3-(2-methyl-5-nitro-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-67)


General procedure IV was followed using 6-nitroanthranilic acid (100 mg, 0.549 mmol), acetic acid (31 μ L, 0.549 mmol), P(OPh)₃ (361 μ L, 1.37 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (108 mg, 0.659 mmol) to afford the title compound as a white solid (29 mg, 17%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH₂Cl₂). MS (ESI) calcd for C₁₄H₁₃N₄O₅ [M+H]⁺ 317.09, found 317.58.



General procedure V: Amide coupling

N-benzyl-2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamide (D-15)

In a 4 mL glass vial, 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxylic acid (10 mg, 0.033 mmol, 1 equiv), HATU (13 mg, 0.033 mmol, 1 equiv), DIPEA (17 μ L, 0.099 mmol, 3 equiv) and benzyl amine (4 μ L, 0.036 mmol, 1.1 equiv) in DMF (331 μ L, 0.1 M) was stirred at room temperature overnight. The reaction mixture was diluted with MeOH to 4 mL, filtered and then purified by preparative HPLC to afford the title compound as a white solid (6 mg, 46%). MS (ESI) calcd for C₂₁H₁₈N₃O₅ [M+H]⁺ 392.12, found 392.33.



General procedure VI: Nucleophilic aromatic substitution

4-(benzylamino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-16)

In a 4 mL glass vial, 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (10 mg, 0.036 mmol, 1 equiv), benzyl amine (4.4 μ L, 0.040 mmol, 1.1 equiv) and DIPEA (13 μ L, 0.072 mmol, 2 equiv) in NMP (362 μ L, 0.1 M) was heated to 90 °C overnight. The reaction mixture was cooled to room temperature and taken up in EtOAc (15 mL). The organic layer was washed with NaHCO₃ (aq) (15 mL), water (15 mL) and brine (3x15 mL), and subsequently dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (0-100% EtOAc in hexanes) to afford the title compound as a yellow film (5 mg, 38%). ¹H NMR (500 MHz, Chloroform-*d*) δ 8.10 (s, 1H), 7.44 (dd, *J* = 8.5, 7.1 Hz, 1H), 7.40 – 7.25 (m, 5H), 7.12 (d, *J* = 7.1 Hz, 1H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.71 (t, *J* = 5.9 Hz, 1H), 4.93 (dd, *J* = 12.3, 5.3 Hz, 1H), 4.51 (d, *J* = 5.9 Hz, 2H), 2.93 – 2.66 (m, 3H), 2.21 – 2.07 (m, 1H); MS (ESI) calcd for C₂₀H₁₈N₃O₄ [M+H]⁺ 364.13, found 364.31.

2-(2,6-dioxopiperidin-3-yl)-4-(isopropylamino)isoindoline-1,3-dione (D-18)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), isopropylamine (10 μ L, 0.119 mmol) and DIPEA (21 μ L, 0.119 mmol) to afford the title compound as a yellow film (11 mg, 32%) following purification by flash column chromatography on silica gel (0-100 % EtOAc in hexanes). MS (ESI) calcd for C₁₆H₁₈N₃O₄ [M+H]⁺ 316.13, found 316.65.

4-(diethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-21)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), diethylamine (11 μ L, 0.130 mmol) and DIPEA (32 μ L, 0.181 mmol) to afford the title compound as a yellow film (28 mg, 97%) following purification by flash column chromatography on silica gel (0-100 % EtOAc in hexanes). MS (ESI) calcd for C₁₇H₂₀N₃O₄ [M+H]⁺ 330.14, found 330.62.

5-(benzylamino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-25)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), benzyl amine (13 μ L, 0.119 mmol) and

DIPEA (38 μ L, 0.217 mmol) to afford the title compound as a yellow film (6 mg, 15%) following purification by flash column chromatography on silica gel (0-100 % EtOAc in hexanes). MS (ESI) calcd for $C_{20}H_{18}N_3O_4$ $[M+H]^+$ 364.13, found 364.34.

2-(2,6-dioxopiperidin-3-yl)-5-(isopropylamino)isoindoline-1,3-dione (D-26)

5 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), isopropyl amine (11 μ L, 0.130 mmol) and DIPEA (38 μ L, 0.217 mmol) to afford the title compound as a yellow film (6 mg, 17%) following purification by flash column chromatography on silica gel (0-100 % EtOAc in hexanes). ^1H NMR (500 MHz, Chloroform-*d*) δ 8.00 (s, 1H), 7.53 (d, J = 8.3 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 6.64 (dd, J = 8.3, 2.2 Hz, 1H), 4.86 (dd, J = 12.3, 5.4 Hz, 1H), 4.30 (d, J = 7.8 Hz, 1H), 2.86 – 2.58 (m, 3H), 2.12 – 2.01 (m, 1H), 1.26 – 1.15 (m, 6H); MS (ESI) calcd for $C_{16}H_{18}N_3O_4$ $[M+H]^+$ 316.13, found 316.30.

5-(diethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-27)

15 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), diethylamine (14 μ L, 0.130 mmol) and DIPEA (38 μ L, 0.217 mmol) to afford the title compound as a yellow film (6 mg, 31%) following purification by flash column chromatography on silica gel (0-100 % EtOAc in hexanes). ^1H NMR (500 MHz, Chloroform-*d*) δ 8.08 (s, 1H), 7.57 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 8.7, 2.4 Hz, 1H), 4.90 – 4.80 (m, 1H), 3.40 (q, J = 7.1 Hz, 4H), 2.89 – 2.61 (m, 3H), 2.11 – 2.01 (m, 1H), 1.16 (t, J = 7.1 Hz, 6H); MS (ESI) calcd for $C_{17}H_{20}N_3O_4$ $[M+H]^+$ 330.14, found 330.69.

2-(2,6-dioxopiperidin-3-yl)-5-((furan-2-ylmethyl)amino)isoindoline-1,3-dione (D-28)

25 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (50 mg, 0.181 mmol), furfurylamine (18 μ L, 0.199 mmol) and DIPEA (63 μ L, 0.362 mmol) to afford the title compound as a yellow film (8 mg, 13%) following purification by flash column chromatography on silica gel (0-5 % MeOH in CH_2Cl_2). MS (ESI) calcd for $C_{18}H_{16}N_3O_4$ $[M+H]^+$ 354.11, found 354.25.

***tert*-butyl (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)carbamate (D-29)**

30 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (50 mg, 0.181 mmol), 1-Boc-ethylendiamine (32 mg, 0.199 mmol) and DIPEA (63 μ L, 0.362 mmol) to afford the title compound as a yellow film (31 mg, 41%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, $CDCl_3$) δ 8.08 (bs, 1H), 7.50 (dd, J = 8.5, 7.1 Hz,

1H), 7.12 (d, $J = 7.1$ Hz, 1H), 6.98 (d, $J = 8.5$ Hz, 1H), 6.39 (t, $J = 6.1$ Hz, 1H), 4.96 – 4.87 (m, 1H), 4.83 (bs, 1H), 3.50 – 3.41 (m, 2H), 3.41 – 3.35 (m, 2H), 2.92 – 2.66 (m, 3H), 2.16 – 2.09 (m, 1H), 1.45 (s, 9H); MS (ESI) calcd for $C_{20}H_{25}N_4O_6$ $[M+H]^+$ 417.18, found 417.58.

tert-butyl (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-

5 yl)amino)ethyl)carbamate (D-30)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisindoline-1,3-dione (50 mg, 0.181 mmol), 1-Boc-ethylendiamine (32 mg, 0.199 mmol) and DIPEA (63 μ L, 0.362 mmol) to afford the title compound as a yellow film (22 mg, 29%) following purification by flash column chromatography on silica gel (0-10 %
10 MeOH in CH_2Cl_2). MS (ESI) calcd for $C_{20}H_{25}N_4O_6$ $[M+H]^+$ 417.18, found 417.32.

2-(2,6-dioxopiperidin-3-yl)-4-((furan-2-ylmethyl)amino)isoindoline-1,3-dione (D-31)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (19.5 mg, 0.0706 mmol), furfurylamine (7 μ L, 0.078 mmol) and DIPEA (25 μ L, 0.141 mmol) to afford the title compound as a yellow film (19 mg, 76%)
15 following purification by flash column chromatography on silica gel (0-2.5 % MeOH in CH_2Cl_2). MS (ESI) calcd for $C_{18}H_{16}N_3O_4$ $[M+H]^+$ 354.11, found 354.27.

3-(5-(benzylamino)-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-39)

With the exception that the reaction mixture was heated to 170°C instead of 90 °C, general procedure VI was followed using 3-(5-fluoro-2-methyl-4-oxoquinazolin-3(4H)-
20 yl)piperidine-2,6-dione (30 mg, 0.104 mmol), benzylamine (13 μ L, 0.114 mmol) and DIPEA (36 μ L, 0.207 mmol) to afford the title compound as a white solid (15 mg, 38%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, Chloroform- d) δ 8.73 (t, $J = 5.7$ Hz, 1H), 8.39 (s, 1H), 7.41 (t, $J = 8.1$ Hz, 1H), 7.39 – 7.19 (m, 5H), 6.77 (d, $J = 7.7$ Hz, 1H), 6.41 (d, $J = 8.3$ Hz, 1H), 4.67 (dd, $J =$
25 11.5, 5.9 Hz, 1H), 4.43 (d, $J = 5.7$ Hz, 2H), 3.03 – 2.79 (m, 2H), 2.72 – 2.61 (m, 1H), 2.60 (s, 3H), 2.15 – 2.07 (m, 1H); MS (ESI) calcd for $C_{21}H_{21}N_4O_3$ $[M+H]^+$ 377.16, found 377.02.

3-(5-(isopropylamino)-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione (D-40)

With the exception that the reaction mixture was heated to 170°C instead of 90 °C, general procedure VI was followed using 3-(5-fluoro-2-methyl-4-oxoquinazolin-3(4H)-
30 yl)piperidine-2,6-dione (30 mg, 0.104 mmol), isopropylamine (10 μ L, 0.114 mmol) and DIPEA (36 μ L, 0.207 mmol) to afford the title compound as a white solid (5 mg, 15%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, Chloroform- d) δ 8.31 (s, 1H), 8.21 (d, $J = 7.2$ Hz, 1H), 7.50 – 7.37 (m, 1H), 6.70 (dd, $J = 7.9, 0.9$ Hz, 1H), 6.47 (d, $J = 8.4$ Hz, 1H), 4.65 (dd, $J = 11.4, 5.9$

Hz, 1H), 3.69 – 3.56 (m, 1H), 3.03 – 2.80 (m, 3H), 2.58 (s, 3H), 2.14 – 2.03 (m, 1H), 1.27 (d, $J = 2.7$ Hz, 3H), 1.26 (d, $J = 2.7$ Hz, 3H); MS (ESI) calcd for $C_{17}H_{21}N_4O_3$ $[M+H]^+$ 329.16, found 329.97.

2-(2,6-dioxopiperidin-3-yl)-4-((2-hydroxyethyl)amino)isoindoline-1,3-dione (D-68)

5 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (30 mg, 0.109 mmol), aminoethanol (7 μ L, 0.119 mmol) and DIPEA (38 μ L, 0.217 mmol) to afford the title compound as a yellow film (6 mg, 18%) following purification by flash column chromatography on silica gel (0-5 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, Chloroform- d) δ 8.26 (s, 1H), 7.50 (dd, $J = 8.5, 7.1$ Hz, 1H), 7.12 (d, $J = 7.0$ Hz, 1H), 6.95 (d, $J = 8.5$ Hz, 1H), 6.50 (t, $J = 5.9$ Hz, 1H), 4.97 – 4.85 (m, 1H), 3.94 – 3.79 (m, 2H), 3.47 (q, $J = 5.5$ Hz, 2H), 3.03 – 2.68 (m, 3H), 2.19 – 2.04 (m, 1H); MS (ESI) calcd for $C_{15}H_{16}N_3O_5$ $[M+H]^+$ 318.11, found 318.22.

4-(cyclopropylamino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D47)

15 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (20 mg, 0.0724 mmol), cyclopropylamine (6 μ L, 0.080 mmol) and DIPEA (25 μ L, 0.141 mmol) to afford the title compound as a yellow film (16 mg, 70%) following purification by flash column chromatography on silica gel (0-5 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, Chloroform- d) δ 8.05 (s, 1H), 7.53 (dd, $J = 8.5, 7.1$ Hz, 1H), 7.33 – 7.21 (m, 1H), 7.15 (dd, $J = 7.1, 0.7$ Hz, 1H), 6.44 (bs, 1H), 4.95 – 4.85 (m, 1H), 2.98 – 2.66 (m, 3H), 2.62 – 2.50 (m, 1H), 2.19 – 2.06 (m, 1H), 0.92 – 0.78 (m, 2H), 0.67 – 0.56 (m, 2H); MS (ESI) calcd for $C_{16}H_{16}N_3O_4$ $[M+H]^+$ 314.11, found 314.54.

4-((2-(1*H*-indol-3-yl)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-48)


25 General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (20 mg, 0.0724 mmol), tryptamine (13 mg, 0.080 mmol) and DIPEA (25 μ L, 0.144 mmol) to afford the title compound as a yellow film (10 mg, 33%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH_2Cl_2). ^1H NMR (500 MHz, Chloroform- d) δ 8.14 (s, 1H), 8.11 (s, 1H), 7.65 – 7.55 (m, 1H), 7.45 (dd, $J = 8.6, 7.1$ Hz, 1H), 7.37 (dt, $J = 8.2, 0.9$ Hz, 1H), 7.21 (ddd, $J = 8.2, 7.0, 1.2$ Hz, 1H), 7.16 – 7.04 (m, 3H), 6.88 (d, $J = 8.5$ Hz, 1H), 6.34 (t, $J = 5.6$ Hz, 1H), 4.89 (dd, $J = 12.4, 5.4$ Hz, 1H), 3.59 (td, $J = 6.8, 5.5$ Hz, 2H), 3.19 – 3.03 (m, 2H), 2.93 – 2.64 (m, 3H), 2.14 – 2.04 (m, 1H); MS (ESI) calcd for $C_{23}H_{21}N_4O_4$ $[M+H]^+$ 417.16, found 417.26.

2-(2,6-dioxopiperidin-3-yl)-4-((4-hydroxyphenethyl)amino)isoindoline-1,3-dione (D-49)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (20 mg, 0.0724 mmol), tyramine (11 mg, 0.080 mmol) and DIPEA (25 μ L, 0.144 mmol) to afford the title compound as a yellow film (15 mg, 54%) following purification by flash column chromatography on silica gel (0-5 % MeOH in CH₂Cl₂). ¹H NMR (500 MHz, Chloroform-*d*) δ 8.20 (s, 1H), 7.51 (dd, *J* = 8.5, 7.1 Hz, 1H), 7.17 – 7.08 (m, 2H), 6.90 (d, *J* = 8.5 Hz, 1H), 6.85 – 6.72 (m, 2H), 4.95 – 4.90 (m, 1H), 3.52 – 3.46 (m, 2H), 2.97 – 2.87 (m, 2H), 2.86 – 2.72 (m, 2H), 2.21 – 2.09 (m, 1H); MS (ESI) calcd for C₂₁H₂₀N₃O₅ [M+H]⁺ 394.14, found 394.25.

4-((2-(1H-imidazol-2-yl)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-50)

General procedure VI was followed using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (20 mg, 0.0724 mmol), histamine (15 mg, 0.080 mmol) and DIPEA (25 μ L, 0.144 mmol) to afford the title compound as a yellow film (5 mg, 19%) following purification by flash column chromatography on silica gel (0-10 % MeOH in CH₂Cl₂). ¹H NMR (500 MHz, Chloroform-*d*) δ 8.19 (s, 1H), 7.61 (d, *J* = 1.2 Hz, 1H), 7.47 (dd, *J* = 8.5, 7.1 Hz, 1H), 7.07 (d, *J* = 6.9 Hz, 1H), 6.96 – 6.83 (m, 2H), 6.39 (t, *J* = 5.7 Hz, 1H), 4.97 – 4.79 (m, 1H), 3.59 (q, *J* = 6.5 Hz, 2H), 2.95 (t, *J* = 6.6 Hz, 2H), 2.92 – 2.62 (m, 2H), 2.16 – 2.04 (m, 1H); MS (ESI) calcd for C₁₈H₁₈N₅O₄ [M+H]⁺ 368.14, found 368.47.



General procedure VII: Acylation of primary amines


***N*-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)methyl)cyclopropanecarboxamide (D-22)**

In a 4 mL glass vial, 4-(aminomethyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (25 mg, 0.087 mmol, 1 equiv) and DIPEA (30 μ L, 0.174 mmol, 2 equiv) in MeCN (250 μ L, 0.35 M) was cooled to 0 °C. Cyclopropanecarbonyl chloride (8.7 μ L, 0.096 mmol) was added slowly and the reaction mixture was stirred at room temperature overnight. The product was isolated by filtration to afford the title compound as a white solid (4.8 mg, 15%),

that was used without further purification. MS (ESI) calcd for $C_{18}H_{18}N_3O_5$ $[M+H]^+$ 356.12, found 356.32.


***N*-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)methyl)acetamide (D-23)**

General procedure VII was followed using 4-(aminomethyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (25 mg, 0.087 mmol), DIPEA (30 μ L, 0.174 mmol) and acetyl chloride (7 μ L, 0.096 mmol) to afford the title compound as a white solid (4.5 mg, 16%). ^1H NMR (500 MHz, DMSO- d_6) δ 11.13 (s, 1H), 8.47 (t, J = 6.0 Hz, 1H), 7.88 – 7.76 (m, 2H), 7.70 (dt, J = 7.3, 1.1 Hz, 1H), 5.15 (dd, J = 12.7, 5.4 Hz, 1H), 4.69 (d, J = 6.0 Hz, 2H), 2.90 (ddd, J = 16.8, 13.8, 5.4 Hz, 1H), 2.64 – 2.44 (m, 2H), 2.15 – 2.01 (m, 1H), 1.92 (s, 3H); MS (ESI) calcd for $C_{16}H_{16}N_3O_5$ $[M+H]^+$ 330.11, found 330.05.



2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethan-1-aminium 2,2,2-trifluoroacetate (D-33)

A stirred solution of *tert*-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethyl carbamate (205 mg, 0.492 mmol, 1 equiv) in dichloromethane (2.25 mL) was added trifluoroacetic acid (0.250 mL). The reaction mixture was stirred at room temperature for 4 h, whereupon the volatiles were removed *in vacuo*. The title compound was obtained as a yellow solid (226 mg, >95%), that was used without further purification. ^1H NMR (500 MHz, MeOD) δ 7.64 (d, J = 1.4 Hz, 1H), 7.27 – 7.05 (m, 2H), 5.10 (dd, J = 12.5, 5.5 Hz, 1H), 3.70 (t, J = 6.0 Hz, 2H), 3.50 – 3.42 (m, 2H), 3.22 (t, J = 6.0 Hz, 1H), 2.93 – 2.85 (m, 1H), 2.80 – 2.69 (m, 2H), 2.17 – 2.10 (m, 1H); MS (ESI) calcd for $C_{15}H_{17}N_4O_4$ $[M+H]^+$ 317.12, found 317.53.




General procedure VIII: Phenol alkylation**2-(2,6-dioxopiperidin-3-yl)-4-((4-(morpholinomethyl)benzyl)oxy)isoindoline-1,3-dione (D-45)**

In a 4 mL glass vial, 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (30 mg, 0.109 mmol, 1 equiv) and K_2CO_3 (15 mg, 0.109 mmol, 1 equiv) in DMF (365 μ L, 0.3 M) was stirred at room temperature. 4-(4-(bromomethyl)benzyl)morpholine (30 mg, 0.109 mmol, 1 equiv) in DMF (200 μ L) was added and the reaction mixture was stirred at room temperature for 4 days. The reaction mixture was taken up in water (15 mL) and EtOAc (15 mL), and the organic layer was washed with brine (3x15 mL), dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (0 to 10% MeOH in CH_2Cl_2) to afford the title compound as a white solid (20 mg, 40%).

^1H NMR (500 MHz, $DMSO-d_6$) δ 11.10 (s, 1H), 7.82 (dd, J = 8.5, 7.2 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.50 – 7.42 (m, 3H), 7.35 (d, J = 8.1 Hz, 2H), 5.35 (s, 2H), 5.09 (dd, J = 12.8, 5.5 Hz, 1H), 3.64 – 3.51 (m, 4H), 3.46 (s, 2H), 2.88 (ddd, J = 17.0, 14.1, 5.4 Hz, 1H), 2.63 – 2.47 (m, 2H), 2.38 – 2.31 (m, 4H), 2.07 – 1.99 (m, 1H); MS (ESI) calcd for $C_{25}H_{26}N_3O_6$ $[M+H]^+$ 464.18, found 464.00.

4-(benzyloxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-46)

General procedure VIII was followed using 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (30 mg, 0.109 mmol), K_2CO_3 (15 mg, 0.109 mmol) and benzyl bromide (8 μ L, 0.109 mmol) to afford the title compound as a white solid (8 mg, 20%) after purification by flash column chromatography on silica gel (0 to 10% MeOH in CH_2Cl_2). ^1H NMR (500 MHz, $DMSO-d_6$) δ 11.10 (s, 1H), 7.83 (dd, J = 8.5, 7.3 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.53 – 7.50 (m, 2H), 7.47 (d, J = 7.2 Hz, 1H), 7.45 – 7.39 (m, 2H), 7.38 – 7.32 (m, 1H), 5.38 (s, 2H), 5.09 (dd, J = 12.8, 5.5 Hz, 1H), 2.88 (ddd, J = 16.9, 13.8, 5.5 Hz, 1H), 2.64 – 2.46 (m, 2H), 2.07 – 1.99 (m, 1H); MS (ESI) calcd for $C_{20}H_{17}N_2O_5$ $[M+H]^+$ 365.11, found 365.21.

**2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethyl 4-methylbenzenesulfonate (D-44)**

In a 4 mL glass vial, 2-(2,6-dioxopiperidin-3-yl)-4-((2-hydroxyethyl)amino)isoindoline-1,3-dione (7 mg, 0.0221 mmol, 1 equiv) and Et₃N (3 μ L, 0.033 mmol, 1.5 equiv) in CH₂Cl₂ (200 μ L) was stirred at room temperature. Tosyl chloride (6 mg, 0.026 mmol, 1.2 equiv) in CH₂Cl₂ (100 μ L) was added, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* and the residue was purified by flash column chromatography on silica gel (0-10% MeOH in CH₂Cl₂) to afford the title compound as a white solid (4 mg, 40%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.13 (s, 1H), 7.64 – 7.59 (m, 2H), 7.46 (dd, *J* = 8.6, 7.1 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.04 – 6.93 (m, 2H), 6.58 (t, *J* = 6.4 Hz, 1H), 5.09 (dd, *J* = 12.7, 5.4 Hz, 1H), 4.15 (t, *J* = 5.1 Hz, 2H), 3.65 – 3.52 (m, 2H), 2.97 – 2.83 (m, 1H), 2.67 – 2.46 (m, 2H), 2.27 (s, 3H), 2.12 – 2.02 (m, 1H); MS (ESI) calcd for C₂₂H₂₂N₃O₇S [M+H]⁺ 472.12, found 472.39.

(R)-4-hydroxy-2-(3-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-52)

Hydroxyisobenzofuran-1,3-dione (147.08 mg, 0.896 mmol, 1 eq) was added to (*R*)-3-amino-3-methylpiperidine-2,6-dione hydrochloric acid (127.32 mg, 0.896 mmol, 1 eq). Pyridine (3.584 mL, 0.25 M) was then added to the mixture and it was stirred at 110 °C for 17 hours. The mixture was diluted with methanol and was condensed under reduced pressure. The crude material was purified by column chromatography (ISCO, 24 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white oil (110.9 mg, 42.63 % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 7.61 (dd, *J* = 8.4, 7.2 Hz, 1H), 7.27 – 7.14 (m, 2H), 2.73 – 2.63 (m, 1H), 2.57 – 2.51 (m, 1H), 2.04 – 1.97 (m, 1H), 1.86 (s, 3H).

LCMS 289 (M+H).

(S)-4-hydroxy-2-(3-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-53)

4-hydroxyisobenzofuran-1,3-dione (148.99 mg, 0.907 mmol, 1 eq) was added to (*S*)-3-amino-3-methylpiperidine-2,6-dione hydrochloric acid (128.97 mg, 0.907 mmol, 1 eq). Pyridine (3.628 mL, 0.25 M) was then added to the mixture and it was stirred at 110 °C for 17 hours. The mixture was diluted with methanol and was condensed under reduced pressure. The crude material was purified by column chromatography (ISCO, 24 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white oil (150 mg, 57.4 % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 7.62 (dd, *J* = 8.4, 7.2 Hz, 1H), 7.27 – 7.16 (m, 2H), 2.75 – 2.62 (m, 1H), 2.55 (dd, *J* = 14.0, 4.3 Hz, 1H), 2.05 – 1.96 (m, 1H), 1.86 (s, 3H). LCMS 289 (M+H).

(S)-2-((2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (D-55)

TFA (0.63 ml, 0.1 M) was added to *tert*-butyl (S)-2-((2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetate (25.4 mg, 0.063 mmol, 1 eq) and the mixture was stirred at 50 °C for an hour. The mixture was then diluted with methanol and condensed under reduced pressure to give a white powder (20.5 mg, 93.9% yield) that was carried forward without further purification. ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.81 – 7.75 (m, 1H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.45 (d, *J* = 8.6 Hz, 2H), 7.43 – 7.37 (m, 3H), 5.09 (dd, *J* = 12.8, 5.5 Hz, 1H), 4.76 (s, 2H), 4.63 (dd, *J* = 9.1, 5.2 Hz, 1H), 3.66 – 3.55 (m, 30H), 3.51 – 3.41 (m, 5H), 2.90 – 2.83 (m, 1H), 2.79 – 2.71 (m, 2H), 2.69 (s, 3H), 2.43 (s, 3H), 2.14 (ddt, *J* = 10.5, 5.5, 3.2 Hz, 1H), 1.69 (s, 3H). LCMS 347 (M+H).

(R)-2-((2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (D-54)

TFA (1.78 ml, 0.1 M) was added to *tert*-butyl (R)-2-((2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetate (71.3 mg, 0.178 mmol, 1 eq) and the mixture was stirred at 50 °C for an hour. The mixture was then diluted with methanol and condensed under reduced pressure to give a white powder (47.2 mg, 76.63% yield) that was carried forward without further purification. ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.72 (ddd, *J* = 8.5, 7.3, 5.0 Hz, 1H), 7.46 – 7.42 (m, 1H), 7.30 (dd, *J* = 8.6, 4.5 Hz, 1H), 4.94 (d, *J* = 5.3 Hz, 2H), 2.81 – 2.56 (m, 2H), 2.24 – 2.07 (m, 1H), 2.00 (s, 2H), 0.90 (t, *J* = 6.5 Hz, 2H). LCMS 347 (M+H).


4,7-dichloro-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (D-51)

4,7-dichloroisobenzofuran-1,3-dione (434.6 mg, 2.002 mmol, 1 eq) was added to 3-aminopiperidine-2,6-dione hydrochloric acid (362.6 mg, 2.203 mmol, 1.1 eq). Potassium acetate (609.07 mg, 6.206 mmol, 3.1 eq) and acetic acid (6.67 ml, 0.3 M) were then added to the mixture and it was stirred at 90 °C for 18 hours. The mixture was cooled down to room temperature, diluted with DI water and centrifuged for 5 minutes. The precipitate was diluted with methanol and was condensed under reduced pressure. The crude material was purified by column chromatography (ISCO, 12 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white powder (160.4 mg, 24.5 % yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.15 (s, 1H), 7.91 (s, 2H), 5.17 (dd, *J* = 12.9, 5.4 Hz, 1H), 2.88 (ddd, *J* = 17.2, 13.9, 5.4 Hz, 1H), 2.68 – 2.54 (m, 1H), 2.05 (ddd, *J* = 10.5, 5.4, 2.7 Hz, 1H). LCMS 328 (M+H).

Synthesis of Exemplary Compounds

Unless otherwise indicated, starting materials are either commercially available or readily accessible through laboratory synthesis by anyone reasonably familiar with the art. Described generally below, are procedures and general guidance for the synthesis of compounds as described generally and in subclasses and species herein.

Example 1: Synthesis of dBET1



(1) Synthesis of JQ-acid

JQ1 (1.0 g, 2.19 mmol, 1 eq) was dissolved in formic acid (11 mL, 0.2 M) at room temperature and stirred for 75 hours. The mixture was concentrated under reduced pressure to give a yellow solid (0.99 g, quant yield) that was used without purification. ^1H NMR (400 MHz, Methanol- d_4) δ 7.50 – 7.36 (m, 4H), 4.59 (t, J = 7.1 Hz, 1H), 3.51 (d, J = 7.1 Hz, 2H), 2.70 (s, 3H), 2.45 (s, 3H), 1.71 (s, 3H). LCMS 401.33 (M+H).


N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamidetrifluoroacetate was synthesized according to the previously published procedure (Fischer *et al.* *Nature* **2014**, 512, 49).

(2) Synthesis of dBET1

JQ-acid (11.3 mg, 0.0281 mmol, 1 eq) and N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (14.5 mg, 0.0281 mmol, 1 eq) were dissolved in DMF (0.28 mL, 0.1 M) at room temperature. DIPEA (14.7 microliters, 0.0843 mmol, 3 eq) and HATU (10.7 mg, 0.0281 mmol, 1 eq) were then


added and the mixture was stirred for 19 hours. The mixture was then purified by preparative HPLC to give dBET1 as a yellow solid (15.90 mg, 0.0202 mmol, 72%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.77 (dd, *J* = 8.3, 7.5 Hz, 1H), 7.49 (d, *J* = 7.3 Hz, 1H), 7.47 – 7.37 (m, 5H), 5.07 (dd, *J* = 12.5, 5.4 Hz, 1H), 4.74 (s, 2H), 4.69 (dd, *J* = 8.7, 5.5 Hz, 1H), 3.43 – 3.32 (m, 3H), 3.29 – 3.25 (m, 2H), 2.87 – 2.62 (m, 7H), 2.43 (s, 3H), 2.13 – 2.04 (m, 1H), 1.72 – 1.58 (m, 7H). ¹³C NMR (100 MHz, *cd*₃od) δ 174.41, 172.33, 171.27, 171.25, 169.87, 168.22, 167.76, 166.73, 166.70, 156.26, 138.40, 138.23, 137.44, 134.83, 133.92, 133.40, 132.30, 132.28, 131.97, 131.50, 129.87, 121.85, 119.31, 118.00, 69.53, 54.90, 50.54, 40.09, 39.83, 38.40, 32.12, 27.74, 27.65, 23.61, 14.42, 12.97, 11.57. LCMS 785.44 (M+H).

Example 2: Synthesis of dBET4




A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.438 mL, 0.0438 mmol 1.2 eq) was added to (R)-JQ-acid (prepared from (R)-JQ1 in an analogous method to JQ-acid) (14.63 mg, 0.0365 mmol, 1 eq) at room temperature. DIPEA (19.1 microliters, 0.1095 mmol, 3 eq) and HATU (15.3 mg, 0.0402 mmol, 1.1 eq) were added and the mixture was stirred for 24 hours, then diluted with MeOH and concentrated under reduced pressure. The crude material was purified by preparative HPLC to give a yellow solid (20.64 mg, 0.0263 mmol, 72%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.79 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.51 (d, *J* = 7.3 Hz, 1H), 7.47 – 7.39 (m, 5H), 5.11 – 5.06 (m, 1H), 4.75 (s, 2H), 4.68 (dd, *J* = 8.8, 5.5 Hz, 1H), 3.47 – 3.31 (m, 5H), 2.83 – 2.65 (m, 7H), 2.44 (s, 3H), 2.13 – 2.06 (m, 1H), 1.68 (s, 3H), 1.67 – 1.60 (m, 4H). ¹³C NMR (100 MHz, *cd*₃od) δ 174.43, 172.40, 171.29, 169.92, 168.24, 167.82, 166.71, 156.31, 153.14, 138.38, 138.24, 137.54, 134.88, 133.86, 133.44, 132.29, 132.00, 131.49, 129.88, 122.46, 121.90, 119.38, 118.02, 69.59, 54.96, 50.55, 40.09, 39.84, 38.45, 32.14, 27.75, 27.65, 23.62, 14.41, 12.96, 11.56. MS 785.48 (M+H).

Example 3: Synthesis of dBET3



A 0.1 M solution of *N*-(2-aminoethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.475 mL, 0.0475 mmol, 1.2 eq) was added to JQ-acid (15.86 mg, 0.0396 mmol, 1 eq) at room temperature. DIPEA (20.7 microliters, 0.1188 mmol, 3 eq) and HATU (16.5 mg, 0.0435 mmol, 1.1 eq) were then added and the mixture was stirred for 24 hours, then purified by preparative HPLC to give a yellow solid (22.14 mg, 0.0292 mmol, 74%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.82 – 7.75 (m, 1H), 7.52 – 7.32 (m, 6H), 5.04 (dd, *J* = 11.6, 5.5 Hz, 1H), 4.76 (d, *J* = 3.2 Hz, 2H), 4.66 (d, *J* = 6.6 Hz, 1H), 3.58 – 3.35 (m, 6H), 2.78 – 2.58 (m, 6H), 2.48 – 2.41 (m, 3H), 2.11 – 2.02 (m, 1H), 1.70 (d, *J* = 11.8 Hz, 3H). ¹³C NMR (100 MHz, cd₃od) δ 174.38, 171.26, 171.19, 170.26, 168.86, 168.21, 167.76, 166.72, 156.27, 153.14, 138.44, 138.36, 138.19, 134.87, 133.71, 132.31, 131.57, 131.51, 129.90, 129.86, 121.81, 119.36, 117.95, 69.48, 54.83, 50.52, 40.09, 39.76, 38.30, 32.09, 23.63, 14.40, 11.61. LCMS 757.41 (M+H).


Example 4: Synthesis of dBET5



A 0.1M solution of *N*-(6-aminohexyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.247 mL, 0.0247 mmol, 1 eq)

was added to JQ-acid (9.9 mg, 0.0247 mmol, 1 eq) at room temperature. DIPEA (12.9 microliters, 0.0741 mmol, 3 eq) and HATU (9.4 mg, 0.0247 mmol, 1 eq) were then added. the mixture was stirred for 21 hours, then diluted with MeOH and concentrated under reduced pressure. The crude material was purified by preparative HPLC to give a yellow solid (13.56 mg, 0.0167 mmol, 67%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.82 – 7.78 (m, 1H), 7.53 (dd, *J* = 7.3, 2.0 Hz, 1H), 7.49 – 7.37 (m, 5H), 5.10 (dt, *J* = 12.4, 5.3 Hz, 1H), 4.76 (s, 2H), 4.70 (dd, *J* = 8.7, 5.5 Hz, 1H), 3.42 – 3.33 (m, 2H), 3.25 (dt, *J* = 12.3, 6.0 Hz, 3H), 2.87 – 2.67 (m, 7H), 2.48 – 2.42 (m, 3H), 2.14 – 2.09 (m, 1H), 1.69 (d, *J* = 4.8 Hz, 3H), 1.58 (s, 4H), 1.42 (d, *J* = 5.2 Hz, 4H). ¹³C NMR (100 MHz, cd₃od) δ 174.51, 171.31, 171.26, 169.82, 168.27, 168.26, 167.75, 156.26, 150.46, 138.20, 134.92, 133.92, 133.47, 132.34, 132.01, 131.52, 129.88, 121.69, 119.34, 117.95, 111.42, 69.39, 54.97, 50.56, 40.39, 40.00, 38.40, 32.15, 30.46, 30.16, 27.58, 27.48, 23.64, 14.41, 12.96, 11.55. LCMS 813.38.

Example 5-1: Synthesis of dBET6



A 0.1M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.191 mL, 0.0191 mmol, 1 eq) was added to JQ-acid (7.66 mg, 0.0191 mmol, 1 eq) at room temperature. DIPEA (10 microliters, 0.0574 mmol, 3 eq) and HATU (7.3 mg, 0.0191 mmol, 1 eq) were added and the mixture was stirred for 22 hours, diluted with MeOH, and concentrated under reduced pressure. The crude material was purified by preparative HPLC to give a cream colored solid. (8.53 mg, 0.0101 mmol, 53%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.80 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.53 (d, *J* = 7.4 Hz, 1H), 7.49 – 7.36 (m, 5H), 5.10 (dt, *J* = 12.3, 5.3 Hz, 1H), 4.75 (s, 2H), 4.69 (dd, *J* = 8.8, 5.3 Hz, 1H), 3.42 (dd, *J* = 15.0, 8.9 Hz, 1H), 3.30 – 3.18 (m, 4H), 2.90 – 2.64 (m, 7H), 2.45 (s, 3H), 2.13 (dt, *J* = 10.8, 5.2, 2.6 Hz, 1H), 1.71 (d, *J* = 4.4 Hz, 3H), 1.56 (d, *J* = 6.2 Hz, 4H), 1.33 (d, *J* = 17.1 Hz, 8H). ¹³C NMR (100 MHz, cd₃od) δ 174.50, 172.38, 171.30, 169.81, 168.28, 167.74, 166.64, 156.25, 138.38, 138.20, 137.55, 134.92,

133.88, 133.42, 132.27, 132.02, 131.50, 129.85, 121.66, 119.30, 117.95, 69.37, 55.01, 50.58, 40.51, 40.12, 38.44, 32.18, 30.46, 30.33, 30.27, 30.21, 27.91, 27.81, 23.63, 14.42, 12.96, 11.55. LCMS 841.64 (M+H).

5 Example 5-2: Synthesis of dBET6

Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione

3-Hydroxyphthalic anhydride (1.641 g, 10 mmol, 1 eq) and 3-aminopiperidine-2,6-dione hydrochloride (1.646 g, 10 mmol, 1 eq) were dissolved in pyridine (40 mL, 0.25 M) and heated to 110 °C. After 14 hours, the mixture was cooled to room temperature and concentrated under reduced pressure. Purification by column chromatography (ISCO, 24 g silica column, 0-10% MeOH/DCM) gave the desired product as a tan solid (2.424 g, 8.84 mmol, 88%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.08 (s, 2H), 7.65 (dd, *J* = 8.4, 7.2 Hz, 1H), 7.36 – 7.28 (m, 1H), 7.25 (dd, *J* = 8.4, 0.6 Hz, 1H), 5.07 (dd, *J* = 12.8, 5.4 Hz, 1H), 2.88 (ddd, *J* = 17.3, 14.0, 5.4 Hz, 1H), 2.63 – 2.50 (m, 2H), 2.08 – 1.95 (m, 1H).

15 *Step 2: Synthesis of tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate*

2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (1.568 g, 5.71 mmol, 1 eq) was dissolved in DMF (57 mL, 0.1 M) at room temperature. Potassium carbonate (1.19 g, 8.58 mmol, 1.5 eq) and tert-butyl bromoacetate (0.843 mL, 5.71 mmol, 1 eq) were then added. After 2 hours, the mixture was diluted with EtOAc and washed once with water then twice with brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 24 g silica column, 0-100%EtOAc/hexanes, 21 minute gradient) gave the desired product as a cream colored solid (2.06 g, 5.30 mmol, 93%). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.94 (s, 1H), 7.67 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.52 (d, *J* = 6.8 Hz, 1H), 7.11 (d, *J* = 8.3 Hz, 1H), 4.97 (dd, *J* = 12.3, 5.3 Hz, 1H), 4.79 (s, 2H), 2.95 – 2.89 (m, 1H), 2.85 – 2.71 (m, 2H), 2.14 (dtd, *J* = 10.2, 5.0, 2.7 Hz, 1H), 1.48 (s, 9H). LCMS 389.33 (M+H).

Step 3: Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid

tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate (2.06 g, 5.30 mmol, 1 eq) was dissolved in TFA (53 mL, 0.1M) at room temperature. After 4 hours, the solution was diluted with DCM and concentrated under reduced pressure. The resultant cream colored solid (1.484 g, 4.47 mmol, 84%) was deemed sufficiently pure and carried onto the next step without further purification. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.11 (s, 1H), 7.79 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.6 Hz, 1H), 5.10

(dd, $J = 12.8, 5.4$ Hz, 1H), 4.99 (s, 2H), 2.93 – 2.89 (m, 1H), 2.63 – 2.51 (m, 2H), 2.04 (ddd, $J = 10.5, 5.4, 3.1$ Hz, 1H). **LCMS** 333.25 (M+H).


Step 4: Synthesis of tert-butyl (8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)octyl)carbamate

5 Boc-1,8-diaminooctane (2.10 g, 8.59 mmol, 1.1 eq) was dissolved in DMF (86 mL). In a separate flask, 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (2.60 g, 7.81 mmol, 1 eq) was dissolved in DMF (78 mL). The solution of Boc-1,8-diaminooctane in DMF was then added, followed by DIPEA (4.08 mL, 23.4 mmol, 3 eq) and HATU (2.97 g, 7.81 mmol, 1 eq). The mixture was stirred for 19 hours at room temperature, then diluted with EtOAc (600 mL). The organic layer was washed sequentially with 200 mL of half saturated sodium chloride, 200 mL 10% citric acid (aq.), 200 mL of half saturated sodium chloride, 200 mL of saturated sodium bicarbonate (aq.), 200 mL water and twice with 200 mL brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 40 g column, 0-5% MeOH/DCM, 35 minute gradient) gave the desired product as a white solid (3.53 g, 6.32 mmol, 81%). **¹H NMR** (500 MHz, Chloroform-*d*) δ 8.49 (s, 1H), 7.74 (dd, $J = 8.3, 7.4$ Hz, 1H), 7.55 (d, $J = 7.2$ Hz, 1H), 7.39 (t, $J = 5.3$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 1H), 4.97 (dd, $J = 12.4, 5.3$ Hz, 1H), 4.63 (d, $J = 2.2$ Hz, 2H), 4.59 (d, $J = 10.0$ Hz, 1H), 3.36 (q, $J = 6.9$ Hz, 2H), 3.12 – 3.03 (m, 2H), 2.95 – 2.72 (m, 3H), 2.16 (ddt, $J = 10.3, 5.2, 2.7$ Hz, 1H), 1.59 (p, $J = 7.1$ Hz, 2H), 1.37 (d, $J = 67.6$ Hz, 19H). **LCMS** 559.47 (M+H).

Step 5: Synthesis of N-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate


tert-butyl (8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)octyl)carbamate (3.53 g, 6.32 mmol, 1 eq) was dissolved in TFA (63 mL, 0.1M) and heated to 50 °C. After 1 hour, the mixture was cooled to room temperature, diluted with MeOH and concentrated under reduced pressure. The crude material was triturated with diethyl ether and dried under vacuum to give a white solid (2.93 g, 5.12 mmol, 81%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 7.82 (dd, $J = 8.4, 7.4$ Hz, 1H), 7.55 (d, $J = 7.2$ Hz, 1H), 7.44 (d, $J = 8.4$ Hz, 1H), 5.14 (dd, $J = 12.5, 5.5$ Hz, 1H), 4.76 (s, 2H), 3.33 (dd, $J = 6.8, 1.8$ Hz, 1H), 3.30 (s, 1H), 2.94 – 2.85 (m, 3H), 2.80 – 2.69 (m, 2H), 2.19 – 2.11 (m, 1H), 1.60 (dq, $J = 24.8, 7.0$ Hz, 4H), 1.37 (s, 8H). **LCMS** 459.45 (M+H).

Step 6: Synthesis of dBET6



(*S*)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetic acid (0.894 g, 2.23 mmol, 1 eq) and *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (1.277 g) were dissolved in DMF (22.3 mL, 0.1M) at room temperature. DIPEA (1.17 mL, 6.69 mmol, 3 eq) was added, followed by HATU (0.848 g, 2.23 mmol, 1 eq). The mixture was stirred for 23 hours, and then diluted with EtOAc. The organic layer was washed with saturated sodium bicarbonate, water and three times with brine. The organic layer was then dried under sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 40 g column, 4-10% MeOH/DCM, 35 minute gradient) gave dBET6 as a cream colored solid (1.573 g, 1.87 mmol, 84%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.80 (dd, *J* = 8.3, 7.5 Hz, 1H), 7.53 (d, *J* = 7.3 Hz, 1H), 7.46 – 7.37 (m, 5H), 5.11 (ddd, *J* = 12.6, 8.2, 5.5 Hz, 1H), 4.75 (s, 2H), 4.63 (dd, *J* = 9.0, 5.2 Hz, 1H), 3.41 (ddd, *J* = 14.9, 9.0, 2.2 Hz, 1H), 3.30 – 3.14 (m, 5H), 2.86 (ddt, *J* = 19.8, 14.6, 5.2 Hz, 1H), 2.78 – 2.66 (m, 5H), 2.44 (s, 3H), 2.13 (ddq, *J* = 15.3, 7.7, 4.8, 3.8 Hz, 1H), 1.69 (s, 3H), 1.61 – 1.51 (m, 4H), 1.35 (s, 8H). ¹³C NMR (126 MHz, MeOD) δ 174.49, 172.65, 171.30, 169.80, 168.28, 167.74, 166.18, 157.03, 156.24, 152.18, 138.19, 138.08, 137.97, 134.92, 133.52, 133.23, 132.02, 131.99, 131.33, 129.76, 121.65, 119.30, 117.94, 69.36, 55.27, 50.57, 40.49, 40.13, 38.84, 32.19, 30.49, 30.34, 30.31, 30.22, 27.92, 27.82, 23.64, 14.42, 12.92, 11.60. LCMS 841.48 (M+H).


Example 6: Synthesis of dBET9



A 0.1M solution of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.321 mL, 0.0321 mmol, 1 eq) was added to JQ-acid (12.87 mg, 0.0321 mmol, 1 eq) at room temperature. DIPEA (16.8 microliters, 0.0963 mmol, 3 eq) and HATU (12.2 mg, 0.0321 mmol, 1 eq) were added and the mixture was stirred for 24 hours, diluted with MeOH, and concentrated under reduced pressure. The crude material was purified by preparative HPLC to give a yellow oil. (16.11 mg, 0.0176 mmol, 55%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.79 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.49 – 7.36 (m, 5H), 5.10 (dd, *J* = 12.5, 5.5 Hz, 1H), 4.78 – 4.67 (m, 3H), 3.64 – 3.52 (m, 11H), 3.48 – 3.32 (m, 6H), 2.94 – 2.64 (m, 7H), 2.52 – 2.43 (m, 3H), 2.18 – 2.08 (m, 1H), 1.81 (p, *J* = 6.3 Hz, 4H), 1.73 – 1.67 (m, 3H). LCMS 918.45 (M+H).

Example 7: Synthesis of dBET17




A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.281 mL, 0.0281 mmol 1 eq) was added to (*S*)-2-(4-(4-cyanophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-

α [[1,4]diazepin-6-yl)acetic acid (11 mg, 0.0281 mmol, 1 eq) at room temperature. DIPEA (14.7 microliters, 0.0843 mmol, 3 eq) and HATU (10.7 mg, 0.0281 mmol, 1 eq) were added and the mixture was stirred for 24 hours, diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (ISCO, 4 g silica column 0-10%MeOH/DCM) gave a white solid (14.12 mg, 0.0182 mmol, 65%).

^1H NMR (400 MHz, Methanol- d_4) δ 7.82 – 7.72 (m, 3H), 7.61 (dd, J = 8.5, 2.0 Hz, 2H), 7.51 (d, J = 7.9 Hz, 1H), 7.44 – 7.40 (m, 1H), 5.11 – 5.05 (m, 1H), 4.76 (s, 2H), 4.66 (dd, J = 9.0, 5.1 Hz, 1H), 3.48 – 3.32 (m, 4H), 3.30 – 3.23 (m, 1H), 2.87 – 2.61 (m, 7H), 2.43 (s, 3H), 2.10 (dt, J = 10.7, 5.2 Hz, 1H), 1.70 – 1.59 (m, 7H). ^{13}C NMR (100 MHz, cd_3od) δ 174.42, 172.65, 171.27, 169.92, 168.25, 167.80, 165.88, 156.31, 143.55, 138.24, 134.88, 133.92, 133.50, 133.39, 131.72, 131.46, 130.55, 121.93, 119.39, 119.21, 118.02, 115.17, 69.59, 55.50, 50.55, 40.10, 39.83, 38.86, 32.11, 27.78, 27.67, 23.62, 14.41, 12.91, 11.64. LCMS 776.39 (M+H).

Example 8: Synthesis of dBET15




N-(6-aminoethyl)-2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamide trifluoroacetate (13.29 mg, 0.258 mmol, 1 eq) and JQ-acid (10.3 mg, 0.0258 mmol, 1 eq) were dissolved in DMF (0.26 mL). DIPEA (13.5 microliters, 0.0775 mmol, 3 eq) was added, followed by HATU (9.8 mg, 0.0258 mmol, 1 eq) and the mixture was stirred at room temperature. After 24 hours, the material was diluted with DCM and purified by column chromatography (ISCO, 0-15%MeOH/DCM) followed by preparative HPLC to give a pale yellow solid (11.44 mg, 0.0146 mmol 57%).

^1H NMR (400 MHz, Methanol- d_4) δ 8.29 – 8.23 (m, 2H), 7.93 (dd, J = 8.1, 4.2 Hz, 1H), 7.50 – 7.34 (m, 4H), 5.17 – 5.11 (m, 1H), 4.75 – 4.69 (m, 1H), 3.53 – 3.32 (m, 6H), 3.25 (dd, J = 13.8, 6.7 Hz, 1H), 2.90 – 2.67 (m, 6H), 2.49 – 2.38 (m, 3H), 2.18 – 2.10 (m, 1H), 1.64 (d, J = 22.4 Hz, 6H), 1.47 (s, 4H). ^{13}C NMR (100 MHz, cd_3od) δ 174.48, 171.17, 168.05, 168.03, 167.99, 167.70, 166.63, 141.81, 138.40, 137.47, 135.09, 134.77, 134.74, 133.96, 133.94,


133.38, 132.24, 132.05, 131.44, 129.85, 124.57, 123.12, 123.09, 54.98, 50.78, 40.88, 40.08, 38.37, 32.13, 30.40, 30.23, 27.34, 27.26, 23.58, 14.40, 12.96, 11.54. LCMS 783.43 (M+H).

Example 9: Synthesis of dBET2



5


(1) Synthesis of (R)-ethyl 4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoate



10 (R)-2-chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (44.2 mg, 0.15 mmol, 1 eq), ethyl 4-amino-3-methoxybenzoate (35.1 mg, 0.18 mmol, 1.2 eq), Pd₂dba₃ (6.9 mg, 0.0075 mmol, 5 mol %), XPhos (10.7 mg, 0.0225 mmol, 15 mol %) and potassium carbonate (82.9 mg, 0.60 mmol, 4 eq) were dissolved in tBuOH (1.5 mL, 0.1 M) and heated to 100 °C. After 21 hours, the mixture was cooled to room temperature, filtered
15 through celite, washed with DCM and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-100% EtOAc/hexanes over an 18 minute gradient) gave a yellow oil (52.3 mg, 0.115 mmol, 77%). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.57 (d, *J* = 8.5 Hz, 1H), 7.69 (td, *J* = 6.2, 2.9 Hz, 2H), 7.54 (d, *J* = 1.8 Hz, 1H), 4.52 (t, *J* = 7.9 Hz, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 4.23 (dd, *J* = 7.9, 3.7 Hz, 1H), 3.97 (s,
20 3H), 3.33 (s, 3H), 2.20 – 2.12 (m, 1H), 2.03 – 1.97 (m, 1H), 1.86 (ddd, *J* = 13.9, 7.6, 3.6 Hz,

4H), 1.78 – 1.65 (m, 4H), 1.40 (t, $J = 7.1$ Hz, 3H), 0.88 (t, $J = 7.5$ Hz, 3H). LCMS 454.32 (M+H).

(2) Synthesis of (*R*)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid



5

(*R*)-ethyl 4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoate (73.8 mg, 0.163 mmol, 1 eq) and LiOH (11.7 mg, 0.489 mmol, 3 eq) were dissolved in MeOH (0.82 mL) THF (1.63 mL) and water (0.82 mL). After 20 hours, an additional 0.82 mL of water was added and the mixture was stirred for an additional 24 hours before being purified by preparative HPLC to give a cream colored solid (53 mg, 0.125 mmol, 76%). ^1H NMR (400 MHz, Methanol- d_4) δ 7.97 (d, $J = 8.4$ Hz, 1H), 7.67 (dd, $J = 8.3, 1.6$ Hz, 1H), 7.64 – 7.59 (m, 2H), 4.38 (dd, $J = 7.0, 3.2$ Hz, 1H), 4.36 – 4.29 (m, 1H), 3.94 (s, 3H), 3.30 (s, 3H), 2.13 – 1.98 (m, 2H), 1.95 – 1.87 (m, 2H), 1.87 – 1.76 (m, 2H), 1.73 – 1.57 (m, 4H), 0.86 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (100 MHz, cd_3od) δ 168.67, 163.72, 153.59, 150.74, 150.60, 130.95, 127.88, 125.97, 123.14, 121.68, 116.75, 112.35, 61.76, 61.66, 56.31, 29.40, 29.00, 28.68, 28.21, 23.57, 23.41, 8.69. LCMS 426.45 (M+H).


(3) Synthesis of dBET2

A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.183 mL, 0.0183 mmol 1.2 eq) was added to (*R*)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid (6.48 mg, 0.0152 mmol, 1 eq) at room temperature.

DIPEA (7.9 microliters, 0.0456 mmol, 3 eq) and HATU (6.4 mg, 0.0168 mmol, 1.1 eq) were added and the mixture was stirred for 23 hours, before being purified by preparative HPLC to give a yellow solid (9.44 mg, 0.0102 mmol, 67%). ^1H NMR (400 MHz, Methanol- d_4) δ 7.84 – 7.77 (m, 2H), 7.58 (d, $J = 1.8$ Hz, 2H), 7.53 – 7.46 (m, 2H), 7.42 (d, $J = 8.4$ Hz, 1H), 5.11 – 5.05 (m, 1H), 4.76 (s, 2H), 4.48 (dd, $J = 6.5, 3.1$ Hz, 1H), 4.33 – 4.24 (m, 1H), 3.95 (s, 3H), 3.49 – 3.35 (m, 4H), 2.97 (d, $J = 10.5$ Hz, 3H), 2.89 – 2.65 (m, 5H), 2.17 – 1.99 (m, 4H), 1.89 (dd, $J = 14.5, 7.3$ Hz, 2H), 1.69 – 1.54 (m, 6H), 1.36 (dt, $J = 7.6, 3.9$ Hz, 1H), 0.85 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (100 MHz, cd_3od) δ 176.52, 174.48, 173.05, 171.34, 169.99, 168.91, 168.25, 167.80, 164.58, 156.34, 154.48, 153.10, 150.63, 138.22, 134.89, 133.96, 129.53, 123.93, 121.87, 120.78, 119.36, 117.99, 111.54, 69.55, 63.29, 63.10, 56.68, 50.55, 40.71,

39.86, 32.15, 29.43, 29.26, 28.73, 28.63, 27.81, 27.77, 24.25, 23.63, 8.47. LCMS 810.58 (M+H).

Example 10: Synthesis of dBET7



5

A 0.1 M solution *N*-(6-aminohexyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.186 mL, 0.0186 mmol 1 eq) was added to (*R*)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid (7.9 mg, 0.0186 mmol, 1 eq) at room temperature. DIPEA


10 (9.7 microliters, 0.0557 mmol, 3 eq) and HATU (7.1 mg, 0.0186 mmol, 1 eq) were added and the mixture was stirred for 19 hours, before being purified by preparative HPLC to give the desired trifluoroacetate salt as a yellow solid (13.62 mg, 0.0143 mmol, 77%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.80 (t, *J* = 8.3 Hz, 2H), 7.61 – 7.57 (m, 2H), 7.55 – 7.49 (m, 2H), 7.42 (d, *J* = 8.4 Hz, 1H), 5.13 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.75 (s, 2H), 4.48 (dd, *J* = 6.5, 3.2 Hz, 1H), 4.33 – 4.24 (m, 1H), 3.97 (s, 3H), 3.40 (t, *J* = 7.1 Hz, 2H), 3.34 (d, *J* = 6.7 Hz, 2H), 3.30 (s, 3H), 2.98 (d, *J* = 8.5 Hz, 1H), 2.89 – 2.82 (m, 1H), 2.79 – 2.63 (m, 3H), 2.17 – 2.00 (m, 4H), 1.91 (dt, *J* = 14.4, 7.1 Hz, 3H), 1.61 (dt, *J* = 13.4, 6.6 Hz, 7H), 1.47 – 1.41 (m, 3H), 0.86 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, cd₃od) δ 174.54, 171.37, 169.84, 168.84, 168.27, 167.74, 164.59, 156.26, 154.47, 153.18, 150.69, 138.19, 134.91, 134.05, 129.47, 124.78, 124.01, 121.65, 120.77, 119.29, 117.92, 117.86, 111.55, 69.34, 63.31, 63.13, 56.67, 50.53, 40.97, 39.96, 32.16, 30.42, 30.19, 29.42, 29.26, 28.72, 28.62, 27.65, 27.46, 24.26, 23.65, 8.47. LCMS 838.60 (M+H).

15

20


Example 11: Synthesis of dBET8



A 0.1 M solution *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.186 mL, 0.0186 mmol 1 eq) was added to (*R*)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid (7.9 mg, 0.0186 mmol, 1 eq) at room temperature. DIPEA (9.7 microliters, 0.0557 mmol, 3 eq) and HATU (7.1 mg, 0.0186 mmol, 1 eq) were added and the mixture was stirred for 16 hours, before being purified by preparative HPLC to give the desired trifluoroacetate salt as an off-white solid (7.15 mg, 0.007296 mmol, 39%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.83 – 7.77 (m, 2H), 7.61 – 7.56 (m, 2H), 7.55 – 7.50 (m, 2H), 7.42 (d, *J* = 8.5 Hz, 1H), 5.13 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.75 (s, 2H), 4.49 (dd, *J* = 6.6, 3.3 Hz, 1H), 4.33 – 4.24 (m, 1H), 3.97 (s, 3H), 3.39 (t, *J* = 7.1 Hz, 2H), 3.34 – 3.32 (m, 2H), 3.30 (s, 3H), 3.01 – 2.83 (m, 2H), 2.82 – 2.65 (m, 3H), 2.17 – 2.01 (m, 4H), 1.91 (dt, *J* = 14.2, 7.4 Hz, 1H), 1.68 – 1.54 (m, 7H), 1.37 (s, 7H), 0.86 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, cd₃od) δ 174.52, 171.35, 169.81, 168.85, 168.28, 167.74, 164.58, 156.27, 154.47, 153.89, 150.64, 138.19, 134.93, 134.18, 129.52, 129.41, 124.91, 123.83, 121.67, 120.76, 119.31, 117.95, 117.89, 111.57, 69.37, 63.37, 63.17, 56.67, 50.58, 41.12, 40.12, 32.19, 30.43, 30.28, 30.22, 30.19, 29.40, 29.25, 28.71, 28.62, 27.94, 27.75, 24.29, 23.65, 8.46. LCMS 866.56 (M+H).


Example 12: Synthesis of dBET10



A 0.1 M solution *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.172 mL, 0.0172 mmol 1 eq) was added to (*R*)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid (7.3 mg, 0.0172 mmol, 1 eq) at room temperature. DIPEA (9.0 microliters, 0.0515 mmol, 3 eq) and HATU (6.5 mg, 0.0172 mmol, 1 eq) were added and the mixture was stirred for 23 hours, before being purified by preparative HPLC to give the desired trifluoroacetate salt as an off-white oil (10.7 mg, 0.0101 mmol, 59%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.78 (d, *J* = 8.3 Hz, 1H), 7.75 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.56 – 7.51 (m, 2H), 7.49 – 7.44 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 1H), 5.08 (dd, *J* = 12.4, 5.4 Hz, 1H), 4.69 (s, 2H), 4.44 (dd, *J* = 6.7, 3.2 Hz, 1H), 4.30 – 4.21 (m, 1H), 3.92 (s, 3H), 3.59 – 3.42 (m, 12H), 3.35 (t, *J* = 6.7 Hz, 2H), 3.25 (s, 3H), 2.95 – 2.64 (m, 5H), 2.13 – 1.95 (m, 4H), 1.91 – 1.71 (m, 7H), 1.65 – 1.48 (m, 4H), 0.81 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, cd₃od) δ 174.50, 171.35, 169.83, 168.77, 168.25, 167.68, 164.57, 156.26, 154.47, 153.05, 150.59, 138.19, 134.92, 133.89, 129.53, 124.57, 123.98, 121.72, 120.75, 119.26, 117.95, 117.86, 111.54, 71.51, 71.46, 71.28, 71.20, 70.18, 69.65, 69.41, 63.27, 63.07, 56.71, 50.57, 38.84, 37.59, 32.17, 30.41, 30.32, 29.46, 29.26, 28.73, 28.64, 24.27, 23.65, 8.49. LCMS 942.62 (M+H).

Example 13: Synthesis of dBET16




A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.402 mL, 0.0402 mmol 1 eq) was added (*R*)-4-((4-cyclopentyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-*b*]pyrazin-6-yl)amino)-3-methoxybenzoic acid (16.55 mg, 0.0402 mmol, 1 eq) at room temperature.

DIPEA (21 microliters, 0.1206 mmol, 3 eq) and HATU (15.3 mg, 0.0402 mmol, 1 eq) were added and the mixture was stirred for 21 hours, before being purified by preparative HPLC, followed by column chromatography (ISCO, 12 g NH₂-silica column, 0-15% MeOH/DCM, 20 min gradient) to give HPLC to give a brown solid (10.63 mg, 0.0134 mmol, 33%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.22 (d, *J* = 8.4 Hz, 1H), 7.78 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.73 – 7.68 (m, 1H), 7.49 (d, *J* = 7.4 Hz, 2H), 7.46 – 7.39 (m, 2H), 6.98 (d, *J* = 8.8 Hz, 1H), 5.97 – 5.87 (m, 1H), 5.06 (dd, *J* = 12.6, 5.4 Hz, 1H), 4.76 (s, 2H), 3.98 (s, 3H), 3.61 (s, 2H), 3.44 – 3.36 (m, 4H), 2.92 (s, 1H), 2.78 (dd, *J* = 14.3, 5.2 Hz, 1H), 2.68 (ddd, *J* = 17.7, 8.2, 4.5 Hz, 2H), 2.36 – 2.26 (m, 2H), 2.10 – 1.90 (m, 5H), 1.76 – 1.62 (m, 6H), 1.31 (d, *J* = 16.0 Hz, 4H). LCMS 795.38 (M+H).

Example 14: Synthesis of dBET11



(1) Synthesis of ethyl 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoate

5 2-chloro-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(1H)-one (82.4 mg, 0.30 mmol, 1 eq), ethyl 4-amino-3-methoxybenzoate (70.3 mg, 0.36 mmol, 1.2 eq) Pd₂dba₃ (13.7 mg, 0.015 mmol, 5 mol%), XPhos (21.5 mg, 0.045 mmol, 15 mol%) and potassium carbonate (166 mg, 1.2 mmol, 4 eq) were dissolved in tBuOH (3.0 mL) and heated to 100 °C. After 17 hours, the mixture was cooled room temperature and filtered through
10 celite. The mixture was purified by column chromatography (ISCO, 12 g silica column, 0-100% EtOAc/hexanes, 19 min gradient) to give an off white solid (64.3 mg, 0.148 mmol, 49%).

¹H NMR (400 MHz, 50% cd₃od/cdcl₃) δ 8.51 (d, *J* = 8.5 Hz, 1H), 8.17 (s, 1H), 7.73 (ddd, *J* = 18.7, 8.1, 1.7 Hz, 2H), 7.52 (d, *J* = 1.8 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.15 – 7.10 (m, 2H),
15 4.34 (q, *J* = 7.1 Hz, 4H), 3.95 (s, 3H), 3.47 (s, 3H), 3.43 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, 50% cd₃od/cdcl₃) δ 169.28, 167.39, 164.29, 155.64, 151.75, 149.73, 147.45, 146.22, 133.88, 133.18, 132.37, 126.44, 124.29, 123.70, 123.36, 122.26, 120.58, 118.05, 116.83, 110.82, 61.34, 56.20, 38.62, 36.25, 14.51. LCMS 434.33 (M+H).

(2) Synthesis of 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoic acid

20 Ethyl 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoate (108.9 mg, 0.251 mmol, 1 eq) and LiOH (18 mg) were dissolved in THF (2.5 mL) and water (1.25 mL). After 24 hours, MeOH (0.63 mL)

was added to improved solubility) and stirred for an additional 24 hours before being diluted with MeOH and purified by preparative HPLC to give a light yellow solid (41.31 mg).


¹H NMR (400 MHz, Methanol-*d*₄) δ 8.51 (d, *J* = 8.5 Hz, 1H), 8.22 (s, 1H), 7.73 (ddd, *J* = 11.8, 8.1, 1.7 Hz, 2H), 7.57 (d, *J* = 1.8 Hz, 1H), 7.49 – 7.44 (m, 1H), 7.19 – 7.11 (m, 2H),
5 3.97 (s, 3H), 3.48 (s, 3H), 3.45 (s, 3H). LCMS 406.32 (M+H).

(3) Synthesis of dBET11

A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.190 mL, 0.0190 mmol 1 eq) was added to 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5*H*-benzo[*e*]pyrimido[5,4-
10 *b*][1,4]diazepin-2-yl)amino)-3-methoxybenzoic acid (7.71 mg, 0.0190 mmol, 1 eq) at room temperature. DIPEA (9.9 microliters, 0.0571 mmol, 3 eq) and HATU (7.2 mg, 0.0190 mmol, 1 eq) were added and the mixture was stirred for 22 hours, before being purified by preparative HPLC to give HPLC to give the desired trifluoroacetate salt as a cream colored solid (6.72 mg, 0.00744 mmol, 39%).

15 ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.46 (d, *J* = 8.3 Hz, 1H), 8.21 (s, 1H), 7.79 – 7.73 (m, 2H), 7.52 (d, *J* = 7.1 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.33 (d, *J* = 8.2 Hz, 1H), 7.15 (dd, *J* = 7.7, 5.9 Hz, 2H), 4.98 (dd, *J* = 12.0, 5.5 Hz, 1H), 4.69 (s, 2H), 3.97 (s, 3H), 3.49 (s, 3H), 3.46 – 3.34 (m, 7H), 2.81 – 2.67 (m, 3H), 2.13 – 2.08 (m, 1H), 1.69 (dt, *J* = 6.6, 3.5 Hz, 4H). ¹³C
NMR (100 MHz, cd₃od) δ 173.40, 170.10, 169.68, 169.00, 168.85, 167.60, 167.15, 164.77,
20 156.01, 155.42, 151.83, 150.03, 148.21, 137.82, 134.12, 133.48, 132.58, 132.52, 128.11, 126.72, 124.54, 122.33, 121.06, 120.63, 118.77, 118.38, 117.94, 117.62, 109.67, 68.90, 56.33, 49.96, 40.16, 39.48, 38.72, 36.34, 31.82, 27.24, 23.16. LCMS 790.48 (M+H).


Example 15: Synthesis of dBET12



A 0.1 M solution *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.186 mL, 0.0186 mmol 1 eq) was added to 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-*b*][1,4]diazepin-2-yl)amino)-3-methoxybenzoic acid (7.53 mg, 0.0186 mmol, 1 eq) at room temperature. DIPEA (9.7 microliters, 0.0557 mmol, 3 eq) and HATU (7.1 mg, 0.0186 mmol, 1 eq) were added and the mixture was stirred for 22 hours, before being purified by preparative HPLC to give HPLC to give the desired trifluoroacetate salt as a cream colored solid (7.50 mg, 0.00724 mmol, 39%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.46 (d, *J* = 8.9 Hz, 1H), 8.21 (s, 1H), 7.73 (dd, *J* = 15.2, 7.8 Hz, 2H), 7.50 – 7.42 (m, 3H), 7.28 (d, *J* = 8.5 Hz, 1H), 7.15 (t, *J* = 7.7 Hz, 2H), 5.01 (dd, *J* = 11.8, 5.8 Hz, 1H), 4.68 (s, 2H), 3.97 (s, 3H), 3.67 – 3.58 (m, 7H), 3.58 – 3.43 (m, 10H), 3.39 (t, *J* = 6.8 Hz, 2H), 3.35 (s, 2H), 2.97 (s, 1H), 2.84 – 2.70 (m, 3H), 2.16 – 2.07 (m, 1H), 1.93 – 1.76 (m, 4H). LCMS 922.57 (M+H).

Example 16: Synthesis of dBET13



A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.501 mL, 0.0501 mmol 1 eq) was added to 2-((2-


(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-*a*]pyrazin-3-yl)amino)acetic acid (synthesized as in McKeown et al, J. Med. Chem, 2014, 57, 9019) (18.22 mg, 0.0501 mmol, 1 eq) at room temperature. DIPEA (26.3 microliters, 0.150 mmol, 3 eq) and HATU (19.0 mg, 0.0501 mmol, 1 eq) were added and the mixture was stirred for 21 hours, before being

5 purified by preparative HPLC to give HPLC to give the desired trifluoroacetate salt as a dark yellow oil (29.66 mg, 0.0344 mmol, 69%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.09 (s, 1H), 8.65 (d, *J* = 5.2 Hz, 1H), 8.14 – 8.06 (m, 2H), 7.94 – 7.88 (m, 1H), 7.80 – 7.74 (m, 1H), 7.59 – 7.47 (m, 3H), 7.40 (dd, *J* = 8.4, 4.7 Hz, 1H), 5.11 – 5.06 (m, 1H), 4.72 (d, *J* = 9.8 Hz, 2H), 3.90 (s, 2H), 3.25 – 3.22 (m, 1H), 3.12 (t, *J* = 6.4 Hz, 1H), 2.96 (s, 2H), 2.89 – 2.79 (m, 1H),

10 2.76 – 2.62 (m, 2H), 2.48 – 2.42 (m, 3H), 2.29 (s, 3H), 2.10 (ddq, *J* = 10.2, 5.3, 2.7 Hz, 1H), 1.49 – 1.45 (m, 2H), 1.37 (dd, *J* = 6.7, 3.6 Hz, 2H). ¹³C NMR (100 MHz, cd₃od) δ 174.45, 171.98, 171.35, 169.88, 168.17, 167.85, 167.40, 159.88, 156.28, 141.82, 138.26, 135.85, 134.82, 133.09, 132.06, 130.75, 129.67, 122.07, 121.94, 119.30, 118.98, 118.06, 117.24, 69.56, 50.56, 40.05, 39.73, 32.13, 27.53, 23.62, 18.71, 17.28, 11.64, 10.85. LCMS 748.49

15 (M+H).

Example 17: Synthesis of dBET14




A 0.1 M solution *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.510 mL, 0.0510 mmol 1 eq) was added to 2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-*a*]pyrazin-3-yl)amino)acetic acid (synthesized as in McKeown et al, J. Med. Chem, 2014, 57, 9019) (18.52 mg, 0.0510 mmol, 1 eq) at room temperature. DIPEA (26.6 microliters, 0.153 mmol, 3 eq) and HATU (19.4 mg, 0.0510 mmol, 1 eq) were added

and the mixture was stirred for 22 hours, before being purified by preparative HPLC to give HPLC to give the desired trifluoroacetate salt as a dark yellow oil (32.63 mg, 0.0328 mmol, 64%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 9.09 (s, 1H), 8.66 (d, *J* = 5.4 Hz, 1H), 8.17 – 8.08 (m, 2H), 7.92 (d, *J* = 5.6 Hz, 1H), 7.77 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.60 – 7.47 (m, 3H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.09 (dd, *J* = 12.4, 5.5 Hz, 1H), 4.71 (s, 2H), 3.91 (s, 2H), 3.62 – 3.46 (m, 10H), 3.38 (dt, *J* = 16.0, 6.4 Hz, 3H), 3.18 (t, *J* = 6.8 Hz, 2H), 2.97 (s, 1H), 2.89 – 2.81 (m, 1H), 2.78 – 2.66 (m, 2H), 2.47 (s, 3H), 2.31 (s, 3H), 2.16 – 2.08 (m, 1H), 1.79 (dt, *J* = 12.8, 6.5 Hz, 2H), 1.64 (t, *J* = 6.3 Hz, 2H). ¹³C NMR (100 MHz, *cd*₃od) δ 174.48, 171.88, 171.34, 169.80, 168.22, 167.69, 167.42, 159.87, 156.24, 141.87, 138.21, 135.89, 134.88, 133.13, 132.04, 130.76, 129.67, 122.08, 121.69, 119.20, 117.94, 117.23, 71.44, 71.22, 71.10, 69.92, 69.62, 69.38, 50.57, 49.64, 38.11, 37.55, 32.16, 30.30, 30.20, 23.63, 11.67, 10.88. LCMS 880.46 (M+H).

Example 18: Synthesis of dBET18



(1) Synthesis of (S)-tert-butyl 4-(3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propyl)piperazine-1-carboxylate

JQ-acid (176.6 mg, 0.441 mmol, 1 eq) was dissolved in DMF (4.4 mL) at room temperature. HATU (176 mg, 0.463 mmol, 1.05 eq) was added, followed by DIPEA (0.23 mL, 1.32 mmol, 3 eq). After 10 minutes, *tert*-butyl 4-(3-aminopropyl)piperazine-1-

carboxylate (118 mg, 0.485 mmol, 1.1 eq) was added as a solution in DMF (0.44 mL). After 24 hours, the mixture was diluted with half saturated sodium bicarbonate and extracted twice with DCM and once with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (ISCO, 24 g silica column, 0-15% MeOH/DCM, 23 minute gradient) gave a yellow oil (325.5 mg, quant yield)

¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (t, *J* = 5.3 Hz, 1H), 7.41 – 7.28 (m, 4H), 4.58 (dd, *J* = 7.5, 5.9 Hz, 1H), 3.52 – 3.23 (m, 8H), 2.63 (s, 9H), 2.37 (s, 3H), 1.80 – 1.69 (m, 2H), 1.64 (s, 3H), 1.42 (s, 9H). ¹³C NMR (100 MHz, cdcl₃) δ 171.41, 164.35, 155.62, 154.45, 150.20, 136.92, 136.64, 132.19, 131.14, 130.98, 130.42, 129.98, 128.80, 80.24, 56.11, 54.32, 52.70, 38.96, 37.85, 28.42, 25.17, 14.43, 13.16, 11.82. LCMS 626.36 (M+H).

(2) Synthesis of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)-N-(3-(piperazin-1-yl)propyl)acetamide

(S)-*tert*-butyl 4-(3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetamido)propyl)piperazine-1-carboxylate (325.5 mg) was dissolved in DCM (5 mL) and MeOH (0.5 mL). A solution of 4M HCl in dioxane (1 mL) was added and the mixture was stirred for 16 hours, then concentrated under a stream of nitrogen to give a yellow solid (231.8 mg) which was used without further purification.

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.64 – 7.53 (m, 4H), 5.05 (t, *J* = 7.1 Hz, 1H), 3.81 – 3.66 (m, 6H), 3.62 – 3.33 (m, 9H), 3.30 (p, *J* = 1.6 Hz, 1H), 2.94 (s, 3H), 2.51 (s, 3H), 2.09 (dq, *J* = 11.8, 6.1 Hz, 2H), 1.72 (s, 3H). ¹³C NMR (100 MHz, cd₃od) δ 171.78, 169.38, 155.83, 154.03, 152.14, 140.55, 136.33, 134.58, 134.53, 133.33, 132.73, 130.89, 130.38, 56.07, 53.54, 41.96, 37.22, 36.23, 25.11, 14.48, 13.14, 11.68. LCMS 526.29 (M+H).

(3) Synthesis of (S)-*tert*-butyl (6-(4-(3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetamido)propyl)piperazin-1-yl)-6-

oxohexyl)carbamate

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)-N-(3-(piperazin-1-yl)propyl)acetamide (62.1 mg) and 6-((*tert*-butoxycarbonyl)amino)hexanoic acid (24.0 mg, 0.1037 mmol, 1 eq) were dissolved in DMF (1 mL). DIPEA (72.2 microliters, 0.4147 mmol, 4 eq) was added, followed by HATU (39.4 mg, 0.1037 mmol, 1 eq) and the mixture was stirred for 25 hours. The mixture was diluted with half saturated sodium bicarbonate and extracted three times with DCM. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 15 minute gradient) gave a yellow oil (71.75 mg, 0.0970 mmol, 94%).

¹H NMR (400 MHz, Chloroform-*d*) δ 7.61 (s, 1H), 7.43 – 7.28 (m, 4H), 4.63 (s, 1H), 4.61 – 4.56 (m, 1H), 3.82 – 3.21 (m, 10H), 3.11 – 3.01 (m, 2H), 2.61 (d, *J* = 24.3 Hz, 9H), 2.38 (s, 3H), 2.28 (t, *J* = 7.4 Hz, 2H), 1.73 (dq, *J* = 13.8, 7.4 Hz, 2H), 1.63 – 1.55 (m, 2H), 1.53 – 1.24 (m, 14H). ¹³C NMR (100 MHz, cdcl₃) δ 171.63, 171.11, 164.34, 156.17, 155.66, 150.21, 136.96, 136.72, 132.25, 131.14, 131.01, 130.47, 130.00, 128.85, 79.11, 56.42, 54.46, 53.06, 52.82, 45.04, 41.02, 40.47, 39.29, 38.33, 33.00, 29.90, 28.54, 26.60, 25.29, 24.86, 14.47, 13.20, 11.86. LCMS 739.37 (M+H).

(4) Synthesis of (S)-N-(3-(4-(6-aminohexanoyl)piperazin-1-yl)propyl)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetamide

(S)-*tert*-butyl (6-(4-(3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetamido)propyl)piperazin-1-yl)-6-oxohexyl)carbamate (71.75 mg, 0.0970 mmol, 1 eq) was dissolved in DCM (2 mL) and MeOH (0.2 mL). A solution of 4M HCl in dioxane (0.49 mL) was added and the mixture was stirred for 2 hours, then concentrated under a stream of nitrogen, followed by vacuum to give a yellow foam (59.8 mg, 0.0840 mmol, 87%).

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.68 – 7.53 (m, 4H), 5.04 (d, *J* = 6.6 Hz, 1H), 4.66 (d, *J* = 13.6 Hz, 1H), 4.23 (d, *J* = 13.6 Hz, 1H), 3.63 – 3.34 (m, 7H), 3.29 – 3.00 (m, 5H), 2.95 (d, *J* = 6.0 Hz, 5H), 2.51 (d, *J* = 9.2 Hz, 5H), 2.08 (s, 2H), 1.77 – 1.62 (m, 7H), 1.45 (dt, *J* = 15.3, 8.6 Hz, 2H). ¹³C NMR (100 MHz, cd₃od) δ 173.77, 171.84, 169.35, 155.85, 153.99, 140.56, 136.40, 134.58, 133.35, 132.70, 130.39, 55.83, 53.57, 52.92, 52.70, 43.57, 40.55, 39.67, 37.33, 36.25, 33.17, 28.26, 26.94, 25.33, 25.26, 14.49, 13.15, 11.65. LCMS 639.35 (M+H).

(5) Synthesis of dBET18


(S)-N-(3-(4-(6-aminohexanoyl)piperazin-1-yl)propyl)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetamide dihydrochloride (20.0 mg, 0.0281 mmol, 1 eq) and 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (9.32 mg, 0.0281 mmol, 1 eq) were dissolved in DMF (0.281 mL). DIPEA (19.6 microliters, 0.1124 mmol, 4 eq) was added, followed by HATU (10.7 mg, 0.0281 mmol, 1 eq). After 24 hours, the mixture was diluted with MeOH and purified by preparative HPLC to give the desired trifluoroacetate salt.

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.83 – 7.79 (m, 1H), 7.54 (d, *J* = 7.1 Hz, 1H), 7.45 (q, *J* = 8.8 Hz, 5H), 5.12 (dd, *J* = 12.5, 5.4 Hz, 1H), 4.76 (s, 2H), 4.68 (t, *J* = 7.3 Hz, 1H), 3.59 – 3.32 (m, 8H), 3.28 – 3.18 (m, 4H), 2.87 (ddd, *J* = 19.0, 14.7, 5.3 Hz, 2H), 2.80 – 2.65 (m, 6H), 2.44 (d, *J* = 6.8 Hz, 5H), 2.33 – 2.25 (m, 1H), 2.14 (dd, *J* = 9.8, 4.9 Hz, 1H), 2.06 – 1.89 (m, 3H), 1.70 (s, 3H), 1.61 (dq, *J* = 14.4, 7.3, 6.9 Hz, 4H), 1.45 – 1.37 (m, 2H). ¹³C NMR

(100 MHz, cd_3od) δ 174.52, 173.97, 173.69, 171.44, 169.88, 168.26, 167.83, 166.72, 156.36, 138.28, 137.84, 134.89, 133.52, 132.12, 131.83, 131.38, 129.89, 121.87, 119.32, 118.01, 69.52, 55.64, 55.03, 52.79, 50.58, 43.69, 39.77, 38.57, 36.89, 33.47, 32.16, 29.93, 27.34, 25.76, 25.45, 23.63, 14.39, 12.94, 11.66. LCMS 953.43 (M+H).


5

Example 19: Synthesis of dBET19




A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (235 microliters, 0.0235 mmol, 1 eq) was added to (*S*)-2-(4-(4-chlorophenyl)-2-(cyanomethyl)-3,9-dimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetic acid (10 mg, 0.0235 mmol, 1 eq) at room temperature. DIPEA (12.3 microliters, 0.0704 mmol, 3 eq) and HATU (8.9 mg, 0.0235 mmol, 1 eq) were added and the mixture was stirred for 18.5 hours. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (12.96 mg, 0.0160 mmol, 68%). $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.80 (dd, $J = 8.4, 7.4$ Hz, 1H), 7.55 – 7.37 (m, 6H), 5.14 – 5.06 (m, 1H), 4.77 (d, $J = 1.5$ Hz, 2H), 4.64 (dd, $J = 8.0, 5.6$ Hz, 1H), 3.45 – 3.32 (m, 5H), 3.29 – 3.21 (m, 2H), 2.83 – 2.66 (m, 6H), 2.58 (s, 3H), 2.14 – 2.06 (m, 1H), 1.71 – 1.57 (m, 4H). LCMS 810.30, M+H).

Example 20: Synthesis of dBET20



3-((2-((4-(4-(4-aminobutanoyl)piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)-*N*-(*tert*-butyl)benzenesulfonamide trifluoroacetate (7.41 mg, 0.0107 mmol, 1 eq) and 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (3.6 mg, 0.0107 mmol, 1 eq) were dissolved in DMF (214 microliters, 0.05M) at room temperature. DIPEA (5.6 microliters, 0.0321 mmol, 3 eq) and HATU (4.1 mg, 0.0107 mmol, 1 eq) were added. After 22.5 hours, the mixture was diluted with MeOH and purified by preparative HPLC to give the desired product as a brown residue (6.27 mg, 0.00701 mmol, 65%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 8.06 (s, 1H), 7.84 – 7.75 (m, 3H), 7.65 (s, 1H), 7.55 (t, *J* = 7.8 Hz, 2H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.25 – 7.20 (m, 2H), 6.99 (d, *J* = 8.8 Hz, 2H), 5.11 (dd, *J* = 12.5, 5.4 Hz, 1H), 4.78 (s, 2H), 3.79 – 3.66 (m, 4H), 3.40 (t, *J* = 6.6 Hz, 2H), 3.24 – 3.13 (m, 4H), 2.82 – 2.68 (m, 3H), 2.52 (t, *J* = 7.4 Hz, 2H), 2.24 – 2.19 (m, 3H), 2.12 (dd, *J* = 10.2, 5.1 Hz, 1H), 1.92 (dd, *J* = 13.4, 6.4 Hz, 2H), 1.18 (s, 9H). LCMS 895.63 (M+H).


Example 21: Synthesis of dBET21



A 0.1 M solution of 4-((10-aminodecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate in DMF (232 microliters, 0.0232 mmol, 1 eq) was added to JQ-acid (9.3 mg, 0.0232 mmol, 1 eq) at room temperature. DIPEA (12.1 microliters, 0.0696 mmol, 3


eq) and HATU (8.8 mg, 0.0232 mmol, 1 eq) were added and the mixture was stirred for 18 hours. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by preparative HPLC followed by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as an off-white residue (1.84 mg, 0.00235 mmol, 10%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.77 – 7.73 (m, 1H), 7.50 – 7.33 (m, 6H), 5.09 (dd, *J* = 12.5, 5.5 Hz, 1H), 4.62 (s, 1H), 4.21 (t, *J* = 6.4 Hz, 2H), 3.36 (s, 2H), 2.87 – 2.67 (m, 6H), 2.44 (s, 3H), 1.88 – 1.82 (m, 2H), 1.70 (s, 3H), 1.58 (s, 4H), 1.29 (s, 8H). LCMS 784.51 (M+H).

Example 22: Synthesis of dBET22



A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (247 microliters, 0.0247 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (10.98 mg, 0.0247 mmol, 1 eq) at room temperature. DIPEA (12.9 microliters, 0.0740 mmol, 3 eq) and HATU (9.4 mg, 0.0247 mmol, 1 eq) were added. The mixture was then stirred for 21 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (9.79 mg, 0.0118 mmol, 48%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.80 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.51 (dd, *J* = 7.1, 1.5 Hz, 1H), 7.48 – 7.34 (m, 5H), 5.11 (ddd, *J* = 12.4, 5.4, 3.5 Hz, 1H), 4.76 (s, 2H), 4.69 (td, *J* = 7.2, 1.4 Hz, 1H), 3.76 (s, 3H), 3.55 (d, *J* = 7.2 Hz, 2H), 3.48 – 3.33 (m, 4H), 2.93 – 2.82 (m, 1H), 2.78 – 2.64 (m, 5H), 2.14 – 2.07 (m, 1H), 1.96 (d, *J* = 0.9 Hz, 3H), 1.66 (s, 4H). LCMS 829.39 (M+H).

Example 23: Synthesis of dBET23



5 A 0.1 M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (220 microliters, 0.0220 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (9.87 mg, 0.0220 mmol, 1 eq) at room temperature. DIPEA (11.5 microliters, 0.0660 mmol, 3 eq) and HATU (8.4 mg, 0.0220 mmol, 1 eq) were added. The mixture was then stirred for 21 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (8.84 mg, 0.00998 mmol, 45%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.81 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.53 (d, *J* = 7.3 Hz, 1H), 7.50 – 7.39 (m, 5H), 5.12 (dd, *J* = 12.6, 5.4 Hz, 1H), 4.75 (s, 2H), 4.68 (t, *J* = 7.2 Hz, 1H), 3.76 (s, 3H), 3.54 (d, *J* = 7.2 Hz, 2H), 3.39 – 3.32 (m, 3H), 3.29 (s, 1H), 2.90 – 2.83 (m, 1H), 2.79 – 2.68 (m, 5H), 2.14 (dd, *J* = 8.9, 3.7 Hz, 1H), 1.99 (s, 3H), 1.65 – 1.53 (m, 4H), 1.36 (d, *J* = 6.5 Hz, 8H). LCMS 885.47 (M+H).

20

Example 24: Synthesis of dBET24

Step 1: Synthesis of tert-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)carbamate

25 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (200 mg, 0.602 mmol, 1 eq) was dissolved in DMF (6.0 mL, 0.1M). HATU (228.9 mg, 0.602 mmol, 1 eq), DIPEA (0.315 mL, 1.81 mmol, 3 eq) and *N*-Boc-2,2'-(ethylenedioxy)diethylamine (0.143 mL, 0.602 mmol, 1 eq) were added sequentially. After 6 hours, additional HATU (114

mg, 0.30 mmol, 0.5 eq) were added to ensure completeness of reaction. After an additional 24 hours, the mixture was diluted with EtOAc, and washed with saturated sodium bicarbonate, water and twice with brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 12 g silica column, 0-15% MeOH/DCM, 15 minute gradient) gave the desired product as a yellow oil (0.25 g, 0.44 mmol, 74%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.82 – 7.75 (m, 1H), 7.51 (d, *J* = 7.4 Hz, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 5.13 (dd, *J* = 12.4, 5.5 Hz, 1H), 4.76 (s, 2H), 3.66 – 3.58 (m, 6H), 3.53 – 3.45 (m, 4H), 3.19 (t, *J* = 5.6 Hz, 2H), 2.95 – 2.83 (m, 1H), 2.80 – 2.67 (m, 2H), 2.19 – 2.12 (m, 1H), 1.41 (s, 9H). LCMS 563.34 (M+H).

Step 2: Synthesis of *N*-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate


tert-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)carbamate (0.25 g, 0.44 mmol, 1 eq) was dissolved in TFA (4.5 mL) and heated to 50 °C. After 3 hours, the mixture was cooled to room temperature, diluted with MeOH, and concentrated under reduced pressure. Purification by preparative HPLC gave the desired product as a tan solid (0.197 g, 0.342 mmol, 77%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.81 (ddd, *J* = 8.4, 7.4, 1.1 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 5.13 (dd, *J* = 12.7, 5.5 Hz, 1H), 4.78 (s, 2H), 3.74 – 3.66 (m, 6H), 3.64 (t, *J* = 5.4 Hz, 2H), 3.52 (t, *J* = 5.3 Hz, 2H), 3.14 – 3.08 (m, 2H), 2.89 (ddd, *J* = 17.5, 13.9, 5.2 Hz, 1H), 2.80 – 2.66 (m, 2H), 2.16 (dtd, *J* = 13.0, 5.7, 2.7 Hz, 1H). LCMS 463.36 (M+H).

Step 2: Synthesis of dBET24

A 0.1 M solution of *N*-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.324 mL, 0.0324 mmol, 1 eq) was added to JQ-acid (13.0 mg, 0.324 mmol, 1 eq). DIPEA 16.9 microliters, 0.0972 mmol, 3 eq) and HATU (12.3 mg, 0.0324 mmol, 1 eq) were then added and the mixture was stirred for 18 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as an off-white solid (20.0 mg, 0.0236 mmol, 73%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.77 – 7.72 (m, 1H), 7.49 (d, *J* = 7.4 Hz, 1H), 7.45 – 7.35 (m, 5H), 5.09 (ddd, *J* = 12.3, 5.4, 3.7 Hz, 1H), 4.76 (s, 2H), 4.60 (dd, *J* = 8.9, 5.3 Hz, 1H), 3.68 – 3.62 (m, 6H), 3.59 (t, *J* = 5.6 Hz, 2H), 3.54 – 3.48 (m, 2H), 3.47 – 3.35 (m,

4H), 2.84 (ddd, $J = 19.4, 9.9, 4.6$ Hz, 1H), 2.77 – 2.69 (m, 2H), 2.68 (d, $J = 1.8$ Hz, 3H), 2.43 (s, 3H), 2.12 (dt, $J = 9.8, 5.3$ Hz, 1H), 1.68 (s, 3H). **LCMS** 845.39 (M+H).

Example 25: Synthesis of dBET25




A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (183 microliters, 0.0183 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-2,9-dimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-3-carboxylic acid (8.16 mg, 0.0183 mmol, 1 eq) at room temperature. DIPEA (9.6 microliters, 0.0550 mmol, 3 eq) and HATU (7.0 mg, 0.0183 mmol, 1 eq) were added. The mixture was then stirred for 23 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a yellow solid (4.39 mg, 0.00529 mmol, 29%). **¹H** NMR (400 MHz, Methanol-*d*₄) δ 7.82 (dd, $J = 8.4, 7.4$ Hz, 1H), 7.55 (d, $J = 7.3$ Hz, 1H), 7.45 (d, $J = 8.2$ Hz, 1H), 7.43 – 7.31 (m, 4H), 5.16 – 5.10 (m, 1H), 4.77 (d, $J = 1.5$ Hz, 2H), 4.56 (s, 1H), 3.74 (d, $J = 1.8$ Hz, 3H), 3.66 – 3.60 (m, 1H), 3.50 (dd, $J = 16.5, 7.3$ Hz, 1H), 3.37 – 3.32 (m, 1H), 3.28 (s, 3H), 2.85 (t, $J = 7.2$ Hz, 2H), 2.75 (d, $J = 7.8$ Hz, 1H), 2.71 (d, $J = 0.9$ Hz, 3H), 2.59 (d, $J = 1.0$ Hz, 3H), 2.18 – 2.10 (m, 1H), 1.36 – 1.24 (m, 4H). **LCMS** 829.38 (M+H).

10

15

20


Example 26: Synthesis of dBET26



A 0.1 M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (186 microliters, 0.0186 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-2,9-dimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-3-carboxylic acid (8.26 mg, 0.0186 mmol, 1 eq) at room temperature. DIPEA (9.7 microliters, 0.0557 mmol, 3 eq) and HATU (7.1 mg, 0.0186 mmol, 1 eq) were added. The mixture was then stirred for 23 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (6.34 mg, 0.00716 mmol, 38%).


¹H NMR (400 MHz, Methanol-*d*₄) δ 7.83 – 7.78 (m, 1H), 7.53 (dd, *J* = 7.3, 2.2 Hz, 1H), 7.45 – 7.38 (m, 3H), 7.32 (dd, *J* = 8.5, 1.3 Hz, 2H), 5.16 – 5.08 (m, 1H), 4.76 (s, 2H), 4.56 (s, 1H), 3.75 (s, 3H), 3.66 (dd, *J* = 15.9, 8.7 Hz, 1H), 3.50 (dd, *J* = 16.9, 6.9 Hz, 1H), 3.32 (d, *J* = 2.8 Hz, 4H), 2.84 – 2.74 (m, 3H), 2.70 (d, *J* = 1.1 Hz, 3H), 2.66 – 2.54 (m, 3H), 2.14 (d, *J* = 5.3 Hz, 1H), 1.62 – 1.22 (m, 12H). LCMS 885.48 (M+H).

Example 27: Synthesis of dBET27



A 0.1 M solution of 4-(2-(2-aminoethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate in DMF (257 microliters, 0.0257 mmol, 1 eq) was added to JQ-acid (10.3 mg, 0.0257 mmol, 1 eq). DIPEA (13.4 microliters, 0.0771 mmol, 3 eq) and HATU (9.8 mg, 0.0257 mmol, 1 eq) were then added and the mixture was stirred for 18 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (14.53 mg, 0.0195 mmol, 76%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.75 (ddd, *J* = 8.5, 7.3, 1.3 Hz, 1H), 7.47 – 7.30 (m, 6H), 5.00 (ddd, *J* = 25.4, 12.2, 5.2 Hz, 1H), 4.61 (td, *J* = 9.4, 5.0 Hz, 1H), 4.36 (q, *J* = 4.8 Hz, 2H), 3.96 – 3.89 (m, 2H), 3.74 (q, *J* = 5.6 Hz, 2H), 3.53 – 3.41 (m, 3H), 3.30 – 3.24 (m, 1H), 2.78 – 2.53 (m, 6H), 2.41 (d, *J* = 3.9 Hz, 3H), 2.09 – 1.98 (m, 1H), 1.67 (d, *J* = 5.0 Hz, 3H).

Example 28: Synthesis of dBET28




A 0.1 M solution of 4-(4-aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate in DMF (202 microliters, 0.0202 mmol, 1 eq) was added to JQ-acid (8.1 mg, 0.0202 mmol, 1 eq). DIPEA (10.6 microliters, 0.0606 mmol, 3 eq) and HATU (7.7 mg, 0.0202 mmol, 1 eq) were then added and the mixture was stirred for 18.5 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (10.46 mg, 0.0144 mmol, 71%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.76 (t, *J* = 7.5 Hz, 1H), 7.43 (td, *J* = 6.5, 2.5 Hz, 4H), 7.34 (t, *J* = 8.8 Hz, 2H), 5.08 – 4.98 (m, 1H), 4.64 (td, *J* = 9.1, 5.0 Hz, 1H), 4.26 (t, *J* = 5.3 Hz, 2H), 3.57 – 3.32 (m, 4H), 2.84 – 2.59 (m,

6H), 2.45 – 2.37 (m, 3H), 2.08 – 2.01 (m, 1H), 2.00 – 1.91 (m, 2H), 1.82 (dq, $J = 13.8, 6.9$ Hz, 2H), 1.68 (d, $J = 11.7$ Hz, 3H). **LCMS** 728.38 (M+H).


Example 29: Synthesis of dBET29

5




A 0.1 M solution of 4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione in DMF (205 microliters, 0.0205 mmol, 1 eq) was added to JQ-acid (8.2 mg, 0.0205 mmol, 1 eq). DIPEA (10.7 microliters, 0.0614 mmol, 3 eq) and HATU (7.8 mg, 0.0205 mmol, 1 eq) were then added and the mixture was stirred for 19 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (8.04 mg, 0.0106 mmol, 52%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.75 – 7.71 (m, 1H), 7.51 – 7.34 (m, 6H), 5.07 (ddd, $J = 12.1, 5.4, 2.4$ Hz, 1H), 4.62 (dd, $J = 9.0, 5.2$ Hz, 1H), 4.22 (t, $J = 6.4$ Hz, 2H), 3.44 – 3.32 (m, 2H), 3.29 – 3.21 (m, 2H), 2.88 – 2.65 (m, 6H), 2.43 (s, 3H), 2.13 – 2.06 (m, 1H), 1.86 (dt, $J = 13.9, 6.7$ Hz, 2H), 1.68 (s, 3H), 1.59 (dq, $J = 14.2, 7.0$ Hz, 4H), 1.54 – 1.45 (m, 2H). **LCMS** 756.40 (M+H).

Example 30: Synthesis of dBET30



A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (163 microliters, 0.0163 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-3,9-dimethyl-6-(2-((3-(4-methylpiperazin-1-yl)propyl)amino)-2-oxoethyl)-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (9.31 mg, 0.0163 mmol, 1 eq) at room temperature. DIPEA (8.5 microliters, 0.0490 mmol, 3 eq) and HATU (6.2 mg, 0.0163 mmol, 1 eq) were added. The mixture was then stirred for 23.5 hours, then purified by preparative HPLC to give the desired product as a yellow oil (11.48 mg, 0.0107 mmol, 66%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.82 – 7.78 (m, 1H), 7.54 – 7.35 (m, 6H), 5.09 (td, *J* = 12.7, 5.4 Hz, 1H), 4.77 – 4.70 (m, 3H), 3.56 – 3.31 (m, 12H), 3.23 (dd, *J* = 8.0, 6.0 Hz, 3H), 3.05 (d, *J* = 3.2 Hz, 2H), 2.93 – 2.81 (m, 5H), 2.78 – 2.63 (m, 5H), 2.15 – 2.05 (m, 2H), 1.96 – 1.86 (m, 4H), 1.68 (s, 4H). LCMS 954.55 (M+H).

Example 31: Synthesis of dBET31




A 0.1 M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (153 microliters, 0.0153 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-3,9-dimethyl-6-(2-((3-(4-methylpiperazin-1-yl)propyl)amino)-2-oxoethyl)-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (8.7 mg, 0.0153 mmol, 1 eq) at room temperature. DIPEA (7.9 microliters, 0.0458 mmol, 3 eq) and HATU (5.8 mg, 0.0153 mmol, 1 eq) were added. The mixture was then stirred for 25 hours, then purified by preparative HPLC to give the desired product as a nice brown (not like poop brown, kind of like brick) oil (9.52 mg, 0.00847 mmol, 55%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.81 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.59 – 7.40 (m, 6H), 5.12 (dd, *J* = 12.5, 5.4 Hz, 1H), 4.75 (s, 2H), 4.71 (t, *J* = 7.4 Hz, 1H), 3.53 – 3.34 (m, 8H), 3.29 – 3.11 (m, 6H), 3.03 – 2.61 (m, 13H), 2.15 (s, 1H), 2.01 – 1.84 (m, 5H), 1.59 (s, 4H), 1.37 (s, 8H). LCMS 1010.62 (M+H).

Example 32: Synthesis of dBET32


A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (180 microliters, 0.0180 mmol, 1 eq) was added to 4-(4-(4-((3-(*N*-(*tert*-butyl)sulfamoyl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-4-oxobutanoic acid (10.7 mg, 0.0180 mmol, 1 eq) at room temperature. DIPEA (9.4 microliters, 0.0539 mmol, 3 eq) and HATU (6.8 mg, 0.0180 mmol, 1 eq) were added and the mixture was stirred for 19 hours. The mixture was then diluted with methanol and purified by preparative HPLC to give the desired product as a brown oil (4.40 mg, 0.00449 mmol, 25%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 8.08 (d, *J* = 13.6 Hz, 1H), 7.84 – 7.76 (m, 3H), 7.63 (s, 1H), 7.57 – 7.51 (m, 2H), 7.41 (d, *J* = 8.4 Hz, 1H), 7.22 (td, *J* = 6.7, 2.2 Hz, 2H), 7.03 – 6.97 (m, 2H), 5.14 (dd, *J* = 12.5, 5.5 Hz, 1H), 4.76 (d, *J* = 16.8 Hz, 2H), 3.72 (dt, *J* = 10.0, 5.2 Hz, 4H), 3.34 – 3.33 (m, 1H), 3.23 – 3.12 (m, 5H), 2.97 (dd, *J* = 8.8, 4.0 Hz, 3H), 2.80 – 2.69 (m, 4H), 2.64 (dd, *J* = 7.6, 5.5 Hz, 1H), 2.50 (t, *J* = 6.8 Hz, 1H), 2.22 (dd, *J* = 2.4, 0.9 Hz, 3H), 2.17 – 2.11 (m, 1H), 1.67 – 1.52 (m, 4H), 1.18 (d, *J* = 0.8 Hz, 9H). LCMS 980.64 (M+H).

Example 33: Synthesis of dBET33




A 0.1 M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (188 microliters, 0.0188 mmol, 1 eq) was added to 4-(4-(4-((3-(*N*-(*tert*-butyl)sulfamoyl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-4-oxobutanoic acid (10.8 mg, 0.0188 mmol, 1 eq) at room temperature. DIPEA (9.8 microliters, 0.0564 mmol, 3 eq) and HATU (7.1 mg, 0.0188 mmol, 1 eq) were added and the mixture was stirred for 23 hours. The mixture was then diluted with methanol and purified by preparative HPLC to give the desired product as a brown residue (7.41 mg, 0.00715 mmol, 38%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 8.06 (s, 1H), 7.80 (ddd, *J* = 10.5, 7.6, 3.2 Hz, 3H), 7.65 (d, *J* = 4.5 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.41 (dd, *J* = 8.4, 2.9 Hz, 1H), 7.25 (td, *J* = 6.7, 2.9 Hz, 2H), 7.02 (t, *J* = 8.0 Hz, 2H), 5.16 – 5.09 (m, 1H), 4.75 (d, *J* = 9.5 Hz, 2H), 3.76 (dq, *J* = 16.0, 5.3 Hz, 4H), 3.29 – 3.12 (m, 7H), 3.00 – 2.67 (m, 7H), 2.51 (t, *J* = 6.8 Hz, 1H), 2.22 (d, *J* = 3.1 Hz, 3H), 2.13 (dtd, *J* = 10.4, 5.7, 3.1 Hz, 1H), 1.59 – 1.52 (m, 2H), 1.51 – 1.43 (m, 2H), 1.32 (t, *J* = 16.6 Hz, 8H), 1.18 (d, *J* = 1.3 Hz, 9H). **LCMS** 1036.69 (M+H).

Example 34: Synthesis of dBET34



A 0.1 M solution of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (173
 5 microliters, 0.0173 mmol, 1 eq) was added to 4-(4-(4-((4-((3-(*N*-(*tert*-butyl)sulfamoyl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-4-oxobutanoic acid (10.3 mg, 0.0173 mmol, 1 eq) at room temperature. DIPEA (9.0 microliters, 0.0519 mmol, 3 eq) and HATU (6.6 mg, 0.0173 mmol, 1 eq) were added and the mixture was stirred for 25 hours. The mixture was then diluted with methanol and purified by preparative
 10 HPLC to give the desired product as a brown residue (7.99 mg, 0.00718 mmol, 42%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 8.06 (s, 1H), 7.83 – 7.76 (m, 3H), 7.65 (s, 1H), 7.58 – 7.50 (m, 2H), 7.43 (dd, *J* = 17.7, 8.4 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.02 (t, *J* = 8.0 Hz, 2H), 5.13 (dt, *J* = 12.7, 5.2 Hz, 1H), 4.76 (d, *J* = 12.4 Hz, 2H), 3.73 (q, *J* = 6.3 Hz, 4H), 3.63 – 3.49 (m, 10H), 3.41 (q, *J* = 6.6 Hz, 2H), 3.27 – 3.15 (m, 5H), 3.01 – 2.81 (m, 4H), 2.79 – 2.63 (m,
 15 5H), 2.50 (t, *J* = 6.8 Hz, 1H), 2.22 (d, *J* = 2.3 Hz, 3H), 2.17 – 2.11 (m, 1H), 1.88 – 1.70 (m, 4H), 1.18 (d, *J* = 1.2 Hz, 9H). LCMS 1112.74 (M+H).


Example 35: Synthesis of dBET35



20

A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)acetamide trifluoroacetate in DMF (185 microliters, 0.0185 mmol, 1 eq) was added to JQ-acid (7.4 mg, 0.0185 mmol, 1 eq). DIPEA (9.6 microliters, 0.0554 mmol, 3 eq) and HATU (7.0 mg, 0.0185 mmol, 1 eq) were then added and the mixture was stirred for 17 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (2.71 mg, 0.00351 mmol, 19%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.48 – 7.37 (m, 4H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.14 (dd, *J* = 7.4, 2.4 Hz, 1H), 6.67 (d, *J* = 8.1 Hz, 1H), 5.14 (td, *J* = 13.5, 5.2 Hz, 1H), 4.66 – 4.60 (m, 1H), 4.59 (d, *J* = 8.3 Hz, 2H), 4.43 – 4.31 (m, 2H), 3.88 (s, 2H), 3.25 (dd, *J* = 14.8, 7.1 Hz, 4H), 2.94 – 2.72 (m, 3H), 2.68 (d, *J* = 4.9 Hz, 3H), 2.49 – 2.40 (m, 4H), 2.21 – 2.12 (m, 1H), 1.68 (s, 3H), 1.53 (s, 4H). LCMS 770.51 (M+H).


Example 36: Synthesis of dBET36



A 0.1 M solution of *N*-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)acetamide trifluoroacetate in DMF (222 microliters, 0.0222 mmol, 1 eq) was added to JQ-acid (8.9 mg, 0.0222 mmol, 1 eq). DIPEA (11.6 microliters, 0.0666 mmol, 3 eq) and HATU (8.4 mg, 0.0222 mmol, 1 eq) were then added and the mixture was stirred for 17.5 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (12.42 mg, 0.0156 mmol, 70%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.80 – 7.74 (m, 2H), 7.68 (d, *J* = 6.8 Hz, 1H), 7.42 (q, *J* = 8.7 Hz, 4H), 5.11

(dt, $J = 12.3, 4.6$ Hz, 1H), 4.63 (dd, $J = 8.8, 5.5$ Hz, 1H), 4.10 – 4.00 (m, 2H), 3.39 (ddd, $J = 14.9, 8.8, 2.5$ Hz, 1H), 3.30 – 3.21 (m, 5H), 2.88 – 2.76 (m, 1H), 2.74 – 2.65 (m, 5H), 2.44 (s, 3H), 2.15 – 2.08 (m, 1H), 1.69 (s, 3H), 1.63 – 1.55 (m, 4H). **LCMS** 769.49 (M+H).

5 Example 37: Synthesis of dBET37



A 0.1 M solution of 6-amino-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)methyl)hexanamide trifluoroacetate in DMF (195 microliters, 0.0195 mmol, 1 eq) was added to JQ-acid (7.8 mg, 0.0195 mmol, 1 eq). DIPEA (10.2 microliters, 0.0584 mmol, 3 eq) and HATU (7.4 mg, 0.0195 mmol, 1 eq) were then added and the mixture was stirred for 18 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (11.83 mg, 0.0151 mmol, 77%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 7.78 – 7.74 (m, 2H), 7.71 (dd, $J = 5.3, 3.5$ Hz, 1H), 7.42 (q, $J = 8.5$ Hz, 4H), 5.13 (dd, $J = 12.6, 5.5$ Hz, 1H), 4.82 (s, 2H), 4.63 (dd, $J = 8.8, 5.5$ Hz, 1H), 3.40 (ddd, $J = 15.0, 8.8, 1.6$ Hz, 1H), 3.30 – 3.21 (m, 3H), 2.86 (ddd, $J = 18.4, 14.6, 4.8$ Hz, 1H), 2.74 (ddd, $J = 13.8, 10.1, 2.8$ Hz, 2H), 2.69 (s, 3H), 2.44 (s, 3H), 2.30 (t, $J = 7.4$ Hz, 2H), 2.13 (dtd, $J = 12.9, 4.9, 2.3$ Hz, 1H), 1.74 – 1.64 (m, 5H), 1.59 (p, $J = 7.0$ Hz, 2H), 1.46 – 1.38 (m, 2H). **LCMS** 783.47 (M+H).

Example 38: Synthesis of dBET38

Step 1: Synthesis of *tert*-butyl (3-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)propoxy)propyl)carbamate


tert-butyl (3-(3-aminopropoxy)propyl)carbamate (134.5 mg, 0.579 mmol, 1 eq) was dissolved in DMF (5.79 ml, 0.05 M) then added to 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-

dioxoisindolin-4-yl)oxy)acetic acid (192.38 mg, 0.579 mmol, 1eq). DIPEA (0.28 ml, 1.74 mmol, 3 eq) and HATU (153.61 mg, 0.579 mmol, 1 eq) were added and the mixture was stirred for 18 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a yellow oil (157.1 mg). The crude material was purified by column chromatography (ISCO, 12 g silica column, 0 to 15% MeOH/DCM 25 minute gradient) to give a yellow oil (121.3 mg, 0.222 mmol, 38.27 %). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.78 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 5.13 (dd, *J* = 12.4, 5.5 Hz, 1H), 4.75 (s, 2H), 3.53 – 3.37 (m, 6H), 3.14 – 3.07 (m, 2H), 2.94 – 2.88 (m, 1H), 2.79 – 2.68 (m, 2H), 2.16 (ddd, *J* = 12.8, 6.6, 2.7 Hz, 1H), 1.81 (p, *J* = 6.4 Hz, 2H), 1.73 – 1.65 (m, 2H), 1.40 (s, 9H). LCMS 547.6 (M+H).

Step 2: Synthesis of N-(3-(3-aminopropoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate salt

TFA (2.22ml, 0.1 M) was added to *tert*-butyl (3-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)propoxy)propyl)carbamate (121.3 mg, 0.222 mmol, 1 eq) and the mixture was stirred at 50° C for 2 hours. The mixture was then dissolved in MeOH and concentrated under reduced pressure to give a brown oil (114.1 mg) that was carried forward without further purification. ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.81 – 7.74 (m, 1H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 5.12 (dd, *J* = 12.7, 5.5 Hz, 1H), 4.76 (s, 2H), 3.57 – 3.52 (m, 2H), 3.48 (t, *J* = 5.9 Hz, 2H), 3.40 (t, *J* = 6.6 Hz, 2H), 3.06 (t, *J* = 6.5 Hz, 2H), 2.87 (ddd, *J* = 14.1, 10.1, 7.0 Hz, 1H), 2.79 – 2.65 (m, 2H), 2.15 (dtd, *J* = 12.8, 5.5, 2.6 Hz, 1H), 1.92 (dt, *J* = 11.7, 5.9 Hz, 2H), 1.81 (p, *J* = 6.3 Hz, 2H). LCMS 447.2 (M+H).


Step 3: Synthesis of dBET38



A 0.1 M solution of *N*-(3-(3-aminopropoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.215 mL, 0.0215 mmol, 1


eq) was added to JQ-acid (8.6 mg, 0.0215 mmol, 1 eq) at room temperature. DIPEA (11.2 microliters, 0.0644 mmol, 3 eq) and HATU (8.2 mg, 0.0215 mmol, 1 eq) were added. After 19 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (10.6 mg, 0.0127 mmol, 59%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.79 – 7.74 (m, 1H), 7.50 (d, *J* = 8.1 Hz, 1H), 7.46 – 7.36 (m, 5H), 5.11 (ddd, *J* = 12.4, 5.5, 1.7 Hz, 1H), 4.73 (s, 2H), 4.62 (ddd, *J* = 8.7, 5.4, 1.4 Hz, 1H), 3.50 (q, *J* = 6.3 Hz, 4H), 3.43 (t, *J* = 6.5 Hz, 2H), 3.41 – 3.32 (m, 3H), 3.29 – 3.24 (m, 1H), 2.85 (ddd, *J* = 18.3, 14.6, 4.2 Hz, 1H), 2.77 – 2.65 (m, 5H), 2.43 (s, 3H), 2.17 – 2.09 (m, 1H), 1.80 (h, *J* = 6.4 Hz, 4H), 1.68 (s, 3H). LCMS 829.32 (M+H).

Example 39: Synthesis of dBET39



A 0.1 M solution of 4-((10-aminodecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate in DMF (0.212 mL, 0.0212 mmol, 1 eq) was added to JQ-acid (8.5 mg, 0.0212 mmol, 1 eq) at room temperature. DIPEA (11.1 microliters, 0.0636 mmol, 3 eq) and HATU (8.1 mg, 0.0212 mmol, 1 eq) were added. After 19 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-15% MeOH/DCM, 25 minute gradient) and preparative HPLC gave the desired product (0.39 mg, 0.00048 mmol, 2.3%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.77 – 7.73 (m, 1H), 7.56 – 7.31 (m, 6H), 5.11 – 5.06 (m, 1H), 4.62 (dd, *J* = 9.2, 5.0 Hz, 1H), 4.58 (s, 2H), 4.21 (t, *J* = 6.3 Hz, 2H), 3.42 – 3.38 (m, 1H), 3.24 – 3.20 (m, 1H), 2.90 – 2.68 (m, 6H), 2.45 (d, *J* = 6.7 Hz, 3H), 2.11 (s, 1H), 1.83 (dd, *J* = 14.7, 6.6 Hz, 2H), 1.70 (s, 3H), 1.61 – 1.49 (m, 4H), 1.32 (d, *J* = 23.2 Hz, 10H). LCMS 812.60 (M+H).

Example 40: Synthesis of dBET40



5 A 0.1 M solution of 4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate in DMF (0.242 mL, 0.0242 mmol, 1 eq) was added to JQ-acid (9.7 mg, 0.0242 mmol, 1 eq) at room temperature. DIPEA (12.6 microliters, 0.0726 mmol, 3 eq) and HATU (9.2 mg, 0.0242 mmol, 1 eq) were added. After 22 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and
10 brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) and preparative HPLC gave the desired product as a brown oil (4.74 mg, 0.00601mmol, 25%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.77 – 7.67 (m, 1H), 7.52 – 7.36 (m, 5H), 5.09 – 5.03 (m, 1H), 4.64 (d, *J* = 4.8 Hz, 1H), 4.40 – 4.32 (m, 2H), 3.97 – 3.88 (m, 2H), 3.81 – 3.74 (m, 2H), 3.69 – 3.60 (m, 5H), 3.55 – 3.38 (m, 4H), 2.89 – 2.54 (m, 6H), 2.45 (d, *J* = 5.9 Hz, 3H), 2.11 (s, 1H), 1.70 (d, *J* = 8.6 Hz, 3H). LCMS 788.42 (M+H).

Example 41: Synthesis of dBET41

20 *Step 1: Synthesis of tert-butyl (4-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)methyl)benzyl)carbamate*


tert-butyl (4-(aminomethyl)benzyl)carbamate (183.14 mg, 0.755 mmol, 1 eq) was dissolved in DMF (15.1 ml, 0.05 M) and added to 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid (250.90 mg, 0.755 mmol, 1 eq). DIPEA (0.374 ml, 2.265 mmol, 3 eq) and HATU (296.67 mg, 0.755 mmol, 1 eq) were added and the mixture was stirred for 20 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a light brown oil. The crude material was purified by column chromatography (ISCO, 12 g silica column, 0 to 15% MeOH/DCM 25

minute gradient) to give a light brown oil (373.1 mg, 0.678 mmol, 89.8 %). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 11.10 (s, 2H), 8.48 (t, *J* = 5.8 Hz, 1H), 7.80 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.40 (d, *J* = 8.6 Hz, 1H), 7.26 – 7.08 (m, 4H), 5.11 (dd, *J* = 12.9, 5.4 Hz, 1H), 4.86 (s, 2H), 4.33 (d, *J* = 3.9 Hz, 2H), 4.09 (d, *J* = 5.3 Hz, 2H), 2.65 – 2.51 (m, 3H), 2.07 – 1.99 (m, 1H), 1.38 (s, 9H). **LCMS** 551.5 (M+H).

Step 2: Synthesis of N-(4-(aminomethyl)benzyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate salt

TFA (6.77 ml, 0.1 M) was added to *tert*-butyl 4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)methyl)benzyl)carbamate (373.1 mg, 0.677 mmol, 1 eq) and the mixture was stirred at 50° C for 1.5 hours. The mixture was then dissolved in MeOH and concentrated under reduced pressure to give a brown oil (270.29 mg) that was carried forward without further purification. **¹H NMR** (500 MHz, DMSO-*d*₆) δ 11.11 (s, 1H), 8.55 (t, *J* = 6.2 Hz, 1H), 8.07 (s, 3H), 7.81 (dd, *J* = 8.5, 7.3 Hz, 1H), 7.51 (d, *J* = 7.2 Hz, 1H), 7.40 (dd, *J* = 14.9, 8.3 Hz, 3H), 7.31 (d, *J* = 8.2 Hz, 2H), 5.11 (dd, *J* = 12.9, 5.4 Hz, 1H), 4.87 (s, 2H), 4.37 (d, *J* = 6.1 Hz, 2H), 4.01 (q, *J* = 5.8 Hz, 2H), 2.66 – 2.51 (m, 3H), 2.07 – 1.99 (m, 1H). **LCMS** 451.3 (M+H).

Step 3: Synthesis of dBET41




A 0.1 M solution of *N*-(4-(aminomethyl)benzyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (0.237 mL, 0.0237 mmol, 1 eq) was added to JQ-acid (9.5 mg, 0.0237 mmol, 1 eq) at room temperature. After 23 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (11.8 mg, 0.0142 mmol, 60%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 7.80 – 7.75 (m, 1H), 7.51 (dd, *J* = 7.3, 1.5 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 1H), 7.36 (d, *J* = 2.2 Hz, 4H), 7.34 – 7.28 (m, 4H),

5.10 – 5.00 (m, 1H), 4.82 (s, 2H), 4.67 – 4.64 (m, 1H), 4.61 – 4.42 (m, 4H), 4.34 (dd, $J = 14.9, 12.8$ Hz, 1H), 3.49 (ddd, $J = 14.8, 9.5, 5.2$ Hz, 1H), 2.83 – 2.75 (m, 1H), 2.73 – 2.61 (m, 5H), 2.44 – 2.39 (m, 3H), 2.06 (ddq, $J = 9.8, 4.7, 2.6$ Hz, 1H), 1.66 (d, $J = 4.2$ Hz, 3H).

LCMS 832.92 (M+H).


5

Example 42: Synthesis of dBET42




A 0.1 M solution of 5-amino-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pentanamide trifluoroacetate in DMF (222 microliters, 0.0222 mmol, 1 eq) was added to JQ-acid (8.9 mg, 0.0222 mmol, 1 eq). DIPEA (11.6 microliters, 0.0666 mmol, 3 eq) and HATU (8.4 mg, 0.0222 mmol, 1 eq) were then added and the mixture was stirred for 24 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a white solid (12.23 mg, 0.0165 mmol, 74%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 7.76 – 7.71 (m, 1H), 7.66 – 7.62 (m, 1H), 7.51 (td, $J = 7.8, 2.5$ Hz, 1H), 7.45 – 7.35 (m, 4H), 5.11 (ddd, $J = 13.2, 11.3, 5.2$ Hz, 1H), 4.63 (ddd, $J = 8.8, 5.7, 3.2$ Hz, 1H), 4.47 (s, 2H), 3.45 – 3.32 (m, 3H), 3.30 – 3.27 (m, 1H), 2.90 – 2.80 (m, 1H), 2.73 – 2.63 (m, 4H), 2.49 (t, $J = 7.4$ Hz, 2H), 2.46 – 2.38 (m, 4H), 2.11 (ddtd, $J = 12.8, 10.5, 5.3, 2.3$ Hz, 1H), 1.84 – 1.75 (m, 2H), 1.66 (dd, $J = 16.2, 7.6$ Hz, 5H). **LCMS** 741.46 (M+H).

Example 43: Synthesis of dBET43



A 0.1 M solution of 7-amino-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)heptanamide trifluoroacetate in DMF (227 microliters, 0.0227 mmol, 1 eq) was added to
 5 JQ-acid (9.1 mg, 0.0227 mmol, 1 eq). DIPEA (11.9 microliters, 0.0681 mmol, 3 eq) and HATU (8.6 mg, 0.0227 mmol, 1 eq) were then added and the mixture was stirred for 25.5 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column
 10 chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as an off-white solid (12.58 mg, 0.0164 mmol, 72%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.71 (d, *J* = 7.9 Hz, 1H), 7.64 (d, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.8 Hz, 1H), 7.46 – 7.38 (m, 4H), 5.14 (ddd, *J* = 13.3, 5.2, 2.2 Hz, 1H), 4.62 (ddd, *J* = 8.6, 5.6, 2.1 Hz, 1H), 4.49 – 4.45 (m, 2H), 3.39 (ddd, *J* = 14.9, 8.7, 1.3 Hz, 1H), 3.30 – 3.24 (m, 3H), 2.93 –
 15 2.83 (m, 1H), 2.79 – 2.65 (m, 4H), 2.50 – 2.40 (m, 6H), 2.16 (ddq, *J* = 9.9, 5.2, 2.6 Hz, 1H), 1.78 – 1.70 (m, 2H), 1.68 (d, *J* = 2.1 Hz, 3H), 1.63 – 1.57 (m, 2H), 1.50 – 1.42 (m, 4H).
 LCMS 769.55 (M+H).


Example 44: Synthesis of dBET44



A 0.1 M solution of 8-amino-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)octanamide trifluoroacetate in DMF (217 microliters, 0.0217 mmol, 1 eq) was added to

JQ-acid (8.7 mg, 0.0217 mmol, 1 eq). DIPEA (11.3 microliters, 0.0651 mmol, 3 eq) and HATU (8.3 mg, 0.0217 mmol, 1 eq) were then added and the mixture was stirred for 20.5 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (14.28 mg, 0.0182 mmol, 84%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.72 – 7.68 (m, 1H), 7.64 (d, *J* = 7.5 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.46 – 7.39 (m, 4H), 5.14 (dt, *J* = 13.3, 5.0 Hz, 1H), 4.62 (dd, *J* = 8.8, 5.4 Hz, 1H), 4.48 – 4.44 (m, 2H), 3.40 (ddd, *J* = 14.9, 8.8, 0.9 Hz, 1H), 3.26 (dt, *J* = 13.2, 6.9 Hz, 3H), 2.88 (ddd, *J* = 18.7, 13.5, 5.4 Hz, 1H), 2.75 (dddd, *J* = 17.6, 7.1, 4.5, 2.4 Hz, 1H), 2.68 (d, *J* = 2.2 Hz, 3H), 2.49 – 2.39 (m, 6H), 2.17 (ddt, *J* = 9.8, 5.3, 2.3 Hz, 1H), 1.76 – 1.70 (m, 2H), 1.70 – 1.67 (m, 3H), 1.61 – 1.54 (m, 2H), 1.42 (s, 6H). LCMS 783.53 (M+H).

Example 45: Synthesis of dBET45




A 0.1 M solution of *N*-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (268 microliters, 0.0268 mmol, 1 eq) was added to (R)-4-((4-cyclopentyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-*b*]pyrazin-6-yl)amino)-3-methoxybenzoic acid (11.0 mg, 0.0268 mmol, 1 eq) at room temperature. DIPEA (14.0 microliters, 0.0804 mmol, 3 eq) and HATU (10.2 mg, 0.0268 mmol, 1 eq) were then added and the mixture was stirred for 18.5 hours. The mixture was then diluted with methanol and purified by preparative HPLC to give the desired product as a dark brown solid (10.44 mg, 0.0108 mmol, 40%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 8.38 (d, *J* = 8.4 Hz, 1H), 7.80 – 7.75 (m, 1H), 7.55 – 7.48 (m, 1H), 7.48 – 7.35 (m, 3H), 7.27 (d, *J*

= 8.3 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 5.12 (dd, J = 12.5, 5.5 Hz, 1H), 4.72 (d, J = 5.1 Hz, 2H), 4.53 (s, 1H), 4.28 (d, J = 6.8 Hz, 1H), 3.98 (d, J = 4.1 Hz, 3H), 3.48 – 3.33 (m, 4H), 2.90 – 2.82 (m, 1H), 2.80 – 2.69 (m, 2H), 2.18 – 2.01 (m, 4H), 1.88 – 1.52 (m, 10H), 1.34 (d, J = 42.9 Hz, 10H), 1.17 (d, J = 6.8 Hz, 3H). **LCMS** 851.67 (M+H).


5

Example 46: Synthesis of dBET46




A 0.1 M solution of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (256
10 microliters, 0.0256 mmol, 1 eq) was added to (*R*)-4-((4-cyclopentyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-*b*]pyrazin-6-yl)amino)-3-methoxybenzoic acid (10.5 mg, 0.0256 mmol, 1 eq) at room temperature. DIPEA (13.4 microliters, 0.0767 mmol, 3 eq) and HATU (9.7 mg, 0.0256 mmol, 1 eq) were then added and the mixture was stirred for 20 hours. The
15 mixture was then diluted with methanol and purified by preparative HPLC to give the desired product as a dark brown solid (13.69 mg, 0.0132 mmol, 51%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 8.28 – 8.24 (m, 1H), 7.74 – 7.71 (m, 1H), 7.49 (dd, J = 7.3, 3.7 Hz, 1H), 7.39 – 7.34 (m, 2H), 7.28 – 7.25 (m, 1H), 7.14 – 7.10 (m, 1H), 6.34 (d, J = 8.3 Hz, 1H), 5.01 – 4.97 (m, 1H), 4.62 (s, 2H), 4.25 (q, J = 6.7 Hz, 1H), 3.95 (d, J = 5.4 Hz, 3H), 3.60 (ddd, J =
20 9.0, 6.1, 1.6 Hz, 8H), 3.53 – 3.46 (m, 6H), 3.40 – 3.37 (m, 2H), 2.78 (td, J = 11.1, 6.6 Hz, 3H), 2.16 – 2.00 (m, 4H), 1.84 (ddt, J = 33.5, 13.0, 6.4 Hz, 7H), 1.75 – 1.60 (m, 6H), 1.17 (d, J = 6.8 Hz, 3H). **LCMS** 927.74 (M+H).

Example 47: Synthesis of dBET50




A 0.1 M solution of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200
 5 microliters, 0.0200 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (8.9 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. The mixture was then stirred for 17 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and
 10 brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a cream colored solid (9.31 mg, 0.00968 mmol, 48%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.82 – 7.78 (m, 1H), 7.52 (dd, *J* = 7.1, 1.6 Hz, 1H), 7.49 – 7.40 (m, 5H), 5.10 (ddd, *J* = 12.8, 5.5, 2.9 Hz, 1H), 4.74 (s, 2H), 4.67 (t, *J* = 7.1 Hz, 1H), 3.76 (s, 3H), 3.62 – 3.50 (m, 14H), 3.49 – 3.43 (m, 2H), 3.40 (q, *J* = 6.5 Hz, 2H), 2.87 (ddd, *J* = 17.6, 14.0, 5.3 Hz, 1H), 2.79 – 2.67 (m, 5H), 2.12 (ddq, *J* = 10.3, 5.4, 2.9 Hz, 1H), 2.00 (s, 3H), 1.86 (q, *J* = 6.3 Hz, 2H), 1.80 (p, *J* = 6.4 Hz, 2H). LCMS 961.67 (M+H).

20 Example 48: Synthesis of dBET51




A 0.1 M solution of *N*-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.0200 mmol, 1 eq) was added to (*S*)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine-2-carboxylic acid (8.9 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. The mixture was then stirred for 17 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as an off-white solid (8.38 mg, 0.00942 mmol, 47%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.80 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.52 (dd, *J* = 7.2, 1.3 Hz, 1H), 7.48 – 7.38 (m, 5H), 5.08 (ddd, *J* = 12.7, 5.5, 1.6 Hz, 1H), 4.74 (d, *J* = 2.7 Hz, 2H), 4.66 (t, *J* = 7.1 Hz, 1H), 3.75 (d, *J* = 3.0 Hz, 3H), 3.65 (t, *J* = 4.1 Hz, 6H), 3.59 (t, *J* = 5.3 Hz, 2H), 3.57 – 3.49 (m, 4H), 3.49 – 3.40 (m, 2H), 2.93 – 2.84 (m, 1H), 2.78 – 2.64 (m, 5H), 2.15 – 2.09 (m, 1H), 2.00 (d, *J* = 0.9 Hz, 3H). LCMS 889.58 (M+H).

Example 49: Synthesis of dBET52



A 0.1 M solution of *N*-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.020 mmol, 1 eq) was added to JQ-acid (8.0 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. After 17.5 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as a colorless residue (9.12 mg, 0.01025 mmol, 51%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.77 (t, *J* = 7.9 Hz, 1H), 7.50 (dd, *J* = 7.3, 1.5 Hz, 1H), 7.47 – 7.36 (m, 5H), 5.09 (ddd, *J* = 13.0, 7.6, 5.5 Hz, 1H), 4.76 (s, 2H), 4.62 (dd, *J* = 9.1, 5.1 Hz, 1H), 3.62 (ddt, *J* = 17.3, 11.2, 6.5 Hz, 12H), 3.52 – 3.41 (m, 5H), 3.28 (d, *J* = 5.1 Hz, 1H), 2.90 – 2.81 (m, 1H), 2.79 – 2.66 (m, 5H), 2.44 (s, 3H), 2.16 – 2.09 (m, 1H), 1.69 (s, 3H). LCMS 889.38 (M+H).


Example 50: Synthesis of dBET53



A 0.1 M solution of *N*-(14-amino-3,6,9,12-tetraoxatetradecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.020 mmol, 1 eq) was added to JQ-acid (8.0 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. After 17.5 hours, additional HATU (7.6 mg) and DIPEA (10.5 microliters were added) and the mixture was stirred for an additional 5 hours. The mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined

organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product (3.66 mg). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.79 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.51 (d, *J* = 7.3 Hz, 1H), 7.45 (d, *J* = 7.7 Hz, 2H), 7.43 – 7.36 (m, 3H), 5.08 (ddd, *J* = 12.7, 5.5, 2.2 Hz, 1H), 4.78 – 4.74 (m, 2H), 4.62 (dd, *J* = 9.1, 5.1 Hz, 1H), 3.70 – 3.51 (m, 16H), 3.50 – 3.41 (m, 5H), 3.27 (dd, *J* = 5.1, 2.3 Hz, 1H), 2.87 (ddt, *J* = 18.2, 9.5, 4.9 Hz, 1H), 2.78 – 2.66 (m, 5H), 2.44 (s, 3H), 2.16 – 2.09 (m, 1H), 1.69 (s, 3H). LCMS 933.43 (M+H).


Example 51: Synthesis of dBET54



A 0.1 M solution of *N*-(17-amino-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.020 mmol, 1 eq) was added to JQ-acid (8.0 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. After 16 hours the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product (6.27 mg, 0.00641 mmol, 32%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.81 – 7.76 (m, 1H), 7.51 (d, *J* = 7.1 Hz, 1H), 7.47 – 7.38 (m, 5H), 5.09 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.77 (s, 2H), 4.62 (dd, *J* = 8.8, 5.0 Hz, 1H), 3.67 – 3.55 (m, 20H), 3.46 (ddd, *J* = 20.1, 10.2,


4.7 Hz, 5H), 3.28 (d, $J = 5.1$ Hz, 1H), 2.91 – 2.83 (m, 1H), 2.78 – 2.68 (m, 5H), 2.44 (s, 3H), 2.16 – 2.10 (m, 1H), 1.72 – 1.66 (m, 3H). **LCMS** 977.50 (M+H).

Example 52: Synthesis of dBET55



A 0.1 M solution of *N*-(29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.020 mmol, 1 eq) was added to JQ-acid (8.0 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. After 18 hours the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product (10.55 mg, 0.00914 mmol, 46%). **¹H NMR** (500 MHz, Methanol-*d*₄) δ 7.82 (dd, $J = 8.4, 7.4$ Hz, 1H), 7.55 (d, $J = 7.0$ Hz, 1H), 7.49 – 7.41 (m, 5H), 5.13 (dd, $J = 12.6, 5.5$ Hz, 1H), 4.80 (s, 2H), 4.65 (dd, $J = 9.1, 5.1$ Hz, 1H), 3.68 – 3.58 (m, 36H), 3.53 – 3.44 (m, 5H), 2.94 – 2.86 (m, 1H), 2.81 – 2.70 (m, 5H), 2.46 (s, 3H), 2.19 – 2.13 (m, 1H), 1.74 – 1.69 (m, 3H). **LCMS** 1153.59 (M+H).


Example 53: Synthesis of dBET56



A 0.1 M solution of *N*-(35-amino-3,6,9,12,15,18,21,24,27,30,33-undeca-oxapentatriacontyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (200 microliters, 0.020 mmol, 1 eq) was added to JQ-acid (8.0 mg, 0.020 mmol, 1 eq) at room temperature. DIPEA (10.5 microliters, 0.060 mmol, 3 eq) and HATU (7.6 mg, 0.020 mmol, 1 eq) were added. After 20 hours the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH/DCM, 25 minute gradient) gave the desired product as an oily residue (9.03 mg, 0.00727 mmol, 36%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.81 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.53 (d, *J* = 7.1 Hz, 1H), 7.50 – 7.40 (m, 5H), 5.11 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.78 (s, 2H), 4.68 (dd, *J* = 8.6, 5.0 Hz, 1H), 3.69 – 3.56 (m, 44H), 3.52 – 3.43 (m, 5H), 3.34 (dd, *J* = 7.9, 3.5 Hz, 1H), 2.88 (ddd, *J* = 18.0, 14.0, 5.2 Hz, 1H), 2.79 – 2.68 (m, 5H), 2.46 (s, 3H), 2.17 – 2.12 (m, 1H), 1.71 (s, 3H). LCMS 1241.60 (M+H).


Example 54: Synthesis of dBET57

Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione




A solution of 4-fluoroisobenzofuran-1,3-dione (200 mg, 1.20 mmol, 1 equiv) in AcOH (4.0 mL, 0.3 M) was added 2,6-dioxopiperidin-3-amine hydrochloride (218 mg, 1.32 mmol, 1.1 equiv) and potassium acetate (366 mg, 3.73 mmol, 3.1 equiv). The reaction mixture was heated to 90 °C overnight, whereupon it was diluted with water to 20 mL and cooled on ice for 30 min. The resulting slurry was filtered, and the black solid was purified by flash column chromatography on silica gel (2% MeOH in CH₂Cl₂, *R_f* = 0.3) to afford the title compound as a white solid (288 mg, 86%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.15 (s, 1H), 7.96 (ddd, *J* = 8.3, 7.3, 4.5 Hz, 1H), 7.82 – 7.71 (m, 2H), 5.17 (dd, *J* = 13.0, 5.4 Hz, 1H), 2.90 (ddd, *J* = 17.1, 13.9, 5.4 Hz, 1H), 2.65 – 2.47 (m, 2H), 2.10 – 2.04 (m, 1H), MS (ESI) calcd for C₁₃H₁₀FN₂O₄ [M+H]⁺ 277.06, found 277.25.

Step 2: Synthesis of *tert*-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethyl)carbamate




A stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisobenzofuran-1,3-dione (174 mg, 0.630 mmol, 1 equiv) in DMF (6.3 mL, 0.1 M) was added DIPEA (220 μL, 1.26 mmol, 2 equiv) and 1-Boc-ethylendiamine (110 μL, 0.693 mmol, 1.1 equiv). The reaction mixture was heated to 90 °C overnight, whereupon it was cooled to room temperature and taken up in EtOAc (30 mL) and water (30 mL). The organic layer was washed with brine (3x20 mL), dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (0→10% MeOH in CH₂Cl₂) to give the title compound as a yellow solid (205 mg, 79%). ¹H NMR (500 MHz, CDCl₃) δ 8.08 (bs, 1H), 7.50 (dd, *J* = 8.5, 7.1 Hz, 1H), 7.12 (d, *J* = 7.1 Hz, 1H), 6.98 (d, *J* = 8.5 Hz, 1H), 6.39 (t, *J* = 6.1 Hz, 1H), 4.96 – 4.87 (m, 1H), 4.83 (bs, 1H), 3.50 – 3.41 (m, 2H), 3.41 – 3.35 (m, 2H), 2.92 – 2.66 (m, 3H), 2.16 – 2.09 (m, 1H), 1.45 (s, 9H); MS (ESI) calcd for C₂₀H₂₅N₄O₆ [M+H]⁺ 417.18, found 417.58.

Step 3: Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethan-1-aminium 2,2,2-trifluoroacetate



A stirred solution of *tert*-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethyl)carbamate (205 mg, 0.492 mmol, 1 equiv) in dichloromethane (2.25 mL) was added trifluoroacetic acid (0.250 mL). The reaction mixture was stirred at room temperature for 4 h, whereupon the volatiles were removed *in vacuo*. The title compound was obtained as a yellow solid (226 mg, >95%), that was used without further purification. ¹H NMR (500 MHz, MeOD) δ 7.64 (d, *J* = 1.4 Hz, 1H), 7.27 – 7.05 (m, 2H), 5.10 (dd, *J* = 12.5, 5.5 Hz, 1H), 3.70 (t, *J* = 6.0 Hz, 2H), 3.50 – 3.42 (m, 2H), 3.22 (t, *J* = 6.0 Hz, 1H), 2.93 – 2.85 (m, 1H), 2.80 – 2.69 (m, 2H), 2.17 – 2.10 (m, 1H); MS (ESI) calcd for C₁₅H₁₇N₄O₄ [M+H]⁺ 317.12, found 317.53.

Step 2: Synthesis of dBET57




JQ-acid (8.0 mg, 0.0200 mmol, 1 eq) and 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethan-1-aminium 2,2,2-trifluoroacetate (8.6 mg, 0.0200 mmol, 1 equiv) were dissolved in DMF (0.200 mL, 0.1 M) at room temperature. DIPEA (17.4 μ L, 0.100 mmol, 5 equiv) and HATU (7.59 mg, 0.0200 mmol, 1 equiv) were then added and the mixture was stirred at room temperature overnight. The reaction mixture was taken up in EtOAc (15 mL), and washed with satd. NaHCO₃ (aq) (15 mL), water (15 mL) and brine (3x15 mL). The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (0 $\rightarrow$ 10% MeOH in CH₂Cl₂, *R_f* = 0.3 (10% MeOH in CH₂Cl₂)) to give the title compound as a bright yellow solid (11.2 mg, 80%). ¹H NMR (400 MHz, CDCl₃) δ 8.49 (bs, 0.6H), 8.39 (bs, 0.4H), 7.51 – 7.43 (m, 1H), 7.38 (d, *J* = 7.8 Hz, 2H), 7.29 (dd, *J* = 8.8, 1.7 Hz, 2H), 7.07 (dd, *J* = 7.1, 4.9 Hz, 1H), 6.97

(dd, $J = 8.6, 4.9$ Hz, 1H), 6.48 (t, $J = 5.9$ Hz, 1H), 6.40 (t, $J = 5.8$ Hz, 0.6H), 4.91 – 4.82 (m, 0.4H), 4.65 – 4.60 (m, 1H), 3.62 – 3.38 (m, 6H), 2.87 – 2.64 (m, 3H), 2.63 (s, 3H), 2.40 (s, 6H), 2.12 – 2.04 (m, 1H), 1.67 (s, 3H), rotamers; MS (ESI) calcd for $C_{34}H_{32}ClN_8O_5S$ $[M+H]^+$ 700.19, found 700.34.


5

Example 55: Synthesis of dGR1




10


Example 56: Synthesis of dGR2:



5 Example 57: Synthesis of dGR3:



Example 58: Synthesis of dFKBP-1



(1) Synthesis of SLF-succinate


SLF (25 mg, 2.5 mL of a 10 mg/mL solution in MeOAc, 0.0477 mmol, 1 eq) was
 5 combined with DMF (0.48 mL, 0.1 M) and succinic anhydride (7.2 mg, 0.0715 mmol, 1.5 eq)
 and stirred at room temperature for 24 hours. Low conversion was observed and the mixture
 was placed under a stream of N_2 to remove the MeOAc. An additional 0.48 mL of DMF was
 added, along with an additional 7.2 mg succinic anhydride and DMAP (5.8 mg, 0.0477
 mmol, 1 eq). The mixture was then stirred for an additional 24 hours before being purified
 10 by preparative HPLC to give SLF-succinate as a yellow oil (24.06 mg, 0.0385 mmol, 81%).
 ^1H NMR (400 MHz, Methanol- d_4) δ 7.62 (d, J = 10.7 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.26
 (td, J = 7.9, 2.7 Hz, 1H), 7.07 – 6.97 (m, 1H), 6.80 (dd, J = 8.1, 2.1 Hz, 1H), 6.74 – 6.66 (m,
 2H), 5.73 (dd, J = 8.1, 5.5 Hz, 1H), 5.23 (d, J = 4.8 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.39 –
 3.29 (m, 4H), 3.21 (td, J = 13.2, 3.0 Hz, 1H), 2.68 – 2.50 (m, 5H), 2.37 – 2.19 (m, 2H), 2.12 –
 15 2.02 (m, 1H), 1.79 – 1.61 (m, 4H), 1.49 – 1.30 (m, 2H), 1.27 – 1.05 (m, 6H), 0.82 (dt, J =
 41.2, 7.5 Hz, 3H). LCMS 624.72 (M+H).

(2) Synthesis of dFKBP-1

N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-
 yl)oxy)acetamide trifluoroacetate (9.9 mg, 0.0192 mmol, 1 eq) was added to SLFsuccinate
 20 (11.98 mg, 0.0192 mmol, 1 eq) as a solution in 0.192 mL DMF (0.1 M). DIPEA (10.0
 microliters, 0.0575 mmol, 3 eq) was added, followed by HATU (7.3 mg, 0.0192 mmol, 1 eq).
 The mixture was stirred for 17 hours, then diluted with MeOH and purified by preparative
 HPLC to give dFKBP-1 (7.7 mg, 0.00763 mmol, 40%) as a yellow solid.

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.81 (s, 1H), 7.77 – 7.70 (m, 1H), 7.55 – 7.49 (m, 2H), 7.26 (dd, *J* = 8.0, 5.3 Hz, 2H), 7.05 – 6.99 (m, 1H), 6.77 (d, *J* = 8.8 Hz, 1H), 6.66 (d, *J* = 6.8 Hz, 2H), 5.77 – 5.72 (m, 1H), 5.24 (d, *J* = 4.8 Hz, 1H), 4.99 (dd, *J* = 12.3, 5.7 Hz, 1H), 4.68 – 4.59 (m, 2H), 3.82 (s, 3H), 3.81 (s, 3H), 3.32 (dt, *J* = 3.3, 1.6 Hz, 4H), 3.26 – 3.14 (m, 3H), 2.79 (dd, *J* = 18.9, 10.2 Hz, 3H), 2.64 – 2.48 (m, 5H), 2.34 (d, *J* = 14.4 Hz, 1H), 2.22 (d, *J* = 9.2 Hz, 1H), 2.14 – 2.02 (m, 2H), 1.78 – 1.49 (m, 9H), 1.43 – 1.30 (m, 2H), 1.20 – 1.04 (m, 6H), 0.90 – 0.76 (m, 3H). ¹³C NMR (100 MHz, cd₃od) δ 208.51, 173.27, 172.64, 171.63, 169.93, 169.51, 168.04, 167.69, 167.09, 166.71, 154.92, 149.05, 147.48, 140.76, 138.89, 137.48, 133.91, 133.67, 129.36, 122.19, 120.61, 120.54, 119.82, 118.41, 118.12, 117.79, 112.12, 111.76, 68.54, 56.10, 55.98, 51.67, 46.94, 44.57, 39.32, 39.01, 38.23, 32.64, 31.55, 31.43, 26.68, 26.64, 25.08, 23.52, 23.21, 22.85, 21.27, 8.76. LCMS 1009.66 (M+H).

Example 59: Synthesis of dFKBP-2



(1) Synthesis of tert-butyl (1-chloro-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate
 tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (1.0 g, 3.12 mmol, 1 eq) was dissolved in THF (31 mL, 0.1 M). DIPEA (0.543 mL, 3.12 mmol, 1 eq) was added and the solution was cooled to 0 °C. Chloroacetyl chloride (0.273 mL, 3.43 mmol, 1.1 eq) was added and the mixture was warmed slowly to room temperature. After 24 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a yellow oil (1.416 g) that was carried forward without further purification. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.24 (s, 1H), 5.00 (s, 1H), 3.98 – 3.89 (m, 2H), 3.54 (dddt, *J* = 17.0, 11.2, 5.9, 2.2 Hz, 10H), 3.47 – 3.40 (m, 2H), 3.37 – 3.31 (m, 2H), 3.17 – 3.07

(m, 2H), 1.79 – 1.70 (m, 2H), 1.67 (p, $J = 6.1$ Hz, 2H), 1.35 (s, 9H). ^{13}C NMR (100 MHz, cdCl_3) δ 165.83, 155.97, 78.75, 70.49, 70.47, 70.38, 70.30, 70.14, 69.48, 42.61, 38.62, 38.44, 29.62, 28.59, 28.40. LCMS 397.37 (M+H).

(2) Synthesis of dimethyl 3-((2,2-dimethyl-4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazahenicosan-21-yl)oxy)phthalate

tert-butyl (1-chloro-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (1.41 g, 3.12 mmol, 1 eq) was dissolved in MeCN (32 mL, 0.1 M). Dimethyl 3-hydroxyphthalate (0.721 g, 3.43 mmol, 1.1 eq) and cesium carbonate (2.80 g, 8.58 mmol, 2.75 eq) were added. The flask was fitted with a reflux condenser and heated to 80 °C for 19 hours. The mixture was cooled to room temperature and diluted water and extracted once with chloroform and twice with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (ISCO, 24 g silica column, 0-15% MeOH/DCM 22 minute gradient) to give a yellow oil (1.5892 g, 2.78 mmol, 89% over two steps).

^1H NMR (400 MHz, Chloroform- d) δ 7.52 (d, $J = 7.8$ Hz, 1H), 7.35 (t, $J = 8.1$ Hz, 1H), 7.04 (d, $J = 8.3$ Hz, 1H), 7.00 (t, $J = 5.3$ Hz, 1H), 5.06 (s, 1H), 4.46 (s, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.47 (ddd, $J = 14.9, 5.5, 2.8$ Hz, 8H), 3.39 (dt, $J = 9.4, 6.0$ Hz, 4H), 3.29 (q, $J = 6.5$ Hz, 2H), 3.09 (d, $J = 6.0$ Hz, 2H), 1.70 (p, $J = 6.5$ Hz, 2H), 1.63 (p, $J = 6.3$ Hz, 2H), 1.31 (s, 9H). ^{13}C NMR (100 MHz, cdCl_3) δ 167.68, 167.36, 165.45, 155.93, 154.41, 130.87, 129.60, 125.01, 123.20, 117.06, 78.60, 70.40, 70.17, 70.06, 69.39, 68.67, 68.25, 52.77, 52.57, 38.38, 36.58, 29.55, 29.20, 28.34. LCMS 571.47 (M+H).

(3) Synthesis of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate

Dimethyl 3-((2,2-dimethyl-4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazahenicosan-21-yl)oxy)phthalate (1.589 g, 2.78 mmol, 1 eq) was dissolved in EtOH (14 mL, 0.2 M).

Aqueous 3M NaOH (2.8 mL, 8.34 mmol, 3 eq) was added and the mixture was heated to 80 °C for 22 hours. The mixture was then cooled to room temperature, diluted with 50 mL DCM and 20 mL 0.5 M HCl. The layers were separated and the organic layer was washed with 25 mL water. The aqueous layers were combined and extracted three times with 50 mL chloroform. The combined organic layers were dried over sodium sulfate, filtered and condensed to give 1.53 g of material that was carried forward without further purification. LCMS 553.44.

The resultant material (1.53 g) and 3-aminopiperidine-2,6-dione hydrochloride (0.480 g, 2.92 mmol, 1 eq) were dissolved in pyridine (11.7 mL, 0.25 M) and heated to 110 °C for

17 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to give crude *tert*-butyl (1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate as a black sludge (3.1491 g) that was carried forward without further purification. LCMS 635.47.

5 The crude *tert*-butyl (1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (3.15 g) was dissolved in TFA (20 mL) and heated to 50 °C for 2.5 hours. The mixture was cooled to room temperature, diluted with MeOH and concentrated under reduced pressure. The material was purified by preparative HPLC to give *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (1.2438 g, 1.9598 mmol, 71%
10 over 3 steps) as a dark red oil.

¹H NMR (400 MHz, Methanol-*d*₄) δ 7.77 (dd, *J* = 8.3, 7.5 Hz, 1H), 7.49 (d, *J* = 7.3 Hz, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 5.12 (dd, *J* = 12.8, 5.5 Hz, 1H), 4.75 (s, 2H), 3.68 – 3.51 (m, 12H), 3.40 (t, *J* = 6.8 Hz, 2H), 3.10 (t, *J* = 6.4 Hz, 2H), 2.94 – 2.68 (m, 3H), 2.16 (dtd, *J* = 12.6, 5.4, 2.5 Hz, 1H), 1.92 (p, *J* = 6.1 Hz, 2H), 1.86 – 1.77 (m, 2H). ¹³C NMR (100 MHz, cd₃od) δ 173.17, 169.97, 168.48, 166.87, 166.30, 154.82, 136.89, 133.41, 120.29, 117.67, 116.58, 69.96, 69.68, 69.60, 68.87, 68.12, 67.92, 49.19, 38.62, 36.14, 30.80, 28.92, 26.63, 22.22. LCMS 536.41 (M+H).

(4) Synthesis of dFKBP-2

20 *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (12.5 mg, 0.0193 mmol, 1 eq) was added to SLF-succinate (12.08 mg, 0.0193 mmol, 1 eq) as a solution in 0.193 mL in DMF (0.1 M). DIPEA (10.1 microliters, 0.0580 mmol, 3 eq) and HATU (7.3 mg, 0.0193 mmol, 1 eq) were added and the mixture was stirred for 19 hours. The mixture was then diluted with
25 MeOH and purified by preparative HPLC to give dFKBP-2 (9.34 mg, 0.00818 mmol, 42%) as a yellow oil.

¹H NMR (400 MHz, 50% MeOD/Chloroform-*d*) δ 7.76 – 7.70 (m, 1H), 7.58 – 7.45 (m, 3H), 7.26 (t, *J* = 8.2 Hz, 2H), 7.05 – 6.98 (m, 1H), 6.77 (d, *J* = 7.9 Hz, 1H), 6.71 – 6.63 (m, 2H), 5.73 (dd, *J* = 8.1, 5.6 Hz, 1H), 5.23 (d, *J* = 5.4 Hz, 1H), 5.03 – 4.95 (m, 1H), 4.64 (s, 2H),
30 3.82 (s, 3H), 3.80 (s, 3H), 3.62 – 3.52 (m, 8H), 3.47 (t, *J* = 6.1 Hz, 2H), 3.44 – 3.33 (m, 3H), 3.27 – 3.14 (m, 3H), 2.84 – 2.70 (m, 3H), 2.64 – 2.47 (m, 6H), 2.34 (d, *J* = 14.1 Hz, 1H), 2.24 (dd, *J* = 14.3, 9.3 Hz, 2H), 2.13 – 2.00 (m, 2H), 1.83 (p, *J* = 6.3 Hz, 2H), 1.67 (dtd, *J* = 38.4, 16.8, 14.8, 7.0 Hz, 7H), 1.51 – 1.26 (m, 3H), 1.22 – 1.05 (m, 6H), 0.80 (dt, *J* = 39.8, 7.5 Hz, 3H). ¹³C NMR (100 MHz, cdcl₃) δ 208.64, 173.39, 173.01, 171.76, 170.11, 169.62, 168.24,

167.92, 167.36, 166.69, 155.02, 149.23, 147.66, 140.94, 139.18, 137.57, 134.09, 133.91,
129.49, 122.32, 120.75, 120.52, 119.93, 118.42, 117.75, 112.33, 111.98, 70.77, 70.51, 70.40,
69.45, 69.04, 68.48, 56.20, 56.10, 51.88, 47.09, 44.78, 38.40, 37.48, 36.91, 32.80, 32.71,
31.70, 31.59, 31.55, 29.53, 29.30, 26.77, 25.22, 23.63, 23.33, 22.98, 21.43. LCMS 1141.71
5 (M+H).

Example 60: Synthesis of dFKBP-3

SLF-succinate was prepared according to step (1) of the synthesis of dFKBP-1.

A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-
10 dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (0.233 mL, 0.0233 mmol, 1 eq) was
added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-(3,3-dimethyl-2-
oxopentanoyl)pyrrolidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (13.3 mg, 0.0233
mmol, 1 eq). DIPEA (12.2 microliters, 0.0700 mmol, 3 eq) was added, followed by HATU
(8.9 mg, 0.0233 mmol, 1 eq). The mixture was stirred for 23 hours, then diluted with MeOH
15 and purified by preparative HPLC to give a white solid (10.72 mg, 0.0112 mmol, 48%).
¹H NMR (400 MHz, Methanol-*d*₄) δ 7.79 – 7.74 (m, 1H), 7.52 (d, *J* = 7.4 Hz, 1H), 7.33 (d, *J*
= 8.4 Hz, 1H), 7.26 (t, *J* = 8.1 Hz, 1H), 6.97 – 6.90 (m, 2H), 6.89 – 6.84 (m, 1H), 6.79 (dd, *J*
= 8.2, 1.9 Hz, 1H), 6.73 – 6.64 (m, 2H), 5.73 – 5.65 (m, 1H), 5.07 – 4.99 (m, 1H), 4.67 (s,
2H), 4.57 – 4.51 (m, 1H), 4.48 (dd, *J* = 5.7, 2.5 Hz, 2H), 3.82 (d, *J* = 1.9 Hz, 3H), 3.80 (s,
20 3H), 3.66 – 3.39 (m, 3H), 2.88 – 2.48 (m, 6H), 2.42 – 1.87 (m, 9H), 1.73 – 1.51 (m, 6H), 1.19
– 0.92 (m, 6H), 0.75 (dt, *J* = 56.7, 7.5 Hz, 3H). LCMS 954.52 (M+H).

Example 61: Synthesis of dFKBP-4

SLF-succinate was prepared according to step (1) of the synthesis of dFKBP-1.

A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-
25 dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (0.182 mL, 0.0182 mmol, 1 eq) was
added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-(3,3-dimethyl-2-
oxopentanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (10.6 mg, 0.0182 mmol,
1 eq). DIPEA (9.5 microliters, 0.0545 mmol, 3 eq) was added, followed by HATU (6.9 mg,
30 0.0182 mmol, 1 eq). The mixture was stirred for 26 hours, then diluted with MeOH and
purified by preparative HPLC to give a white solid (9.74 mg, 0.01006 mmol, 55%).
¹H NMR (400 MHz, Methanol-*d*₄) δ 7.75 (dd, *J* = 8.3, 7.4 Hz, 1H), 7.53 (d, *J* = 2.3 Hz, 1H),
7.33 – 7.25 (m, 2H), 7.00 – 6.84 (m, 3H), 6.79 (dd, *J* = 8.1, 2.5 Hz, 1H), 6.72 – 6.65 (m, 2H),
5.75 – 5.70 (m, 1H), 5.23 (d, *J* = 4.9 Hz, 1H), 5.05 – 4.96 (m, 1H), 4.66 (s, 2H), 4.46 (s, 2H),

3.82 (s, 3H), 3.81 (s, 3H), 3.39 – 3.32 (m, 4H), 3.20 – 3.12 (m, 1H), 2.82 – 2.69 (m, 3H), 2.62 – 2.49 (m, 2H), 2.37 – 2.00 (m, 5H), 1.78 – 1.30 (m, 11H), 1.24 – 1.08 (m, 6H), 0.81 (dt, $J = 32.9, 7.5$ Hz, 3H). LCMS 968.55 (M+H).


5 Example 62: Synthesis of dFKBP-5

SLF-succinate was prepared according to step (1) of the synthesis of dFKBP-1.

A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (0.205 mL, 0.0205 mmol, 1 eq) was added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-(2-phenylacetyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (11.8 mg, 0.0205 mmol, 1 eq). DIPEA (10.7 microliters, 0.0615 mmol, 3 eq) was added, followed by HATU (7.8 mg, 0.0205 mmol, 1 eq). The mixture was stirred for 29 hours, then diluted with MeOH and purified by preparative HPLC to give a white solid (10.62 mg, 0.01106 mmol, 54%).

^1H NMR (400 MHz, Methanol- d_4) δ 7.77 – 7.72 (m, 1H), 7.52 (s, 1H), 7.31 – 7.11 (m, 7H), 6.92 – 6.77 (m, 4H), 6.68 – 6.62 (m, 2H), 5.70 – 5.64 (m, 1H), 5.38 (d, $J = 3.8$ Hz, 1H), 4.99 (d, $J = 4.6$ Hz, 1H), 4.65 (s, 2H), 4.45 – 4.39 (m, 2H), 3.80 (dd, $J = 6.7, 2.4$ Hz, 8H), 3.13 – 3.03 (m, 1H), 2.83 – 2.68 (m, 3H), 2.63 – 2.45 (m, 3H), 2.34 – 1.93 (m, 6H), 1.71 – 1.52 (m, 7H), 1.34 – 1.20 (m, 3H). LCMS 960.54 (M+H).


20 Example 63: Synthesis of dFKBP-6



N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (11.9 mg, 0.0231 mmol, 1 eq) is added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (16.0 mg, 0.0231 mmol, 1 eq) as a solution in
 5 0.231 mL DMF (0.1 M). DIPEA (12.1 microliters, 0.0692 mmol, 3 eq) and HATU (8.8 mg, 0.0231 mmol, 1 eq) are added and the mixture is stirred for 21 hours. The mixture is diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer is dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.


10

Example 64: Synthesis of dFKBP-7




N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (12.3 mg, 0.0189 mmol, 1 eq) is
 15 added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl) piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (13.1 mg, 0.0189 mmol, 1 eq) as a solution in 0.189 mL DMF (0.1 M). DIPEA (9.9 microliters, 0.0566 mmol, 3 eq) and HATU (7.2 mg, 0.0189 mmol, 1 eq) are added and the mixture is stirred for 17 hours. The mixture is diluted with EtOAc and washed with saturated sodium bicarbonate,
 20 water and brine. The organic layer is dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.

Example 65: Synthesis of dFKBP-8




N-(6-aminohexyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (12.7 mg, 0.0233 mmol, 1.3 eq) is added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (12.4 mg, 0.0179 mmol, 1 eq) as a solution in 0.233 mL DMF (0.1 M). DIPEA (9.3 microliters, 0.0537 mmol, 3 eq) and HATU (6.8 mg, 0.0179 mmol, 1 eq) are added and the mixture is stirred for 22 hours. The mixture is diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer is dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.

Example 66: Synthesis of dFKBP-9



N-(8-aminoctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (10.4 mg, 0.0181 mmol, 1 eq) is added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (12.5 mg, 0.0181 mmol, 1 eq) as a solution in 0.181 mL DMF (0.1 M). DIPEA (9.5 microliters, 0.0543 mmol, 3 eq) and HATU (6.9 mg, 0.0181 mmol, 1 eq) are added and the mixture is stirred for 22 hours. The mixture is diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer is dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.


Example 67: Synthesis of dFKBP




X2

FKBP*-acid (14.0 mg, 0.0202 mmol, 1 eq) and 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethan-1-aminium 2,2,2-trifluoroacetate (8.7 mg, 0.0202 mmol, 1 equiv) are dissolved in DMF (0.202 mL, 0.1 M) at room temperature. DIPEA (17.6 μ L, 0.101 mmol, 5 equiv) and HATU (7.6 mg, 0.0200 mmol, 1 equiv) are then added and the mixture is stirred at room temperature overnight. The reaction mixture is taken up in EtOAc (15 mL), and washed with satd. NaHCO₃ (aq) (15 mL), water (15 mL) and brine (3x15 mL). The organic layer is dried over Na₂SO₄ and concentrated *in vacuo*. The crude material is purified by column chromatography.

Example 68: Synthesis of diaminoethyl-acetyl-O-thalidomide trifluoroacetate




(1) Synthesis of *tert*-Butyl (2-(2-chloroacetamido)ethyl)carbamate



tert-butyl (2-aminoethyl)carbamate (0.40 mL, 2.5 mmol, 1 eq) was dissolved in THF (25 mL, 0.1 M) and DIPEA (0.44 mL, 2.5 mmol, 1 eq) at 0 °C. Chloroacetyl chloride (0.21 mL, 2.75 mmol, 1.1 eq) was added and the mixture was allowed to warm to room temperature. After 22 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and concentrated under reduced pressure to give a white solid (0.66 g, quantitative


yield) that carried forward to the next step without further purification. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.16 (s, 1H), 4.83 (s, 1H), 4.04 (s, 2H), 3.42 (q, J = 5.4 Hz, 2H), 3.32 (q, J = 5.6 Hz, 2H), 1.45 (s, 9H). LCMS 237.30 (M+H).

(2) Synthesis of dimethyl 3-(2-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-oxoethoxy)phthalate



tert-butyl (2-(2-chloroacetamido)ethyl)carbamate (0.66 g, 1 eq) was dissolved in MeCN (17 mL, 0.15 M). Dimethyl 3-hydroxyphthalate (0.578 g, 2.75 mmol, 1.1 eq) and cesium carbonate (2.24 g, 6.88 mmol, 2.75 eq) were then added. The flask was fitted with a reflux condenser and heated to 80 °C for 32 hours. The mixture was then cooled to room temperature, diluted with EtOAc and washed three times with water. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4g silica column, 0-15% MeOH/DCM over a 15 minute gradient) gave a yellow solid (0.394 g, 0.960 mmol, 38% over 2 steps). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.65 – 7.56 (m, 1H), 7.50 – 7.41 (m, 1H), 7.27 (s, 1H), 7.11 (dd, J = 8.4, 4.1 Hz, 2H), 5.17 (s, 1H), 4.57 (d, J = 6.3 Hz, 2H), 3.94 (s, 2H), 3.88 (s, 2H), 3.40 (p, J = 5.8 Hz, 4H), 3.32 – 3.19 (m, 4H), 1.39 (d, J = 5.7 Hz, 13H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.37, 168.23, 165.73, 156.13, 154.71, 131.24, 130.09, 124.85, 123.49, 117.24, 79.42, 68.48, 53.22, 52.83, 40.43, 39.54, 28.44. LCMS 411.45 (M+H).

(3) Synthesis of diaminoethyl-acetyl-O-thalidomide trifluoroacetate




Dimethyl 3-(2-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-oxoethoxy)phthalate (0.39 g, 0.970 mmol, 1 eq) was dissolved in EtOH (9.7 mL, 0.1 M). Aqueous 3M NaOH (0.97 mL, 2.91 mmol, 3 eq) was added and the mixture was heated to 80 °C for 3 hours. The mixture was cooled to room temperature, diluted with 50 mL DCM, 5 mL 1 M HCl and 20 mL water. The layers were separated and the organic layer was washed with 20 mL water. The combined aqueous layers were then extracted 3 times with 50 mL chloroform. The combined organic layers were dried over sodium sulfate, filtered and concentrated under

reduced pressure to give a yellow solid (0.226 g) that was carried forward without further purification. LCMS 383.36.

The resultant yellow solid (0.226 g) and 3-aminopiperidine-2,6-dione hydrochloride (0.102 g, 0.6197 mmol, 1 eq) were dissolved in pyridine (6.2 mL, 0.1 M) and heated to 110 °C for 16 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to give *tert*-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)ethyl)carbamate as a poorly soluble black tar (0.663 g) which was carried forward without purification (due to poor solubility). LCMS 475.42 (M+H).



The crude *tert*-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)ethyl)carbamate was dissolved in TFA (10 mL) and heated to 50 °C for 3.5 hours, then concentrated under reduced pressure. Purification by preparative HPLC gave a red oil (176.7 mg, 0.362 mmol, 37% over 3 steps). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.85 – 7.76 (m, 1H), 7.57 – 7.50 (m, 1H), 7.48 – 7.41 (m, 1H), 5.13 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.81 (s, 2H), 3.62 (td, *J* = 5.6, 1.8 Hz, 2H), 3.14 (t, *J* = 5.8 Hz, 2H), 2.97 (s, 1H), 2.80 – 2.66 (m, 2H), 2.15 (dddd, *J* = 10.1, 8.0, 5.8, 2.8 Hz, 1H). ¹³C NMR (100 MHz, cd₃od) δ 173.09, 170.00, 169.99, 166.78, 166.62, 154.93, 136.88, 133.46, 120.71, 117.93, 116.77, 68.29, 49.17, 39.37, 38.60, 30.73, 22.19. LCMS 375.30 (M+H for free base).

Example 69: Synthesis of diaminobutyl-acetyl-O-thalidomide trifluoroacetate



Diaminobutyl-acetyl-O-thalidomide trifluoroacetate was prepared according to the procedure in Fischer *et al. Nature*, **2014**, 512, 49–53.


Example 70: Synthesis of diaminohexyl-acetyl-O-thalidomide trifluoroacetate

(1) Synthesis of *tert*-butyl (6-(2-chloroacetamido)hexyl)carbamate

5 *tert*-butyl (6-aminohexyl)carbamate (0.224 mL, 1.0 mmol, 1 eq) was dissolved in THF (10 mL, 0.1 M). DIPEA (0.17 mL, 1.0 mmol, 1 eq) was added and the mixture was cooled to 0 °C. Chloroacetyl chloride (88 microliters, 1.1 mmol, 1.1 eq) was added and the mixture was warmed to room temperature and stirred for 18 hours. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give a white solid (0.2691 g, 0.919 mmol, 92%). ¹H NMR (400 MHz, Chloroform-*d*) δ 6.60 (s, 1H), 4.51 (s, 1H), 4.05 (s, 2H), 3.30 (q, *J* = 6.9 Hz, 2H), 3.11 (d, *J* = 6.7 Hz, 2H), 1.57 – 1.46 (m, 4H), 1.44 (s, 9H), 1.38 – 1.32 (m, 4H). LCMS 293.39 (M+H).


(2) Synthesis of dimethyl 3-(2-(((6-(((*tert*-butoxycarbonyl)amino)hexyl)amino)-2-

15 oxoethoxy)phthalate



tert-butyl (6-(2-chloroacetamido)hexyl)carbamate (0.2691 g, 0.919 mmol, 1 eq) was dissolved in MeCN (9.2 mL, 0.1 M). Dimethyl 3-hydroxyphthalate (0.212 g, 1.01 mmol, 1.1 eq) and cesium carbonate (0.823 g, 2.53 mmol, 2.75 eq) were added. The flask was fitted with a reflux condenser and heated to 80 °C for 14 hours. The mixture was cooled to room temperature and diluted with EtOAc, washed three times with water and back extracted once with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (ISCO, 12 g silica column, 0-15% MeOH/DCM 15 minute gradient) to give a yellow oil (0.304 g, 0.651 mmol, 71%). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 – 7.58 (m, 1H), 7.44 (td, *J* = 8.2, 1.6 Hz, 1H), 7.15 – 7.08 (m, 1H), 6.96 (s, 1H), 4.56 (s, 2H), 3.92 (t, *J* = 1.6 Hz, 3H), 3.88 (t, *J* = 1.6 Hz, 3H), 3.27 (q, *J* = 6.9 Hz, 2H), 3.10 – 3.00 (m, 2H), 1.41 (s, 13H), 1.33 – 1.22 (m, 4H). ¹³C NMR (100 MHz, cdcl₃) δ 167.97, 167.37, 165.58, 155.95, 154.37, 130.97, 129.74, 124.94, 123.26, 116.81, 78.96, 68.04, 52.89, 52.87, 52.69, 52.67, 40.41, 38.96, 29.88, 29.13, 28.39, 26.33, 26.30. LCMS 467.49.

(3) Synthesis of diaminohexyl-acetyl-O-thalidomide trifluoroacetate




Dimethyl 3-(2-(((6-((*tert*-butoxycarbonyl)amino)hexyl)amino)-2-oxoethoxy)phthalate (0.304 g, 0.651 mmol, 1 eq) was dissolved in EtOH (6.5 mL, 0.1 M). Aqueous 3M NaOH (0.65 mL, 1.953 mmol, 3 eq) was added and the mixture was heated to 80 °C for 18 hours. The mixture was cooled to room temperature and diluted with 50 mL DCM and 10 mL 0.5 M HCl. The layers were separated and the organic layer was washed with 20 mL water. The combined aqueous layers were then extracted 3 times with chloroform. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give a yellow foam (0.290 g) that was carried forward without further purification. LCMS 439.47.

The resultant yellow solid (0.290 g) and 3-aminopiperidine-2,6-dione hydrochloride (0.113 g, 0.69 mmol, 1 eq) were dissolved in pyridine (6.9 mL, 0.1 M) and heated to 110 °C for 17 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to give *tert*-butyl (6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)hexyl)carbamate as a black solid (0.4216 g) which was carried forward without purification (due to poor solubility). LCMS 531.41 (M+H).


The crude *tert*-butyl (6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)hexyl)carbamate (0.4216 g) was dissolved in TFA (10 mL) and heated to 50 °C for 2 hours. The mixture was concentrated under reduced pressure, then concentrated under reduced pressure. Purification by preparative HPLC gave a brown solid (379.2 mg).

- 5 ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.79 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 5.13 (dd, *J* = 12.6, 5.5 Hz, 1H), 4.75 (s, 2H), 3.32 (t, *J* = 7.6 Hz, 2H), 2.96 – 2.89 (m, 2H), 2.89 – 2.65 (m, 3H), 2.16 (ddt, *J* = 10.4, 5.4, 2.9 Hz, 1H), 1.63 (dp, *J* = 20.6, 7.1 Hz, 4H), 1.51 – 1.34 (m, 4H). ¹³C NMR (100 MHz, *cd*₃od) δ 174.57, 171.42, 169.90, 168.24, 167.79, 156.23, 138.23, 134.87, 121.69, 119.22, 117.98, 69.36, 50.53, 40.64, 39.91, 32.14, 30.01, 28.44, 27.23, 26.96, 23.63. LCMS 431.37 (M+H).
- 10

Example 71: Synthesis of diaminoctyl-acetyl-O-thalidomide trifluoroacetate



(1) Synthesis of *tert*-Butyl (8-(2-chloroacetamido)octyl)carbamate



15


Octane-1,8-diamine (1.65 g, 11.45 mmol, 5 eq) was dissolved in chloroform (50 mL). A solution of di-*tert*-butyl dicarbonate (0.54 g, 2.291 mmol, 1 eq) in chloroform (10 mL) was added slowly at room temperature and stirred for 16 hours before being concentrated under

reduced pressure. The solid material was resuspended in a mixture of DCM, MeOH, EtOAc and 0.5 N NH₃ (MeOH), filtered through celite and concentrated under reduced pressure.

Purification by column chromatography (ISCO, 12 g NH₂-silica column, 0-15% MeOH/DCM over a 15 minute gradient) gave a mixture (1.75 g) of the desired product and starting material which was carried forward without further purification.

This mixture was dissolved in THF (72 mL) and DIPEA (1.25 mL, 7.16 mmol) and cooled to 0 °C. Chloroacetyl chloride (0.63 mL, 7.88 mmol) was added and the mixture was allowed to warm to room temperature. After 16 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The resultant mixture was purified by column chromatography (ISCO, dry load onto silica, 24 g column, 0-100% EtOAc/hexanes, over a 21 minute gradient) to give a white solid (0.56 g, 1.745 mmol, 76% over 2 steps). ¹H NMR (400 MHz, Chloroform-*d*) δ 6.55 (s, 1H), 4.48 (s, 1H), 4.05 (s, 2H), 3.30 (q, *J* = 6.9 Hz, 2H), 3.10 (d, *J* = 6.2 Hz, 2H), 1.44 (s, 12H), 1.31 (s, 9H). ¹³C NMR (100 MHz, cdcl₃) δ 165.86, 156.14, 77.36, 42.86, 40.73, 40.00, 30.18, 29.44, 29.26, 28.59, 26.86, 26.82. LCMS 321.34 (M+H).

(2) Synthesis of dimethyl 3-(2-((8-((*tert*-butoxycarbonyl)amino)octyl)amino)-2-oxoethoxy)phthalate




tert-butyl (8-(2-chloroacetamido)octyl)carbamate (0.468 g, 1.46 mmol, 1 eq) was dissolved in MeCN (15 mL, 0.1 M). Dimethyl 3-hydroxyphthalate (0.337 g, 1.60 mmol, 1.1 eq) and cesium carbonate (1.308 g, 4.02 mmol, 2.75 eq) were added. The flask was fitted with a reflux condenser and heated to 80 °C for 18 hours. The mixture was cooled to room temperature and diluted water and extracted once with chloroform and twice with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure.

The crude material was purified by column chromatography (ISCO, 24 g silica column, 0-15% MeOH/DCM 20 minute gradient) to give a yellow oil (0.434 g, 0.878 mmol, 60%). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.57 (dd, *J* = 7.9, 0.8 Hz, 1H), 7.40 (t, *J* = 8.1 Hz, 1H), 7.07 (dd, *J* = 8.4, 0.7 Hz, 1H), 6.89 (t, *J* = 5.3 Hz, 1H), 4.63 (s, 1H), 4.52 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 3.22 (q, *J* = 6.9 Hz, 2H), 3.01 (q, *J* = 6.4 Hz, 2H), 1.36 (s, 12H), 1.20 (s, 9H). ¹³C NMR (100 MHz, cdcl₃) δ 167.89, 167.29, 165.54, 155.97, 154.38, 130.95,

129.69, 124.96, 123.23, 116.86, 78.82, 68.05, 52.83, 52.82, 52.66, 52.64, 40.54, 39.06, 29.97, 29.19, 29.10, 29.06, 28.40, 26.66, 26.61. LCMS 495.42 (M+H).

(3) Synthesis of diamino-octyl-acetyl-O-thalidomide trifluoroacetate




Dimethyl 3-(2-((8-((*tert*-butoxycarbonyl)amino)octyl)amino)-2-oxoethoxy)phthalate (0.434 g, 0.878 mmol, 1 eq) was dissolved in EtOH (8.8 mL, 0.1 M) Aqueous 3M NaOH (0.88 mL, 2.63 mmol, 3 eq) was added and the mixture was heated to 80 °C for 24 hours. The mixture was cooled to room temperature and diluted with 50 mL DCM and 10 mL 0.5 M HCl. The layers were separated and the organic layer was washed with 20 mL water. The combined aqueous layers were then extracted 3 times with chloroform. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (0.329 g) that was carried forward without further purification. LCMS 467.41.


The resultant yellow solid (0.329 g) and 3-aminopiperidine-2,6-dione hydrochloride (0.121 g, 0.734 mmol, 1 eq) were dissolved in pyridine (7.3 mL, 0.1 M) and heated to 110 °C for 20 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to give *tert*-butyl (8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido) octyl) carbamate as a black tar (0.293 g) which was carried forward without purification (due to poor solubility). LCMS 559.45 (M+H).

The crude *tert*-butyl (8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamido)octyl)carbamate (0.293 g) was dissolved in TFA (10 mL) and heated to 50 °C for 4 hours. The mixture was concentrated under reduced pressure, then concentrated under reduced pressure. Purification by preparative HPLC gave a brown residue (114.69 mg, 23% over 3 steps). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.84 – 7.78 (m, 1H), 7.54 (d, *J* = 7.3 Hz, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 5.13 (dd, *J* = 12.5, 5.5 Hz, 1H), 4.76 (s, 2H), 3.32 (d, *J* = 4.1 Hz, 1H), 3.30 (d, *J* = 3.3 Hz, 1H), 2.94 – 2.84 (m, 3H), 2.80 – 2.70 (m, 2H), 2.19 – 2.12 (m, 1H), 1.67 – 1.55 (m, 4H), 1.40 – 1.34 (m, 8H). ¹³C NMR (100 MHz, cd₃od) δ 174.57, 171.37, 169.85, 168.26, 167.78, 156.26, 138.22, 134.91, 121.70, 119.28, 117.97, 69.37, 50.57, 40.76, 40.08, 32.17, 30.19, 30.05, 30.01, 28.52, 27.68, 27.33, 23.63. LCMS 459.41 (M+H).

Example 72: Synthesis of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate



(1) Synthesis of *tert*-butyl (1-chloro-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate




5

tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (1.0 g, 3.12 mmol, 1 eq) was dissolved in THF (31 mL, 0.1 M). DIPEA (0.543 mL, 3.12 mmol, 1 eq) was added and the solution was cooled to 0 °C. Chloroacetyl chloride (0.273 mL, 3.43 mmol, 1.1 eq) was added and the mixture was warmed slowly to room temperature. After 24 hours, the mixture was diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a yellow oil (1.416 g) that was carried forward without further purification. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.24 (s, 1H), 5.00 (s, 1H), 3.98 – 3.89 (m, 2H), 3.54 (dddt, *J* = 17.0, 11.2, 5.9, 2.2 Hz, 10H), 3.47 – 3.40 (m, 2H), 3.37 – 3.31 (m, 2H), 3.17 – 3.07 (m, 2H), 1.79 – 1.70 (m, 2H), 1.67 (p, *J* = 6.1 Hz, 2H), 1.35 (s, 9H). ¹³C NMR (100 MHz, cdcl₃) δ 165.83, 155.97, 78.75, 70.49, 70.47, 70.38, 70.30, 70.14, 69.48, 42.61, 38.62, 38.44, 29.62, 28.59, 28.40. LCMS 397.37 (M+H).


15

(2) Synthesis of dimethyl 3-((2,2-dimethyl-4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazahenicosan-21-yl)oxy)phthalate



tert-butyl (1-chloro-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (1.41 g, 3.12 mmol, 1 eq) was dissolved in MeCN (32 mL, 0.1 M). Dimethyl 3-hydroxyphthalate (0.721 g, 3.43 mmol, 1.1 eq) and cesium carbonate (2.80 g, 8.58 mmol, 2.75 eq) were added. The flask was fitted with a reflux condenser and heated to 80 °C for 19 hours. The mixture was cooled to room temperature and diluted with water and extracted once with chloroform and twice with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (ISCO, 24 g silica column, 0-15% MeOH/DCM 22 minute gradient) to give a yellow oil (1.5892 g, 2.78 mmol, 89% over two steps). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.52 (d, *J* = 7.8 Hz, 1H), 7.35 (t, *J* = 8.1 Hz, 1H), 7.04 (d, *J* = 8.3 Hz, 1H), 7.00 (t, *J* = 5.3 Hz, 1H), 5.06 (s, 1H), 4.46 (s, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.47 (ddd, *J* = 14.9, 5.5, 2.8 Hz, 8H), 3.39 (dt, *J* = 9.4, 6.0 Hz, 4H), 3.29 (q, *J* = 6.5 Hz, 2H), 3.09 (d, *J* = 6.0 Hz, 2H), 1.70 (p, *J* = 6.5 Hz, 2H), 1.63 (p, *J* = 6.3 Hz, 2H), 1.31 (s, 9H). ¹³C NMR (100 MHz, *cd*Cl₃) δ 167.68, 167.36, 165.45, 155.93, 154.41, 130.87, 129.60, 125.01, 123.20, 117.06, 78.60, 70.40, 70.17, 70.06, 69.39, 68.67, 68.25, 52.77, 52.57, 38.38, 36.58, 29.55, 29.20, 28.34. LCMS 571.47 (M+H).

(3) Synthesis of *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate




dimethyl 3-((2,2-dimethyl-4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazahenicosan-21-yl)oxy)phthalate (1.589 g, 2.78 mmol, 1 eq) was dissolved in EtOH (14 mL, 0.2 M). Aqueous 3M NaOH (2.8 mL, 8.34 mmol, 3 eq) was added and the mixture was heated to 80 °C for 22 hours. The mixture was then cooled to room temperature, diluted with 50 mL DCM and 20 mL 0.5 M HCl. The layers were separated and the organic layer was washed with 25 mL water. The aqueous layers were combined and extracted three times with 50 mL chloroform. The combined organic layers were dried over sodium sulfate, filtered and

condensed to give 1.53 g of material that was carried forward without further purification. LCMS 553.44.


The resultant material (1.53 g) and 3-aminopiperidine-2,6-dione hydrochloride (0.480 g, 2.92 mmol, 1 eq) were dissolved in pyridine (11.7 mL, 0.25 M) and heated to 110 °C for 17 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to give crude *tert*-butyl (1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate as a black sludge (3.1491 g) that was carried forward without further purification. LCMS 635.47.

The crude *tert*-butyl (1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (3.15 g) was dissolved in TFA (20 mL) and heated to 50 °C for 2.5 hours. The mixture was cooled to room temperature, diluted with MeOH and concentrated under reduced pressure. The material was purified by preparative HPLC to give *N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate (1.2438 g, 1.9598 mmol, 71% over 3 steps) as a dark red oil. ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.77 (dd, *J* = 8.3, 7.5 Hz, 1H), 7.49 (d, *J* = 7.3 Hz, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 5.12 (dd, *J* = 12.8, 5.5 Hz, 1H), 4.75 (s, 2H), 3.68 – 3.51 (m, 12H), 3.40 (t, *J* = 6.8 Hz, 2H), 3.10 (t, *J* = 6.4 Hz, 2H), 2.94 – 2.68 (m, 3H), 2.16 (dtd, *J* = 12.6, 5.4, 2.5 Hz, 1H), 1.92 (p, *J* = 6.1 Hz, 2H), 1.86 – 1.77 (m, 2H). ¹³C NMR (100 MHz, cd₃od) δ 173.17, 169.97, 168.48, 166.87, 166.30, 154.82, 136.89, 133.41, 120.29, 117.67, 116.58, 69.96, 69.68, 69.60, 68.87, 68.12, 67.92, 49.19, 38.62, 36.14, 30.80, 28.92, 26.63, 22.22. LCMS 536.41 (M+H).

Example 73: Synthesis of *N*-(6-aminohexyl)-2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamide




(1) Synthesis of 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxylic acid




1,3-dioxo-1,3-dihydroisobenzofuran-5-carboxylic acid (0.192 g, 1 mmol, 1 eq) and 3-aminopiperidine-2,6-dione hydrochloride (0.165 g, 1 mmol, 1 eq) were dissolved in DMF (2.5 mL) and acetic acid (5 mL) and heated to 80 °C for 24 hours. The mixture was then concentrated under reduced pressure and diluted with EtOH, from which a precipitate slowly
 5 formed. The precipitate was washed twice with EtOH to give a white solid (84.8 mg, 0.28 mmol, 28%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.74 (s, 1H), 11.12 (s, 1H), 8.39 (dd, *J* = 7.8, 1.4 Hz, 1H), 8.26 (s, 1H), 8.04 (d, *J* = 7.8 Hz, 1H), 5.18 (dd, *J* = 12.8, 5.4 Hz, 1H), 2.93 – 2.88 (m, 1H), 2.84 (d, *J* = 4.7 Hz, 0H), 2.66 – 2.50 (m, 2H), 2.12 – 1.99 (m, 1H). LCMS 303.19 (M+H).

10 (2) Synthesis of *tert*-butyl (6-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamido)hexyl)carbamate



2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxylic acid (22.7 mg, 0.0751 mmol, 1 eq) and HATU (31.4 mg, 0.0826 mmol, 1.1 eq) were dissolved in DMF (0.75 mL).
 15 After 5 minutes, DIPA (39.2 microliters, 0.225 mmol, 3 eq) was added. After an additional 5 minutes, *tert*-butyl (6-aminoethyl)carbamate (19.5 mg, 0.0901 mmol, 1.2 eq) was added as a solution in DMF (0.75 mL). The mixture was stirred for 20 hours, then diluted with EtOAc. The organic layer was washed three times with brine, dried over sodium sulfate and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g
 20 column, 0-10% MeOH/DCM, 25 minute gradient) to give a yellow oil (17.18 mg, 0.03432 mmol, 46%). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, *J* = 6.2 Hz, 2H), 8.16 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 6.91 (s, 1H), 5.00 (dd, *J* = 12.4, 5.3 Hz, 1H), 4.58 (s, 1H), 3.47 (q, *J* = 6.7 Hz, 2H), 3.14 (q, *J* = 8.5, 7.3 Hz, 2H), 2.97 – 2.69 (m, 3H), 2.17 (ddd, *J* = 10.4, 4.8, 2.6 Hz, 1H), 1.65 (p, *J* = 6.9 Hz, 2H), 1.53 – 1.32 (m, 15H). ¹³C NMR (100 MHz, cdcl₃) δ
 25 174.69, 170.77, 167.86, 166.67, 165.27, 156.49, 141.06, 133.95, 133.71, 132.13, 124.21, 122.27, 77.36, 49.71, 39.75, 31.54, 30.27, 29.22, 28.57, 25.70, 25.37, 22.73. LCMS 501.28 (M+H).


(3) Synthesis of *N*-(6-aminoethyl)-2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamide




tert-butyl (6-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindoline-5-carboxamido)hexyl)carbamate (17.18 mg, 0.343 mmol, 1 eq) was dissolved in TFA (1 mL) and heated to 50 °C for 2 hours. The mixture was concentrated under reduced pressure to give a yellow oil (13.29 mg) which was deemed sufficiently pure without further purification.

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.27 (dd, *J* = 9.3, 1.3 Hz, 2H), 7.99 (d, *J* = 7.6 Hz, 1H), 5.18 (dd, *J* = 12.5, 5.4 Hz, 1H), 3.48 – 3.40 (m, 2H), 2.96 – 2.84 (m, 3H), 2.76 (ddd, *J* = 17.7, 8.1, 3.7 Hz, 2H), 2.20 – 2.12 (m, 1H), 1.75 – 1.63 (m, 4H), 1.53 – 1.43 (m, 4H). LCMS 401.31 (M+H).

- 10 Example 74: Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetic acid




(1) Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisindoline-1,3-dione




- 15 4-hydroxyisobenzofuran-1,3-dione (0.773 g, 4.71 mmol, 1 eq) and 3-aminopiperidine-2,6-dione hydrochloride (0.775 g, 4.71 mmol, 1 eq) were dissolved in pyridine (19 mL) and heated to 110 °C for 16 hours. The mixture was concentrated under reduced pressure and purified by column chromatography (ISCO, 12 g silica column, 0-10% MeOH/DCM, 25 minute gradient) to give an off white solid (1.14 g, 4.16 mmol, 88%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.19 (s, 1H), 11.07 (s, 1H), 7.65 (dd, *J* = 8.3, 7.3 Hz, 1H), 7.31 (d, *J* = 7.2 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 1H), 5.07 (dd, *J* = 12.8, 5.4 Hz, 1H), 2.88 (ddd, *J* = 17.7, 14.2, 5.4 Hz, 1H), 2.63 – 2.50 (m, 2H), 2.11 – 1.95 (m, 1H). LCMS 275.11 (M+H).
- 20

(2) Synthesis of *tert*-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetate



2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (218.8 mg, 0.798 mmol, 1 eq) was dissolved in DMF (8 mL). Potassium carbonate (165.9 mg, 1.20 mmol, 1.5 eq) was added, followed by tert-butyl bromoacetate (118 microliters, 0.798 mmol, 1 eq) and the mixture was stirred at room temperature for 3 hours. The mixture was diluted with EtOAc and washed once with water and twice with brine. Purification by column chromatography (ISCO, 12 g silica column, 0-100% EtOAc/hex, 17 minute gradient) gave a white solid (0.26 g, 0.669 mmol, 84%). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.74 (s, 1H), 7.61 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.06 (d, *J* = 8.3 Hz, 1H), 4.98 – 4.92 (m, 1H), 4.74 (s, 2H), 2.83 – 2.69 (m, 3H), 2.12 – 2.04 (m, 1H), 1.43 (s, 9H). ¹³C NMR (100 MHz, cdcl₃) δ 171.58, 168.37, 166.96, 166.87, 165.49, 155.45, 136.27, 133.89, 119.78, 117.55, 116.83, 83.05, 66.52, 49.20, 31.37, 28.03, 22.55. LCMS 411.23 (M+Na).

(3) Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid



tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate (47.5 mg, 0.122 mmol, 1 eq) was dissolved in TFA (1.3 mL) at room temperature. After 3 hours, the mixture was diluted with DCM and concentrated under reduced pressure to yield a white solid (42.27 mg), which was deemed sufficiently pure without further purification. ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.76 (dd, *J* = 8.5, 7.3 Hz, 1H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.34 (d, *J* = 8.5 Hz, 1H), 5.11 (dd, *J* = 12.5, 5.5 Hz, 1H), 4.96 (s, 2H), 2.87 (ddd, *J* = 17.8, 14.2, 5.0 Hz, 1H), 2.80 – 2.65 (m, 2H), 2.18 – 2.09 (m, 1H). LCMS 333.15 (M+H).

Example 75: dBET1 treatment downregulates BRD4 levels

dBET1 showed potent binding to the first bromodomain of BRD4 (BRD4(1); IC₅₀ = 20 nM), while the epimeric dBET1(R) was comparatively inactive (IC₅₀ = 6.9 μM) (Fig. 1C). In comparison, the IC₅₀ JQ1 and JQ1-R are 20 nM and 8.8 μM, respectively (Fig. 1C). Selectivity profiling confirmed potent and BET-specific target engagement among 32 bromodomains studied by phage display and displacement (Fig. 11A) (Table 2).

Table 2. Single Point Screening of dBET1 using BromoScan

dBET1, 1 μ M	
DiscoverX Gene Symbol	Percent Control
ATAD2A	44
ATAD2B	62
BAZ2A	90
BAZ2B	59
BRD1	50
BRD2(1)	0
BRD2(2)	0
BRD3(1)	0
BRD3(2)	0
BRD4(1)	0.25
BRD4(2)	0
BRD7	96
BRD9	96
BRDT(1)	1.6
BRDT(2)	0
BRPF1	44
BRPF3	82
CECR2	65
CREBBP	32
EP300	30
FALZ	26
GCN5L2	96
PBRM1(2)	98
PBRM1(5)	100
PCAF	61
SMARCA2	34
SMARCA4	47
TAF1(2)	56
TAF1L(2)	92
TRIM24(PHD,Bromo.)	100
TRIM33(PHD,Bromo.)	100
WDR9(2)	36

A high-resolution crystal structure (1.0 Å) of dBET1 bound to BRD4(1) confirmed the mode of molecular recognition as comparable to JQ1 (Figs. 1D and 1G). Ordered density for the dBET1 ligand was found only to the first two carbon atoms of the butane spacer, suggesting conformational flexibility of the conjugated phthalimide. Using the dBET1-BRD4(1) crystal structure and the recently reported structure of CRBN bound to thalidomide (E. S. Fischer *et al.*, *Nature* 512, 49-53 (2014)), the feasibility of ternary complex formation was modeled *in silico*. An extended conformation of dBET1 was capable of bridging ordered BRD4(1) and CRBN in numerous sampled conformations without destructive steric interactions (Fig. 1E). The modular nature of CRL complexes suggests that chemical

recruitment of BRD4 may lead to CRBN-dependent degradation (E. S. Fischer *et al.*, *Cell* 147, 1024-1039 (2011); M. D. Petroski, R. J. Deshaies, *Nat. Rev. Mol. Cell Biol.* 6, 9-2).

The chemical adaptor function of dBET1 was assessed by a homogeneous proximity assay for recombinant, human CRBN-DDB1 and BRD4 using AlphaScreen technology. As shown in Fig. 11B, luminescence arising from proximity of acceptor (CRBN-bound) and donor (BRD4-bound) beads was increased in the presence of low (10 – 100 nM) concentrations of dBET1. At higher concentrations of dBET1 (*e.g.*, 1 μ M), luminescence diminished, consistent with independent occupancy of CRBN and BRD4 binding sites by excess dBET1 (the hook effect). Inhibition of chemical adaptor function was accomplished with competitive co-incubation with free JQ1 or thalidomide, each in a stereo-specific manner (Fig. 11C).

To functionally assess the effect of dBET1 on BRD4 in cells, a human AML cell line (MV4-11) was treated for 18 hours with increasing concentrations of dBET1 and assayed for endogenous BRD4 levels by immunoblot. Pronounced loss of BRD4 (> 85%) was observed with concentrations of dBET1 as low as 100 nM (Fig. 1F). MV4-11 cells were treated with DMSO or increasing concentrations of dBET1 for 24 hours, lysed in RIPA buffer. Immunoblotting was performed against the indicated proteins. In addition, BRD4 and c-MYC levels were quantified relative to vinculin levels in cells treated with increasing concentrations of dBET1 (Fig. 1H). Notably, JMJD6, a protein that physically interacts with BRD4 was not affected (Fig. 1H). Moreover, HEXIM1 levels which usually increase after BRD4 inhibitor treatment via a transcriptional control mechanism were moderately decreased as well (Fig. 1H).

Molecular recognition of the BRD4 bromodomains by JQ1 is stereo-specific, and only the (+)-JQ1 enantiomer is active; the (-)-JQ1 enantiomer (JQ1R) is inactive (Figs 1A-1C and Fig. 5). The epimeric dBET1(R) compound lacks BRD4 binding (> 300 fold weaker binding in homogenous assays) and was inactive, demonstrating that BRD4 degradation requires target protein engagement (Fig. 2A).

Example 76: Degradation of BRD2, BRD3, and BRD4 by dBET1

MV4-11 cells were treated with DMSO or 100 nM dBET1 for various timepoints between 1 and 24 hours. Cells were lysed in RIPA buffer. Immunoblotting was performed. While BRD3 and BRD4 showed comparable kinetics, BRD2 levels equilibrated faster at later timepoints. The results are shown in Fig. 2K.

To quantify dose-responsive effects on BRD4 protein stability, a cell-count normalized, immunofluorescence-based high-content assay was developed in an adherent human cancer cell line (SUM149 breast cancer cells (Fig. 2B). Potent downregulation of total BRD4 was observed for dBET1 ($EC_{50} = 430$ nM) without apparent activity for dBET1(R). These observations were confirmed by immunoblot in SUM149, which were used for baseline normalization of the assay (Fig. 2C). Additional cultured adherent and non-adherent human cancer cell lines showed comparable response (SUM159, MOLM13) (Figs. 2I and 2J).

The kinetics of BRD4 degradation were determined in a time course experiment using 100 nM dBET1 in MV4-11 cells. Marked depletion of BRD4 was observed at 1 hour and complete degradation was observed at 2 hours of treatment (Fig. 2D). Degradation of BRD4 by dBET1 was associated with a potent inhibitory effect on MV4-11 cell proliferation at 24 hours (measured by ATP content, $IC_{50} = 0.14$ μ M, compared to $IC_{50} = 1.1$ μ M (Fig. 2E), consistent with the reported, pronounced inhibitory effect of RNA silencing of BRD4 in this and other models of MLL-rearranged leukemia (J. Zuber *et al.*, *Nature* 478, 524-528 (2011)). Moreover, dBET1 induced a potent apoptotic consequence in MV4-11 as measured by activated caspase cleavage (Caspase-GLO) (Fig. 2F), cleavage of poly(ADP-ribose) polymerase (PARP), and cleavage of Caspase-3 (Fig. 2N) and Annexin V staining (Fig. 2M). The apoptotic response to dBET1 was confirmed in additional cultured human cell lines including DHL4 (B-cell lymphoma) (Fig. 2F). Kinetic studies of apoptotic response were then performed in MV4-11 cells cultured for either 4 or 8 hours followed by drug washout. Induction of apoptosis was assessed at 24 hours. While pulsed treatment with JQ1 did not yield a pronounced apoptotic response, significantly increased apoptosis was observed after only 4 h of dBET1 treatment that was enhanced at 8 h (Figs. 2P and 2Q).

The rapid biochemical activity and robust apoptotic response of cultured cell lines to dBET1 established the feasibility of assessing effects on primary human AML cells, where *ex vivo* proliferation is negligible in short-term cultures. Exposure of primary leukemic patient blasts to dBET1 elicited dose-proportionate depletion of BRD4 (immunoblot) (Fig. 2G) and induction of apoptosis (Annexin V staining) (Figs. 2H and 2L). Importantly, the effect of BRD4 degradation by dBET1 elicited a significantly greater apoptotic response in primary AML cells and AML cell lines than displacement of BRD4 by JQ1 (Fig. 2H). Together, these data demonstrated ligand-dependent target protein degradation and supported that target degradation can elicit a more pronounced biological consequence than domain-specific target inhibition.

The therapeutic effect of BRD4 degradation was assessed *in vivo* by evaluating the tolerability and anti-tumor efficacy of repeat-dose dBET1 in an established murine xenograft model of human MV4-11 leukemia cells. Tumor-bearing mice were treated with dBET1 administered by intraperitoneal injection (50 mg/kg daily) or vehicle control. After 14 days of therapy a first tumor reached institutional limits for tumor size, and the study was terminated for comparative assessment of efficacy and modulation of BRD4 stability and function. Administration of dBET1 attenuated tumor progression as determined by serial volumetric measurement (Fig. 12A), and decreased tumor weight assessed post-mortem (Fig. 12B). Acute pharmacodynamic degradation of BRD4 was observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP) by immunoblot, accompanied by downregulation of MYC (Fig. 12C). The results were confirmed by quantitative immunohistochemistry for BRD4 and MYC following repeat-dose exposure to dBET1 for 14 days (Fig. 12D). A statistically significant destabilization of BRD4, downregulation of MYC and inhibition of proliferation (Ki67 staining) was observed with dBET1 compared to vehicle control in excised tumors (Figs. 12D and 12E). Pharmacokinetic studies of dBET1 (50 mg/kg IP) corroborated adequate drug exposure *in vivo* (C_{max} = 392 nM; Fig. 13B), above the EC_{50} for BRD4 knock-down observed *in vitro* (<100 nM). Notably, two weeks of dBET1 was well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count (Figs. 13C and 13D).

Example 77: Degradation is specific for dBET1

To critically assess the mechanism of dBET1-induced BRD4 degradation, requirements on proteasome function, BRD4 binding, and CRBN binding, were examined using chemical genetic and gene editing approaches. Treatment with either JQ1 or thalidomide alone was insufficient to induce BRD4 degradation in MV4-11 cells (Figs. 3A and 3E). BRD4 stability was rescued by pre-treatment with the irreversible proteasome inhibitor carfilzomib (0.4 μ M), indicating that proteasome function is required in dBET1-mediated BRD4 degradation (Figs. 3B and 3F). Pre-treatment with excess JQ1 or thalidomide abolished dBET1-induced BRD4 degradation, further confirming the requirement for both BRD4 and CRBN (Figs. 3B and 3F). Cullin-based ubiquitin ligases require neddylation of the cullin subunit for processive E3 ligase activity and target polyubiquitination (G. Lu, *et al.*, Science 343, 305-309 (2014); R. I. Sufan, M. Ohh, *Neoplasia* 8, 956-963 (2006)). Pre-treatment with the selective NAE1 inhibitor MLN4924(29) rescued BRD4 stability from dBET1 exposure, further supporting dependence

on active RING E3 ligase activity (Fig. 3C). Moreover, using a recently published human MM cell line (MM1.S-CRBN^{-/-}) that features an engineered knockout of CRBN by CRISPR/Cas9 technology (G. Lu, *et al.*, *Science* 343, 305-309 (2014)) confirmed the cellular requirement for CRBN (Fig. 3D). These data showed CRBN-dependent proteasomal
 5 degradation of BRD4 by dBET1.

Example 78: Highly selective BET bromodomain degradation by expression proteomics

An unbiased, proteome-wide approach was selected to assess the cellular consequences of dBET1 treatment on protein stability. The acute impact of dBET1 treatment
 10 (250 nM) was compared to JQ1 (250 nM) and vehicle (DMSO 0.0025%) controls on protein stability in MV4-11 cells. A 2 hour incubation was selected to capture primary, immediate consequences of small-molecule action and to mitigate expected, confounding effects on suppressed transactivation of BRD4 target genes. Three biological sample replicates were prepared for each treatment condition using isobaric tagging that allowed the detection of
 15 7429 proteins using a lower cut-off of at least two identified spectra per protein. Following BET bromodomain inhibition with JQ1, few proteomic changes are observed (Fig. 4A). Only MYC was significantly depleted by more than 2-fold after 2 hours of JQ1 treatment, indicating the reported rapid and selective effect of BET bromodomain inhibition on *MYC* expression in AML (Figs. 4A and 4C) (J. Zuber *et al.*, *Nature* 478, 524-528 (2011)). JQ1
 20 treatment also downregulated the oncoprotein PIM1 (Figs. 4A and 4C).

Treatment with dBET1 elicited a comparable, modest effect on MYC and PIM1 expression. Only three additional proteins were identified as significantly ($p < 0.001$) and markedly (> 5 -fold) depleted in dBET1-treated cells: BRD2, BRD3 and BRD4 (Figs. 4B and 4C). Orthogonal detection of BRD2, BRD3, BRD4, MYC and PIM1 was performed by
 25 immunoblot following treatment of MV4-11 leukemia cells with dBET1 or JQ1. BET family members were degraded only by dBET1, whereas MYC and PIM1 abundance was decreased by both dBET1 and JQ1, and to a lesser degree (Fig. 4D). No effect on Ikaros TF expression was observed in either treatment condition (Fig. 4F). Because *MYC* and *PIM1* are often associated with massive adjacent enhancer loci by epigenomic profiling (B. Chapuy *et al.*,
 30 *Cancer Cell* 24, 777-790 (2013); J. Lovén *et al.*, *Cell* 153, 320-334 (2013)) suggestive of a transcriptional mechanism of downregulation, mRNA transcript abundance was measured for each depleted gene product (Fig. 4E). Treatment with either JQ1 or dBET1 downregulated *MYC* and *PIM1* transcription, suggestive of secondary transcriptional effects. Transcription of *BRD4* and *BRD3* were unaffected, consistent with post-transcriptional effects.

Transcription of *BRD2* was affected by JQ1 and dBET1, whereas protein stability of the BRD2 gene product was only influenced by dBET1, indicating transcriptional and post-transcriptional consequences. These data demonstrated a highly selective effect of dBET1 on target protein stability, proteome-wide.

5

Example 79: Negative SAR JQ1-Rev (JQI-II-079)

MV4-11 cells were treated for 24 hours with either DMSO, dBET1 (100nM) or the indicated concentrations of JQ1-REV (JQ-II-079), lysed with RIPA buffer, and immunoblotted for BRD4 and Vinculin as loading control. While BRD4 levels were significantly decreased with dBET 1 treatment, JQ1-Rev treatment did not yield any measureable effect. The results are shown in Fig. 5.

10

Example 80: Decrease in BRD4 protein levels proceed measurable decrease in BRD4 transcript levels

15

MV4-11 cells were treated with dBET1 or JQ1 for 2 and 4 hours at 100 nM or 1uM each. RNA was isolated using Qiagen RNAeasy kit and converted to cDNA using VILO Superscript reverse transcriptase. BRD4 transcript levels were assayed via qRT-PCR. The results are shown in Fig. 6.

20

Example 81: dBET1 mediated degradation of BRD4 is dependent on CRBN availability

Wild type MM1S proficient of CBRN expression (MM1S WT) as well as deficient of CRBN expression (MM1S CRBN^{-/-}) were treated with dBET1 for 8 hours. CRBN deficient isogenic cell line was reported elsewhere (Lu *et al.* Science 2014). Cells were lysed with RIPA buffer and immunoblotted for BRD4 and tubulin as loading control. The results are shown in Fig. 7.

25

Example 82: Effects of dBET2 on BRD4 expression levels

MV4-11 cells were treated with DMSO or increasing concentrations of dBET2 for 8 hours, lysed in RIPA buffer and immunoblotting was performed against BRD4 and tubulin as loading control. The results are shown in Fig. 8.

30

Example 83: Effects of dBET2 on PLK1 expression levels

(A) MV4-11 cells were treated with DMSO or increasing concentrations of dBET2 for 8 hours, lysed in RIPA buffer and immunoblotting was performed against PLK1 and

tubulin as loading control. (B) Quantification of (A). The intensity of the PLK1 bands was quantified to the respective tubulin loading control bands. The results are shown in Fig. 9.

Example 84: dBET1 mediated degradation *in vivo*

Short-term treatment studies were conducted with tumor-bearing mice using the human MV4-11 leukemia murine xenograft model. Mice with established tumors were administered dBET1 (50 mg/kg), JQ1 (50 mg/kg) or a vehicle control, once daily for two days. Pharmacodynamic effects on BRD4 stability were determined 4h after the second drug exposure, by immunoblot. Treatment with dBET1 was associated with unambiguous suppression of BRD4, compared to JQ1 and vehicle controls (Fig. 2O). Corroborating the pharmacologic advantage observed in cell lines and primary patient cells, an increased apoptotic response following dBET1 treatment *in vivo* was observed as measured by immunoblotting for PARP and caspase cleavage (Fig. 2O).

Example 85: dFKBP-1 and dFKBP-2 mediated degradation of FKBP12

Phthalimide-conjugated ligands to the cytosolic signaling protein, FKBP12, were synthesized. FKBP12 has been identified to play a role in cardiac development, ryanodine receptor function, oncogenic signaling, and other biological phenotypes. At a known permissive site on the FKBP12-directed ligand AP1497, two chemical spacers were placed to create the conjugated phthalimides dFKBP-1 and dFKBP-2 (Fig 10A). Both potently decreased FKBP12 abundance in MV4-11 cells (Fig 10B), leading to over 80% reduction of FKBP12 at 0.1 μ M and 50% reduction at 0.01 μ M, a 1000-fold improvement in potency as compared to conjugated PROTAC ligands which demonstrated activity at 25 μ M. As with dBET1, destabilization of FKBP12 by dFKBP-1 was rescued by pre-treatment with carfilzomib, MLN4924, free AP1497 or free thalidomide (Fig 10C). CRBN-dependent degradation was established using previously published isogenic 293FT cell lines which are wild-type (293FT-WT) or deficient (293FT-CRBN^{-/-}) for CRBN (G. Lu, *et al.*, *Science* **343**, 305-309 (2014)). Treatment of 293FT-WT cells with dFKBP-1 induced potent, dose-dependent degradation of FKBP12, whereas 293FT-CRBN^{-/-} were unaffected (Fig 10D).

Example 86: Degradation of BRD proteins by dBET

10,000 cells (293T WT or 293 CRBN^{-/-}) were seeded per well using 384-well plates. On the following day, dBET compounds were added at various concentrations. After being treated with the dBET compounds for 4 hours, cells were fixed with formaldehyde,

permeabilized using 0.1% triton, blocked with LiCor blocking buffer, and incubated with the primary antibody (BRD4, 1:1000) overnight. On the following day, cells were washed (5x TBST) and stained using Odysee Cell Stain (1:500). A secondary antibody recognizing the rabbit BRD4 antibody was added simultaneously (1:800). Images were quantified using
5 LiCOR imager. BRD4 levels in the cells after the dBET treatment were shown in Figs. 14A-BB.

Various cells (BAF3_K-RAS, SEMK2, Monomac1, MM1S^{WT}, MM1S^{CRBN-/-}) were treated with increasing concentrations of dBET1 or dBET6 for ~16 hours. Cells were lysed and the lysates were immunoblotted to measure levels of BRD4. The results are shown in
10 Figs. 15A-15D and 15F.

MV4-11 cells were treated with 50 nM dBET6 or 200 nM dBET18. For the following 24 hours, levels of BRD4 or BRD4, BRD2 and BRD3 were detected by immunoblotting at various time points. The results are shown in Fig. 15E and Fig. 16B.

15 Example 87: Degradation of BRD and other proteins by dBET

293T WT or 293 CRBN^{-/-} were treated with dBET2, dBET7, dBET8, or dBET10 at 1 μM for 16 hours. The cells were then lysed and the lysates were immunoblotted to measure levels of BRD4 and PLK1. The results are shown in Fig. 16A.

20 Example 88: Viability of cells treated with dBET compounds

Various cell lines (T-ALL (MOLT4, DND41, CUTLL1), LOUCY, MV4-11, and RS4-11) were plated in 384 well plates at 1000 cells/well. dBET compounds were then added to the cells and incubated for 48 hours. ATP content was measured as a surrogate for cellular viability using ATPlite (Promega). The results were shown in Fig. 17A-17E and Fig.
25 18A-18C.

Example 89: dGR mediated glucocorticoid receptor degradation

DND41 cells were grown in culture plates. dGR3 was added at various concentrations and incubated for 16 hours. The cells were then lysed, and the lysates were
30 immunoblotted to measure GR levels. The results are shown in Fig. 19.

Example 90: Viability of JQ1-resistant cells treated with dBET6

Various cell lines were seeded into 384-well tissue culture-treated plates at a density of 2,000 cells per well in a volume of 50 μL/well. JQ1 or dBET6 was added with a JANUS

Workstation (PerkinElmer) using a 384-well pinhead tool at 100 nL drug per well. After 72 hours of incubation, cells were analyzed for cell viability using the ATPlite (PerkinElmer) Luminescence Assay Kit per the manufacturer's instructions, using ATP content as a surrogate for viable cell number. Luminescence was read on an EnVision 2104 Multilabel Plate Reader (PerkinElmer). Nonlinear dose-response curves were fitted to the data using Graphpad Prism software, and are shown in Figs. 20-24. The IC₅₀s and E_{max} of dBET6 are shown in comparison with those of JQ1 in Table 3.

Table 3

Cell Line	IC ₅₀ (nM)		E _{max} (%)	
	JQ1	dBET6	JQ1	dBET6
Calu6	-	233.4	-	51.67
NGP	1830	187.6	58.84	21.89
PANC032	3840	1451	38.17	53.25
KP2	1352	512.8	44.76	20.72
ASPC1	1720	1458	43.19	50.38
A549	487.2	1905	31.14	30.86
NMC-G1	54.79	70.02	50.71	36.62
HCT116	97.6	154.3	25.78	26.87
MC116	47.56	20.48	1.05	0.3197
NCI-H460	71.89	437.6	25.2	34.4
NCI-H838	32.33	51.98	53.2	32.2
CCF-STTG1	-	139.7	-	45.77
ZR-75-1_YMB-1	126.6	23.52	38.48	21.57
LCLC-103H	106.4	84.25	28.89	24.04
SW1783	267.3	38.22	24.83	22.2
MKN45	244.2	41.13	24.81	19.44
CI-1	220.7	23.28	18.83	10.69
HCC1315	1051	1057	52.16	41.16
KARPAS	83.18	2.181	24.07	21.04
KP-N-YN	1437	9.41	30.94	42.76
MDA-MB-231	361.2	146.5	42.1	24.2
MDA-MB-436	175.5	39.62	48.23	29.51
SBC-5	1239	841.2	45.24	21.62
SKMEL28	991.2	474.3	77.14	58.95
SUM149	225.2	131	34.73	27.95
SUM149R	450.7	18.48	48.01	10.57
SUM159	113.6	32.53	29.33	12.03
SUM159R	612.6	92.37	51.23	35.95
SUM185	369.8	1.443	62.42	22.88
SUM1315	593.6	13.51	16.56	20.66
T47D	1363	7.458	43.17	49.39

10

Example 91: Protein degradation by dBET6 in JQ1-resistant cells

NGP cells were incubated with various concentrations of JQ1 or dBET6 for 4 hours. Protein levels of BRD4, MYCN, and vinculin (as loading control) were assessed using


immunoblotting for BRD4 (Bethyl antibodies, A301-985), MYCN (Santa Cruz, sc-56729), and vinculin (Santa Cruz, sc-25336). MYCN levels were quantified using ImageStudio software (LiCor BioSciences). Percentage levels were normalized to vinculin levels and relative to DMSO. As shown in Figs. 25A and 25B, dBET6, but not JQ1, degrades BRD4 effectively in NGP cells.

Example 92: Protein degradation by dBET6 in JQ1-resistant cells

NGP cells were incubated with 250 nM dBET6 for 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 16 hr, or 24 hr. Protein levels of BRD2, BRD3, BRD4, MYCN, and vinculin (as loading control) were assessed using immunoblotting for BRD4 (Bethyl, A301-985), BRD3 (abcam, ab56342), BRD2 (Bethyl, A302-582A), (MYCN (Santa Cruz, sc-56729), and vinculin (Santa Cruz, sc-25336). Percentage levels were normalized to vinculin levels and relative to DMSO. As shown in Figs. 25C and 25D, dBET6 effectively degrades BRD2, BRD3, BRD4, and CMYN in NGP cells.


Example 93: Synthesis of dFKBP13 – dFKBP21 and dFKBP24 – dFKBP38

(1) dFKBP13




4-(((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5.59 mg, 0.015 mmol, 1 eq) as a solution in 151.63 μ l DMF (0.1 M) is added to FKBP acid (10.52 mg, 0.015 mmol, 1 eq). DIPEA (7.43 μ l, 0.045 mmol, 3 eq) is added, followed by HATU (5.70 mg, 0.015 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(2) dFKBP14




4-((10-aminodecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (9.45 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.58 mg, 0.022 mmol, 1 eq). DIPEA (10.9 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(3) dFKBP15




4-(2-(2-(2-aminoethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (8.91 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.58 mg, 0.022 mmol, 1 eq). DIPEA (10.91 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 20 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(4) dFKBP16




5-amino-*N*-(2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pentanamide (7.84 mg, 0.0219 mmol, 1 eq) as a solution in 219 μ l DMF (0.1 M) is added to FKBP acid (15.23 mg, 0.0219 mmol, 1 eq). DIPEA (10.87 μ l, 0.065 mmol, 3 eq) is added, followed by HATU (8.32 mg, 0.0219 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(5) dFKBP17




N-(3-(3-aminopropoxy)propyl)-2-((2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (10.27 mg, 0.023 mmol, 1 eq) as a solution in 230 μ l DMF (0.1 M) is added to FKBP acid (15.66 mg, 0.023 mmol, 1 eq). DIPEA (11.07 μ l, 0.067 mmol, 3 eq) is added, followed by HATU (8.74 mg, 0.023 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(6) dFKBP18




4-(4-aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5.31 mg, 0.0154 mmol, 1 eq) as a solution in 153.94 μ l DMF (0.1 M) is added to FKBP acid (10.68 mg, 0.0154 mmol, 1 eq). DIPEA (7.63 μ l, 0.046 mmol, 3 eq) is added, followed by HATU (5.85 mg, 0.0154 mmol, 1 eq). The mixture is stirred for 21 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(7) dFKBP19




4-(2-(2-aminoethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5.77 mg, 0.016 mmol, 1 eq) as a solution in 158.98 μ l DMF (0.1 M) is added to FKBP acid (11.03 mg, 0.016 mmol, 1 eq). DIPEA (7.93 μ l, 0.048 mmol, 3 eq) is added, followed by HATU (6.08 mg, 0.016 mmol, 1 eq). The mixture is stirred for 20 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(8) dFKBP20




8-amino-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)octanamide (8.8 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.48 mg, 0.022 mmol, 1 eq). DIPEA (10.91 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(9) dFKBP21




N-(4-(aminomethyl)benzyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (9.9 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.31 mg, 0.022 mmol, 1 eq). DIPEA (10.91 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 16 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(10) dFKBP24




N-(14-amino-3,6,9,12-tetraoxatetradecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (15.93 mg, 0.024 mmol, 1 eq) as a solution in 240 μ l DMF (0.1 M) is added to FKBP acid (16.76 mg, 0.024 mmol, 1 eq). DIPEA (11.90 μ l, 0.072 mmol, 3 eq) is added, followed by HATU (9.125 mg, 0.024 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(11) dFKBP25




N-(29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (22.1 mg, 0.025 mmol, 1 eq) as a solution in 250 μ l DMF (0.1 M) is added to FKBP acid (17.51 mg, 0.025 mmol, 1 eq). DIPEA (12.4 μ l, 0.075 mmol, 3 eq) is added, followed by HATU (9.5 mg, 0.025 mmol, 1 eq). The mixture is stirred for 19 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(12) dFKBP26




N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (12.4 mg, 0.02 mmol, 1 eq) as a solution in 200 μ l DMF (0.1 M) is added to FKBP acid (14.4 mg, 0.02 mmol, 1 eq). DIPEA (10.29 μ l, 0.062 mmol, 3 eq) is added, followed by HATU (7.6 mg, 0.02 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(13) dFKBP27



N-(17-amino-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (13.87 mg, 0.019 mmol, 1 eq) as a solution in 196 μ l DMF (0.1 M) is added to FKBP acid (13.65 mg, 0.0196 mmol, 1 eq). DIPEA (9.75 μ l, 0.059 mmol, 3 eq) is added, followed by HATU (7.45 mg, 0.0196 mmol, 1 eq). The mixture is stirred for 16 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.


(14) dFKBP28



dFKBP28 (SD-2-90)


N-(23-amino-3,6,9,12,15,18,21-hepta-oxatricosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (16.71 mg, 0.021 mmol, 1 eq) as a solution in 210 μ l DMF (0.1 M) is added to FKBP acid (14.46 mg, 0.021 mmol, 1 eq). DIPEA (10.33 μ l, 0.062 mmol, 3 eq) is added, followed by HATU (7.98 mg, 0.021 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

10 (15) dFKBP29




N-(35-amino-3,6,9,12,15,18,21,24,27,30,33-undeca-oxapentatriacontyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (19.36 mg, 0.0199 mmol, 1 eq) as a solution in 199 μ l DMF (0.1 M) is added to FKBP acid (13.83 mg, 0.0199 mmol, 1 eq). DIPEA (9.88 μ l, 0.059 mmol, 3 eq) is added, followed by HATU (7.56 mg, 0.0199 mmol, 1 eq). The mixture is stirred for 16 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

20 (16) dFKBP30




N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)oxy)acetamide (11.04 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.07 mg, 0.022 mmol, 1 eq). DIPEA (10.91 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(17) dFKBP31




N-(8-amino-octyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (8.56 mg, 0.0154 mmol, 1 eq) as a solution in 154 μ l DMF (0.1 M) is added to FKBP acid (10.7 mg, 0.0154 mmol, 1 eq). DIPEA (7.6 μ l, 0.046 mmol, 3 eq) is added, followed by HATU (4.05 mg, 0.0154 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(18) dFKBP32




N-(8-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)oxy)acetamide (11.8 mg, 0.0212 mmol, 1 eq) as a solution in 212 μ l DMF (0.1 M) is added to FKBP acid (14.75 mg, 0.0212 mmol, 1 eq). DIPEA (10.5 μ l, 0.063 mmol, 3 eq) is added, followed by HATU (8.06 mg, 0.0212 mmol, 1 eq). The mixture is stirred for 16 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(19) dFKBP33




N-(8-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)acetamide (12.23 mg, 0.022 mmol, 1 eq) as a solution in 220 μ l DMF (0.1 M) is added to FKBP acid (15.33 mg, 0.022 mmol, 1 eq). DIPEA (10.9 μ l, 0.066 mmol, 3 eq) is added, followed by HATU (8.36 mg, 0.022 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(20) dFKBP34




N-(4-aminobutyl)amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (9.68 mg, 0.0212 mmol, 1 eq) as a solution in 212 μ l DMF (0.1 M) is added to FKBP acid (14.75 mg, 0.0212 mmol, 1 eq). DIPEA (10.52 μ l, 0.063 mmol, 3 eq) is added, followed by HATU (8.06 mg, 0.0212 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(21) dFKBP35




5-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (9.78 mg, 0.0214 mmol, 1 eq) as a solution in 214 μ l DMF (0.1 M) is added to FKBP acid (14.89 mg, 0.0214 mmol, 1 eq). DIPEA (10.64 μ l, 0.064 mmol, 3 eq) is added, followed by HATU (8.13 mg, 0.0214 mmol, 1 eq). The mixture is stirred for 17 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(22) dFKBP36




4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (10.41 mg, 0.0203 mmol, 1 eq) as a solution in 203 μ l DMF (0.1 M) is added to FKBP acid (14.15 mg, 0.0203 mmol, 1 eq). DIPEA (10.06 μ l, 0.061 mmol, 3 eq) is added, followed by HATU (7.72 mg, 0.0203 mmol, 1 eq). The mixture is stirred for 18 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(23) dFKBP37



5-((2-(2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (11.56 mg, 0.0206 mmol, 1 eq) as a solution in 206 μ l DMF (0.1 M) is added to FKBP acid (14.31 mg, 0.0206 mmol, 1 eq). DIPEA (10.21 μ l, 0.0618 mmol, 3 eq) is added, followed by HATU (7.83 mg, 0.0206 mmol, 1 eq). The mixture is stirred for 22 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

(24) dFKBP38




N-(3-(aminomethyl)phenyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide

(7.35 mg, 0.0134 mmol, 1 eq) as a solution in 134 μ l DMF (0.1 M) is added to FKBP acid (9.35 mg, 0.0134mmol, 1 eq). DIPEA (6.68 μ l, 0.0404 mmol, 3 eq) is added, followed
 5 by HATU (5.09 mg, 0.0133 mmol, 1 eq). The mixture is stirred for 20 hours at room temperature. The mixture is then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer is dried over sodium sulfate, filtered and condensed. The crude material is purified by column chromatography.

10 Example 94: Synthesis of the compounds of the present application


(1)



5-(((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (233.07 mg, 0.051 mmol, 1 eq) as a solution in 510 μ l DMF (0.1 M) was added to JQ1-acid (20.46
 15 mg, 0.051 mmol, 1 eq). DIPEA (25.28 μ l, 0.153 mmol, 3 eq) was added, followed by HATU (19.39 mg, 0.051 mmol, 1 eq). The mixture was stirred for 20 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white oil (31.3 mg, 84.4 % yield). The crude material was purified by column
 20 chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a yellow oil (16.7 mg, 45 % yield). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.51 (dd, *J* = 8.4, 1.3 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.36 – 7.30 (m, 2H), 6.95 (t, *J* = 2.0 Hz, 1H), 6.81 (ddd, *J* = 8.4, 2.2, 1.2 Hz, 1H), 5.01 (ddd, *J* = 12.7, 5.5, 3.0 Hz, 1H), 4.64 (dd, *J* = 9.0, 5.2 Hz, 1H), 3.47 – 3.34 (m, 2H), 3.25 (tt, *J* = 9.7, 6.2 Hz, 2H), 2.88 – 2.79 (m, 1H), 2.77 – 2.70 (m, 1H),


2.68 (s, 3H), 2.42 (s, 4H), 2.07 (ddq, $J = 10.3, 5.4, 2.8$ Hz, 1H), 1.75 – 1.68 (m, 5H), 1.67 – 1.63 (m, 3H), 1.29 (s, 1H). **LCMS** 728 (M+H)

(2)



5 4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (23.59 mg, 0.046 mmol, 1 eq) as a solution in 460 μ l DMF (0.1 M) was added to JQ1-acid (18.68 mg, 0.046 mmol, 1 eq). DIPEA (23.1 μ l, 0.139 mmol, 3 eq) was added, followed by HATU (17.49 mg, 0.046 mmol, 1 eq). The mixture was stirred for 18 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water
10 then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white powder (26 mg, 72.18 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a yellow oil (17.1 mg, 47.4 % yield). **¹H NMR** (500 MHz, Methanol- d_4) δ 7.52 (dd, $J = 8.6, 7.2$ Hz, 1H), 7.46 – 7.43 (m, 2H), 7.39 (d, $J = 8.6$ Hz, 2H), 7.00 (dd, $J = 7.6, 2.0$ Hz, 2H),
15 5.03 (dd, $J = 12.5, 5.5$ Hz, 1H), 4.62 (dd, $J = 9.0, 5.2$ Hz, 1H), 3.40 (dd, $J = 14.9, 9.0$ Hz, 1H), 3.28 (d, $J = 6.8$ Hz, 2H), 3.27 – 3.17 (m, 2H), 2.89 – 2.79 (m, 1H), 2.74 (dd, $J = 4.4, 2.6$ Hz, 1H), 2.68 (s, 3H), 2.43 (s, 4H), 2.13 – 2.01 (m, 1H), 1.68 (s, 3H), 1.63 (q, $J = 7.2$ Hz, 1H), 1.56 (q, $J = 7.0$ Hz, 2H), 1.46 – 1.34 (m, 9H), 1.29 (s, 1H). **LCMS** 784 (M+H)

(3)




20

4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (22.71 mg, 0.0497 mmol, 1 eq) as a solution in 497 μ l DMF (0.1 M) was added to JQ1-acid (19.95 mg, 0.0497 mmol, 1 eq). DIPEA (24.67 μ l, 0.149 mmol, 3 eq) was added, followed by HATU (18.89 mg, 0.0497 mmol, 1 eq). The mixture was stirred for 17 hours at room temperature.
25 The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to


give a white oil (30.4 mg, 72 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a yellow oil (26.6 mg, 63.6 % yield). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.51 (ddd, *J* = 8.3, 7.1, 0.8 Hz, 1H), 7.45 – 7.41 (m, 2H), 7.34 (dd, *J* = 8.7, 3.4 Hz, 2H), 7.06 – 7.00 (m, 2H), 5.01 (ddd, *J* = 12.9, 10.8, 5.5 Hz, 1H), 4.62 (ddd, *J* = 9.0, 5.3, 2.3 Hz, 1H), 3.44 – 3.33 (m, 3H), 3.27 (ddd, *J* = 14.7, 5.2, 2.2 Hz, 1H), 2.83 (ddd, *J* = 14.2, 5.4, 2.6 Hz, 1H), 2.76 – 2.70 (m, 2H), 2.43 (s, 3H), 2.07 (dt, *J* = 12.9, 5.4, 2.9 Hz, 1H), 1.76 – 1.68 (m, 5H), 1.66 (s, 3H). LCMS 728 (M+H)

(4)




N-(23-amino-3,6,9,12,15,18,21-heptaooxatricosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (60.49 mg, 0.076 mmol, 1 eq) as a solution in 760 μl DMF (0.1 M) was added to JQ1-acid (30.80 mg, 0.076 mmol, 1 eq). DIPEA (38 μl, 0.23 mmol, 3 eq) was added, followed by HATU (28.89 mg, 0.076 mmol, 1 eq). The mixture was stirred for 20 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white oil (42.8 mg, 52.8 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white oil (36.6 mg, 45.2 % yield). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.81 – 7.75 (m, 1H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.45 (d, *J* = 8.6 Hz, 2H), 7.43 – 7.37 (m, 3H), 5.09 (dd, *J* = 12.8, 5.5 Hz, 1H), 4.76 (s, 2H), 4.63 (dd, *J* = 9.1, 5.2 Hz, 1H), 3.66 – 3.55 (m, 30H), 3.51 – 3.41 (m, 5H), 2.90 – 2.83 (m, 1H), 2.79 – 2.71 (m, 2H), 2.69 (s, 3H), 2.43 (s, 3H), 2.14 (ddt, *J* = 10.5, 5.5, 3.2 Hz, 1H), 1.69 (s, 3H). LCMS 1065 (M+H)

(5)



N-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)acetamide (28.9 mg, 0.052 mmol, 1 eq) as a solution in 524 μ l DMF (0.1 M) was added to JQ1-acid (21.01 mg, 0.052 mmol, 1 eq). DIPEA (524 μ l, 0.157 mmol, 3 eq) was added, followed by HATU (19.77 mg, 0.052 mmol, 1 eq). The mixture was stirred for 20 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white powder (33.7 mg, 78 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white powder (13.8 mg, 32 % yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.39 (dd, *J* = 8.2, 4.7 Hz, 3H), 7.31 (dd, *J* = 8.5, 3.5 Hz, 3H), 7.23 (dd, *J* = 7.6, 3.8 Hz, 1H), 6.65 (dd, *J* = 8.0, 3.4 Hz, 1H), 5.20 – 5.00 (m, 2H), 4.63 (q, *J* = 7.1 Hz, 2H), 3.87 (d, *J* = 5.6 Hz, 1H), 3.52 (ddd, *J* = 29.5, 14.8, 7.8 Hz, 1H), 3.37 – 3.13 (m, 6H), 2.71 – 2.54 (m, 7H), 2.39 (d, *J* = 3.3 Hz, 5H), 1.66 (d, *J* = 5.7 Hz, 5H), 1.52 (t, *J* = 7.1 Hz, 1H), 1.43 (dt, *J* = 17.8, 5.3 Hz, 3H), 1.35 – 1.21 (m, 3H). LCMS 827 (M+H)


(6)



N-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)oxy)acetamide (29.52 mg, 0.053 mmol, 1 eq) as a solution in 536 μ l DMF (0.1 M) was added to JQ1-acid (12.51 mg, 0.053 mmol, 1 eq). DIPEA (26.6 μ l, 0.161 mmol, 3 eq) was added, followed by HATU (20.15 mg, 0.053 mmol, 1 eq). The mixture was stirred for 20 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white oil (27.4 mg, 62.5 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white oil (19.6 mg, 44.7 % yield). ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.50 – 7.41 (m, 4H), 7.41 – 7.37 (m, 2H), 7.12 (dd, *J* = 7.9, 1.4 Hz, 1H), 5.14 (dt, *J* = 11.4, 3.2 Hz, 1H), 4.66 – 4.60 (m, 3H), 4.58 – 4.47 (m, 2H), 3.44 – 3.34 (m, 1H), 3.30 – 3.20 (m, 4H), 2.94 – 2.84 (m, 1H), 2.76 (ddq, *J* = 17.7, 5.0, 2.5 Hz, 1H), 2.68 (s, 3H), 2.53 – 2.45 (m,

1H), 2.43 (s, 3H), 2.17 (ddt, $J = 10.0, 4.9, 2.6$ Hz, 1H), 1.68 (s, 3H), 1.53 (dp, $J = 21.0, 6.8$ Hz, 4H), 1.39 – 1.24 (m, 9H). **LCMS** 827 (M+H)

(7)




5 *N*-(9-aminononyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)acetamide (7.5 mg, 0.0135 mmol, 1 eq) as a solution in 135 μ l DMF (0.1 M) was added to JQ1-acid (5.41 mg, 0.0135 mmol, 1 eq). DIPEA (6.7 μ l, 0.0405 mmol, 3 eq) was added, followed by HATU (5.13 mg, 0.0135 mmol, 1 eq). The mixture was stirred for 19 hours at room temperature. The mixture was then diluted with EtOAc and washed with saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a white powder (10.5 mg, 94.3 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a white powder (6.8 mg, 61 % yield). **¹H NMR** (500 MHz, Methanol- d_4) δ 7.81 – 7.73 (m, 2H), 7.67 (dd, $J = 7.5, 1.2$ Hz, 1H), 7.47 – 7.43 (m, 2H), 7.40 (d, $J = 8.7$ Hz, 2H), 5.11 (dd, $J = 12.7, 5.5$ Hz, 1H), 4.63 (dd, $J = 8.9, 5.3$ Hz, 1H), 4.10 (q, $J = 7.1$ Hz, 1H), 4.04 (d, $J = 4.1$ Hz, 2H), 3.41 (dd, $J = 14.9, 9.0$ Hz, 1H), 3.29 – 3.20 (m, 2H), 3.17 (td, $J = 6.9, 2.0$ Hz, 2H), 2.90 – 2.80 (m, 1H), 2.78 – 2.70 (m, 2H), 2.44 (s, 3H), 2.12 (ddd, $J = 7.8, 5.7, 2.7$ Hz, 1H), 2.01 (s, 1H), 1.70 (s, 3H), 1.56 (q, $J = 7.3$ Hz, 2H), 1.49 (q, $J = 6.8$ Hz, 2H), 1.38 – 1.28 (m, 11H), 1.24 (t, $J = 7.1$ Hz, 1H), 0.95 – 0.81 (m, 1H). **LCMS** 839 (M+H)

10

15


20 (8)



(*R*)-*N*-(4-aminobutyl)-2-((2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide (47.1 mg, 0.113 mmol, 1 eq) as a solution in 1.13 ml DMF (0.1 M) was added to JQ1-acid (45.3 mg, 0.113 mmol, 1 eq). DIPEA (56.02 μ l, 0.339 mmol, 3 eq) was added, followed by HATU (42.96 mg, 0.113 mmol, 1 eq). The mixture was stirred for 21 hours at room temperature. The mixture was then diluted with EtOAc and washed with


25

saturated sodium bicarbonate, water then brine. The organic layer was dried over sodium sulfate, filtered and condensed to give a yellow powder (49.2 mg, 54.5 % yield). The crude material was purified by column chromatography (ISCO, 4 g silica column, 0 to 10% MeOH/DCM 25 minute gradient) to give a yellow powder (20.1 mg, 22 % yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.77 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.47 (s, 1H), 7.44 (d, *J* = 2.1 Hz, 1H), 7.42 (d, *J* = 1.3 Hz, 2H), 7.40 (d, *J* = 2.3 Hz, 2H), 7.38 (d, *J* = 2.6 Hz, 1H), 4.73 (s, 2H), 4.66 – 4.61 (m, 1H), 3.45 – 3.34 (m, 3H), 2.98 (s, 2H), 2.68 (d, *J* = 11.1 Hz, 5H), 2.44 (dd, *J* = 8.2, 0.9 Hz, 4H), 1.96 (s, 3H), 1.69 – 1.62 (m, 7H), 0.95 – 0.81 (m, 4H). LCMS 799 (M+H)



Example 95: Synthesis of

N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)oxy)acetamide trifluoroacetate salt (13.0 mg, 0.020 mmol, 1 eq) is added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (13.9 mg, 0.020 mmol, 1 eq) as a 0.1 M solution in DMF (200 μ L). DIPEA (19.5 μ L, 0.060 mmol, 3 eq) is added, followed by HATU (7.6 mg, 0.020 mmol, 1 eq). The mixture is stirred at room temperature for 22 hours, then diluted with EtOAc. The organic layer is washed with 10% citric acid (aq), brine, saturated sodium bicarbonate (aq), water and brine. The organic layer is then dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.



Example 96: Synthesis of

4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetate salt (9.7 mg, 0.020 mmol, 1 eq) is added to 2-(3-((*R*)-3-(3,4-dimethoxyphenyl)-1-(((*S*)-1-((*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-

carbonyl)oxy)propyl)phenoxy)acetic acid (13.9 mg, 0.020 mmol, 1 eq) as a 0.1 M solution in DMF (200 uL). DIPEA (19.5 uL, 0.060 mmol, 3 eq) is added, followed by HATU (7.6 mg, 0.020 mmol, 1 eq). The mixture is stirred at room temperature for 23 hours, then diluted with EtOAc. The organic layer is washed with 10% citric acid (aq), brine, saturated sodium bicarbonate (aq), water and brine. The organic layer is then dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography.

Example 97: Biological activities of the compounds of the application

10 Using the biological assays disclosed in the application, such as the procedures described in Example 94, compounds of the present application were demonstrated to have potent biological activities, *e.g.*, binding to the protein target, mediating protein degradation, *etc.*, as shown in the tables below.

Table 4-1

Cmpd. No.	IC ₅₀ (nM)									
	BRD4	BRDT	PLK1	797	CUTL1	DND41	MOLT4	NGP	MV4;11	LRRK2
dBET1	20	70		568	937.8	490.2	1508	3099	8.5	
dBET2	134	405	6.15	113	81.21	110	192.5	155.9	6.3	
dBET3	32	88								
dBET4	6866	17650		>20000	>20000	>20000	>20000	>20000		
dBET5	33	110								
dBET6	14	56		24	70.78	34.4	65.33	187.6		
dBET7	161	549		16	29.2	31.4	46.6	130.8		
dBET8	269	820		39	42	47.2	88.5	153		
dBET9	15	52		296	1547	1525	1498	8425	28	
dBET10	83	309	10.2	163	151.9	271.1	451.8	412.9	28	
dBET11	958	2903		>20000					3.378	7.3
dBET12	2084	5872		>20000					>20000	32
dBET13	6930									
dBET14	8830									
dBET15	31	93		1274	6840	10420	6959	>20000	312	
dBET16	2278			4901						
dBET17	46	217		5016	>20000	17320	13510	>20000		
dBET18	11	28		1362	2838	1794	1923	4960		
dBET19	212	1131		>20000						
dBET20	5697			14670						
dBET21	175			630						
dBET25	182			6858						
dBET26	282			7015						
dBET32	3303			5732						
dBET33	4989			3996						
dBET34	1544			3916						
dBET35	7.2			372						
dBET36	80			725						
dBET37	13			1024						
dBET38	31			770						
dBET40	89			299						
dBET41	63			726						
dBET42	27			7720						

Cmpd. No.	IC ₅₀ (nM)									
	BRD4	BRDT	PLK1	797	CUTL1	DND41	MOLT4	NGP	MV4;11	LRRK2
dBET43	25			2254						
dBET44	30			719						
dBET45	15420			3451						
dBET46	2230			9447						

Table 4-2

Cmpd. No.	BRD4 max degradation (%)		BRD4 DC ₅₀ (nM)	
	Cell Western	Dual Luciferase	Cell Western	Dual Luciferase
dBET1	54	34 (45)	45	143 (27)
dBET2	56	39	11	19
dBET3	31.6	13	62	22
dBET4	<5	23		15510
dBET5	66	53	41	68
dBET6	71	61 (71)	5	11 (3.6)
dBET7	63	54	7.1	7.6
dBET8	49	39	10.6	8.4
dBET9	41	25	52	59
dBET10	20	25	58	N/A
dBET15	24	18	113	335
dBET16		55		6
dBET17	52	36	535	1439
dBET18	57	37	196	243
dBET19		>5		
dBET20		<10		
dBET21		21		N/A
dBET22		73		40
dBET23		73		0.5
dBET24		50		131
dBET25		42		3065
dBET26		40		1014
dBET27		30		161
dBET28		>5		
dBET29		19		N/A
dBET30		79		2096
dBET31		55		554
dBET32		50		N/A
dBET33		<10		
dBET34		24		N/A
dBET35		12		2656
dBET36		54		47
dBET37		46		49

Cmpd. No.	BRD4 max degradation (%)		BRD4 DC ₅₀ (nM)	
	Cell Western	Dual Luciferase	Cell Western	Dual Luciferase
dBET38		30		15
dBET40		<10		
dBET41		43		25
dBET42		10		
dBET43		13		
dBET44		<10		
dBET45		30		25
dBET46		22		55

Table 4-3

Cmpd. No.	THAL ALPHA (IC ₅₀) (M)	Dimer Amplitude	Dimer Mean	Dimer SD	FKBP7 rescue (EC ₅₀) (M)	BRD4 Alpha (IC ₅₀) (M)	BRD4 -Emax (percent remaining)	Conc@Emax (uM)	max degradation (dual luc)	pDC ₅₀ (dual luc)
dBET1	3.09E-09	16010	-7.703	0.6604	4.68E-05	2.00E-08	63.37817	1.58113883	34.24	6.844
dBET2	7.30E-09	20549	-7.428	0.7005	6.10E-05	1.34E-07	59.82452	0.158113883	38.8	7.723
dBET3	1.04E-08	16389	-7.497	0.6763	4.75E-05	3.20E-08	83.99794	0.5	12.71	7.663
dBET4	1.16E-07	NA	NA	NA	1.69E-05	6.87E-06	76.9159	50	23.2	4.809
dBET5	2.17E-07	18644	-6.277	0.4127	2.70E-05	3.30E-08	44.70985	1.58113883	53.03	7.167
dBET6	1.34E-07	22711	-6.555	0.4699	1.38E-05	1.40E-08	37.73316	0.5	60.5	7.973
dBET7	4.17E-07	31800	-6.18	0.4549	2.17E-04	1.61E-07	43.6606	0.5	54.11	8.121
dBET8	3.72E-08	16683	-6.796	0.6849	-	2.69E-07	56.41379	0.158113883	38.69	8.076
dBET9	1.48E-08	16889	-7.496	0.5198	0.1309	1.50E-08	70.96368	1.58113883	24.84	7.232
dBET10	1.27E-08	12824	-7.349	0.5165	8.12E-06	8.30E-08	73.14457	50	25.27	NA
dBET11	2.51E-08	308.3	-5.917	2.226	0.002432	9.58E-07	NT	NT	NT	NT
dBET12	2.38E-08	173.7	-6.366	3.287	3.44E-05	2.08E-06	NT	NT	NT	NT
dBET13	1.07E-08	NA	NA	NA	0.0002196	6.93E-06	NT	NT	NT	NT
dBET14	1.24E-08	NA	NA	NA	0.0002271	8.83E-06	NT	NT	NT	NT
dBET15	4.04E-08	13540	-7.111	0.6279	4.82E-05	3.10E-08	78.22129	5	18.18	6.475
dBET16	4.84E-09	NT	NT	NT	NT	2.28E-06	NT	NT	55	8.301
dBET17	6.41E-09	16182	-7.422	0.7258	0.05363	4.60E-08	62.79548	15.8113883	35.97	5.842
dBET18	1.57E-09	13116	-8.173	0.618	0.0007493	1.10E-08	65.43201	1.58113883	36.46	6.614
dBET19	3.62E-09	1722	-7.069	1.225	0.004333	2.12E-07	93.2869575	15.8113883	-1.3	NA
dBET20	NT	NT	NT	NT	NT	5.70E-06	NT	NT	7.04	6.686
dBET21	3.90E-08	758.9	-6.306	1.327	7.43E-06	1.75E-07	78.0640975	0.5	13.62	5.568
dBET22	2.84E-08	26153	-7.636	0.9644	0.03404	NT	26.34682	50	72.72	7.401
dBET23	2.69E-08	31936	-7.49	0.6751	1.62E-05	NT	22.7120575	0.5	73.26	9.298
dBET24	1.03E-08	31348	-7.489	0.6531	0.0001372	NT	42.964015	5	50.42	6.883
dBET25	NT	NT	NT	NT	NT	1.82E-07	NT	NT	41.72	5.514
dBET26	NT	NT	NT	NT	NT	2.82E-07	NT	NT	39.93	5.994
dBET27	4.11E-08	11278	-7.202	0.7693	1.20E-05	NT	67.2831525	0.5	30.01	6.794
dBET28	1.71E-08	1752	-7.037	1.263	7.73E-06	NT	91.1683825	0.001581139	NA	NA
dBET29	6.05E-09	1454	-7.756	0.7393	1.62E-06	NT	75.53291	0.05	19.03	NA
dBET30	2.65E-08	30326	-7.422	0.8533	0.003141	NT	26.2243275	50	78.52	5.679
dBET31	2.68E-08	32323	-7.374	0.6046	NT	NT	45.56037	15.8113883	55.37	6.257
dBET32	NT	NT	NT	NT	NT	0.00003303	NT	NT	50	NA

Cmpd. No.	THAL ALPHA (IC ₅₀) (M)	Dimer Amplitude	Dimer Mean	Dimer SD	FKBP7 rescue (EC ₅₀) (M)	BRD4 Alpha (IC ₅₀) (M)	BRD4 -Emax (percent remaining)	Conc@Emax (uM)	max degradation (dual luc)	pDC ₅₀ (dual luc)
dBET33	NT	NT	NT	NT	NT	0.000004989			9.96	NA
dBET34	NT	NT	NT	NT	NT	0.000001544			24	NA
dBET35	NT	NT	NT	NT	NT	7.211E-09			11.68	5.575771929
dBET36	NT	NT	NT	NT	NT	8.028E-08			54.37	7.332360294
dBET37	NT	NT	NT	NT	NT	1.321E-08			46.38	7.309006968
dBET38	NT	NT	NT	NT	NT	3.14E-08			30.38	7.836540448
dBET39	NT	NT	NT	NT	NT	NT			NT	
dBET40	NT	NT	NT	NT	NT	8.946E-08			3.59	5.521000868
dBET41	NT	NT	NT	NT	NT	6.283E-08			43.37	7.598254918
dBET42	NT	NT	NT	NT	NT	2.693E-08			10	NA
dBET43	NT	NT	NT	NT	NT	2.451E-08			13	NA
dBET44	NT	NT	NT	NT	NT	3.003E-08			5.94	5.297914279
dBET45	NT	NT	NT	NT	NT	0.00001542			29.94	7.605373236
dBET46	NT	NT	NT	NT	NT	0.00000223			21.52	7.257982253

NA: not active

NT: not tested

Table 5

Cmpd. No.	IC ₅₀ (nM)		Max Degradation (dual luciferase, %)				DC ₅₀ (nM)		
	FKBP	FKBP 36V	FKBP	FKBP 36V	CRBN +/- FKBP F36V	FKBP	FKBP 36V	CRBN +/- FKBP F36V	
dFKBP-1	274	237	44	35		11	153		
dFKBP-2	218	174	53	43		26	19		
dFKBP-3	1830	1203	22	12		19700			
dFKBP-4	408	369	34	21		2.97			
dFKBP-5	>50000	2294	11	<5		2971			

Table 6

Compound No.	CRBN alpha IC50 (M)	Nluc/Fluc IKZF1 IC50 (M)	Nluc/Fluc IKZF1 Max Degradation
D-1	2.89E-08	>5E-5	N/A
D-2	4.13E-06	>5E-5	N/A
D-3	6.67E-07	4.44E-07	38.24
D-4	6.31E-08	4.35E-09	66.43
D-5	2.66E-07	>5E-5	N/A
D-8	9.49E-08	1.19E-07	19.42
D-9	1.45E-05	7.61E-06	67.23
D-10	3.25E-06	>5E-5	N/A
D-11	1.26E-04	>5E-5	N/A
D-13	3.01E-07	>5E-5	N/A
D-14	6.08E-07	>5E-5	N/A
D-15	6.19E-07	>5E-5	N/A
D-16	7.14E-08	2.39E-08	67.23
D-17	8.76E-07	1.71E-07	67.59
D-18	2.53E-08	N/A*	41.1
D-19	1.47E-07	1.11E-07	63.37
D-21	1.64E-07	1.40E-07	17.98
D-22	3.75E-07	5.34E-07	52.96
D-23	6.46E-07	1.02E-06	59.03
D-24	4.93E-07	>5E-5	N/A
D-25	5.89E-08	>5E-5	N/A
D-26	1.13E-07	>5E-5	N/A
D-27	2.00E-07	>5E-5	N/A
D-28	4.01E-08		
D-29	1.40E-07		
D-30	1.52E-08		
D-31	1.21E-08		
D-32	2.14E-08		
D-51	1.17E-06		
D-52	3.95E-05		
D-53	5.61E-05		
D-54	>5E-5		
D-55	>5E-5		

Compound No.	CRBN alpha IC50 (M)	Nluc/Fluc IKZF1 IC50 (M)	Nluc/Fluc IKZF1 Max Degradation
D-56	3.06E-06		
D-57	8.70E-08		
D-58	7.15E-07		
D-59	>5E-5		
D-60	2.59E-07		
D-61	2.66E-06		
D-62	2.68E-07		
D-63	4.84E-07		
D-64	2.13E-06		
D-65	1.12E-06		

Example 98: Biological activity of compounds of the present application

Cmpd ID	Structures	R ^{AR1}	R ^{AR2}	R
dFKBP-7-m1				
dFKBP-7-o1				

dFKBP-13-ml					
dFKBP-13-ol					

Cmpd ID	IC50 (nM)				
	FKBP WT Alpha Screen	FKBP F36V Alpha Screen	Mv411-Luc	FKBP WT 293WT	FKBP F36V 293T
dFKBP-7-ml	100.7	3.809	0.133		0.289
dFKBP-7-ol	>50,000	332.4	2.18	>25,000	38.9
dFKBP-13-ml	544.7	4.369	0.130	4.803	0.119
dFKBP-13-ol	>50,000	919.1	10.8	>25,000	13.4

Example 99: Experimental procedures

Protein purification and crystal structure

A construct of human BRD4 covering residues 44-168 in the pNIC28Bsa4 vector (Addgene) was overexpressed in E. coli BL21 (DE3) in LB medium in the presence of 50 mg/ml of kanamycin. Cells were grown at 37°C to an OD of 0.8, induced with 500 µM isopropyl-1-thio-D-galactopyranoside, incubated overnight at 17°C, collected by centrifugation, and stored at -80°C. Cell pellets were sonicated in buffer A (50 mM hepes 7.5 + 300 mM NaCl + 10% glycerol + 10 mM Imidazole + 3 mM BME) and the resulting lysate was centrifuged at 35,000 xg for 40 min. Ni-NTA beads (Qiagen) were mixed with lysate supernatant for 30 min and washed with buffer A. Beads were transferred to an FPLC-compatible column and the bound protein was washed with 15% buffer B (50 mM hepes 7.5 + 300 mM NaCl + 10% glycerol + 300 mM Imidazole + 3 mM BME) and eluted with 100% buffer B. TEV was added to the eluted protein and incubated at 4°C overnight. The sample was then passed through a desalting column (26/10 column) equilibrate with buffer A (without imidazole), and the eluted protein was subjected to a second Ni-NTA step to remove His-tag and TEV. The eluant was concentrated and passed through a Superdex-200 10/300 column in 20 mM hepes7.5 + 150 mM NaCl + 1 mM DTT. Fractions were pooled, concentrated to 14 mg/ml, and frozen at -80°C.

Crystallization, data collection and structure determination

A 1.5-fold excess of 10 mM dBET1 (in DMSO) was mixed with 500 µM protein and crystallized by sitting-drop vapor diffusion at 20°C in the following crystallization buffer: 15% PEG3350, 0.1 M Succinate. Crystals were transferred briefly into crystallization buffer containing 25% glycerol prior to flash-freezing in liquid nitrogen. Diffraction data from complex crystals were collected at beamline 24ID-C of the NE-CAT at the Advanced Photon Source (Argonne National Laboratory), and data-sets were integrated and scaled using XDS (Kabsch, W. *Acta crystallographica Section D, Biological crystallography* **2010**, 66, 133). Structures were solved by molecular replacement using the program Phaser (Mccoy *et al.*, *Journal of Applied Crystallography* **2007**, 40, 658) and the search model PDB entry XXXX. The ligand was automatically positioned and refined using Buster (Smart *et al.* *Acta crystallographica Section D, Biological crystallography* **2012**, 68, 368). Iterative model building and refinement using Phenix (Adams *et al.* *Acta crystallographica Section D, Biological crystallography* **2010**, 66, 213) and Coot (Emsley, P.; Cowtan, K. *Acta crystallographica Section D, Biological crystallography* **2004**, 60, 2126) led to a model with statistics shown in Table 4.

Table 7. Data collection and refinement statistics.

	BRD4a/DB-2-190
Wavelength (Å)	0.9792
Resolution range (Å)	34.31 - 0.99 (1.025 - 0.99)
Space group	P 21 21 21
Unit cell	38.01 43.05 79.7 90 90 90
Total reflections	440045 (17524)
Unique reflections	67392 (4589)
Multiplicity	6.5 (3.8)
Completeness (%)	91.60 (63.09)
Mean I/sigma(I)	21.20 (2.46)
Wilson B-factor	9.95
R-merge	0.04633 (0.6184)
R-meas	0.05011
CC1/2	0.999 (0.742)
CC*	1 (0.923)
Reflections used for R-free	
R-work	0.1887 (0.2620)
R-free	0.1863 (0.2788)
CC(work)	
CC(free)	
Number of non-hydrogen atoms	1333
macromolecules	1059
ligands	55
water	219
Protein residues	128
RMS(bonds)	0.005
RMS(angles)	1.07
Ramachandran favored (%)	9.80E+01
Ramachandran allowed (%)	
Ramachandran outliers (%)	0
Clashscore	4.63
Average B-factor	14.5
macromolecules	12.4
ligands	22.8
solvent	22.8

Statistics for the highest-resolution shell are shown in parentheses.

5

BRD4 AlphaScreen

Assays were performed with minimal modifications from the manufacturer's protocol (PerkinElmer, USA). All reagents were diluted in 50 mM HEPES, 150 mM NaCl, 0.1% w/v BSA, 0.01% w/v Tween20, pH 7.5 and allowed to equilibrate to room temperature prior to

addition to plates. After addition of Alpha beads to master solutions all subsequent steps were performed under low light conditions. A 2x solution of components with final concentrations of BRD4 at 40 nM, Ni-coated Acceptor Bead at 10 µg/mL, and 20 nM biotinylated-JQ1 (Anders *et al. Nature Biotechnology* 2013, 32, 92) was added in 10 µL to 384-well plates (AlphaPlate-384, PerkinElmer, USA). Plates were spun down at 150x g, 100 nL of compound in DMSO from stock plates were added by pin transfer using a Janus Workstation (PerkinElmer, USA). The streptavidin-coated donor beads (10 µg/mL final) were added as with previous the solution in a 2x, 10 µL volume. Following this addition, plates were sealed with foil to prevent light exposure and evaporation. The plates were spun down again at 150xg. Plates were incubated at room temperature for 1 hour and then read on an Envision 2104 (PerkinElmer, USA) using the manufacturer's protocol. The data were analyzed using PRISM Graphpad v6 to obtain IC₅₀ values.

BRD4 dual luciferase assay

A lentiviral construct containing the fusion BRD4 adjoined to nanoluciferase (Nluc) and a separate firefly luciferase (Fluc) was produced in 293 FT cells and used to transduce 293 FT cells. Transduced cells were selected with puromycin and expanded. For assays cells were dispensed into white 384-well culture plates in 20 µL at 1000 cells/well. The cells were allowed to adhere to the plate overnight, and then pinned with 100 nL of compound in DMSO using a JANUS workstation (PerkinElmer). Cells were incubated with compound for 4 hours at 37°C, 5% CO₂ and then allowed to cool to room temperature. To each plate was added 25 µL of Fluc buffer (200 mM Tris, 15 mM MgSO₄, 100 uM EDTA, 1 mM DTT, 1 mM ATP, 200 uM Coenzyme A, 400 uM D-Luciferin, 0.1% Triton X-100). The plates were incubated for 15 min at RT, and then read on an Envision 2104 (PerkinElmer) for luminescence. 25 µL of Nluc buffer (25 mM Na₄PPi, 10 mM NaOAc, 15 mM EDTA, 500 mM NaSO₄, 500 mM NaCl, 16 uM coelenterazine, 50 µM 4-(6-methyl-1,3-benzothiazol-2-yl)aniline [Santa Cruz Biotechnology, sc-276812]) was then added to each well and the plate incubated for 15 min at RT and then read for luminescence. Luminescence values for each reading on each plate were normalized to DMSO controls and then the ratio of Nluc/Fluc signal was taken for each well. These data were further analyzed using PRISM Graphpad v6 to obtain IC₅₀ and maximum degradation values (*see, e.g.*, Table 4-3 "Conc@Emax (uM)", "max degradation (dual luc)", and "pDC₅₀ (dual luc)").

IKZF1 dual luciferase assay

A lentiviral construct containing the fusion IKZF1 adjoined to nanoluciferase (Nluc) and a separate firefly luciferase (Fluc) was produced in 293 FT cells and used to transduce

293 FT cells. Transduced cells were selected with puromycin at 2 µg/mL and expanded. For assays cells were dispensed into white 384-well culture plates in 20 µL at 1000 cells/well. The cells were allowed to adhere to the plate overnight, and then pinned with 100 nL of compound in DMSO using a JANUS workstation (PerkinElmer). Cells were incubated with compound for 4 hours at 37°C, 5% CO₂ and then allowed to cool to room temperature. To each plate was added 25 µL of Fluc buffer (200 mM Tris, 15 mM MgSO₄, 100 uM EDTA, 1 mM DTT, 1 mM ATP, 200 uM Coenzyme A, 400 uM D-Luciferin, 0.1% Triton X-100). The plates were incubated for 15 min at RT, and then read on an Envision 2104 (PerkinElmer) for luminescence. 25 µL of Nluc buffer (25 mM Na₄PPi, 10 mM NaOAc, 15 mM EDTA, 500 mM NaSO₄, 500 mM NaCl, 16 uM coelenterazine, 50 µM 4-(6-methyl-1,3-benzothiazol-2-yl)aniline [Santa Cruz Biotechnology, sc-276812]) was then added to each well and the plate incubated for 15 min at RT and then read for luminescence. Luminescence values for each reading on each plate were normalized to DMSO controls and then the ratio of Nluc/Fluc signal was taken for each well. These data were further analyzed using PRISM Graphpad v6 to obtain IC₅₀ and maximum degradation values (*see, e.g.*, Table 6).

FKBP dual luciferase assay

Wild-type 293FT cells or cereblon mutant 293FT cells (CRBN^{-/-}) were transduced with a lentiviral vector expressing a fusion of FKBP12 to nanoluciferase (NLuc; HA-tagged) as well as Firefly luciferase (FLuc) from the same multicistronic transcript, or with a lentiviral vector expressing a fusion of mutant FKBP12 to nanoluciferase (NLuc; HA-tagged) as well as Firefly luciferase (FLuc) from the same multicistronic transcript. The cells were treated with increasing concentrations of various dFKBPs for 4 hours. The amount of NLuc and FLuc was measured, and the abundance of the FKBP12-HA-NLuc was quantified by calculating the signal ratio of NLuc/FLuc.

FKBP12 (WT and 36V) Ligand-displacement AlphaScreen assay

In 384-well AlphaPlates (Perkin Elmer), 90 nM GST-FKBP12 (WT or 36V) and 62.5 nM biotin-SLF were diluted in 20 uL assay buffer (PBS containing 0.1% BSA and 0.01% Triton X-100) containing competitor compound or DMSO. Following a 30 min-incubation, 20 uL detection solution containing Streptavidin Donor Beads and Glutathione Acceptor Beads diluted to 20 ng/uL in assay buffer was added to each well. After 1 hr incubation at RT, luminescence was measured on the Envision 2104 plate reader. Percent activity values were calculated by setting the average background (no protein wells) to 0% the average DMSO wells to 100% activity. Standard deviations were determined from at least four replicate measurements for compound concentration. Data were analyzed and plotted

using GraphPad PRISM v6 and IC₅₀ values were determined using the ‘log(inhibitor) vs normalized response –variable slope’ analysis module (*see, e.g.*, Table 5).

CRBN-DDB1 expression and purification

Expression and purification of CRBN-DDB1 were performed as described in Fischer, E. S. *et al.*, *Nature* 512, 49 (2014), using Sf9 cells (Invitrogen). pFastBac vectors encoding human CRBN and DDB1 were used for expression of the proteins.

CRBN-DDB1/BRD4 Dimerization Assay

AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-DDB1 (6XHIS-tagged) were diluted to 125 nM and 250 nM, respectively, in assay buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM TCEP, and 0.1% BSA), and 20 uL of protein mixture was added to each well of a 384-well AlphaPlate (PerkinElmer). Compounds were then added at 100 nL per well from DMSO stock plates using a Janus Workstation (PerkinElmer). After 1 hr incubation at room temperature, Nickel Chelate AlphaLISA® Acceptor and Glutathione AlphaLISA® Donor beads (PerkinElmer) were diluted in assay buffer to a 2X concentration (20 ng/uL) and added at 20 uL per well. Plates were incubated for 1 hr at room temperature prior to luminescence detection on an Envision 2104 plate reader (PerkinElmer). For competition assays, GST-BRD4[49-170] and CRBN-DDB1 were diluted as above in the presence of 111 nM dBET1. Compound addition and subsequent detection was performed as described above.

Data were analyzed and plotted using GraphPad PRISM v6. Dimer Amplitude, Dimer Mean, and Dimer SD values were determined using the ‘Guassian’ analysis module (*see, e.g.*, Table 4-3).

CRBN-DDB1 ligand-displacement AlphaScreen assay

A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC₅₀) of thalidomide conjugates and novel IMiDs to CRBN-DDB1. In 384-well AlphaPlates (Perkin Elmer), 50 nM CRBN-DDB1 and 125 nM biotin-thalidomide were diluted in 20 uL assay buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM TCEP, and 0.1% BSA) containing competitor compound or DMSO. Following a 30 min incubation, 20 uL detection solution containing Streptavidin Donor Beads and Nickel Chelate AlphaLISA® Acceptor Beads diluted to 20 ng/uL in assay buffer was added to each well. After 1 hr incubation at RT, luminescence was measured on the Envision 2104 plate reader. Percent activity values were calculated by setting the average background (no protein wells) to 0% the average DMSO wells to 100% activity. Standard deviations were determined from at least

four replicate measurements for compound concentration. Data were analyzed and plotted using GraphPad PRISM v6 and CRBN Alpha IC₅₀ values were determined using the 'log(inhibitor) vs normalized response –variable slope' analysis module (*see, e.g.*, Table 4-3 "THAL ALPHA (IC₅₀)" and Table 6).

5 Intracellular CRBN Engagement Assay

A lentiviral construct containing the fusion FKBP(36V) adjoined to nanoluciferase (Nluc) and a separate firefly luciferase (Fluc) was produced in 293 FT cells and used to transduce 293 FT cells. For assays cells were dispensed into white 384-well culture plates in 20 µL at 4000 cells / well. The cells were allowed to adhere to the plate overnight, and then
10 pinned with 100 nL of competitor compound in DMSO followed by the addition of 80 nM dFKBP7 using a JANUS workstation (PerkinElmer). Cells were incubated with compounds for 3 hours at 37°C, 5% CO₂ and then allowed to cool to room temperature for 30 min. To each plate was added 25 µL of Fluc buffer (200 mM Tris, 15 mM MgSO₄, 100 uM EDTA, 1 mM DTT, 1 mM ATP, 200 uM Coenzyme A, 400 uM D-Luciferin, 0.1% Triton X-100),
15 plates were incubated for 15 min at RT, and then read on an Envision 2104 (PerkinElmer) for luminescence. 25 µL of Nluc buffer (25 mM Na₄PPi, 10 mM NaOAc, 15 mM EDTA, 500 mM NaSO₄, 500 mM NaCl, 16 uM coelenterazine, 50 uM 4-(6-methyl-1,3-benzothiazol-2-yl)aniline [sc-276812]) was then added to each well and the plate incubated for 15 min at RT and then read for luminescence. The ratio of Nluc/Fluc signal was taken for each well, and
20 these values were normalized by setting dFKBP7 only wells to 0% and DMSO only wells to 100%. Data were further analyzed and plotted using GraphPad PRISM v6 and IC₅₀ values were determined using the 'log(agonist) vs normalized response –variable slope' analysis module (*see, e.g.*, Table 4-3 "FKBP7 rescue (EC₅₀)", and Table 5).

Cell lines

25 293FT and 293FT^{CRBN-/-} were cultured in DMEM supplemented with 10% FCS and 1% Penicillin/Streptomycin. MV4-11, MOLM13, MM1S and MM1S^{CRBN-/-} were cultured in RPMI supplemented with 10% FCS and 1% Penicillin/Streptomycin. SUM149 cells were cultured in HUME medium (cell application, 815-500) with DMEM F12 (corning cellgro, 10-090-CV) (1:1) and final 5% FCS with 1% Penicillin/Streptomycin.

30 Culture of primary patient material

Cells were freshly thawed and grown for 24 hours in StemSpan SFEM media (Stemcell) supplemented with (all in ng/ml final concentration): IL-3 (20), IL-6 (20), FLT3L (100), SCF (100) and GSCF (20). After that, cells were treated with dBET1 or JQ1 at the

indicated concentrations with renewed cytokines for 24 hours. Subsequently, cells were either used for immunoblot analysis or for FACS analysis.

Analysis of apoptotic cells by Flow Cytometry

For each sample, cells were washed with 500 μ L of PBS and spun down at 400xg for 5 minutes and media aspirated off. Cells were then resuspended in Annexin V binding buffer: 140 mM NaCl, 10 mM HEPES, 2.5 mM CaCl_2 , pH 7.4 and 500 μ L of each sample transferred to 5 mL polystyrene FACS tubes (Falcon Cat. No. 352054). Cells were spun down at 400xg for 5 minutes and buffer aspirated off. To each sample, 400 μ L of Annexin V binding buffer with 250 ng/mL FITC-Annexin V and 500 ng/mL propidium iodide were added for staining. Cells were then sorted on a BD LSRFortessa and analyzed using FlowJo V10 software (Tree Star, Inc).

Analysis of apoptotic cells by Caspase glo assay

Caspaseglo assay (Promega) has been conducted following the manufacturer's recommendations. Cells were seeded at a density of 5000 cells/well in a white 384 well plate (Thermo Scientific Nunc, #164610) in a total volume of 40 μ L with respective compound or vehicle control treatment. After a 24 h incubation, 30 μ L of the Caspaseglo substrate were added per well. Plate was incubated in the dark for 90 minutes and read on Envision plate reader (Perkin Elmer).

BRD4-high content assay

SUM149 cells were plated at a density of 3×10^5 cells/well using the inner 60 wells of a 96 well plate. 24 hours later, compounds were added in at the respective concentrations. Assays were performed with minimal modifications from the manufacturer's protocol (LICOR In-Cell Western Assay Kit). In brief, cells were fixed in 3.7% formaldehyde in PBS for 20 minutes on room temperature (200 μ L per well) and subsequently permeabilized using 1xPBS with 0.1% Triton X-100 (5 x 200 μ L per well). Then, cells were blocked using 100 μ L of a 1:1 diluted Odyssey Blocking Buffer (LICOR) for 90 minutes on room temperature. Next, cells were incubated with BRD4 antibody diluted 1:1000 in Odyssey Blocking Buffer (LICOR) (50 μ L per well) overnight on 4°C. Next day, plate was washed 5 times with TBST (200 μ L per well). Then, plates are stained with a 1:800 dilution of IRDye 800CW goat anti-Rabbit antibody (LICOR) and simultaneously with CellTag 700 Stain (1:500, LICOR) for cell normalization. Plates were incubated for 1h in the dark on RT, washed 5 times with TBST (200 μ L per well) and imaged on the Odyssey CLx Imager (LI-COR).

qRT-PCR

RNA was isolated using RNeasy Plus Mini Kit (Qiagen) and 500 ng of total RNA have been used per sample for reverse transcription using SuperScript Reverse Transcriptase (Life Technologies). cDNA has been diluted 1:9 and 2 ul have been used as template for qRT-PCR using SYBR Select master mix. The following primers have been used:

5	GAPDH (F): CCACTCCTCCACCTTTGAC	SEQ ID NO. 1
	GAPDH (R): ACCCTGTTGCTGTAGCCA	SEQ ID NO. 2
	BRD2 (F): GTGGTTCTCGGCGGTAAG	SEQ ID NO. 3
	BRD2 (R): GGTTGACACCCCGGATTAC	SEQ ID NO. 4
	BRD3 (F): TTGGCAAACCTCATCTCAAA	SEQ ID NO. 5
10	BRD3 (R): GATGTCCGGCTGATGTTCTC	SEQ ID NO. 6
	BRD4 (F): CTCCGCAGACATGCTAGTGA	SEQ ID NO. 7
	BRD4 (R): GTAGGATGACTGGGCCTCTG	SEQ ID NO. 8
	c-MYC (F): CACCGAGTCGTAGTCGAGGT	SEQ ID NO. 9
	c-MYC (R): GCTGCTTAGACGCTGGATTT	SEQ ID NO. 10
15	PIM1 (F): TCATACAGCAGGATCCCCA	SEQ ID NO. 11
	PIM1 (R): CCGTCTACACGGACTTCGAT	SEQ ID NO. 12

Sample preparation for quantitative mass spectrometry analysis

Sample were prepared as previously described (Weekes, M. P. *et al.*, *Cell* 157, 1460 (2014)) with the following modification. All solutions are reported as final concentrations. Lysis buffer (8 M Urea, 1% SDS, 50 mM Tris pH 8.5, Protease and Phosphatase inhibitors from Roche) was added to the cell pellets to achieve a cell lysate with a protein concentration between 2-8 mg/mL. A micro-BCA assay (Pierce) was used to determine the final protein concentration in the cell lysate. Proteins were reduced and alkylated as previously described. Proteins were precipitated using methanol/chloroform. In brief, four volumes of methanol was added to the cell lysate, followed by one volume of chloroform, and finally three volumes of water. The mixture was vortexed and centrifuged to separate the chloroform phase from the aqueous phase. The precipitated protein was washed with one volume of ice cold methanol. The washed precipitated protein was allowed to air dry. Precipitated protein was resuspended in 4 M Urea, 50 mM Tris pH 8.5. Proteins were first digested with LysC (1:50; enzyme:protein) for 12 hours at 25 °C. The LysC digestion is diluted down to 1 M Urea, 50 mM Tris pH8.5 and then digested with trypsin (1:100; enzyme:protein) for another 8 hours at 25 °C. Peptides were desalted using a C₁₈ solid phase extraction cartridges. Dried peptides were resuspended in 200 mM EPPS, pH 8.0. Peptide quantification was performed using the micro-BCA assay (Pierce). The same amount of peptide from each condition was labeled with tandem mass tag (TMT) reagent (1:4; peptide:TMT label) (Pierce). The 10-plex

labeling reactions were performed for 2 hours at 25 °C. Modification of tyrosine residue with TMT was reversed by the addition of 5% hydroxyl amine for 15 minutes at 25 °C. The reaction was quenched with 0.5% TFA and samples were combined at a 1:1:1:1:1:1:1:1:1:1 ratio. Combined samples were desalted and offline fractionated into 24 fractions as previously described.

Liquid chromatography-MS3 spectrometry (LC-MS/MS)

12 of the 24 peptide fraction from the basic reverse phase step (every other fraction) were analyzed with an LC-MS3 data collection strategy (McAlister, G. C. *et al.*, *Anal. Chem.* 86, 7150 (2014)) on an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific) equipped with a Proxeon Easy nLC 1000 for online sample handling and peptide separations. Approximately 5 µg of peptide resuspended in 5% formic acid + 5% acetonitrile was loaded onto a 100 µm inner diameter fused-silica micro capillary with a needle tip pulled to an internal diameter less than 5 µm. The column was packed in-house to a length of 35 cm with a C₁₈ reverse phase resin (GP118 resin 1.8 µm, 120 Å, Sepax Technologies). The peptides were separated using a 120 min linear gradient from 3% to 25% buffer B (100% ACN + 0.125% formic acid) equilibrated with buffer A (3% ACN + 0.125% formic acid) at a flow rate of 600 nL/min across the column. The scan sequence for the Fusion Orbitrap began with an MS1 spectrum (Orbitrap analysis, resolution 120,000, 400–1400 m/z scan range, AGC target 2×10^5 , maximum injection time 100 ms, dynamic exclusion of 75 seconds). “Top N” (the top 10 precursors) was selected for MS2 analysis, which consisted of CID (quadrupole isolation set at 0.5 Da and ion trap analysis, AGC 4×10^3 , NCE 35, maximum injection time 150 ms). The top ten precursors from each MS2 scan were selected for MS3 analysis (synchronous precursor selection), in which precursors were fragmented by HCD prior to Orbitrap analysis (NCE 55, max AGC 5×10^4 , maximum injection time 150 ms, isolation window 2.5 Da, resolution 60,000).

LC-MS3 data analysis

A suite of in-house software tools were used to for RAW file processing and controlling peptide and protein level false discovery rates, assembling proteins from peptides, and protein quantification from peptides as previously described. MS/MS spectra were searched against a Uniprot human database (February 2014) with both the forward and reverse sequences. Database search criteria are as follows: tryptic with two missed cleavages, a precursor mass tolerance of 50 ppm, fragment ion mass tolerance of 1.0 Da, static alkylation of cysteine (57.02146 Da), static TMT labeling of lysine residues and N-termini of peptides (229.162932 Da), and variable oxidation of methionine (15.99491 Da).

TMT reporter ion intensities were measured using a 0.003 Da window around the theoretical m/z for each reporter ion in the MS3 scan. Peptide spectral matches with poor quality MS3 spectra were excluded from quantitation (<200 summed signal-to-noise across 10 channels and <0.5 precursor isolation specificity).

5 MV4-11 Xenograft experiment

1x10⁷ MV4-11 cells were injected subcutaneously in a volume of 200ul of PBS per mouse (NSG). Successful engraftment was monitored via bioluminescence and caliper measurement. 11 days post injection of MV4-11 cells, tumors were palpable and mice were distributed in either the control (vehicle) or the dBET1 treated groups. Mice were treated once daily with 50 mg/kg dBET1 or vehicle (captisol) via intraperitoneal injection. Tumor volume was recorded via caliper measurement. The study was terminated 14 days post treatment start when the tumor size of a vehicle treated mouse reached institutional limits.

Expression proteomics

5x10⁶ cells have been treated with DMSO, 250 nM dBET1 or 250 nM JQ1 in triplicate for 2 hours, washed with 3 times with ice-cold PBS and snap-frozen in liquid N₂. Next, samples were mechanically homogenized in lysis buffer (8 M Urea, 1% SDS, 50mM Tris, pH 8.5, protease and phosphatase inhibitors) and protein quantification was performed using the micro-BCA kit (Pierce). After protein quantification lysates were immediately reduced with DTT and alkylated with iodoacetimide. 600µg protein was precipitated by methanol/chloroform and digestion was performed using LysC and trypsin. 50 µg of each sample was labeled with Tandem Mass Tag (TMT, Thermo Scientific) reagent and fractionated for total proteomic analysis.

Reverse-Phase fractionation was conducted under the following conditions: Buffer A: 5% ACN, 50 mMAmBic pH 8.0, Buffer B: 90% ACN, 50 mMAmBic pH 8.0 (Fraction size – 37 seconds (~300 µL))

Proteins were fractionated by bRP and collected into two sets of 12 fractions each. One complete set (12 fractions) from HPRP was analyzed on an Orbitrap Fusion mass spectrometer. Peptides were separated using a gradient of 3 to 25% acetonitrile in 0.125% formic acid over 200 minutes. Peptides were detected (MS1) and quantified (MS3) in the Orbitrap, peptides were sequenced (MS2) in the ion trap. MS2 spectra were searched using the SEQUEST algorithm against a Uniprot composite database derived from the human proteome containing its reversed complement and known contaminants. All peptide spectral matches were filtered to a 1% false discovery rate (FDR) using the target-decoy strategy

combined with linear discriminant analysis. Proteins were quantified only from peptides with a summed SN threshold of ≥ 200 and MS2 isolation specificity of 0.5.

Immunoblotting

Cells have been lysed using RIPA buffer supplemented with protease inhibitor
5 cocktail (Roche) and 0.1% benzonase (Novagen) on ice for 15 minutes. The lysates were
spun at 16000xg for 15 minutes on 4°C and protein concentration was determined using BCA
assay (Pierce). The following primary antibodies were used in this study: BRD2 (Bethyl
labs), BRD3 (abcam), BRD4 (Bethyl labs), MYC, tubulin and vinculin (all Santa Cruz) as
well as PIM1 (Cell Signaling Technology) and IKZF3 (Novus Biologicals). Blots were
10 imaged using fluorescence-labeled secondary antibodies (LI-COR) on the
OdysseyCLxImager (LI-COR). Quantification of band intensities has been performed using
OdysseyCLx software (LI-COR).

Immunohistochemistry

BRD4 staining was performed using the A301-985A antibody (Bethyl labs) following
15 the recommended parameters at a concentration of 1:2000. MYC and Ki67 stainings were
performed as described previously. Quantification of positively stained nuclei was conducted
using the aperio software (Leica Biosystems).

EQUIVALENTS

20 Those skilled in the art will recognize, or be able to ascertain using no more than
routine experimentation, many equivalents to the specific embodiments and methods
described herein. Such equivalents are intended to be encompassed by the scope of the
present application.

All patents, patent applications, and literature references cited herein are hereby
25 expressly incorporated by reference.

CLAIMS

1. A bifunctional compound for use in treating a disease or condition, wherein the compound is of the structure

Degron–Linker–Targeting Ligand,


5 wherein the Linker is covalently bound to at least one Degron and at least one Targeting Ligand, the Degron is a compound capable of binding to a ubiquitin ligase, and the Targeting Ligand is capable of binding to a targeted protein, and wherein the disease or condition is resistant to the Targeting Ligand.

10 2. The bifunctional compound for use of claim 1, wherein the Degron is a compound that is capable of binding to an E3 ubiquitin ligase.


3. The bifunctional compound for use of claim 1 or claim 2, wherein the Degron is a compound that is capable of binding to cereblon.

15

4. The bifunctional compound for use of any one of the preceding claims, wherein the Degron is a compound of Formula D0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein:



20

Y is a bond, Y₁, O, NH, NR₂, C(O)O, C(O)NR₂', Y₁-O, Y₁-NH, Y₁-NR₂, Y₁-C(O), Y₁-C(O)O, Y₁-OC(O), Y₁-C(O)NR₂', or Y₁-NR₂'C(O), wherein Y₁ is C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆alkynylene;

X is C(O) or C(R₃)₂;

25

X₁-X₂ is C(R₃)=N or C(R₃)₂-C(R₃)₂;

each R₁ is independently halogen, nitro, NH₂, OH, C(O)OH, C₁-C₆ alkyl, or C₁-C₆ alkoxy;

R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C(O)-C₁-C₆ alkyl, C(O)-C₂-C₆ alkenyl, C(O)-C₃-C₈ cycloalkyl, or C(O)-3- to 8-membered heterocycloalkyl, and R₂ is optionally substituted with one or more of halogen, N(R_a)₂, NHC(O)R_a, NHC(O)OR_a, OR_b, C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

R₂' is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, or 3- to 8-membered heterocycloalkyl, and R₂', when not being H, is optionally substituted with one or more of halogen, N(R_a)₂, NHC(O)R_a, NHC(O)OR_a, OR_b, C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈ cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

each R₃ is independently H or C₁-C₃ alkyl optionally substituted with C₆-C₁₀ aryl or 5- to 10-membered heteroaryl;

each R₃' is independently C₁-C₃ alkyl;

each R₄ is independently H or C₁-C₃ alkyl; or two R₄, together with the carbon atom to which they are attached, form C(O), a C₃-C₆ carbocycle, or a 4-, 5-, or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from N and O;

R₅ is H, C₁-C₃ alkyl, F, or Cl;

each R_a independently is H or C₁-C₆ alkyl;

R_b is H or tosyl;


t is 0 or 1;

m is 0, 1, 2 or 3; and

n is 0, 1 or 2;

wherein the compound is covalently bonded to the Linker via $\text{---}\frac{\text{S}}{\text{S}}\text{---}$.


5. The bifunctional compound for use of any one of the preceding claims, wherein the Degron is a compound of Formula D1:



or an enantiomer, diastereomer, or stereoisomer thereof.


6. The bifunctional compound for use of any one of the preceding claims, wherein the
5 Degron is selected from Table D, D1, D2, D3, or D4.

7. The bifunctional compound for use of any one of the preceding claims, wherein the
Degron is selected from




wherein R is a Linker.

8. The bifunctional compound for use of any one of the preceding claims, wherein the
15 Degron is selected from



9. The bifunctional compound for use of any one of the preceding claims, wherein the




Degron is

5 10. The bifunctional compound for use of any one of the preceding claims, wherein the Linker is a bond or a carbon chain comprising at least 5 chain atoms selected from C, O, N, and S.

11. The bifunctional compound for use of any one of the preceding claims, wherein the

10 Linker is of Formula L0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein

p1 is an integer selected from 0 to 12;

p2 is an integer selected from 0 to 12;

15 p3 is an integer selected from 0 to 6;

each W is independently absent, CH₂, O, S, NH or NR₅;

Z is absent, CH₂, O, NH or NR₅;

each R₅ is independently C₁-C₃ alkyl; and


Q is absent, -C(O)NH-, -C(O)O-, -CH₂C(O)NH-, or -CH₂C(O)O- when p3 is an

20 integer selected from 1 to 6; or Q is Q₁, -C₁-C₄ alkylene-Q₂, or Q₁-C₁-C₄ alkylene-Q₂ when p3 is an integer selected from 0 to 6, wherein each of Q₁ and Q₂ independently is C₃-C₈ cycloalkylene, 3- to 8-membered heterocycloalkylene, C₆-C₁₀ arylene, or 5- to 10-membered heteroarylene, each of which is optionally substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;


25 wherein the Linker is covalently bonded to the Degron with the  next to Q, and

covalently bonded to the Targeting Ligand with the  next to Z, and wherein the total number of chain atoms in the Linker is less than 30.

12. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-I:



or a pharmaceutically acceptable salt thereof, wherein:



A₁ is S or C=C;

A₂ is N Ra₅ or O;

nn1 is 0, 1, or 2;

each Ra₁ is independently C₁-C₃ alkyl, (CH₂)₀₋₃-CN, (CH₂)₀₋₃-halogen, (CH₂)₀₋₃-OH, (CH₂)₀₋₃-C₁-C₃ alkoxy, C(O)N Ra₅L, OL, N Ra₅L, or L;

Ra₂ is H, C₁-C₆ alkyl, (CH₂)₀₋₃-heterocyclyl, (CH₂)₀₋₃-phenyl, or L, wherein the heterocyclyl comprises one saturated 5- or 6-membered ring and 1-2 heteroatoms selected from N, O, and S and is optionally substituted with C₁-C₃ alkyl, L, or C(O)L, and wherein the phenyl is optionally substituted with C₁-C₃ alkyl, CN, halogen, OH, C₁-C₃ alkoxy, or L;

nn2 is 0, 1, 2, or 3;

each Ra₃ is independently C₁-C₃ alkyl, (CH₂)₀₋₃-CN, (CH₂)₀₋₃-halogen, L, or C(O)N Ra₅L;


Ra₄ is C₁-C₃ alkyl;

Ra₅ is H or C₁-C₃ alkyl; and


L is a Linker,

provided that The bifunctional compound for use of Formula TL-I is substituted with only one L.


13. The bifunctional compound for use of any one of claims 1-12, wherein the Targeting Ligand is a compound of Formula TL-I1, TL-I2, or TL-I3:



(TL-I1),




(TL-I2), or



(TL-I3).

14. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting
5 Ligand is a compound of Formula TL-II:



(TL-II),

or a pharmaceutically acceptable salt thereof, wherein:

T₆ is CRb₄ or N;

Rb₁, Rb₂, and Rb₅ are each independently H or C₁-C₃ alkyl;

10 Rb₃ is C₃-C₆ cycloalkyl;

each Rb₄ is independently H, C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

nn₃ is 0, 1, 2, or 3;


each Rb₆ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

Rb₇ is C(O)NRb₈L, OL, NRb₈L, or L;

15 Rb₈ is H or C₁-C₃ alkyl; and

L is a Linker.

15. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting
Ligand is a compound of Formula TL-III:



or a pharmaceutically acceptable salt thereof, wherein:

nn4 is 0 or 1;

Rc1 is C(O)NRc6L, OL, NRc6L, or L;

5 Rc2 is H, C₁-C₃ alkyl, C(O)NRc6L, OL, NRc6L, or L;

Rc3 is H, C₁-C₃ alkyl, C(O)L, or L;

nn5 is 0, 1, or 2;

each Rc4 is independently C₁-C₃ alkyl or C₁-C₃ alkoxy;


each Rc5 is independently H or C₁-C₃ alkyl;

10 Rc6 is independently H or C₁-C₃ alkyl; and

L is a Linker,

provided that The bifunctional compound for use of Formula TL-III is substituted with only one L.

15 16. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-IV:



or a pharmaceutically acceptable salt thereof, wherein:

each Rd1 is independently H or C₁-C₃ alkyl;

20 nn6 is 0, 1, 2, or 3;

nn7 is 0, 1, 2, or 3;


each Rd2 is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;

Rd3 is C(O)NRd4L, OL, NRd4L, or L;

Rd4 is H or C₁-C₃ alkyl; and

L is a Linker.

17. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-V:



or a pharmaceutically acceptable salt thereof, wherein:

each Re_1 is independently H or C_1 - C_3 alkyl;

$nn8$ is 0, 1, 2, or 3;

$nn9$ is 0, 1, 2, or 3;


10 each Re_2 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

Re_3 is $NH-(CH_2)_{1-3}-C(O)NRe_4L$, $C(O)NRe_4L$, OL, NRe_4L , or L;

Re_4 is H or C_1 - C_3 alkyl; and

L is a Linker.

15 18. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-VI:




or a pharmaceutically acceptable salt thereof, wherein:

Rf_1 is $C(O)NRf_2L$, OL, NRf_2L , or L;

20 Rf_2 is independently H or C_1 - C_3 alkyl; and

L is a Linker.

19. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-VII:



or a pharmaceutically acceptable salt thereof, wherein:

T_7 is CH_2 or CH_2CH_2 ;

R_{g1} is $C(O)R_{g5}$ or C_1 - C_3 alkyl substituted with R_{g6} ;

5 $nn10$ is 0, 1, 2, or 3;

$nn11$ is 0, 1, 2, or 3;

each R_{g2} is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

R_{g3} is $C(O)NR_{g4}L$, OL, $NR_{g4}L$, L, $O-(CH_2)_{1-3}-C(O)NR_{g4}L$, or $NHC(O)-(CH_2)_{1-3}-C(O)NR_{g4}L$;

10 R_{g4} is H or C_1 - C_3 alkyl;

R_{g5} is C_1 - C_6 alkyl;


R_{g6} is phenyl optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

and

L is a Linker.

15

20. The bifunctional compound for use of any one of claims 1-11, wherein the Targeting Ligand is a compound of Formula TL-VIII:



or a pharmaceutically acceptable salt thereof, wherein:

20 each R_{h1} is independently H or C_1 - C_3 alkyl;

$nn12$ is 0, 1, 2, or 3;

each R_{h2} is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

R_{h3} is $C(O)L$ or $C(O)-(CH_2)_{1-3}-C(O)NR_{h6}L$;


R_{h6} is H or C_1 - C_3 alkyl;

Rh₄ is H or C₁-C₃ alkyl;

Rh₅ is C₁-C₆ alkyl; and

L is a Linker.

21. The bifunctional compound for use of any one of the preceding claims, wherein the bifunctional compound has the structure of



22. The bifunctional compound for use of any one of the preceding claims, wherein the bifunctional compound is selected from Table I-1 and Table I-2.

23. A method of treating a disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a bifunctional compound having the structure

Degron-Linker-Targeting Ligand,


wherein the Linker is covalently bound to at least one Degron and at least one Targeting Ligand, the Degron is a compound capable of binding to a ubiquitin ligase, and the Targeting Ligand is capable of binding to a targeted protein, and wherein the disease or condition is resistant to the Targeting Ligand.

20


24. The method of claim 23, wherein the Degron is a compound that is capable of binding to an E3 ubiquitin ligase.

25. The method of claim 23 or claim 24, wherein the Degron is a compound that is capable of binding to cereblon.

26. The method of any one of claims 23-25, wherein the Degron is a compound of Formula D0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein:



Y is a bond, Y₁, O, NH, NR₂, C(O)O, C(O)NR₂', Y₁-O, Y₁-NH, Y₁-NR₂, Y₁-C(O),
 5 Y₁-C(O)O, Y₁-OC(O), Y₁-C(O)NR₂', or Y₁-NR₂'C(O), wherein Y₁ is C₁-C₆ alkylene, C₂-C₆
 alkenylene, or C₂-C₆alkynylene;

X is C(O) or C(R₃)₂;

X₁-X₂ is C(R₃)=N or C(R₃)₂-C(R₃)₂;

each R₁ is independently halogen, nitro, NH₂, OH, C(O)OH, C₁-C₆ alkyl, or C₁-C₆
 10 alkoxy;

R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, 3- to 8-membered
 heterocycloalkyl, C(O)-C₁-C₆ alkyl, C(O)-C₂-C₆ alkenyl, C(O)-C₃-C₈ cycloalkyl, or C(O)-3-
 to 8-membered heterocycloalkyl, and R₂ is optionally substituted with one or more of
 halogen, N(R_a)₂, NHC(O)R_a, NHC(O)OR_a, OR_b, C₃-C₈ cycloalkyl, 3- to 8-membered
 15 heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈
 cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl
 is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH,
 C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

R₂' is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, or 3- to 8-membered
 20 heterocycloalkyl, and R₂', when not being H, is optionally substituted with one or more of
 halogen, N(R_a)₂, NHC(O)R_a, NHC(O)OR_a, OR_b, C₃-C₈ cycloalkyl, 3- to 8-membered
 heterocycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl, wherein each of the C₃-C₈
 cycloalkyl, 3- to 8-membered heterocycloalkyl, C₆-C₁₀ aryl or 5- to 10-membered heteroaryl
 is optionally further substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH,
 25 C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;

each R₃ is independently H or C₁-C₃ alkyl optionally substituted with C₆-C₁₀ aryl or 5-
 to 10-membered heteroaryl;

each R₃' is independently C₁-C₃ alkyl;

each R_4 is independently H or C_1 - C_3 alkyl; or two R_4 , together with the carbon atom to which they are attached, form $C(O)$, a C_3 - C_6 carbocycle, or a 4-, 5-, or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from N and O;

R_5 is H, C_1 - C_3 alkyl, F, or Cl;

5 each R_a independently is H or C_1 - C_6 alkyl;

R_b is H or tosyl;


t is 0 or 1;

m is 0, 1, 2 or 3; and

n is 0, 1 or 2;

10 wherein the compound is covalently bonded to the Linker via .


27. The method of any one of claims 23-26, wherein the Degron is a compound of Formula D1:




15 or an enantiomer, diastereomer, or stereoisomer thereof.

28. The method of any one of claims 23-27, wherein the Degron is selected from Table D, D1, D2, D3, or D4.


20 29. The method of any one of claims 23-28, wherein the Degron is selected from






wherein R is a Linker.

30. The method of any one of claims 23-29, wherein the Degron is selected from




31. The method of any one of claims 23-30, wherein the Degron is



32. The method of any one of claims 23-31, wherein the Linker is a bond or a carbon chain comprising at least 5 chain atoms selected from C, O, N, and S.

33. The method of any one of claims 23-32, wherein the Linker is of Formula L0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein

p1 is an integer selected from 0 to 12;

p2 is an integer selected from 0 to 12;

p3 is an integer selected from 0 to 6;

each W is independently absent, CH₂, O, S, NH or NR₅;

Z is absent, CH₂, O, NH or NR₅;


each R₅ is independently C₁-C₃ alkyl; and

Q is absent, -C(O)NH-, -C(O)O-, -CH₂C(O)NH-, or -CH₂C(O)O- when p₃ is an integer selected from 1 to 6; or Q is Q₁, -C₁-C₄ alkylene-Q₂, or Q₁-C₁-C₄ alkylene-Q₂ when p₃ is an integer selected from 0 to 6, wherein each of Q₁ and Q₂ independently is C₃-C₈ cycloalkylene, 3- to 8-membered heterocycloalkylene, C₆-C₁₀ arylene, or 5- to 10-membered heteroarylene, each of which is optionally substituted with one or more of halogen, NH₂, CN, nitro, OH, C(O)OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy;


wherein the Linker is covalently bonded to the Degron with the $\text{---}\frac{\xi}{\xi}\text{---}$ next to Q, and

covalently bonded to the Targeting Ligand with the $\text{---}\frac{\xi}{\xi}\text{---}$ next to Z, and wherein the total number of chain atoms in the Linker is less than 30.

34. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-I:



15 or a pharmaceutically acceptable salt thereof, wherein:



A₁ is S or C=C;

A₂ is N Ra₅ or O;

nn1 is 0, 1, or 2;

20 each Ra₁ is independently C₁-C₃ alkyl, (CH₂)₀₋₃-CN, (CH₂)₀₋₃-halogen, (CH₂)₀₋₃-OH, (CH₂)₀₋₃-C₁-C₃ alkoxy, C(O)N Ra₅L, OL, N Ra₅L, or L;

Ra₂ is H, C₁-C₆ alkyl, (CH₂)₀₋₃-heterocyclyl, (CH₂)₀₋₃-phenyl, or L, wherein the heterocyclyl comprises one saturated 5- or 6-membered ring and 1-2 heteroatoms selected from N, O, and S and is optionally substituted with C₁-C₃ alkyl, L, or C(O)L, and wherein the phenyl is optionally substituted with C₁-C₃ alkyl, CN, halogen, OH, C₁-C₃ alkoxy, or L;

nn2 is 0, 1, 2, or 3;

each Ra_3 is independently C_1 - C_3 alkyl, $(CH_2)_{0-3}$ -CN, $(CH_2)_{0-3}$ -halogen, L, or $C(O)NRa_5L$;


Ra_4 is C_1 - C_3 alkyl;

Ra_5 is H or C_1 - C_3 alkyl; and


5 L is a Linker,

provided that the compound of Formula TL-I is substituted with only one L.


35. The method of any one of claims 23-34, wherein the Targeting Ligand is a compound of Formula TL-I1, TL-I2, or TL-I3:



(TL-I1),




(TL-I2), or



(TL-I3).

36. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-II:



(TL-II),

or a pharmaceutically acceptable salt thereof, wherein:

T_6 is CRb_4 or N;

Rb_1 , Rb_2 , and Rb_5 are each independently H or C_1 - C_3 alkyl;

Rb_3 is C_3 - C_6 cycloalkyl;

each Rb_4 is independently H, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

$nn3$ is 0, 1, 2, or 3;

each Rb₆ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, CN, or halogen;


Rb₇ is C(O)NRb₈L, OL, NRb₈L, or L;

Rb₈ is H or C₁-C₃ alkyl; and

L is a Linker.

5

37. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-III:



or a pharmaceutically acceptable salt thereof, wherein:

10

nn₄ is 0 or 1;

Rc₁ is C(O)NRc₆L, OL, NRc₆L, or L;

Rc₂ is H, C₁-C₃ alkyl, C(O)NRc₆L, OL, NRc₆L, or L;

Rc₃ is H, C₁-C₃ alkyl, C(O)L, or L;

nn₅ is 0, 1, or 2;

15

each Rc₄ is independently C₁-C₃ alkyl or C₁-C₃ alkoxy;

each Rc₅ is independently H or C₁-C₃ alkyl;


Rc₆ is independently H or C₁-C₃ alkyl; and

L is a Linker,

provided that the compound of Formula TL-III is substituted with only one L.

20

38. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-IV:



or a pharmaceutically acceptable salt thereof, wherein:

each Rd_1 is independently H or C_1 - C_3 alkyl;

$nn6$ is 0, 1, 2, or 3;

$nn7$ is 0, 1, 2, or 3;


each Rd_2 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;

5 Rd_3 is $C(O)NRd_4L$, OL, NRd_4L , or L;

Rd_4 is H or C_1 - C_3 alkyl; and

L is a Linker.

39. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound
10 of Formula TL-V:



or a pharmaceutically acceptable salt thereof, wherein:

each Re_1 is independently H or C_1 - C_3 alkyl;

$nn8$ is 0, 1, 2, or 3;

15 $nn9$ is 0, 1, 2, or 3;

each Re_2 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, CN, or halogen;


Re_3 is $NH-(CH_2)_{1-3}-C(O)NRe_4L$, $C(O)NRe_4L$, OL, NRe_4L , or L;

Re_4 is H or C_1 - C_3 alkyl; and

L is a Linker.

20

40. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound
of Formula TL-VI:




or a pharmaceutically acceptable salt thereof, wherein:

25 Rf_1 is $C(O)NRf_2L$, OL, NRf_2L , or L;

Rf_2 is independently H or C_1 - C_3 alkyl; and

L is a Linker.

41. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-VII:



or a pharmaceutically acceptable salt thereof, wherein:

5 T_7 is CH_2 or CH_2CH_2 ;

Rg_1 is $\text{C}(\text{O})\text{Rg}_5$ or $\text{C}_1\text{-C}_3$ alkyl substituted with Rg_6 ;

$nn10$ is 0, 1, 2, or 3;

$nn11$ is 0, 1, 2, or 3;

each Rg_2 is independently $\text{C}_1\text{-C}_3$ alkyl, $\text{C}_1\text{-C}_3$ alkoxy, CN, or halogen;

10 Rg_3 is $\text{C}(\text{O})\text{NRg}_4\text{L}$, OL, NRg_4L , L, $\text{O}-(\text{CH}_2)_{1-3}-\text{C}(\text{O})\text{NRg}_4\text{L}$, or $\text{NHC}(\text{O})-(\text{CH}_2)_{1-3}-\text{C}(\text{O})\text{NRg}_4\text{L}$;

Rg_4 is H or $\text{C}_1\text{-C}_3$ alkyl;


Rg_5 is $\text{C}_1\text{-C}_6$ alkyl;

Rg_6 is phenyl optionally substituted with $\text{C}_1\text{-C}_3$ alkyl, $\text{C}_1\text{-C}_3$ alkoxy, CN, or halogen;

15 and

L is a Linker.

42. The method of any one of claims 23-33, wherein the Targeting Ligand is a compound of Formula TL-VIII:



or a pharmaceutically acceptable salt thereof, wherein:

each Rh_1 is independently H or $\text{C}_1\text{-C}_3$ alkyl;

$nn12$ is 0, 1, 2, or 3;

each Rh_2 is independently $\text{C}_1\text{-C}_3$ alkyl, $\text{C}_1\text{-C}_3$ alkoxy, CN, or halogen;

Rh₃ is C(O)L or C(O)-(CH₂)₁₋₃-C(O)NRh₆L;


Rh₆ is H or C₁-C₃ alkyl;

Rh₄ is H or C₁-C₃ alkyl;

Rh₅ is C₁-C₆ alkyl; and

5 L is a Linker.

43. The method of any one of claims 23-42, wherein the bifunctional compound has the structure of



10

44. The method of any one of claims 23-43, wherein the bifunctional compound is selected from Table I-1 and Table I-2.

1/48




Fig. 1




Fig. 1 (continued)




Fig. 1 (continued)




Fig. 2




Fig. 2 (continued)




Fig. 2 (continued)

K




Fig. 2 (continued)




Fig. 2 (continued)

9/48




Fig. 2 (continued)




Fig. 2 (continued)





Fig. 3

12/48

E



F




Fig. 3 (continued)




Fig. 4






Fig. 4 (continued)




Fig. 5




Fig. 6

17/48




Fig. 7

18/48




Fig. 8




Fig. 9

20/48

A






Fig. 10

B



C



D




Fig. 10 (continued)




Fig. 11




Fig. 12




Fig. 12 (continued)

25/48




Fig. 13

26/48




Fig. 13 (continued)




Fig. 14




Fig. 14 (continued)

29/48




Fig. 14 (continued)

30/48




Fig. 14 (continued)




Fig. 14 (continued)




Fig. 14 (continued)

33/48




Fig. 14 (continued)




Fig. 15




Fig. 15 (continued)

36/48





Fig. 16






Fig. 17 (continued)




Fig. 18




Fig. 18 (continued)




Fig. 18 (continued)

42/48




Fig. 19




Fig.20




Fig.21

45/48




Fig.22




Fig.23




Fig.24




Fig.25

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/039048

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D471/04 C07D471/14 A61K47/4813 A61K47/48346
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, COMPENDEX, EMBASE, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2015/160845 A2 (ARVINAS INC [US]) 22 October 2015 (2015-10-22) the whole document	1-44
Y	ERIC S. FISCHER ET AL: "Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide", NATURE, 23 May 2014 (2014-05-23), XP055256437, United Kingdom ISSN: 0028-0836, DOI: 10.1038/nature13527 figure 2; compound 5	1-44
Y	WO 2013/106643 A2 (UNIV YALE [US]; GLAXOSMITHKLINE IP DEV LTD [GB]; CAMBRIDGE ENTPR LTD U) 18 July 2013 (2013-07-18) claim 1	1-44



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 September 2016

Date of mailing of the international search report

09/09/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bareyt, Sébastien

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/039048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015160845 A2	22-10-2015	US 2015291562 A1 WO 2015160845 A2	15-10-2015 22-10-2015
-----	-----	-----	-----
WO 2013106643 A2	18-07-2013	AU 2013207900 A1 CA 2861066 A1 CN 104736569 A EP 2802608 A2 HK 1208875 A1 JP 2015508414 A KR 20150010935 A RU 2014133019 A US 2014356322 A1 WO 2013106643 A2	24-07-2014 18-07-2013 24-06-2015 19-11-2014 18-03-2016 19-03-2015 29-01-2015 27-02-2016 04-12-2014 18-07-2013
-----	-----	-----	-----